NZ720726B2 - Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments - Google Patents
Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments Download PDFInfo
- Publication number
- NZ720726B2 NZ720726B2 NZ720726A NZ72072614A NZ720726B2 NZ 720726 B2 NZ720726 B2 NZ 720726B2 NZ 720726 A NZ720726 A NZ 720726A NZ 72072614 A NZ72072614 A NZ 72072614A NZ 720726 B2 NZ720726 B2 NZ 720726B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- indazol
- mmol
- carboxamide
- pyridine
- oxoethyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 121
- 239000003814 drug Substances 0.000 title abstract description 15
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 150000003857 carboxamides Chemical class 0.000 title description 23
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- -1 6-substituted indazoles Chemical class 0.000 abstract description 259
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 50
- 238000011321 prophylaxis Methods 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 13
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 8
- 201000004681 Psoriasis Diseases 0.000 abstract description 7
- 201000009273 Endometriosis Diseases 0.000 abstract description 5
- 206010025323 Lymphomas Diseases 0.000 abstract description 5
- 208000002780 macular degeneration Diseases 0.000 abstract description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 505
- 150000001875 compounds Chemical class 0.000 description 242
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 226
- 239000000203 mixture Substances 0.000 description 170
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 154
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 146
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 146
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 142
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 132
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 124
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 119
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 112
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 111
- 239000000243 solution Substances 0.000 description 96
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 93
- 229910052736 halogen Inorganic materials 0.000 description 87
- 238000005160 1H NMR spectroscopy Methods 0.000 description 85
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 85
- 150000003254 radicals Chemical class 0.000 description 85
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 83
- 150000002367 halogens Chemical class 0.000 description 82
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 77
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 67
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 66
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 65
- 239000007787 solid Substances 0.000 description 59
- 125000004093 cyano group Chemical group *C#N 0.000 description 57
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 57
- 239000012043 crude product Substances 0.000 description 56
- 239000002253 acid Substances 0.000 description 52
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 52
- 238000003786 synthesis reaction Methods 0.000 description 51
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 50
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 50
- 239000011541 reaction mixture Substances 0.000 description 46
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 44
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 43
- 230000015572 biosynthetic process Effects 0.000 description 41
- 239000012071 phase Substances 0.000 description 41
- 238000005481 NMR spectroscopy Methods 0.000 description 40
- 229910052739 hydrogen Inorganic materials 0.000 description 38
- 239000001257 hydrogen Substances 0.000 description 38
- 238000010626 work up procedure Methods 0.000 description 38
- 125000003118 aryl group Chemical group 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 37
- 208000035475 disorder Diseases 0.000 description 37
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 35
- 238000000746 purification Methods 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 33
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 33
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- 238000011282 treatment Methods 0.000 description 30
- 108020000411 Toll-like receptor Proteins 0.000 description 29
- 102000002689 Toll-like receptor Human genes 0.000 description 28
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 27
- 125000006239 protecting group Chemical group 0.000 description 27
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 25
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 24
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 24
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 24
- 150000003839 salts Chemical class 0.000 description 24
- 239000000460 chlorine Substances 0.000 description 23
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 22
- 229910052757 nitrogen Inorganic materials 0.000 description 22
- 239000002244 precipitate Substances 0.000 description 22
- 230000008569 process Effects 0.000 description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 21
- 239000012074 organic phase Substances 0.000 description 21
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- 230000001404 mediated effect Effects 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 18
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical class OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 18
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 18
- 229940127590 IRAK4 inhibitor Drugs 0.000 description 17
- 229910052801 chlorine Inorganic materials 0.000 description 17
- 238000002953 preparative HPLC Methods 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 238000001035 drying Methods 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 15
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 14
- 229910052794 bromium Inorganic materials 0.000 description 14
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 14
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 14
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- GSCCALZHGUWNJW-UHFFFAOYSA-N N-Cyclohexyl-N-methylcyclohexanamine Chemical compound C1CCCCC1N(C)C1CCCCC1 GSCCALZHGUWNJW-UHFFFAOYSA-N 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- 238000005859 coupling reaction Methods 0.000 description 13
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 13
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 13
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 13
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 13
- 125000004076 pyridyl group Chemical group 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 239000011737 fluorine Substances 0.000 description 12
- 229910052731 fluorine Inorganic materials 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 12
- 229910052763 palladium Inorganic materials 0.000 description 12
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 239000011591 potassium Substances 0.000 description 12
- 229910052700 potassium Inorganic materials 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 11
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 11
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 11
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 11
- 235000015165 citric acid Nutrition 0.000 description 11
- 230000002265 prevention Effects 0.000 description 11
- 230000019491 signal transduction Effects 0.000 description 11
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 10
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 10
- 238000001994 activation Methods 0.000 description 10
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 10
- 125000004193 piperazinyl group Chemical group 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- 125000003003 spiro group Chemical group 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 10
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 235000019253 formic acid Nutrition 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 230000008506 pathogenesis Effects 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 150000002941 palladium compounds Chemical class 0.000 description 8
- 229910052701 rubidium Inorganic materials 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 238000001291 vacuum drying Methods 0.000 description 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 7
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 7
- 208000019693 Lung disease Diseases 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 201000006417 multiple sclerosis Diseases 0.000 description 7
- 125000003386 piperidinyl group Chemical group 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 6
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 229960002170 azathioprine Drugs 0.000 description 6
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 6
- 125000002393 azetidinyl group Chemical group 0.000 description 6
- 239000004305 biphenyl Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 206010025135 lupus erythematosus Diseases 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 5
- 208000026326 Adult-onset Still disease Diseases 0.000 description 5
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 5
- 150000001408 amides Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000012964 benzotriazole Substances 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 125000005553 heteroaryloxy group Chemical group 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 230000010534 mechanism of action Effects 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000001117 sulphuric acid Substances 0.000 description 5
- 235000011149 sulphuric acid Nutrition 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 4
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 4
- KJDIGQWBDQJIFR-UHFFFAOYSA-N 3-(trifluoromethyl)pyridine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=C1C(F)(F)F KJDIGQWBDQJIFR-UHFFFAOYSA-N 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 4
- 201000003274 CINCA syndrome Diseases 0.000 description 4
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 4
- 101000852255 Homo sapiens Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 4
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 4
- 102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 4
- 229910017711 NHRa Inorganic materials 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 4
- 206010069351 acute lung injury Diseases 0.000 description 4
- 150000001350 alkyl halides Chemical class 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- IEMGWBMVQLVHEY-UHFFFAOYSA-N ethyl 2-(3-amino-6,7-dihydro-5h-cyclopenta[b]pyridin-7-yl)acetate Chemical compound NC1=CN=C2C(CC(=O)OCC)CCC2=C1 IEMGWBMVQLVHEY-UHFFFAOYSA-N 0.000 description 4
- 238000000105 evaporative light scattering detection Methods 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- JEGUKCSWCFPDGT-UHFFFAOYSA-M hydroxide;hydrate Chemical compound O.[OH-] JEGUKCSWCFPDGT-UHFFFAOYSA-M 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 4
- 229910000105 potassium hydride Inorganic materials 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229960004641 rituximab Drugs 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 4
- 235000019798 tripotassium phosphate Nutrition 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- LTUUGSGSUZRPRV-UHFFFAOYSA-N 6-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=CC(C(O)=O)=N1 LTUUGSGSUZRPRV-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000009137 Behcet syndrome Diseases 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 208000035690 Familial cold urticaria Diseases 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 102100037907 High mobility group protein B1 Human genes 0.000 description 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 description 3
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 150000001502 aryl halides Chemical class 0.000 description 3
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 3
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 239000012039 electrophile Substances 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- ARFLASKVLJTEJD-UHFFFAOYSA-N ethyl 2-bromopropanoate Chemical compound CCOC(=O)C(C)Br ARFLASKVLJTEJD-UHFFFAOYSA-N 0.000 description 3
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- BXGTVNLGPMZLAZ-UHFFFAOYSA-N n'-ethylmethanediimine;hydrochloride Chemical compound Cl.CCN=C=N BXGTVNLGPMZLAZ-UHFFFAOYSA-N 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 229960005235 piperonyl butoxide Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000012041 precatalyst Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 3
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 2
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 description 2
- PLCMVACJJSYDFV-UHFFFAOYSA-N 1,3-oxazole-2-carboxamide Chemical class NC(=O)C1=NC=CO1 PLCMVACJJSYDFV-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- DEPDDPLQZYCHOH-UHFFFAOYSA-N 1h-imidazol-2-amine Chemical compound NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 description 2
- XBTOSRUBOXQWBO-UHFFFAOYSA-N 1h-indazol-5-amine Chemical compound NC1=CC=C2NN=CC2=C1 XBTOSRUBOXQWBO-UHFFFAOYSA-N 0.000 description 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 2
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 2
- ATRQECRSCHYSNP-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC=N1 ATRQECRSCHYSNP-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- OIJDAJASYWQSPS-UHFFFAOYSA-N 5-nitro-1H-indazol-6-ol Chemical compound Oc1cc2[nH]ncc2cc1[N+]([O-])=O OIJDAJASYWQSPS-UHFFFAOYSA-N 0.000 description 2
- XSMRRJXIDVNINP-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-2-carboxamide Chemical compound NC(=O)C1=CC=CC(C(F)(F)F)=N1 XSMRRJXIDVNINP-UHFFFAOYSA-N 0.000 description 2
- OKBHXGBLXDNJJD-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=N1 OKBHXGBLXDNJJD-UHFFFAOYSA-N 0.000 description 2
- XURXQNUIGWHWHU-UHFFFAOYSA-N 6-bromopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(Br)=N1 XURXQNUIGWHWHU-UHFFFAOYSA-N 0.000 description 2
- QIXSOYWBGCLBKY-UHFFFAOYSA-N 6-ethoxy-5-nitro-1h-indazole Chemical compound C1=C([N+]([O-])=O)C(OCC)=CC2=C1C=NN2 QIXSOYWBGCLBKY-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 208000027496 Behcet disease Diseases 0.000 description 2
- LGDUFOOLXVALPY-UHFFFAOYSA-N C1(=C(C=CC=C1)P(C1=C(C=CC=C1)C)[C-]1C=CC=C1)C.[C-]1(C=CC=C1)P(C1=C(C=CC=C1)C)C1=C(C=CC=C1)C.[Fe+2] Chemical compound C1(=C(C=CC=C1)P(C1=C(C=CC=C1)C)[C-]1C=CC=C1)C.[C-]1(C=CC=C1)P(C1=C(C=CC=C1)C)C1=C(C=CC=C1)C.[Fe+2] LGDUFOOLXVALPY-UHFFFAOYSA-N 0.000 description 2
- 101100063435 Caenorhabditis elegans din-1 gene Proteins 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 101710082751 Carboxypeptidase S1 homolog A Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 238000003747 Grignard reaction Methods 0.000 description 2
- 101710113864 Heat shock protein 90 Proteins 0.000 description 2
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 208000018208 Hyperimmunoglobulinemia D with periodic fever Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 2
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 2
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- HINRMTWTFZZZOO-UHFFFAOYSA-N NCOC1=CC2=CN(CC(OCC3=CC=CC=C3)=O)N=C2C=C1 Chemical compound NCOC1=CC2=CN(CC(OCC3=CC=CC=C3)=O)N=C2C=C1 HINRMTWTFZZZOO-UHFFFAOYSA-N 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 229910003827 NRaRb Inorganic materials 0.000 description 2
- 238000006411 Negishi coupling reaction Methods 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 102000000551 Syk Kinase Human genes 0.000 description 2
- 108010016672 Syk Kinase Proteins 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical compound [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- XQPRBTXUXXVTKB-UHFFFAOYSA-M caesium iodide Chemical compound [I-].[Cs+] XQPRBTXUXXVTKB-UHFFFAOYSA-M 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- HEYJXYIODWNEKL-UHFFFAOYSA-N ethyl 2-(5-amino-6-fluoroindazol-2-yl)acetate Chemical compound NC1=CC2=CN(N=C2C=C1F)CC(=O)OCC HEYJXYIODWNEKL-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229940101532 meted Drugs 0.000 description 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000000802 nitrating effect Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 150000002901 organomagnesium compounds Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 125000005981 pentynyl group Chemical group 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- VUNXBQRNMNVUMV-UHFFFAOYSA-N phenyl(piperazin-1-yl)methanone Chemical compound C=1C=CC=CC=1C(=O)N1CCNCC1 VUNXBQRNMNVUMV-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 229960003946 selegiline Drugs 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 208000023516 stroke disease Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- WPGLRFGDZJSQGI-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(N)C1 WPGLRFGDZJSQGI-UHFFFAOYSA-N 0.000 description 2
- MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- ASUGUQWIHMTFJL-QGZVFWFLSA-N (2r)-2-methyl-2-[[2-(1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-n-(2,2,2-trifluoroethyl)butanamide Chemical compound FC(F)(F)CNC(=O)[C@@](C)(CC)NC1=CC=NC(C=2C3=CC=CN=C3NC=2)=N1 ASUGUQWIHMTFJL-QGZVFWFLSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- HNVIQLPOGUDBSU-OLQVQODUSA-N (2s,6r)-2,6-dimethylmorpholine Chemical compound C[C@H]1CNC[C@@H](C)O1 HNVIQLPOGUDBSU-OLQVQODUSA-N 0.000 description 1
- HZFFUMBZBGETES-UHFFFAOYSA-N (3-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=CC(B(O)O)=C1 HZFFUMBZBGETES-UHFFFAOYSA-N 0.000 description 1
- SWDZPNJZKUGIIH-QQTULTPQSA-N (5z)-n-ethyl-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-[4-(morpholin-4-ylmethyl)phenyl]-2h-1,2-oxazole-3-carboxamide Chemical compound O1NC(C(=O)NCC)=C(C=2C=CC(CN3CCOCC3)=CC=2)\C1=C1/C=C(C(C)C)C(O)=CC1=O SWDZPNJZKUGIIH-QQTULTPQSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- QAVIPYUSPQRVKA-UHFFFAOYSA-N 1,2-diazaspiro[3.3]heptane Chemical compound C1CCC21NNC2 QAVIPYUSPQRVKA-UHFFFAOYSA-N 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical compound C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 1
- FZNSAOHSKTXHEJ-UHFFFAOYSA-N 1-(2,2,2-trifluoroethyl)piperazine;dihydrochloride Chemical compound Cl.Cl.FC(F)(F)CN1CCNCC1 FZNSAOHSKTXHEJ-UHFFFAOYSA-N 0.000 description 1
- SOJJMSYMCLIQCZ-CYBMUJFWSA-N 1-[(2r)-4-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-9-(2,2,2-trifluoroethyl)purin-8-yl]-2-methylpiperazin-1-yl]ethanone Chemical compound C1CN(C(C)=O)[C@H](C)CN1C1=NC2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N1CC(F)(F)F SOJJMSYMCLIQCZ-CYBMUJFWSA-N 0.000 description 1
- IJBXVKITOJFLBF-UHFFFAOYSA-N 1-azaspiro[2.3]hexane Chemical compound C1NC11CCC1 IJBXVKITOJFLBF-UHFFFAOYSA-N 0.000 description 1
- YKNUXXRRPRLOBW-UHFFFAOYSA-N 1-azaspiro[3.3]heptane Chemical compound C1CCC21NCC2 YKNUXXRRPRLOBW-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- BFPMCZWKUSUMKE-UHFFFAOYSA-N 1-cyclopropyl-n-methylmethanamine Chemical compound CNCC1CC1 BFPMCZWKUSUMKE-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- KYWXRBNOYGGPIZ-UHFFFAOYSA-N 1-morpholin-4-ylethanone Chemical compound CC(=O)N1CCOCC1 KYWXRBNOYGGPIZ-UHFFFAOYSA-N 0.000 description 1
- ZDZHCHYQNPQSGG-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalene Chemical group C1=CC=C2C(C=3C4=CC=CC=C4C=CC=3)=CC=CC2=C1 ZDZHCHYQNPQSGG-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- DITBWPUMEUDVLU-UHFFFAOYSA-N 1h-indazole-3-carboxamide Chemical class C1=CC=C2C(C(=O)N)=NNC2=C1 DITBWPUMEUDVLU-UHFFFAOYSA-N 0.000 description 1
- OFJBYLCQNJHFMI-UHFFFAOYSA-N 2,5-dihydro-1,2-oxazole Chemical compound C1ONC=C1 OFJBYLCQNJHFMI-UHFFFAOYSA-N 0.000 description 1
- FEYDZHNIIMENOB-UHFFFAOYSA-N 2,6-dibromopyridine Chemical compound BrC1=CC=CC(Br)=N1 FEYDZHNIIMENOB-UHFFFAOYSA-N 0.000 description 1
- ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 1
- OXSDDDKLMCHNHF-UHFFFAOYSA-N 2-(6-bromopyridin-2-yl)propan-2-ol Chemical compound CC(C)(O)C1=CC=CC(Br)=N1 OXSDDDKLMCHNHF-UHFFFAOYSA-N 0.000 description 1
- JQDNCGRNPYKRAO-UHFFFAOYSA-N 2-(bromomethyl)pyridine;hydron;bromide Chemical compound Br.BrCC1=CC=CC=N1 JQDNCGRNPYKRAO-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- OQQRUDXMNYGNGF-UHFFFAOYSA-N 2-[5-[(2-methylpropan-2-yl)oxycarbonylamino]-6-(trifluoromethoxy)indazol-2-yl]acetic acid Chemical compound C(C)(C)(C)OC(=O)NC1=CC2=CN(N=C2C=C1OC(F)(F)F)CC(=O)O OQQRUDXMNYGNGF-UHFFFAOYSA-N 0.000 description 1
- CSZRKYIFAHUKKH-UHFFFAOYSA-N 2-[5-[(2-methylpropan-2-yl)oxycarbonylamino]indazol-2-yl]acetic acid Chemical compound C(C)(C)(C)OC(=O)NC1=CC2=CN(N=C2C=C1)CC(=O)O CSZRKYIFAHUKKH-UHFFFAOYSA-N 0.000 description 1
- GXVRIOUOLDBWIH-UHFFFAOYSA-N 2-[5-[(6-bromopyridine-2-carbonyl)amino]-6-methoxyindazol-2-yl]acetic acid Chemical compound BrC1=CC=CC(=N1)C(=O)NC1=CC2=CN(N=C2C=C1OC)CC(=O)O GXVRIOUOLDBWIH-UHFFFAOYSA-N 0.000 description 1
- IJZFEADYXGPLEP-UHFFFAOYSA-N 2-[6-bromo-5-[(2-methylpropan-2-yl)oxycarbonylamino]indazol-2-yl]acetic acid Chemical compound BrC=1C(=CC2=CN(N=C2C=1)CC(=O)O)NC(=O)OC(C)(C)C IJZFEADYXGPLEP-UHFFFAOYSA-N 0.000 description 1
- VXDQNUCPFCPEJR-UHFFFAOYSA-N 2-[6-methoxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]indazol-2-yl]acetic acid Chemical compound C(C)(C)(C)OC(=O)NC1=CC2=CN(N=C2C=C1OC)CC(=O)O VXDQNUCPFCPEJR-UHFFFAOYSA-N 0.000 description 1
- GARKCJKUXNZSKU-UHFFFAOYSA-N 2-[6-methyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]indazol-2-yl]acetic acid Chemical compound C(C)(C)(C)OC(=O)NC1=CC2=CN(N=C2C=C1C)CC(=O)O GARKCJKUXNZSKU-UHFFFAOYSA-N 0.000 description 1
- TXGKRVFSSHPBAJ-JKSUJKDBSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=NC=C(C(N)=O)C(NC=2C=C(C=CC=2)N2N=CC=N2)=N1 TXGKRVFSSHPBAJ-JKSUJKDBSA-N 0.000 description 1
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 1
- MWYDSXOGIBMAET-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide Chemical compound NC1=NC=C(C=N1)C(=O)N=C1N=C2C(=C(C=CC2=C2N1CCN2)OCCCN1CCOCC1)OC MWYDSXOGIBMAET-UHFFFAOYSA-N 0.000 description 1
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical class NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- PBIUDEUWYGBHDW-UHFFFAOYSA-N 2-chloro-1-pyridin-3-ylethanone;hydrochloride Chemical compound Cl.ClCC(=O)C1=CC=CN=C1 PBIUDEUWYGBHDW-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- VNLCHZSSJTZGBR-UHFFFAOYSA-N 2-piperidin-1-ylpropan-1-ol Chemical compound OCC(C)N1CCCCC1 VNLCHZSSJTZGBR-UHFFFAOYSA-N 0.000 description 1
- CYHABBRKFCGZLK-UHFFFAOYSA-N 3-(propylamino)pyridine-2-carboxamide Chemical compound CCCNC1=CC=CN=C1C(N)=O CYHABBRKFCGZLK-UHFFFAOYSA-N 0.000 description 1
- PMQZJXOHAAFBOO-UHFFFAOYSA-N 3-[5-[[6-(trifluoromethyl)pyridine-2-carbonyl]amino]indazol-2-yl]propanoic acid Chemical compound FC(C1=CC=CC(=N1)C(=O)NC1=CC2=CN(N=C2C=C1)CCC(=O)O)(F)F PMQZJXOHAAFBOO-UHFFFAOYSA-N 0.000 description 1
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
- AIOUQYUFHADEHR-UHFFFAOYSA-N 3-methylpyridine-2-carboxamide Chemical compound CC1=CC=CN=C1C(N)=O AIOUQYUFHADEHR-UHFFFAOYSA-N 0.000 description 1
- LQLJNIMZZWZZLE-UHFFFAOYSA-N 4-(iminomethylideneamino)-n,n-dimethylpentan-1-amine;hydrochloride Chemical compound Cl.N=C=NC(C)CCCN(C)C LQLJNIMZZWZZLE-UHFFFAOYSA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- XMODBAPEURJFQH-UHFFFAOYSA-N 5-amino-1H-indazol-6-ol Chemical compound NC=1C=C2C=NNC2=CC1O XMODBAPEURJFQH-UHFFFAOYSA-N 0.000 description 1
- XGSFRTHYHRTUCC-UHFFFAOYSA-N 5-nitro-1,2-dihydroindazol-3-one Chemical compound [O-][N+](=O)C1=CC=C2NNC(=O)C2=C1 XGSFRTHYHRTUCC-UHFFFAOYSA-N 0.000 description 1
- WSGURAYTCUVDQL-UHFFFAOYSA-N 5-nitro-1h-indazole Chemical class [O-][N+](=O)C1=CC=C2NN=CC2=C1 WSGURAYTCUVDQL-UHFFFAOYSA-N 0.000 description 1
- MDLTVYZCSSUQJR-UHFFFAOYSA-N 5-nitro-6-propan-2-yloxy-1h-indazole Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC2=C1C=NN2 MDLTVYZCSSUQJR-UHFFFAOYSA-N 0.000 description 1
- ROPSAGXDMZTJNZ-UHFFFAOYSA-N 6-(2-hydroxypropan-2-yl)pyridine-2-carboxylic acid Chemical compound C(C)(C1=CC=CC(C(=O)O)=N1)(O)C ROPSAGXDMZTJNZ-UHFFFAOYSA-N 0.000 description 1
- OCECRWZJPFFSKH-UHFFFAOYSA-N 6-(5-methyl-1H-pyrazol-4-yl)pyridine-2-carboxylic acid Chemical compound CC1=NNC=C1C1=CC=CC(=N1)C(=O)O OCECRWZJPFFSKH-UHFFFAOYSA-N 0.000 description 1
- CQOXJYFTHXMTNS-UHFFFAOYSA-N 6-(difluoromethyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C(F)F)=N1 CQOXJYFTHXMTNS-UHFFFAOYSA-N 0.000 description 1
- DKMFIJAMIVLPHS-UHFFFAOYSA-N 6-bromo-1h-indazol-5-amine Chemical compound C1=C(Br)C(N)=CC2=C1NN=C2 DKMFIJAMIVLPHS-UHFFFAOYSA-N 0.000 description 1
- VAZNJOLLULMJGT-UHFFFAOYSA-N 6-bromopyridine Chemical compound BrC1=C=CC=C[N]1 VAZNJOLLULMJGT-UHFFFAOYSA-N 0.000 description 1
- 150000007578 6-membered cyclic compounds Chemical class 0.000 description 1
- SAZSDHZXRMXESN-UHFFFAOYSA-N 6-morpholin-4-ylpyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(N2CCOCC2)=N1 SAZSDHZXRMXESN-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- MTVNAPYHLASOSX-UHFFFAOYSA-N 9,9-dimethylxanthene Chemical compound C1=CC=C2C(C)(C)C3=CC=CC=C3OC2=C1 MTVNAPYHLASOSX-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000022715 Autoinflammatory syndrome Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- GXYJGDOYIGDJMO-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1=CC2=CN(N=C2C=C1)CC(=O)OC(C)(C)C Chemical compound C(C)(C)(C)OC(=O)NC1=CC2=CN(N=C2C=C1)CC(=O)OC(C)(C)C GXYJGDOYIGDJMO-UHFFFAOYSA-N 0.000 description 1
- QWWGPUPJKKVFFE-UHFFFAOYSA-N CC(C(C1=CC=CC(C(NCOC2=CC3=CN(CC(OCC4=CC=CC=C4)=O)N=C3C=C2)=O)=N1)=O)O Chemical compound CC(C(C1=CC=CC(C(NCOC2=CC3=CN(CC(OCC4=CC=CC=C4)=O)N=C3C=C2)=O)=N1)=O)O QWWGPUPJKKVFFE-UHFFFAOYSA-N 0.000 description 1
- QAQOVNUPYYEGFT-UHFFFAOYSA-N CC(C)(C)OC(NCC1=CC2=CN(CC(O)=O)N=C2C=C1)=O Chemical compound CC(C)(C)OC(NCC1=CC2=CN(CC(O)=O)N=C2C=C1)=O QAQOVNUPYYEGFT-UHFFFAOYSA-N 0.000 description 1
- KIMBMPLUXNWUAP-UHFFFAOYSA-N CC1=CC=CC(C(NC2=C(C=CC(OC)=C3)C3=NN2CC(O)=O)=O)=N1 Chemical compound CC1=CC=CC(C(NC2=C(C=CC(OC)=C3)C3=NN2CC(O)=O)=O)=N1 KIMBMPLUXNWUAP-UHFFFAOYSA-N 0.000 description 1
- UFYZOYGQCPKCDC-UHFFFAOYSA-N CCN(CCN1C(CN2N=C(C=CC(NC(OC(C)(C)C)=O)=C3)C3=C2)=O)CC1=O Chemical compound CCN(CCN1C(CN2N=C(C=CC(NC(OC(C)(C)C)=O)=C3)C3=C2)=O)CC1=O UFYZOYGQCPKCDC-UHFFFAOYSA-N 0.000 description 1
- LHJRXRMYMBNKHG-UHFFFAOYSA-N CCOC(CN1N=C(C=CC(N)=C2)C2=C1F)=O Chemical compound CCOC(CN1N=C(C=CC(N)=C2)C2=C1F)=O LHJRXRMYMBNKHG-UHFFFAOYSA-N 0.000 description 1
- HSXUZHXKKWVSDJ-UHFFFAOYSA-N CCOC(CN1N=C(C=CC(N)=C2)C2=C1OC(C)C)=O Chemical compound CCOC(CN1N=C(C=CC(N)=C2)C2=C1OC(C)C)=O HSXUZHXKKWVSDJ-UHFFFAOYSA-N 0.000 description 1
- OTBAVXWMAKOEDM-UHFFFAOYSA-N CCOC(CN1N=C(C=CC(N)=C2)C2=C1OCC1=CC=CC=C1)=O Chemical compound CCOC(CN1N=C(C=CC(N)=C2)C2=C1OCC1=CC=CC=C1)=O OTBAVXWMAKOEDM-UHFFFAOYSA-N 0.000 description 1
- JPJTXLGKYHOFLQ-UHFFFAOYSA-N CN(CC1)CCN1C(CN1N=C(C=CC(OCN)=C2)C2=C1)=O Chemical compound CN(CC1)CCN1C(CN1N=C(C=CC(OCN)=C2)C2=C1)=O JPJTXLGKYHOFLQ-UHFFFAOYSA-N 0.000 description 1
- ONFMFASIHUDFLA-UHFFFAOYSA-N COC(C(C1=C2)=NNC1=CC=C2NC(C1=NC(C(F)(F)F)=CC=C1)=O)=O Chemical compound COC(C(C1=C2)=NNC1=CC=C2NC(C1=NC(C(F)(F)F)=CC=C1)=O)=O ONFMFASIHUDFLA-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 101100516572 Caenorhabditis elegans nhr-8 gene Proteins 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 102100040999 Catechol O-methyltransferase Human genes 0.000 description 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 1
- 241000255580 Ceratitis <genus> Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 241000505721 Christia Species 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 238000005361 D2 NMR spectroscopy Methods 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 101100130497 Drosophila melanogaster Mical gene Proteins 0.000 description 1
- 241000876833 Emberizinae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241001302654 Escherichia coli Nissle 1917 Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000537377 Fraxinus berlandieriana Species 0.000 description 1
- RVAQIUULWULRNW-UHFFFAOYSA-N Ganetespib Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O RVAQIUULWULRNW-UHFFFAOYSA-N 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 102000009165 Gonadoliberin Human genes 0.000 description 1
- 108050000048 Gonadoliberin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000981728 Homo sapiens Myeloid differentiation primary response protein MyD88 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 206010072010 Hyper IgD syndrome Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000039996 IL-1 family Human genes 0.000 description 1
- 108091069196 IL-1 family Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 102100023530 Interleukin-1 receptor-associated kinase 3 Human genes 0.000 description 1
- 101710199012 Interleukin-1 receptor-associated kinase 3 Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- 238000005577 Kumada cross-coupling reaction Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 206010072219 Mevalonic aciduria Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101150101095 Mmp12 gene Proteins 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 1
- QJZRFPJCWMNVAV-HHHXNRCGSA-N N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methylbenzamide Chemical compound NCCCN([C@H](C(C)C)C=1N(C(=O)C2=CC=C(Cl)C=C2N=1)CC=1C=CC=CC=1)C(=O)C1=CC=C(C)C=C1 QJZRFPJCWMNVAV-HHHXNRCGSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- QJTLLKKDFGPDPF-QGZVFWFLSA-N N-[8-[(2R)-2-hydroxy-3-morpholin-4-ylpropoxy]-7-methoxy-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]-2-methylpyridine-3-carboxamide Chemical compound CC1=C(C=CC=N1)C(=O)N=C2N=C3C(=C4N2CCN4)C=CC(=C3OC)OC[C@@H](CN5CCOCC5)O QJTLLKKDFGPDPF-QGZVFWFLSA-N 0.000 description 1
- GPVKLYONJSSZFL-UHFFFAOYSA-N NSC 750259 Natural products CCC(C)C=CC(O)C(O)C(O)C(OC)C(=O)NC1CCCCNC1=O GPVKLYONJSSZFL-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- 108010064641 ONX 0912 Proteins 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150023830 PYR1 gene Proteins 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- JXAGDPXECXQWBC-LJQANCHMSA-N Tanomastat Chemical compound C([C@H](C(=O)O)CC(=O)C=1C=CC(=CC=1)C=1C=CC(Cl)=CC=1)SC1=CC=CC=C1 JXAGDPXECXQWBC-LJQANCHMSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102220466167 U1 small nuclear ribonucleoprotein C_H30Q_mutation Human genes 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- LZRSYAVAKOPMAA-UHFFFAOYSA-N [O-][N+](C(C=C1OC(F)(F)F)=CC(C=O)=C1F)=O Chemical compound [O-][N+](C(C=C1OC(F)(F)F)=CC(C=O)=C1F)=O LZRSYAVAKOPMAA-UHFFFAOYSA-N 0.000 description 1
- KUFHPOACIXCOQX-UHFFFAOYSA-N [O-][N+](N(C1=C2)N=CC1=CC=C2OCC1=CC=CC=C1)=O Chemical compound [O-][N+](N(C1=C2)N=CC1=CC=C2OCC1=CC=CC=C1)=O KUFHPOACIXCOQX-UHFFFAOYSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- ZVDDJPSHRNMSKV-UHFFFAOYSA-N acetaldehyde;hydrochloride Chemical compound Cl.CC=O ZVDDJPSHRNMSKV-UHFFFAOYSA-N 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000012082 adaptor molecule Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229940060532 allent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940124626 anti-diarrhoeal drug Drugs 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229930195545 bengamide Natural products 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- OCOMTTHSJBIAMZ-UHFFFAOYSA-N benzyl hypobromite Chemical compound BrOCC1=CC=CC=C1 OCOMTTHSJBIAMZ-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 description 1
- 229950003628 buparlisib Drugs 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical class NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229940087211 ciprofloxacin and metronidazole Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000003113 cycloheptyloxy group Chemical group C1(CCCCCC1)O* 0.000 description 1
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- MPMQSJUYIXMLNP-UHFFFAOYSA-N cyclopropylmethoxy-(2,2,2-trifluoroethoxy)-(trifluoromethoxy)-lambda3-chlorane Chemical compound C1(CC1)COCl(OCC(F)(F)F)OC(F)(F)F MPMQSJUYIXMLNP-UHFFFAOYSA-N 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- OAWZMITZYWYREI-UHFFFAOYSA-N ethyl 2-[5-[(2-methylpropan-2-yl)oxycarbonylamino]-6-phenylmethoxyindazol-2-yl]acetate Chemical compound C(C1=CC=CC=C1)OC=1C(=CC2=CN(N=C2C=1)CC(=O)OCC)NC(=O)OC(C)(C)C OAWZMITZYWYREI-UHFFFAOYSA-N 0.000 description 1
- IYXUAPXCZOLMNL-UHFFFAOYSA-N ethyl 2-[6-fluoro-5-[(2-methylpropan-2-yl)oxycarbonylamino]indazol-2-yl]acetate Chemical compound C(C)(C)(C)OC(=O)NC1=CC2=CN(N=C2C=C1F)CC(=O)OCC IYXUAPXCZOLMNL-UHFFFAOYSA-N 0.000 description 1
- QFLQMMCTNAUTHY-UHFFFAOYSA-N ethyl 2-[6-phenylmethoxy-5-[[6-(trifluoromethyl)pyridine-2-carbonyl]amino]indazol-2-yl]acetate Chemical compound C(C1=CC=CC=C1)OC=1C(=CC2=CN(N=C2C=1)CC(=O)OCC)NC(=O)C1=NC(=CC=C1)C(F)(F)F QFLQMMCTNAUTHY-UHFFFAOYSA-N 0.000 description 1
- BJCUHHMMYBBXCR-UHFFFAOYSA-N ethyl 3-(5-aminoindazol-2-yl)propanoate Chemical compound C1=C(N)C=CC2=NN(CCC(=O)OCC)C=C21 BJCUHHMMYBBXCR-UHFFFAOYSA-N 0.000 description 1
- HQDAEYUHPTZIGU-UHFFFAOYSA-N ethyl 3-[5-[(2-methylpropan-2-yl)oxycarbonylamino]indazol-2-yl]propanoate Chemical compound C(C)(C)(C)OC(=O)NC1=CC2=CN(N=C2C=C1)CCC(=O)OCC HQDAEYUHPTZIGU-UHFFFAOYSA-N 0.000 description 1
- SHTHWCQBJTUESB-UHFFFAOYSA-N ethyl hypofluorite Chemical compound CCOF SHTHWCQBJTUESB-UHFFFAOYSA-N 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- LVZYXEALRXBLJZ-ISQYCPACSA-N f60ne4xb53 Chemical compound N1([C@@H]2O[C@@H]([C@H](C2)NP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)NP(S)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)N)COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)OCC(O)CNC(=O)CCCCCCCCCCCCCCC)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=NC=NC(N)=C3N=C2)C=CC(N)=NC1=O LVZYXEALRXBLJZ-ISQYCPACSA-N 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- WTDFFADXONGQOM-UHFFFAOYSA-N formaldehyde;hydrochloride Chemical compound Cl.O=C WTDFFADXONGQOM-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
- 229950005309 fostamatinib Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- 229950004291 imetelstat Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 description 1
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 description 1
- 108040007659 interleukin-33 receptor activity proteins Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000006316 iso-butyl amino group Chemical group [H]N(*)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 150000002642 lithium compounds Chemical class 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229950005069 luminespib Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- KROUFMZSRRVGQZ-UHFFFAOYSA-N methyl 3-[6-methoxy-5-[[6-(trifluoromethyl)pyridine-2-carbonyl]amino]indazol-2-yl]-2-methylpropanoate Chemical compound COC=1C(=CC2=CN(N=C2C=1)CC(C(=O)OC)C)NC(=O)C1=NC(=CC=C1)C(F)(F)F KROUFMZSRRVGQZ-UHFFFAOYSA-N 0.000 description 1
- JDOUJJWUHGQWRM-UHFFFAOYSA-N methyl 5-amino-1h-indazole-3-carboxylate Chemical compound C1=C(N)C=C2C(C(=O)OC)=NNC2=C1 JDOUJJWUHGQWRM-UHFFFAOYSA-N 0.000 description 1
- TUUGVBZYZYAHPC-UHFFFAOYSA-N methyl 5-nitro-1h-indazole-3-carboxylate Chemical compound C1=C([N+]([O-])=O)C=C2C(C(=O)OC)=NNC2=C1 TUUGVBZYZYAHPC-UHFFFAOYSA-N 0.000 description 1
- PVGPVOJLJIUFBR-UHFFFAOYSA-N methyl 6-(2,2,2-trifluoro-1-hydroxyethyl)pyridine-2-carboxylate Chemical compound FC(C(O)C1=CC=CC(=N1)C(=O)OC)(F)F PVGPVOJLJIUFBR-UHFFFAOYSA-N 0.000 description 1
- PHGKRCGPRHVMDR-AOOOYVTPSA-N methyl 6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridine-2-carboxylate Chemical compound C[C@@H]1CN(C[C@@H](O1)C)C1=CC=CC(=N1)C(=O)OC PHGKRCGPRHVMDR-AOOOYVTPSA-N 0.000 description 1
- DFERTYLJNAEEPK-UHFFFAOYSA-N methyl 6-bromo-3-fluoropyridine-2-carboxylate Chemical compound COC(=O)C1=NC(Br)=CC=C1F DFERTYLJNAEEPK-UHFFFAOYSA-N 0.000 description 1
- SGNCOKUHMXLGAH-UHFFFAOYSA-N methyl 6-bromopyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(Br)=N1 SGNCOKUHMXLGAH-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 206010072221 mevalonate kinase deficiency Diseases 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950007856 mofetil Drugs 0.000 description 1
- 229950008814 momelotinib Drugs 0.000 description 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- ONDPWWDPQDCQNJ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 ONDPWWDPQDCQNJ-UHFFFAOYSA-N 0.000 description 1
- MLMZVWABFOLFGV-LNLSOMNWSA-N n-(3-aminopropyl)-n-[(1r)-1-(3-benzyl-7-chloro-4-oxochromen-2-yl)-2-methylpropyl]-4-methylbenzamide;hydrochloride Chemical compound Cl.NCCCN([C@H](C(C)C)C1=C(C(=O)C2=CC=C(Cl)C=C2O1)CC=1C=CC=CC=1)C(=O)C1=CC=C(C)C=C1 MLMZVWABFOLFGV-LNLSOMNWSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- YYDHPKGSIYLSSC-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-1-amine Chemical compound CCCN(CC)C(C)C YYDHPKGSIYLSSC-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 1
- 229950005750 oprozomib Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 229950011410 pacritinib Drugs 0.000 description 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 description 1
- 229950003608 prinomastat Drugs 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- BPGBAEXPBQHBSV-UHFFFAOYSA-N pyr1 Chemical compound C1=C2C3=C(C)C(C(NC=C4)=O)=C4C(C)=C3NC2=CC=C1OC(=O)C1=CC=CC=C1 BPGBAEXPBQHBSV-UHFFFAOYSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- OIRUWDYJGMHDHJ-AFXVCOSJSA-N retaspimycin hydrochloride Chemical compound Cl.N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OIRUWDYJGMHDHJ-AFXVCOSJSA-N 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- FYGUBWKMMCWIKB-UHFFFAOYSA-N spiro[2.3]hexane Chemical compound C1CC11CCC1 FYGUBWKMMCWIKB-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960004907 tacalcitol Drugs 0.000 description 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- XTIGSUFOTRCYOO-UHFFFAOYSA-N tert-butyl 2-(aminomethyl)azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC1CN XTIGSUFOTRCYOO-UHFFFAOYSA-N 0.000 description 1
- YEJWFRQWLMTMOA-UHFFFAOYSA-N tert-butyl 4-[2-[5-[[6-(trifluoromethyl)pyridine-2-carbonyl]amino]indazol-2-yl]acetyl]piperazine-1-carboxylate Chemical compound FC(C1=CC=CC(=N1)C(=O)NC1=CC2=CN(N=C2C=C1)CC(=O)N1CCN(CC1)C(=O)OC(C)(C)C)(F)F YEJWFRQWLMTMOA-UHFFFAOYSA-N 0.000 description 1
- LAOLPGMYYQEOQV-UHFFFAOYSA-N tert-butyl N-[2-[2-[4-(3-hydroxy-2,2-dimethylpropanoyl)piperazin-1-yl]-2-oxoethyl]-6-methylindazol-5-yl]carbamate Chemical compound OCC(C(=O)N1CCN(CC1)C(CN1N=C2C=C(C(=CC2=C1)NC(OC(C)(C)C)=O)C)=O)(C)C LAOLPGMYYQEOQV-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DTXLBRAVKYTGFE-UHFFFAOYSA-J tetrasodium;2-(1,2-dicarboxylatoethylamino)-3-hydroxybutanedioate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)C(O)C(C([O-])=O)NC(C([O-])=O)CC([O-])=O DTXLBRAVKYTGFE-UHFFFAOYSA-J 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 150000003606 tin compounds Chemical class 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- DSDCDMKASWVZHI-UHFFFAOYSA-M zinc;2-methanidylpropane;bromide Chemical compound Br[Zn+].CC(C)[CH2-] DSDCDMKASWVZHI-UHFFFAOYSA-M 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Abstract
The invention relates to a 6-substituted indazoles of formula (I) with carboxamide side chains, method for the production thereof, to the use thereof alone or in combinations for treating and/or the prophylaxis of diseases and to the use thereof for producing medicaments for treating and/or the prophylaxis of diseases, in particular for treating and/or the prophylaxis of endometriosis, preventing lymphomas, macular degeneration, COPD and psoriasis. hylaxis of diseases, in particular for treating and/or the prophylaxis of endometriosis, preventing lymphomas, macular degeneration, COPD and psoriasis.
Description
Novel carboxamides, processes for their preparation, pharmaceutical preparations
sing them and their use for producing medicaments
The t application s to novel indazolecarboxamides, to processes for their preparation, to
their use for the treatment and/or prophylaxis of diseases and to their use for producing
medicaments for the treatment and/or prophylaxis of es, in particular proliferative disorders,
autoimmune and inflammatory disorders such as, for example, rheumatoid arthritis, chronic
obstructive pulmonary disease viation: COPD), multiple sclerosis, endometriosis and
mation-induced or chronic pain and lymphomas.
IRAK4 plays a key role in the activation of the immune system, in particular in innate immunity.
Innate immunity is based on the fact that microorganisms such as bacteria and viruses have certain
inherent features which are recognized by the immune system, resulting in its activation. What is
recognized are certain pathogen-associated molecular patterns (PAMPs). PAMPs are recognized by
the pattern recognition receptors (PRR) which include toll-like receptors (TLR) (Janeway and
Medzhitov, Annu. Rev. Immunol., 2002). In humans, ten different TLRs have been described.
TLR1 and TLR6 are coreceptors for TLR2. TLR2 recognize inter alia lipoproteins and
lipopeptides. TLR3 recognizes double-stranded RNA. TLR4 recognizes inter alia LPS
(lipopolysaccharides) of gram-negative bacteria and lipoteichoic acid of gram-positive bacteria.
TLR5 recognizes flagellin. CpG motives in bacterial DNA are recognized by TLR9 (Miggin,
O'Neill, J. Leukoc. Biol., 2006). Additional molecules may further modify the recognition ies
of TLRs (Akashi-Takamura and Miyake, Current n in Immunology, 2008). In addition to the
recognition of PAMPs, TLRs are also able to ize DAMPs (damage-associated molecular
n). These are nous cell-derived molecules formed as the result of a trauma, an
ischaemia or other tissue-destroying processes in the absence of any obvious infection. DAMPs can
be constituents both of the cytoplasm and the s. They are secreted, for example HMGB1
(high-mobility group box 1 n), which is ized by TLR2 and TLR4. Other DAMPs are
released de novo or accumulate, for example, in the outer plasma membrane, e.g. HSP90 (heat
shock protein 90), where they are recognized by TLR2 and TLR4. Others for their part are
produced as final degradation products during cell death (Krysko, Garg, et al., Nat Rev Cancer,
2012).
In addition to TLRs, other components such as cytokines also play an important role in innate
immunity. Here, mention may be made in particular of the interleukin (IL)-1 family including
interleukins IL-1, IL-18 and IL-33. They are produced and released by various immune cells in the
presence of infections or cell or tissue stress. The immune response is then triggered by binding to
the respective receptor (Dinarello, Annu. Rev. Immunol., 2009).
TLRs t for TLR3) as well as the receptors of the IL-1 family (IL-1R (receptor), IL-18R and
IL-33R) have the same signal e which is activated by binding of the respective ligand to its
or. The ligand receptor binding leads to the recruitment of the adaptor molecule MyD88
[myeloid differentiation primary response gene (88)] to the receptor Via TIR/TIR demain
interaction which is a constituent both of the receptors and of MyD88. In addition to the TIR
domain, MyD88 has an N-terminal "death domain" (DD) which interacts with the DD domain of
the interleukin—1 or associated kinase-4 (IRAK4). IRAK4 belongs to a serine/threonine
kinase family which also includes the structurally similar kinases IRAKl, [RAKZ and IRAK-M
(Cao et al., e, 1996; Muzio et al., Science, 1997; Wesehe, Gao, et al., Journal of Biological
Chemistry, 1999; Li, Strelow, et al., PNAS, 2002). Except for IRAK«M, which is only expressed in
monocytes and macrophages, the expression of IRAK4, IRAKl and IRAKZ is ubiquitous (Flannery
and Bowie, Biochemical Pharmacology, 2010). As a result of the activation process, several
MyD88 and IRAK4 molecules form a multicomplex which is referred to as “myddosome”
(Precious et al., J. Biol. Chem.. 2009). This myddosome now interacts with IRAKI or IRAK2 via
DD-DD interactions. forming a larger complex in the process (Lin, Lo, et al., Nature. 2010). The
formation of this complex then triggers autophosphorylation of IRAK4, which subsequently results
in the phosphorylation of IRAKI or [RAKl As a consequence of the activation of IRAKI or
IRAKZ, these kinases are autophosphorylated (Kollewe, Mackensen, et al., l of Biological
Chemistry, 2004). The activated lRAKl or IRAK2 interacts with TRAF6 (tumor—necrosis factor—
receptor-associated factor 6) which, with the uhiquitin enzyme complex (E2), acts as ubiquitin
protein ligase, which leads to K62-associated ubiquitination of TRAF6. In turn, this process leads
to fiirther complex formation with other proteins. This complex induces the activation of TAKl
(Xia, Sun, et al., , 2009). ted TAKl mediates the activation of the NF (nuclear factor)-
kB signal pathway and the MAPK (mitogen-activated protein kinase) signal pathway (Wang, Deng,
et al., Nature, 2001). In the first signal pathway, TAKl leads to the activation of the [KK complex
whereby the inhibiting IkB protein is phosphorylated and ed by the proteasome. NF-kB,
which had been blocked by IkB beforehand, now migrates from the cytoplasm into the nucleus
Where it binds to a specific DNA motive, the kB motive, leading to the transcription of various
genes (Gasparini and Feldmann, Curr Pharm Des, 2012).
In the MAPK signal pathway, TAKl phosphorylates various members of the MAPK family such as
MK3, -4, -6 and -7 (Wang, Deng, et al., Nature, 2001). The activation of these kinases results in
the activation of p38 and JNK (c-Jun inal kinase) (Ono and Han, Cellular Signalling, 2000;
Davis, Cell, 2000), The activation both of the NF-kB signal pathway and of the MAPK signal
y leads to various processes associated with different immune processes. Thus, this is an
increased expression of various inflammatory signal molecules and enzymes such as, for e,
cytokines, chemokines and COX-2, and an increased mRNA stability of certain genes (Holtmann,
Enninga, et al., Journal of ical Chemistry, 2001; Datta, Novotny, et al., The Journal of
Immunology, 2004). Furthermore, these processes may be ated with the proliferation and
differentiation of certain cell types (Wan, Chi, et al., Nat Immunol, 2006; McGettrick and J.
l, h Journal of Haematology, 2007).
The central importance of IRAK4 in immunological processes mediated by the TLR (except for
TLR3) and IL—1 receptor family is shown by the deletion of IRAK4. Cells isolated from patients
where absence of 1RAK4 had been trated show no activity after stimulation of various
TLRs (except for TLR3) and the IL-ll3 family (Davidson, Currie, et al., The Journal of
Immunology, 2006; Ku, von Bemuth, ct a1., IBM, 2007). Furthermore, mice with IRAK4 deletion
p no response to IL—IB stimulation and s TLR stimulations except for TLR3 i,
Suzuki, et al., Nature, 2002). Here, in particular the kinase activity of [RAK4 plays a crucial role
(Kim, Staschke, et a1., IBM, 2007). In contrast, deletion of IRAKI or IRAK2 only results in a
signal pathway activity loss after ation (Thomas, Allen, et al., The Journal of Immunology,
1999; Swantek, Tsen, et al., The Journal of Immunology, 2000; Kawagoe, Sato, et al., Nat
Immunol. 2008). For their part, mice having deletion of IRAK2 and IRAKl show a phenotype
comparable to that of animlas with IRAK4 deletion (Kawagoe. Sato. et al.. Nat l. 2003).
The l role of [RAH-1 in the pathology of various inflammatory ers associated with the
p... {1! signal pathway described had already been shown by direct ison of ype (WT) mice
with genetically modified animals having a kinase-inactivated form of M4 (IRAK4 KDKJ).
IRAK4 KDKI animals have an improved clinical picture in the animal model of multiple sclerosis,
atherosclerosis, myocardial infarction and Alzheimer‘s disease (Rekhter, Staschke, et a1.,
mical and BiOphysical Research Communication, 2008; a, Mizue, et a1.,
Circulation, 2009; Staschke, Dong, et al., The Journal of Immunology, 2009; Kim, Febbraio, et al.,
The Journal of Immunology, 2011; Cameron, Tse, et al., The Journal of Neuroscience, 2012).
Furthermore, it was found that deletion of IRAK4 in the animal model protects against virus—
induced myocarditis by virtue of an improved anti—viral reaction with simultaneously reduced
systemic inflammation (Valaperti, Nishii, et a1., Circulation, 2013).
Owing to the central role of IRAK4 in the MyD88—mediated signal cascade of TLRs (except for
TLR3) and the IL-1 receptor family, the inhibition of IRAK4 can be ed for the prophylaxis
and/or treatment of ers mediated by the receptors mentioned. TLR-dependent processes are
ated with a large number of different disorders. Thus, it has been found that TLRs are
involved in the pathogenesis of multiple sclerosis, rheumatoid arthritis, metabolic syndrome,
diabetes, osteoarthritis, Sjogren syndrome and sepsis (Scanzello, Plaas, et a1. Curr Opin Rheumatol,
2008; Roger, vaux, et al, PNAS, 2009; Gambuzza, Licata, et al., Journal of
Neuroimmunology, 2011; Fresno, Archives Of Physiology And Biochemistry, 2011; Goh and
Midwood, Rheumatology, 2012; Dasu, Ramirez, et a1., Clinical Science, 2012; Ramirez and Dasu,
Curr Diabetes Rev, 2012; Li, Wang, et a1., Pharmacology & Therapeutics, 2013). Skin disorders
such as psoriasis, at0pic dermatitis, acne inversa and acne vulgaris are associated with the IRAK4-
mediated TLR signal pathway.
The disorders mentioned are characterized by an increased expression of certain TLR3, and their
pathological immune reactions are ed by certain TLR-associated ation processes
(Gilliet, Conrad, et a1., Archives of Dermatology, 2004; r, Langnickel, et a1., Allergy, 2008;
Miller, Adv Dermatol, 2008; Terhorst, Kalali, et a1., Am J Clin Dermatol, 2010; za,
Wolpert, et al., J Invest Dermatol, 2012; Selway, Kurczab, et a1., BMC Dermatology, 2013;
a, Koch, et a1. Indian Dermatol Online, 2013).
Pulmonary disorders such as pulmonary fibrosis, obstructive pulmonary disease (COPD), acute
respiratory distress syndrome (ARDS), acute lung injury (ALI), interstitial lung disease (ILD),
sarcoidosis and pulmonary hypertension show an ation with various TLR-mediated signal
ys. The pathogenesis of the pulmonary disorders may be either infectiously mediated or
non-infectiously mediated processes (Ramirez Cruz, Maldonado Bernal, et a1., Rev Alerg Mex,
2004; Jeyaseelan. Chu. et al., Infection and Immunity, 2005: Seki, Tasaka. et a1., Inflammation
Research. 2010: Xiang. Fan. et a1., Mediators of Inflammation, 2010: Margaritopoulos. Antonjou,
ct a1., Fibrogencsis 8.: Tissue Repair, 2010: Hilberath, Carlo, et al., The FASEB Journal, 2011;
Nadigel. tainc. et 31.. Respiratory Research. 2011; Kovach and ford. International
Immunophannacology. 2011; Bauer, Shapiro, et a1., Mol Med, 2012; Deng, Yang, et al., PLOS
One, 2013; Freeman, Martinez, et a1., Respiratory Research, 2013; Dubaniewicz, A., Human
Immunology, 2013). For instance, HMGBI (high-mobility group box 1 protein) - an endogenous
ligand of TLR2 and TLR4 - is elevated in patients with pulmonary fibrosis, Blocking of these TLR
signal pathways leads to reduced inflammation in the animal model (Yang, Cui, et al, The Journal
of Immunology, 2009; Entezari, Weiss, at 211., Mol Med, 2012). The involvement of TLR2—
mediated processes in the pathogenesis of sarcoidosis has recently been demonstated in in vitro and
in vivo s (Chen, Song, et a1., American l of Respiratory and Critical Care Medicine,
2010; Gabrilovich, h, et al., Clinical & Experimental Immunology, 2013).
TLRS are also involved in the pathogenesis of other inflammatory ers such as Behcet's
disease, gout and graft rejection, ore, here the inhibition of IRAK4 is a suitable therapeutic
ch (Iriu-Bryan, Scott, et a1., Arthritis & Rheumatism, 2005; Shi, Mucsi, et a1.,
Immunological Reviews, 2010; Leventhal and Schroppel, Kidney Int, 2012; Kreisel and Goldstein,
Transplant ational, 2013; Li, Wang, et a1., Pharmacology & Therapeutics, 2013). Lesions and
peritoneal macrophages of endometriosis ts also have, compared to healthy volunteers, an
enhanced immune response ing LPS (lipopolysaccharide) stimulation (Allhorn, Boing, et a1.,
Reproductive Biology and Endocrinology, 2008; Khan, Kitajima, et a1., Journal of Obstetrics and
Gynaecology Research, 2013).
Patients having lupus erythematosus and adult onset Still disease have an elevated expression of
TLR7, MyD88 and 1RAK4 (Chen, Lin, et a1., Arthritis Res Ther, 2013). In the disease model of
lupus, inhibition of TLR7, 8 and 9 and the use of animals having a deletion of TLR7 and/or TLR9
result in an improved pathogenesis (Christensen, Shupe, et a1., Immunity, 2006; Nickerson,
Christensen, et al., The Journal of Immunology, 2010; Zhu, Jiang, et a1., Autoimmunity, 2013).
Patients suffering from chronic inflammatory bowel diseases such as ulcerative colitis or Crohn's
disease do not only have polymorphisms in various TLR genes. In various s models, it was
shown that certain TLRs are also involved in the pathogenesis of these bowel disorders (Rakoff-
Nahoum, Hao, et al., Immunity, 2006; Heimesaat, Fischer, et al., PLoS ONE, 2007; Cairo,
Inflammatory Bowel Diseases, 2010; Walsh, Carthy, et al., Cytokine & Growth Factor Reviews,
2013).
In addition to the disorders already mentioned, IRAK4—mediated TLR processes have been
bed in the pathogenesis of eye disorders such as keratitis, allergic conjunctivitis,
conjunctivitis sicca, macular degeneration and uveitis (Kaamiranta and Salminen, J Mol
Med (Berl), 2009; Sun and Pearlman, Investigative Ophthalmology & Visual Science, 2009;
Redfern and McDermott, Experimental Eye Research, 2010; Kezic, Taylor, et al., J Leukoc Biol,
2011: Chang, McCluskey. et al., Clinical & Experimental Ophthalmology, 2012; Guo. Gao, et al.,
lmmunol Cell Biol. 2012: Lee. Hattori. et al., igative Ophthalmology & Visual Science.
2012).
The role of TLRs in aneriosclerosis has been supported not only by the is of human samples
but also with the aid of various animal models (Seneviratne, Sivagurunathan, et al., Clinica
Chimica Aeta, 2012; Falck-Hansen, eridi, et al., International Journal of Molecular Sciences,
2013).
By virtue of the central role of IRAK4 in TLR-mediated processes, the inhibition of IRAK4 allows
the treatment and/or prevention of vascular and neurological disorders such as, for example,
myocardial reperfusion , myocardial infarction, hypertension (Oyarna, Blais, et al.,
Circulation, 2004; Timmers, Sluijter, et al., Circulation Research, 2008, Fang and Hu, Med Sci
Monit, 2011; Bijani, International Reviews of Immunology, 2012; Bomfim, Dos Santos, et al., Clin
Sci (Lond), 2012; Christia and Frangogiannis, European Journal of Clinical Investigation, 2013;
Thompson and Webb, Clin Sci (Lond), 2013) and also Alzheimer‘s disease, stroke and Parkinson's
disease (Carty and Bowie, Biochemical Pharmacology, 2011; Lim, Kou, et al., The American
Journal of Pathology, 201 1; Béraud and Maguire—Zeiss, Parkinsonism & Related Disorders, 2012;
Noelker, More], et al., Sci. Rep, 2013; Wang, Wang, eta1., Stroke, 2013).
es as well as lia and astrocytes express a large part of the known TLRs.
In the animal model, on ofTLR? protects against various triggers of pruritus (Nicotra, Loram,
et al., Experimental Neurology, 2012; Liu and Ji, Pflugers Arch, 2013). In addition to the role of
TLRs in pruritus, it was possible to demonstrate involvement in pain processes using various
animal models (Kim, Lee, et al., Toll-like ors: Roles in Infection and thology, 2009;
Guerrero, Cunha, et al., European Journal of Pharmacology, 2012; Nicotra, Loram, et al.,
Experimental Neurology, 2012; David, Ratnayake, et al., Neurobiology of Disease, 2013). s
with pain patients support these findings (Kwok, nson, et al., PLoS ONE, 2012; Chopra and
Cooper, J Neuroimmune Pharmacol, 2013).
Since the TLR signals are mediated via IRAK4, it has to be assumed that there is a therapeutic
effect by inhibition of IRAK4 in the indications mentioned.
This also applies to some oncological disorders. Certain lymphomas have an activating MyD88
mutation which can be treated using an IRAK4 inhibitor (Ngo, Young, et al., Nature, 2011; Treon,
Xu, et al., New England Journal of Medicine, 2012; Choi, Kim, et al., Human ogy, 2013).
Chronic lymphatic leukaemia, melanomas and liver cell carcinomas are likewise associated with
mutations in MyD88 or changes in MyDSS activity (Puente, Pinyol, et al., , 2011;
Srivastava, Geng, et al., Cancer Research, 2012; Liang, Chen, et al., Clinical Cancer Research,
2013). Furthermore, MyD88 plays an important role in pendent tumours, so TRAK4
inhibitors are also suitable for treating these (Kfoury. A.. K. L. Corf. et al.. Journal of the National
Cancer Institute. 2013).
In addition to the mediation of MyDSS- and TLR- (except for TLR3)-associated ses. [RAK4
also mediates the signals of the lL-l receptor family. Inflammatory disorders such as CAPS
(cryopyrin-associated periodic syndromes) ing FCAS (familial cold autoinflammatory
syndrome), MWS (Muckle-Wells syndrome), NOMID (neonatal-onset multisystem inflammatory
disease) and CONCA ic infantile, neurological, ous, and articular) syndrome; FMF
(familial mediterranean fever), HIDS (hyper-lgD syndrome), TRAPS (tumour necrosis factor
receptor l-associated periodic syndrom), juvenile idiopathic arthritis, adult-onset Still’s disease,
Adamantiades-Behcet's disease, rheumatoid arthritis, osteoarthritis, keratoconjunctivitis sicca and
n syndrome are treated by blocking the IL—1 signal pathway; therefore here, too, an IRAK4
inhibitor is suitable for treatment of the diseases mentioned (Narayanan, es, et al., Cornea,
2008; Henderson and Goldbach—Mansky, Clinical Immunology, 2010; Dinarello, European Journal
of Immunology, 2011; Gul, Tugal—Tutkun, et al., Ann Rheum Dis, 2012; Pettersson, Annals of
MedicinePetterson, 2012; Ruperto, Brunner, et al., New England Journal of Medicine, 2012;
Nordstrom, Knight, et al., The Journal of Rheumatology, 2012; Vijmasi, Chen, et al., M01 Vis,
2013; Yamada, Arakaki, et al., Opinion on eutic Targets, 2013). IL—18 in particular is
associated with the pathogenesis of rheumatoid arthritis, adult-onset Still's disease, type-1 diabetes,
multiple sclerosis and lupus erythematosus, thus, by virtue of the mechanism of action, IRAK4
inhibitors can be ed for the treatment and/or prevention of the disorders mentioned (Volin
and Koch, J eron Cytokine Res, 201 l; i, Hagglof, et al., Cell M01 Life Sci, 2013; Yap
and Lai, Nephrology, 2013). rmore, IRAK4 inhibitors are suitable for the ent of type-2
diabetes and the sequelae of a myocardial infarction as there are indications that the inhibition of
the IL-1 signal pathway is a promising therapeutic approach (Abbate, Kontos, et al., The American
Journal of Cardiology, 2010; Akash, Shen, et al., Journal of ceutical Sciences, 2012;
Abbate, Van Tassell, ct al., The American Journal of logy, 2013). Several components of the
IL-1 receptor family are associated with various pulmonary disorders such as asthma, COPD,
idiopathic interstitial pneumonia and acute respiratory distress syndrome (ARDS) and the role in its
pathogenesis was supported in various animal models (Kang, Homer, et al., The Journal of
Immunology, 2007; Imaoka, Hoshino, et al., European Respiratory Journal, 2008; Couillin,
Vasseur, et al., The Journal of Immunology, 2009; Lloyd, Current Opinion in Immunology, 2010;
Pauwels, Bracke, et al., European Respiratory Journal, 2011; Yin, Li, et al., Clinical &
mental Immunology, 2012; Alexander-Brett, et al., The Journal of al Investigation,
2013; Bunting, , et al., BioMed Research International, 2013; Byers, Alexander-Brett, et al.,
The Journal of Clinical Investigation, 2013; Kawayama, Okamoto, et al., J Interferon Cytokine
Res, 2013; ez~Gonzalez, Roca, et al., American Journal of Respiratory Cell and Molecular
Biology, 2013; Qiu, Li, et al., logy, 2013).
Furthermore. various studies have shovm that there is a relation between the amount of lL-iB and
its receptor. IL—IS and 11:33, and the disorder endomriosis (Altman. Lawson. et al.. Human
Reproduction, 2007: Lawson, Bourcier, et al., Journal of Reproductive Immunology, 2003; Sikora,
Mieiczarek—Palacz. et al., American l of Reproductive Immunology: Santulli, Borghese. et
al., Human Reproduction, 2013). Moreover, in the animal model the growth of human endometrial
tissue could be blocked by stration of the endogenous IL-IB inhibitor IL-1R2 (Khoufache,
Bondza, et al., The American Journal of Pathology, 2012). By way of its mechanism of action, an
IRAK4 inhibitor is also effective in this case. Chronic inflammatory bowel diseases such as
Crohn's disease and ulcerative colitis are associated with the dysregulation of the IL-1 receptor
family (Kobori, Yagi, et al., J Gastroenterol, 2010; Hao, Liu, et al., Curr Opin Gastroenterol, 2013).
In addition to the indications mentioned, IRAK4 inhibitors are also le for the treatment and/or
prevention of ogical disorders mediated by the IL-1 receptor family, such as stroke apoplexy,
Alzheimer's disease, stroke, skull-brain trauma and pain such as cancer pain, postOperative pain,
inflammation—induced pain and chronic pain (Wolf, Livshits, et al., Brain, Behavior, and Immunity,
2008; Brough, Tyrrell, et al., Trends in Pharmacological, 2011; SciencesDenes, Kitazawa, Cheng,
et al., The Journal of Immunology, 2011; Pinteaux, et al., Cerebrovascular Diseases, 2011; del Rey,
Apkarian, ct al., Armals of the New York Academy of Sciences, 2012; Denes, son, ct al.,
Disease Models & Mechanisms, 2013; Han, Zhao, et al., Neuroscience, 2013; Zhao, Zhang, ct al.,
Neuroscience, 2013). Owing to the propagation of processes mediated by the [U receptor family
by IRAK4, IRAK4 inhibitors are active in dermatological ers such as psoriasis, atopic
itis and allergic contact dermatitis. The ILI receptor family is ed in the enesis
of the disorders mentioned er, Guigue, et al., Annals of Internal Medicine, 2010; Cevikbas,
Steinhoff, J Invest ol, 2012; Minkis, Aksentijevich, et al., Archives of Dermatology, 2012;
, Ayala, et al., Experimental Dermatology, 2013; Sedimbi, Hagglof, et al., Cell M01 Life Sci,
2013).
Association of IRAK4 with numerous different disorders by mediation of various signals via TLRs
(except for TLR3) and the 1L1 receptor family shows that by inhibition of IRAK4 it is possible to
influence a large number of disorders in a positive manner.
The compounds described in the present invention are capable of inhibiting IRAK4. This is also
ted by the fact that the compounds according to the invention have inhibiting ty in
TLR- and IL} -tnediated processes.
Accordingly, it was an object of the t invention to e novel compounds which, in the
manner described above, act as inhibitors of interleukin—1 receptor associated kinase—4 ).
The novel 1RAK4 inhibitors are suitable in panicular for the ent and for the prevention of
proliferative and inflammatory disorders characterized by an overreacting immune system.
ular mention may be made here of inflammatory skin disorders, cardimascular disorders.
pulmonary disorders, eye disorders, autoimmune disorders and neoplastic disorders.
Numerous IRAK4 inhibitors are known from the prior art. IRAK4 tors are described, for
example, in G. C. Haniman et al. in U82013023l328 and in L. D. Romero et a1. U820120283238.
IRAK4 tors based on a pyrazole[l,5a]pyrimidine skeleton are bed by N. Arora et al.
in U320120015962.
Moreover, V. R. Paidi et al. in 106641 report thiazolyl- or thiadiazolyl-substituted
pyridine derivatives and S. D. Dodd et al. in W02013106614 report triazolyl-substituted pyridine
derivatives. Further pyridine tives are disclosed in WO2013106612.
Aminopyn'midones acting as IRAK4 inhibitors are described by W. M. Seganish et al. in
W02013066729; in addition, W. T. Mcelroy et al in WO 2012129258 also describe
amidopyrazolcs as IRAK inhibitors.
G. Buckeley et al. report, both in Bioorg. Med. Chem. Lett. 18 (2008), 3291 — 3295 and in Bioorg.
Med. Chem. Lett. 18 (2008), 3656 — 3660, imidazole[l,2-a]pyridines. Furthermore, A. D. Frenkel
et al. in U820070037803 report benzimidazole derivatives as IRAK4 inhibitors.
Further IRAK inhibitors having 2-aminoimidazole or 2-aminobenzimididazole structure are
claimed by A. D. Frenkel et al. in U82007/0037803.
IRAK4 inhibitors which, like the compounds according to the invention, are based on an indazole
structure are described by K. Guckian et al. in US8293923. These indazole derivatives are
substituted by a benzimidazolylamino group at position 3 of the indazole. 923 does not
disclose any 2—substituted indazoles.
Further [RAK4 inhibitors based on an indazole structure are reported by C. —Lebrun et al. in
USZOI30274241. These are indazole tives having a triazole—containing substituent at position
3 of the indazole. U820130274241 does not describe any 2-substitution of the indazoles disclosed.
W020! 1043371 describes oxazolecarboxamides linked to monocyclic aromatic heterocycles as
IRAK4 inhibitors. Oxazolecarboxamides linked to an indazole structure as in the nds
according to the ion are not described in W02011043371.
Bicyclic heterocycles having a carboxamide structure as IRAK4 inhibitors, for example substance
L1, are described by B. Anirna et al. in W02013042137. However, only idazole,
benzoxazole and benzothiazole derivatives are described, and no indazole derivatives.
\ O
\ N
\N/NH HNUH}o
G. M. Buckley et a1. rcpon, in Bioorg. Med. Chem. Lett. 18 . 3211 — 3214,
/ \N /
IN—N
L2 HaC L3
carboxamide derivatives as IRAK4 inhibitors. Described are, for example, the molecules LZ and
L3. Lndazole derivatives are not described.
In WO2009019167, A. Bombrun et al. describe 6-amin0pyrimidine—4—carboxamides having a 2-
substituted indazole structure such as, for example, L4. It is ed that the substances described
bind to the sphingosine-l-phosphate receptor. An inhibiting action on IRAK4 kinase is not
described in W02009019167.
“1”“
H36$NWNH /
0 \ [N
V/ N —>—*N\/CH3
0 CH3
U820080058341 describes azaindazoles having a carboxamide structure as CCRl antagonists. 2—
tuted indazole derivatives having an onal amide structure are not disclosed.
A. J. Souers et al. describe, in U820050137187, 2-substituted indazoles as antagonists of MCH
(melanin—concentrating hormone). However, the 2-substituent at the indazole does not comprise a
amide structure.
The present invention provides compounds of the general a (I)
‘ R“
W N 13
it R
/N Y
O \
a1 N
in which:
R° represents hydrogen or C z-Ci-alkyl. where the C .«Ci-allcyl radical may optionally be mono-
or polysubstituted by identical or different radicals from the group consisting of hydroxy
and halogen;
represents hydrogen, halogen, cyano, C(=O)OH, C(=O)OR3, C(=O)NH3, C(=O)N(H)Ra,
C(=0)N{R“)Rb, C(=O)Rd, hydroxy or C1-C6-a1kyl, where the C1-C6-alkyl radical is
optionally mono- or polysubstituted by identical or different ls from the group
consisting of
hydroxy, halogen, cyano, C(=O)OH, R“, S(=O)g-C 1-C6-alkyl, NHZ, NHR“,
b, alkoxy which is optionally mono- or polysubstituted by identical or
different radicals from the group consisting of halogen, C3-C3-cycloalkoxy which is
ally mono- or polysubstituted by cal or different radicals from the group
consisting of halogen, cycloalkyl which is optionally mono— or polysubstituted
by identical or different radicals from the group consisting of R°,
or represents a1koxy, where the C1-C5-alkoxy radical may optionally be mono- or
polysubstituted by identical or different radicals from the group consisting of
hydroxy, halogen, cyano, C(=O)OH, C(=O)OR“, S(=O)2-Cl-C5-alkyl, NHZ, NHR“,
N(R3)Rb, C3—C8-cycloalkyl which is optionally mono- or polysubstituted by
identical or ent radicals from the group consisting of halogen, Cl-Cé-alkoxy
which is optionally mono— or polysubstituted by identical or different ls from
the group consisting of halogen, C3-C3—cycloalkoxy which is optionally mono— or
polysubstituted by identical or different radicals from the group consisting of
halogen, heterocycloalkyl which is optionally rnono- or polysubstituted by identical
or different radicals from the group consisting of RC,
2014/077877
aryl which is optionally mono- or polysubstituted by identical or ent radicals
from the group consisting of R°, or 5- or 6-membered heteroaryl which is
optionally mono- or polysubstituted by identical or different radicals from the
group consisting of R°,
or represents C3—Cg-cyeloalkoxy or heterocycloalkoxy which may optionally be mono— or
polysubstituted by identical or different radicals from the group consisting of hydroxy,
halogen, cyano and C1—C6-a1kyl,
_ .
or represents y or 5— or 6-membered heteroaryloxy in which aryloxy and
- or 6-membered heteroaryloxy may optionally be mono— or polysubstituted by identical
or ent radicals from the group consisting of hydroxy, halogen, cyano, C(=0)OH,
C(=O)OR3, C lqu-alkyl and C 1-Ca—alk0xy,
or represents C3—Ca—cycloalkyl or heterocycloaIkyl which may optionally be mono- or
polysubstituted by identical or different radicals from the group consisting of hydroxy.
halogen. cyano and C ,oCb-alkyl.
or represents C3-C6-alkeny1 or C3-C6-alkynyl,
or represents aryl, 5- to lO-membered heteroaiyl, aryl—Cl—Ci-alkyl or 5— or 6—membered
heteroaryl-Cl-C4-alkyl, where aryl and heteroaryl may optionally be mono— or
polysubstituted by identical or different radicals from the group consisting of halogen,
y, cyano, C(=O)OH, R3, alkyl, C3—Cg-cycloalkyl and C1—C5-alkoxy;
represents C1—C6—alky1, -cycloalkyl, heterocycloalkyl, aryl or heteroaryl,
where alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl may optionally be mono- or
polysubstituted by identical or different radicals from the group consisting of halogen,
hydroxy, cyano, C1—C3—alkyl, C1—C3—alkoxy, heterocycloalkyl, —C(=0)O-C]—C5-alkyl and
S(=O)2-C1-C5-alkyl;
Rb represents C1—C6-alky1 or C3-C m-cycloalkyl;
or R:1 and Rb together with the nitrogen atom form a 5- or ered heterocycle which may
optionally be mono- or polysubs’tituted by identical or different radicals from the group
consisting of hydroxy, halogen, cyano, and C1—C6-alkyl;
RC represents y, halogen, cyano, Cl-C3—alkyl or C1-C3—alkoxy;
Rd ents hydrogen, C1-C6-alkyl or C3-C10-cycloalkyl;
represents hydrogen, alky1 or C3-C6-cycloalkyl;
represents en or C1—C6—alkyl;
represents ered heteroaryl which contains one to three heteroatoms selected from
the group ting of N, O and S and may optionally be monosubstituted by R3 and
optionally be mono— or polysubstituted by identical or different radicals R4 or
represents pyridyl, nyl, zinyl, triazinyl or 1,3,5-tria2inyl which may
optionally be monosubstituted by R3 and optionally be mono- or polysubstituted by
identical or different ls R4;
ents en. halogen. cyano. C(=0)R'. NHZ. NHR'. N{R‘}R", N(H)C(=O}R‘ or C [-
Cb-alkyl, where
C1-Co-alkyl may optionally be mono— or bstiruted by identical or different
radicals from the group consisting of hydroxy, halogen, cyano, C(=O)R',
C(=O)OH, C(=O)ORa, S(=O)g-C1—Cb-alkyl, NHg, NHRa, N(R3)Rb, C1-C6-alkoxy,
C3-Cg-cycloalkoxy,
where C1-C5-alkoxy and C3-Cg-cycloalkoxy may optionally be mono- or
polysubstituted by identical or different halogen radicals;
or C1—C6-alky1 is optionally mono- or polysubstituted by identical or different
radicals from the group consisting of C3-C6-cycloalkyl and heterocycloalkyl,
where C3—C6-cycloalkyl and hctcrocycloalkyl may optionally be mono-, di-
or trisubstituted by cal or different radicals from the group consisting
of halogen, cyano, C1-C3-alkyl and C1-C3—alkoxy,
or C1-C6-alkyl is optionally mono- or polysubstituted by identical or different
radicals from the group consisting of aryl and 5- or 6-membercd hctcroaryl,
where aryl and 5— or 6-membered heteroaryl may optionally be mono-, di-
or trisubstituted by identical or different substituents from the group
consisting of halogen, cyano, C1-C3-alkyl and C1-C3—alkoxy,
represents C1—Cfi—alkoxy, where
C1-C6-alkoxy may optionally be mono—' or polysubstituted by identical or different
radicals from the group consisting of hydroxy, halogen, cyano, C(=O)0Ra, S(=O)2-
C1-C6-alky1, N(R")Rb, C3-Cg-cycloalky1, Cl-C4-alkoxy, C3-Cg-cycloalkoxy,
or represents C3-C6-cycloalkyl, heterocycloalkyl or C5-Cn-spirocycloalkyl, Where
cycloalkyl, heterocycloalkyl and spirocycloalkyl may optionally be mono- or
polysubstituted by identical or different radicals from the group consisting of
hydroxy, halogen, cyano, C(=O)R”, C(=O)OH, C(=O)ORa, C1-C6-alkyl and C1-C4-
alkoxy;
or represents aryl or 5- to 10-mernbered heteroaryl, where
aryl and heteroaryl may optionally be mono— or polysubstituted by identical or
different ls from the group consisting of halogen, hydroxy, cyano,
Ra, S(=O)2—C1~C6-alkyl, N03, NHg, NHR‘“, N(Ra)Rb, N(H)C(=O)Ra, C3—C8—
cycloalkyl, C1-C3-alkoxy and a1kyl, where
Ci-C3-alkyl may optionally be mono- or polysubstituted by identical or
different halogen radicals;
represents n, hydroxy, cyano or C1-Cb-alkyl, where C lkyl may optionally be
mono- or polysubstituted by identical or different radicals from the group consisting of
halogen, C1-C6—alkoxy, where C1-C6-alkoxy may optionally be mono— or polysubstituted by
identical or different radicals from the group ting of halogen, alkenyl, C2—C6—
l, C3-Clg-cycloalkyl, 3— to 10—membered heterocycloalkyl and aryl, where aryl may
optionally be mono- or polysubstituted by identical or different radicals R,
01'
represents aryl or heteroaryl which may optionally be mono- or polysubstituted by identical
or different radicals R,
represents “, C(=O)NH2, C(=O)N(H)Ra, C(=O)N(R3)Rb, C(=0)0R3, NHz, NHR“,
N(Ra)Rb, N(H)C(=O)R", N(R3)C(=O)Ra, N(H)C(=O)NH2, N(H)C(=O)NHR“,
N(H)C(=O)N(R“)Rb, N(R“)C(=O)NH2, N(R“)C(=O)NHR“, N(R")C(=O)N(R3)Rb,
N(H)C(:O)OR“, N(R")C(=O)OR“, N02, N(H)S(=O)Ra, N(Ra)S(=O)R3, N(H)S(=O)2R“,
N(Ra)S(=O)2Ra, N:S(:O)(R“)R", 0C(=O)Ra, OC(=O)NH2, NHR8,
OC(:O)N(Ra)Rb, SH, SR“, S(=O)Ra, S(:O)2Ra, S(=O)2NH2, S(=O)2NHR“, S(=O)2N(R*‘)Rb
or S(=O)(=N—Ra)Rh;
represents n, cyano, C1—Cs—a1ky1, C2-C6-a1kenyl, C2-C6-alkynyl, cycloalkyl, 3-
to 10—membered heterocycloalkyl, aryl, heteroaryl, C(=O)Ra, C(=O)NH2, C(=O)N(H)Ra,
C(=O)N(R8)Rb, C(=O)OR“, NHZ, NHR", N(R3)Rb, N(H)C(=O)R“, N(R“)C(=O)Ra,
N(H)C(=O)NH2, N(H)C(=O)NHR3, N(H)C(=O)N(Ra)Rb, N(R‘)C(=O)NH2,
N(R")C(=O)NHR3, N(Ra)C(=O)N(R“)Rb, N(H)C(=O)0Ra, N(Ra)C(=O)OR"‘, N02,
WO 91426
N(H)S(=O)Ra, N(Ra)S(=O)R“, N(H)S(=O)2R", N(Ra)S(=O)2Ra, N=S(=O)(Ra)Rb, OH, 0,-
Cs-alkoxy, OC(=O)Ra, OC(=O)NHZ, OC(=O)NHR3, OC(=O)N(R“)R", SH, SR", S(=O)R“,
S(=O)2Ra, S(=O)2NH2, NHR“, 3(=0)2N(Ra)Rb or S(=O)(=NR“)R";
n represents 0 or 1 ;
Y represents a group selected from:
R78 R7!) 76
RR7d
( o q
1R5 ,st z
i—N\
a £3me
R R R
and (H)
where ‘ represents the point of attachment of the group to the remainder ofthe molecule;
R5 represents hydrogen, C1—C6-alkyl or C3-C10-cycloalky1, where
C1-C6-alkyl may optionally be mono- or polysuhstituted by cal or different
radicals from the group consisting of hydroxy, halogen, cyano, C(=O)OH,
C(=0)OR“, S(=O)2-C1-C6-alky1, N(Ra)Rb, a1koxy and Cg-Cg-cycloalkyl;
R6 represents hydrogen or C1-C6-alkyl, where
C1-C6-alky1 may optionally be mono- or polysubstituted by identical or different
radicals from the group ting of hydroxy, halogen, cyano, C3—Cm—cycloalkyl,
C(=O)Ra, C(=O)OH, C(=O)OR", -C1-C6-alkyl, N(R3)Rb, Cl-C4-alkoxy and
C3—Cg—cycloalkoxy,
or represents C3-C10—cycloalkyl, where
C3—Cm-Cycloalkyl may Optionally be mono— or polysubstituted by identical or
different radicals from the group consisting of hydroxy, halogen, cyano and C1-C6-
alkyl, where
alky1 may optionally be substituted by hydroxy,
or represents heterocycloalkyl, where
heterocycloalkyl may ally be mono- or polysubstituted by. identical or
3O different radicals from the group consisting of halogen, cyano, Ct-Cg-alkyl and Cl—
Cg-alkoxy,
or represents aryl or 5- or 6—membered heteroaryl, where
aryl and 5- or 6—membered heteroaryl may optionally be mono- or polysubstituted
by identical or different radicals from the group consisting of halogen, cyano, C1—
Cg-alkyl, C1-C3-alkoxy, S(=O)2NH2, S(=O)2NHRa and S(=O)2N(R3)Rb;
R7a represents hydrogen, halogen, N(R“)Rb, C1-C6-alkyl or C3-Clo-cycloalkyl, where
C1—C6—alky1 may optionally be mono- or polysubstituted by identical or different
radicals from the group consisting of hydroxy, halogen, cyano, H,
C(=O)0Ra, S(=O)3-C;-C6-alkyl, N(Ra)Rb, C1-C4—alkoxy, Cg—Cg—cycloalkyl and
heterocycloalkyl;
R7b represents hydrogen, halogen or C1—C6-alkyl, where
C1-C6—alkyl may optionally be mono— or polysubstituted by identical or different
radicals from the group consisting of hydroxy, halogen. Cyano. C(=O)OH.
C(=O)OR’. S(=O}3~C 1-Co-alkyl. N(R')Rb, C1-C4-alkoxy, Cst—cycloalkyl and
heterocycloalkylz
or R73 and R71) together with the carbon atom form C3-C6-cycloa1kyl which may optionally be
mono- or bstituted by cal or different radicals from the group consisting of hydroxy,
halogen, cyano and C1-C6-alkyl,
or R73 and R7b together represent an oxo group;
R7c ents hydrogen, halogen, N(Ra)Rb, C1-C6-alkyl or C3-C10—cycloalkyl, where
C1~C6-alkyl may ally be mono- or polysubstituted by cal or different
radicals from the group consisting of hydroxy, halogen, cyano, C(=O)OH,
C(=O)OR“, —C1—C6—alkyl, N(Ra)Rb, C1-C4-alkoxy, C3—Cg—cycloalkyl and
heterocycloalkyl;
R7d represents hydrogen, halogen or alkyl, where
C1—C6—alkyl may ally be mono- or polysubstituted by identical or different
radicals from the group consisting of hydroxy, halogen, cyano, C(=O)OH,
C(=O)OR“, S(=O)2-C.—C6—alkyl, N(Ra)Rb, C1—C4-alkoxy, cycloalky1 and
heteroeycloalkyl;
or R7c and R7d together with the carbon atom form C3-C6—cycloa1ky1 which may optionally be
mono— or polysubstituted by identical or ent radicals from the group consisting of y,
halogen, cyano and C1-C6-alkyl,
PCT/EPZO 14/077877
or R7“ and R7d together represent an oxo group;
R8“ represents hydrogen, halogen, N(R")Rb, Cl-Cé—alkyl or C3-Clo-cycloalkyl, where
C1—C6—alkyl may ally be mono- or polysubstituted by identical or different
radicals from the group consisting of hydroxy, halogen, cyano, C(=O)OH,
C(=O)OR“, S(=O)2-C1-C6—alkyl, N(R“)Rb, C1—C4—alkoxy, C3-C8-cycloalkyl and
heterocycloalkyl;
R8b ents hydrogen, halogen or C1-C6-alkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by identical or different
radicals from the group ting of hydroxy, halogen, cyano, H,
cement. S(=O)g—C.—Cb—alkyl, NiR‘m", a1koxy, C3-C3—cycloalkyl and
heterocycloalkyl:
or R“ and R81, together with the carbon atom form C_.-C,,-cycloalkyl which may optionally be
mono— or polysubstituted by identical or different ls from the group consisting of hydroxy,
halogen, cyano and C1-C6-alkyl,
R8c represents hydrogen, halogen, N(Ra)Rb, C1-C6-alkyl or C3-C10-cycloalky1, where
C1-C6-a1kyl may optionally be mono- or polysubstituted by identical or different
radicals from the group ting of hydroxy, halogen, eyano, C(=O)OH,
C(=O)OR”, S(=O)2—C1—CG—alkyl, N(Ra)Rb, C1—C4—alkoxy, Cg-Cg-eycloalkyl and
heterocycloalkyl;
R8‘! represents hydrogen, halogen or C1-C6-a1kyl, where
C1—Cfi-alkyl may optionally be mono- or polysubstituted by identical or different
ls from the group consisting of hydroxy, halogen, cyano, C(=O)OH,
C(=O)OR3, S(=O)2-C1-C6-alkyl, N(R“)Rb, Cl-C4-alkoxy, cycloalkyl and
heterocycloalkyl;
or R8C and R8d together with the carbon atom form C3—C6-cycloalkyl which may optionally be
mono— or polysubstituted by identical or ent radicals from the group ting of hydroxy,
halogen, cyano and C1—C5—alkyl,
or R8° and R8“1 together represent an 0x0 group;
0 represents 0, 1 or 2,
p represents 0, l or 2,
WO 91426 PCT/EPZO 14/077877
Cl represents 0, l or 2,
r represents 0, 1 or 2,
3 represents 0, 1 or 2,
where o, p, q, r and 5 do not simultaneously ent 0;
ents a group selected from C(:O), CRng, NR”, 0, S, S(=O) and S(=O)2;
represents hydrogen or C1-C6-a1kyl,
represents hydrogen, halogen, cyano, C(=O)R”, C(=O)OH, C(:0)0Ra, C(=O)NH2,
C(=O)N(H)Ra, C(=O)N(R“)Rb, N(H)C(=O)R“, N(Rb)C(=O)Ra, S(=O)2R“, hydroxy, b
and C3-Cb-alkyl. where
C1—Cb-alkyl may optionally be mono— or polysubstituted by identical or difTerent
radicals from the group consisting of hydroxy, halogen, crane, C(=O)R',
(T(=O)0H. C[=O)OR‘. S(=O)3-C,-C¢.-alk}'l. b. Ci-Cralkoxy and C3-C3-
cycloalkoxy,
or represents C1—C5—alk0xy, where
C1-C6-alkoxy may optionally be mono— or polysubstituted by identical or different
radicals from the group consisting of hydroxy, halogen, cyano, C(=O)OH,
C(=O)OR“, S(=O)2-C1-C6-a1kyl, N(R“)Rb, cyeloalky1, alkoxy, C3~Cg-
cycloalkoxy, heterocycloalkyl, aryl and 5- or 6-membered aryl, where
aryl and 5— or 6-membered heteroaryl may optionally be mono~ or
polysubstituted by cal or different radicals from the group consisting
of halogen, cyano, C1—C3—alkyl and C1-C3—alkoxy,
or represents aryloxy or 5— or 6-membered heteroaryloxy in which
aryloxy and 5- or bered heteroaryloxy may optionally be mono- or
disubstituted by identical or different radicals from the group consisting of
hydroxy, halogen, cyano, C(=O)OH, C(=O)ORa, C1-C3-alkyl and C1-C3-alk0xy,
or represents C3-C8-cycloalkyl, Cg-Cg-cyeloalkyl-C]-C4-alkyl, heterocycloalkyl or
heterocycloalkyl-CI-C4-alkyl, which may optionally be mono— or bstituted by
identical or different radicals from the group consisting of hydroxy, n, cyano,
C(=O)Ra, C(=O)OH, C(=O)OR“, C J-Cfi-alkyl and C1-C6-alkoxy, where
C1—C6—alkoxy may optionally be mono— or polysubstituted by identical or different
halogen radicals or an oxo group;
or represents C2—C6—alkeny1 or Cz—Cfi—alkynyl,
or represents aryl, 5- to lO-membered heteroaryl, aryl-Cl-C4-a1kyl or 5- or 6-membered
heteroaryl-C l -C4-alkyl, where
aryl and heteroaryl may optionally be mono— or bstituted by identical or
different ls from the group consisting of halogen, hydroxy, cyano, H,
C(=O)OR“, NHRa, N(Ra)Rb, C1—C3-alkyl, C3-Cg—cycloalkyl and C1-C3-alkoxy;
or R9 and R10 together with the carbon atom form C3-Cg—cycloalkyl or a 4- to 6-membered
cycle, where
the C3-C3-cycloaikyl radical or the 4- to 6-membered heterocycle may optionally
be mono- or bstituted by identical or different radicals from the group
consisting of hydroxy, n, cyano, C1-C6-alkyl, C(=O)R' and an 0x0 group;
RH represents en. C(=O)R'. C(=O)OR'. H;. C(=O)N(H)R‘, C(=O)N(R‘)Rb.
srzom'. S(=O)3N(R')R" or cluct-aikyi. where
C1—C6-alkyl may optionally be mono— or polysubstituted by identical or different
radicals from the group consisting of hydroxy. halogen. cyano. C{=O)R‘,
C(=O)OR‘, C(=O)NH3, C(=O)N(H)R‘, (R‘)R°, S(=O)3—C,—C6-alkyl,
N(R“)Rb, C3-C3-cycloallcyl, C1-C4—alkoxy and C3-C3-cycloalkoxy, where
C3-C3-cycloa1kyl, alkoxy and C3—Cg-cycloalkoxy may optionally be
mono- or polysubstituted by identical or different radicals from the group
consisting of hydroxy and halogen,
or represents C3-Cg—cycloalkyl, heterocycloalkyl or heterocycloalkyl-C1—C4-alkyl
which may optionally be mono- or polysubstituted by identical or different radicals
from the group consisting of hydroxy, halogen, cyano, C1—C6—alkyl, alk0xy,
where alkyl and alkoxy may Optionally be mono- or polySubstituted by identical or
different ls from the group consisting of halogen and an oxo group,
or represents C2-C6-alkenyl or C2-C6-alkynyl,
or represents aryl, 5— to 10—membered heteroaryl, aryl-Cl—C4-a1kyl or 5- or 6-membered
heteroaryl—C1 -C4-alkyl, where
aryl and heteroaryl may optionally be mono— or polysubstituted by identical or
different radicals from the group consisting of halogen, hydroxy, cyano, C(=O)OH,
C(=O)OR“, C1—C3-a1kyl, C3-Cg-cycloalkyl and C1-C3-alkoxy;
and their diastereorners, enantiomers, their metabolites, their salts, their solvates or the solvates of
their salts.
If, in the synthesis intermediates and working examples of the ion bed below, a
compound is given in the form of a salt of the corresponding base or acid, the exact stoichiometric
composition of such a salt as obtained by the reSpective preparation and/or ation process is
generally not known. Unless specified in more detail, ons to names and structural formulae,
such as "hydrochloride", "trifluoroacetate", "sodium salt" or "X HCl”, "x CF3COOH", "x Na+" are
not to be understood stoichiometrically in the case of such salts, but have only descriptive character
with regard to the salt-forming components comprised therein.
This applies correspondingly if synthesis intermediates or working examples or salts thereof were
obtained by the preparation and/or purification processes described in the form of es, for
IO example hydrates, ofunknown stoichiometric composition (if of a defined type).
Compounds according to the invention are the compounds of the formula (I) and their salts,
solvates and solvates of the salts. the compounds encompassed by formula (I) of the formulae
mentioned below and their salts, solvatcs and solvatcs of the salts and the compounds encompassed
by a (I) and ned below as working examples. and their salts. solvates and solvates of
the salts, if the compounds encompassed by formula (I) and mentioned below are not already salts,
solvates and solvates of the salts.
Preferred salts in the context of the present invention are physiologically acceptable salts of the
compounds according to the invention. The invention also encompasses salts which themselves are
able for ceutical applications but which can be used, for example, for the isolation or
purification of the inventive compounds.
Physiologically acceptable salts of the compounds according to the invention include acid on
salts of mineral acids, carboxylic acids and sulphonic acids, for example salts of hydrochloric acid,
hydrobromie acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid,
toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid,
trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, c acid,
maleic acid and benzoic acid.
Physiologically acceptable salts of the compounds according to the invention also include salts of
conventional bases, by way of example and with preference alkali metal salts (eg. sodium and
3O potassium salts), ne earth metal salts (e.g. calcium and magnesium salts) and ammonium salts
derived from ammonia or organic amines having 1 to 16 carbon atoms, by way of example and
with preference ethylamine, diethylarnine, triethylaminc, iisopropylamine,
monoethanolamine, diethanolamine, anolamine, dicyclohexylamine, ylaminoethanol,
procaine, dibenzylamine, ylmorpholine, arginine, lysine, ethylenediamine and N-
methylpiperidine.
Solvates in the t of the invention are described as those forms of the compounds according to
the invention which form a complex in the solid or liquid state by coordination with solvent
molecules. Hydrates are a specific form of the solvates in which the coordination is with water.
PCT/EP20l4/O77877
The compounds according to the invention may, depending on their structure, exist in different
stereoisomeric forms, i.e. in the form of configurational isomers or else optionally as
mational isomers iomers and/or diastcreomers, including those in the case of
atropisomers). The present invention therefore encompasses the enantiomers and diastereomers,
and the respective mixtures thereof. The stereoisomerically homogeneous tuents can be
isolated from such mixtures of omers and/or diastereomers in a known manner;
chromatography processes are preferably used for this purpose, eSpecially HPLC tography
on an achiral 0r chiral phase.
Where the compounds according to the invention can occur in tautomeric forms, the t
invention encompasses all the tautomeric forms.
The present invention also encompasses all suitable isotopic variants of the compounds according
to the invention. An isotopic variant of a compound according to the invention is understood here
as naming a compound in which at least one atom within the compound according to the invention
has been exchanged for another atom of the same atomic number, but with a different atomic mass
than the atomic mass which usually or predominantly occurs in nature. Examples of isotopes which
can be incorporated into a compound according to the invention are those of hydrogen, carbon,
nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine and iodine, such as 2H
(deuterium), 3H (tritium), 13C, 14C, 15N, 170, 180, 32F, 33F, 338, 348, 353, 363, 18F, 36Cl,
SZBr, 1231, 1241, 1291 and 1311. Particular isotopic ts of a compound according to the
invention, especially those in which one or more radioactive isotopes have been orated, may
be beneficial, for example, for the examination of the mechanism of action or of the active
compound distribution in. the body; due to comparatively easy preparability and detectability,
especially compounds ed with 3H or 14C es are suitable for this purpose. In addition,
the incorporation of isotopes, for example of deuterium, can lead to particular therapeutic benefits
as a consequence of greater lic stability of the compound, for example to an extension of the
half—life in the body or to a reduction in the active dose required; such modifications of the
compounds according to the invention may therefore in some cases also constitute a preferred
embodiment of the present invention. Isotopic variants of the compounds according to the
invention can be prepared by the processes known to those skilled in the art, for example by the
s described further below and the procedures bed in the working examples, by using
corresponding isotopic modifications of the tive reagents and/or starting compounds.
The present invention r provides all the possible crystalline and polymorphous forms of the
compounds ing to the invention, where the polyrnorphs may be t either as single
polymorphs or as a mixture of a plurality of polymorphs in all tration ranges.
In addition, the present ion also encompasses prodrugs of the compounds ing to the
invention. The term "prodrugs" here denotes compounds which may themselves be biologically
active or inactive, but are converted (for e by metabolic or hydrolytic means) to inventive
compounds during their residence time in the body.
In the context of the present invention, unless specified Otherwise, the substituents have the
following gs:
l in the context of the invention is a straight-chain or branched alkyl radical having the
particular number of carbon atoms specified. Examples which may be mentioned are methyl, ethyl,
n-propyl, isopropyl, n—butyl, isobutyl, l-methylpropyl, tert—butyl, n-pentyl, lpropyl, l-
methylbutyl. 2-methylbutyl. 3-methylbutyl, n—hexyl, l—methylpentyl. 2~methyipentyL 3-
methylpcntyl. 4-mcthylpcntyl. l-cthylbutyl and 2-dhylbutyl. Prefcrmce is gixtn to methyl. ethyl.
n-propyl. n-butyl and l—methylpropyl and also tert—butyl.
Alkenyl in the context of the invention is a straight-chain or branched monovalent hydrocarbon
radical having at least one double bond and having the particular number of carbon atoms
specified. These are generally 2 to 6 carbon atoms, preferably 2 to 4 and particularly preferably 2
or 3 carbon atoms.
In the case of a plurality of double bonds, these may be ed or conjugated, with isolated double
bonds being preferred.
Examples which may be mentioned are:
Vinyl, allyl, ethylvinyl, (Z)—2—rnethylvinyl, homoallyl, (E)—but—2—enyl,
(Z)—but—2—enyl, (E)-but-1 -eny1, (Z)-butenyl, pent—4—enyl, (Ej—pent—3-enyl,
(Z)-pentenyl, (E)-pentenyl, (Z)-penteny1, (E)—pent-l—enyl, (Z)-pent—l—enyl,
hex—S-enyl, (E)—hex—4—enyl, (Z)—hex—4—enyl, (E)—hex-3—enyl, (Z)—heX—3—enyl,
(E)—hex—2—enyl, (Z)—hex-2—eny1, (Ej—hex-l-enyl, (Z)-hexenyl, isopropenyl,
ylprop—2—enyl, l-methylprop-Z-enyl, ylprop—1 —enyl, (E)-1 -methylprop—1—enyl,
(Z)-1—methy1prop—I-enyl, 3—methylbut-3 -enyl, 2-methylbut—3 -enyl, ylbutenyl,
3-methy1but—2—enyl, (E)—2—methylbut—2-enyl, (Z)methylbutenyl,
(B—l—methylbut-2—enyl, (Z)-1 —methylbut—2-enyl, (E)-3 -methylbut-1 -eny1,
(Z)—3 —methylbut—1 —eny1, (B—Z—methylbut-l -enyl, (Z)methylbut-l-enyl,
(E)-1 -methylbut—1 ~eny1, (Z)—1-rnethylbut—1-enyl, 1, l —dimethylpropenyl,
l—ethylprop-l-enyl, l-propylvinyl, 1—isopropylvinyl, 4—methylpent—4~enyl,
3-methy1penteny1, ylpent-4—enyl, 1-methylpent—4—enyl, 4-methylpent-3—enyl,
(Bmethylpentenyl, (Z)methylpentenyl, (E)methylpentenyl,
(Z)methylpentenyl, (13methylpent-3 -eny1, (Z)-1 -methylpent-3 -enyl,
2014/077877
ethylperitenyl, (Z)methylpentenyl, (Bmethylpentenyl,
(Z)—3—methy1pentcnyl, (E)methylpentenyl, (Z)methylpentenyl,
(E)—l -methylpent—2—eny1, (Z)— l —methy1pentenyl, (E)methylpent-l -eny1,
(Z)—4—methylpent—l -enyl, (E)methylpent-1—enyl, (Z)-3 -methy1pentenyl,
(E)—2—rnethylpent-l -enyl, methylpent-1 -enyl, (E)- l -methylpent—l —enyl,
(Z)~l—rnethylpentenyl, 3-ethylbut—3 -enyl, 2-ethylbut—3-enyl, 1—ethylbut—3 -enyl,
(E)—3-ethylbuteny1, (Z)ethy1butenyl, (B-Z-ethylbut-Z-enyl, (Z)ethylbutenyl,
(E)-l —ethylbut-2—enyl, (Z)-l -ethylbut-2—enyl, (E)ethylbut-l -enyl, (Z)ethylbutenyl,
2-ethylbut-l —enyl, (EH —ethylbut-l -enyl, (Z)ethylbut-l-eny1, 2-propylprop—2-enyl,
1-propylprop—2—enyl, 2—isopr0pylprop—2—enyl, 1-isopropylprop-2—enyl,
propylprop-l -eny1, (Z)propylprop-l -enyl, (E)—l -propylprop-1—enyl,
(Z)- l —propylprop-l -eny1, (B-Z-iSOpropylprop-I —enyl, (Z)isopropylprop—l -enyl.
(El-l -isopropylprop-l -enyl, (Z). l -isopropylprop-I -enyl. (B—3.3-dimelhylprop-l -enyl.
3-dimethylprop-l -cnyl. I -(1,l dimcthylahylkthenyl. bum-1.3-dicnyl.
penta-1.4-dieny1. hexa-l .S-dienyl. methylhexadienyl.
ular preference is given to Vinyl or allyl.
fly; in the context of the invention is a straight-chain or ed monovalent hydrocarbon
radical having at least one triple bond and having the particular number of carbon atoms specified.
These are generally 2 to 6 carbon atoms, preferably 2 to 4 and ularly preferably 2 or 3 carbon
atoms.
Examples which may be mentioned are:
ethynyl, —ynyl, ~yny1, but-l-ynyl, butyny1, butynyl, pent—l-ynyl,
pent-Z-ynyl, pentynyl, pentynyl, hex-1 -ynyl, hexyny1, hex-3 -ynyl, hexynyl,
hex-S-ynyl, l-methylprop-Q-ynyl, 2-methylbutynyl, l-methylbut-3—ynyl, 1—methylbut—2—ynyl,
3—methylbutynyl, l-ethylprop-Z-ynyl, 3-methylpent-4~ynyl, 2-methylpentynyl,
1—methylpent-4—ynyl, ylpent-3—ynyl, l—methylpent—3—ynyl, 4—methylpent-2—ynyl,
l-methylpent—Z—ynyl, 4-methylpent—l—ynyl, 3—methylpent—l-ynyl, 2—ethylbut—3—ynyl,
l-ethylbutynyl, l—ethylbut—Z—ynyl, l—propylprop—Z-ynyl, 1—isopropylprop-2—ynyl,
methylbutynyl, 1,1-dimethylbut-3—ynyl, 1,1-dimethylbutynyl or
3 ,3-dirnethylbut-l -ynyl.
Particular preference is given to ethynyl, prop-1 —ynyl or prop—Z-ynyl.
Cycloalkyl in the context of the invention is a monocyclic saturated alkyl radical having the
number of carbon atoms specified in each case. Examples which may be mentioned as being
preferred are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and eptyl.
Alkoxy in the context of the invention is a straight-chain or branched alkoxy radical having the
particular number of carbon atoms specified. 1 to 6 or 1 to 4 carbon atoms are preferred. Examples
PCT/EPZO 877
which may be mentioned are methoxy, ethoxy, n-propoxy, poxy, 1-methylpropoxy, n-
butoxy, isobutoxy, tert-butoxy, n-pentoxy, isopentoxy, I-ethylpropoxy, 1-methylbutoxy, 2-
methylbutoxy, 3-methylbut0xy and xy. Preference is given to a linear or ed alkoxy
radical having 1 to 4 carbon atoms. Examples which may be mentioned as being preferred are
methoxy, ethoxy, n-propoxy, l—methylpropoxy, n-butoxy and isobutoxy.
Cycloalkoxy in the context of the invention is a monocyclic saturated alkyl radical which has the
particular number of carbon atoms specified and is attached via an oxygen atom. Examples which
may be mentioned as being preferred are; cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy
and cycloheptoxy.
Ag] in the t of the invention is a monovalent mono- to lic aromatic, carbocyclic ring
system having generally 6 to 14 carbon atoms. Examples which may be mentioned are: phenyl,
naphthyl and hryl. Preference is given to phenyl.
Heterocyclvl or hetemcvclus or heterocvcloallgyl in the context of the invention is a mono— or
polycyclic, preferably mono— or bicyclic, non-aromatic, saturated or partially unsaturated
heterocycle having generally 3 to 10, preferably 3 to 7, ring atoms and up to 3, preferably up to 1 or
2, heteroatoms and/or heterogroups from the group consisting of N, O, S, SO and $02. Preference
is given to 3- to 7-membered, monocyclic saturated heterocyclyl radicals having up to two
atoms from the group consisting of O, N and S. Examples which may be mentioned are:
azetidinyl, oxetanyl, pyrrolidinyl, pyrazolidinyl, tetrahydrofiiranyl, piperidinyl, piperazinyl,
tetrahydmpyranyl, morpholinyl, thiomorpholinyl, dioxidothiomorpholinyl, dihydroindolyl and
dihydroisoindolyl. Preference is given to: azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and
morpholinyl.
agl is a monovalent, aromatic mono— or bicyclie ring system having generally 5 to 10,
ably 5 to 6, ring atoms and preferably 1 to 3 heteroatoms. The atoms may be nitrogen
atoms, oxygen atoms and/or sulphur atoms. The binding valency can be at any aromatic carbon
atom or at a nitrogen atom.
Heteroaryl radicals having 5 ring atoms include, for example, the rings:
thienyl, thiazolyl, furyl, pyrrolyl, oxazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl,
oxadiazolyl, triazolyl, olyl and thiadiazolyl.
Heteroaryl radicals having 6 ring atoms include, for example, the rings:
pyridyl, pyridazinyl, pyrimidinyl, nyl and triazinyl.
A bicyclic heteroaryl radical in ance with the present invention has 9 or 10 ring atoms.
PCT/EP2014/O77877
Heteroaryl radicals having 9 ring atoms include, for example, the rings:
phthalidyl, thiophthalidyl, indolyl, olyl, indazolyl, benzothiazolyl, benzofuryl, benzothienyl,
idazolyl, benzoxazolyl, azocinyl, indolizinyl, purinyl, indolinyl.
Heteroaryl radicals having 10 ring atoms include, for example, the rings:
nolinyl, quinolinyl, quinolizinyl, quinazolinyl, quinoxalinyl, cinnolinyl, phthalazinyl,
1,7- or 1,8-naphthyridinyl, pteiidinyl, chromanyl.
Qéfifl-Spirocycloalkyl 0r heterospirocycloalgl with replacement of 1—4 carbon atoms by nitrogen,
oxygen and/or sulphur, ing the two oxidized forms f, SO and 802, and the derivatives
f modified as the sulphoximine, is understood to mean a fusion of two ring systems which
share a common atom. Examples are 2.2]pentane, spiro[2.3]hexane, azaspiro[2.3]hexane,
spim[3.3]heptane, azaspiro[3.3]heptane. oxamspim[3.3]heptane, thiaazaspiroI3.3]heptane,
oxaspiro[3-3]hep(ane. oxazaspiro[5.3]nonane, oxamspiro[4-3}octanc, oxazaspirflSflundccanc,
diazaspiro[3.3]heptane. thiazaSpim[3.3]heptane, thiazaspiro[4.3]octane. azaspim[5.5]decane, and
the further homologous spiro[3.4], spiro[4.4], spiro[5.5]. 6.6}. spiro[2.-t]. spiro[2.5].
spiro[2.6], spiro[3.5}, spiro[3.6], 4.5], spiro[4.6] and spiro[5.6] systems including the variants
modified by heteroatoms according to the ion.
Halogen in the context of the invention is fluorine, chlorine and bromine. Preference is given to
fluorine and chlorine.
Hydroxy in the context of the invention is OH.
An 0x0 group in the t of the invention is an oxygen atom attached to a carbon atom via a
double bond.
A symbol * at a bond denotes the point of attachment in the molecule.
When radicals in the compounds according to the invention are substituted, the radicals may be
mono— or polysubstituted, unless ed otherwise. In the context of the present ion, it is
the case that for all radicals which occur more than once, their meaning is independent of the
others. Substitution by one, two or three identical or different substituents is preferred.
Preference is given to compounds of the formula (Din which
W represents 5-membered aryl which contains one to three heteroatoms selected from
the group consisting of N, O and S and may optionally be monosubstituted by R3 and
optionally be mono- or polysubstituted by identical or different radicals R4, where a ring
heteroatom is located next to the ring carbon atom which is the point of ment to the
remainder of the molecule
represents pyridyl, nyl, pyridazinyl, 1,2,4-triazinyl or 1,3,5-triazinyl which may
optionally be monosubstituted by R3 and optionally be mono— or polysubstituted by
identical or different radicals R4, where a ring heteroatom is located next to the ring carbon
atom which is the point of attachment of the group to the remainder of the le.
ence is furthermore given to compounds of the formula (I) in which
W represents a group selected from the following general formulae (III) to (IX):
0 \ S \ N” N \
k . .
. I .
N A )L
R12 0
R12 \N R12/NKN Ru
III IV V VI
(R4 m
a S
i / \ *
/ >_*
N __
R12/ \N N
R12 N
VII VIII IX
in which
R[2 represents hydrogen, halogen, C1-C6-alkyl which is optionally mono— or polysubstituted
by identical or ent halogen radicals, C3-C6-cycloalkyl which is optionally mono- or
bstituted by cal or different halogen radicals, aryl which is optionally mono— or
polysubstituted by identical or different radicals from the group consisting of Rc or 5— or 6-
membered heteroaryl which is Optionally mono- or polysubstituted by identical or different
radicals from the group consisting of Rc or represents NHR“;
m represents 0, l, 2 or 3 and
R3 and R4 have the meanings given above and
* represents the point of attachment of the
group to the remainder of the molecule.
Particular ence is furthermore given to compounds of the general formula (I) in which W
represents a group of the general formula (IX)
(1X)
in whichin = 0 or 1 and
R3 is a C1—C6—alkyl radical which is optionally mono- or polysubstituted by halogen and/or
hydroxy, is halogen, cyano or a C3—C6-cycloalkyl radical which is optionally mono- or
polysubstituted by halogen and/0r hydroxy.
Preferably, R3 is a C1-C3-alkyl radical which is unsubstituted or mono- or polysubstitutcd by
hydroxy and/or halogen.
For the purpose of the ion, particularly preferred Cl-C3—alkyls radical for R3 are methyl and
ethyl. Preferably, R3 is a C1-C5-alkyl radical which is ally monosubstituted by y
and/or mono- to trisubstituted by fluorine.
Particularly preferably, R3 is a CI-Cg—alkyl radical which is optionally monosubstituted by y
and/or mono- to tn'substituted by fluorine.
Preferred substituted C1-C3-alkyl radicals for R3 an: trifluoro-C,-C;-alkyl. hydroxymcthyl, l-
hydroxycthyl. 2-hydroxypropanyl and 2.2,2-trifluorohydroxyethyl. Here. particular
preference is given to a trifluoromethyl radical.
Also preferred for R3 is a ropyl radical.
In an exemplary manner, the following radicals may be mentioned for W:
1 —1H—pyrazol—3—yl, 2,4'—bipyridin—6 -yl, 2-(4—fluorophenyl)-1,3—thiazol—4—yl, 2-(4—
methoxyphenyl)-l ,3—thiazolyl, 2-(azetidin—3—ylamino)—1,3-thiazolyl, 2—(pyridinyl)-1,3-
thiazoly1, 2-(pyridin-4—yl)-1,3-thiazoly1, fluoromethyl)-l,3-thiazolyl, o-l,3—
thiazoly1, 2-cyclopr0pyl-1,3-oxazolyl, 2-methyl-l ,3-oxazolyl, 2-methyl—1,3-oxazoIyl, 2-
phenyl-21—I-1,2,3—triazol—4—yl, (tert-butoxycarbonyl)azetidiny1]amino}-1,3-thiazol—4—yl, 4‘—
methyl—2,3'-bipyridin—6—yl, 4—(trifluoromethy1)-1,3-thiazoly1, 5‘-rnethyl—2,3‘-bipyridin—6-yl, 5—
fluoro—é—(l -rnethyl-1 H—pyrazol4—y1)pyridinyl, S-fluoropyridin-Z-yl, 6‘-acetamido~2,3'-bipyridin-
6—yl, 6'—amino—2,3’—bipyridin—6—y1, h0xy—2,3‘—bipyridin~6—yl, 6'—rnethyl—2,3'-bipyridin—6-y1, 6-
(1,3—dimethyl—lH—pyrazol—4—yl)pyridin—2—yl, 6—(1 —methyl—l H—pyrazol-4—y1)pyridin—2—yl, 6-(1—
methyl—1H—pyrazol—S—yl)pyridin-2—yl, 6—(1H—l,2,4—triazol—l—yl)pyridin—2—yl, 6-(1 H—pyrazol—l —
y1)pyridin—2—yl, 6—(3—hydr0xyazetidin—l—yl)pyridin-2—yl, 6—(3-rnethyl—1H—pyrazol—4-yl)pyridin—2—yl,
6-(4-ch10r0-lH-pyrazol-l-yl)pyridin-2—yl, 6-(4H-1,2,4-triazol—4-yl)pyridin—Z-yl, 6—(azetidin—3—
ylamino)py1‘idin—2—yl, 6—(cyclopropylmethoxy)pyridinyl, 6—(dimethylamino)pyridiny1, 6-
(morpholinyl)pyridin—2—yl, 6—(morpholin—4-yl)pyridin—2-yl, 6—(trifluoromethyl)pyridiny1, 6—
[1-hydroxyethyl]pyridin—2—yl, 6— [(2R,6S)—2,6—dimethylmorpholin-4—yl]pyridin—2—yl, 6—[3-
(methylsulphonyl)phenyl]pyridin—Z—yl, 6-[3—(trifluoromethyl)—1H-pyrazol-4—yl]pyridin-Z-yl, 6—
acetamidopyridin-2—yl, opyridin—2-yl, nopyridin—2—yl, 6—bromopyridin—2—yl, 6—
chloropyridin-Z-yl, 6-cyclopropylpyridin-Z-yl, 6-ethoxypyridinyl, 6-ethylpyridinyl, 6-
PCT/EP2014/O77877
fluoropyridin-Z-yl, 6-methoxypyridin—2-yl, 6-methylpyridinyl, 6- { azetidin
ylmethyl]amino}pyridiny1 and 6-(2-hydroxypropanyl)pyridinyl.
Preferred for W are the following radicals:
uorophenyl)-1,3—thiazolyl, 2—(4—methoxyphenyl)—l,3-thiazol—4-yl, 2-(azetidin—3-ylarnino)—
1,3-thiazolyl, 2-(pyridinyl)—l,3—thiazolyl, 2-cyclopropyl~l,3—oxazol—4-yl, 5-fluoro(l-
methyl-lH-pyrazolyl)pyridin-2—yl, 6—(l—methyl-1H-pyrazol—4-yl)pyridin-2—y1, 6-(1H—1,2,4-
l—l-yl)pyridinyl, 6-(lHopyrazol-l-y1)pyridin—2—yl, 6-(3—methyl—1H—pflazol—4—yl)pyridin—2-
yl, 6-(azetidin—3-ylan1ino)pyridin—2-yl, 6-(dimethylamino)pyridinyl, 6-(morpholin—4-yl)pyfidin-
2-yl, 6—(trifluoromethyl)pyridinyl, 6-[1—hydroxyethyi]pyridinyl, 6-[3-(trifluoromethyl)—1H—
pyrazol—4-yl}pytidinyl, 6-cyclopropy1pyridinyl, 6-methylpyn'dinyl and 6—(2—
hydroxypropan-E-yl)pyTidin—IZ-yl_
If W represents a group of the general formula (IX) and m = 1, R‘ is preferably located in the
position ortho to R3:
If W represents a group of the general formula (X), R4 is preferably hydrogen, C1—C3—alky],
fluorine, chlorine, bromine, cyano or trifluoromethyl.
Particularly preferably, W represents a group ofthe general formula (X) in which R4 is hydrogen.
Particularly preferred for W are the following radicals:
6-(1—methyl—lH—pyrazol—4—yI)pyridinyl, 6—(1H—1,2,4-triazoly1)pyridin-2—yl, pyrazol-l—
yl)pyridin-2—yl, 6—(3—methyl-lH—pyrazolyl)pyridin-2—yl, 6—(azetidin—3-ylamino)pyridiny1, 6—
(dimethylamino)pyridin—2-yl, 6—(morpholin—4—y1)pyridiny1, 6-(trifluoromethyl)pyridin—2—yl, 6—[1—
hydroxyethyl]pyridin-2 -yl, 6—[3 -(trifluor0methyl)-l H-pyrazol—4-yl]pyridin—Z-yl, 6-
cyclopropylpyridin-Z—yl, ylpyridin—2-yl and 6~(2—hydroxypropan—2-y1)pyridi_nyl.
Preference is furthermore given to nds in which R1 is hydrogen, halogen, hydroxy, cyano,
C1-C6-alk0xy, alkyl, C3-Cg-cycloalkyl, aryloxy or heteroaryloxy.
W0 20'15/091426
In a preferred embodiment, C1-C6—alkoxy in the sense of R] is methoxy, ethoxy, isopropoxy or else
isobutoxy. C1-C6-Alkoxy may be mono- or polysubstituted, preferably by one or more halogens or
else by cycloalkyl mono- or polysubstituted by identical or different halogens.
If R1 represents mono- or polyhalogenated C1-C6-alkoxy, preference is given to fluorine. Here,
trifluoromethoxy, difluoromethoxy and 2,2,2-trifluoroethoxy may be mentioned by way of
example. Trifluoromethoxy and 2,2,2—trifluoroethoxy are very particularly preferred.
If R1 represents a C1-C6-a1koxy l which is mono- or polysnbstituted by C3-Cg-cycloalkyl,
ence is given to C3-C5-cycloalkyl, in particular to a cyclopropyl radical. ropylmethoxy
may be mentioned as an example thereof.
If RI is a C1-Cb-alkoxy radical substituted by an aryl group
, preference is given to aryl groups
having 6 carbon atoms, for example benzyloxy.
If RI is a alkoxy l substituted by a heteroaryl group, preference is given to 6-
membered hereroaql radicals. Here, a pyrimidylmethoxy radical may be mentioned as an example
for R}.
r preferred embodiments for R1 in the sense of Cl-CG-alkyl are methyl or ethyl.
If RI is a halogen, preference is given to bromine, fluorine or chlorine. Particular preference is
2O given to ne.
Furthermore, R1 may be a hydroxy-substituted C1-C5-alkyl radical. Here, particular mention may be
made ot‘Z-hydroxypropan—Z—yl or 3-hydroxypentanyl. Preference is given to a 2-hydroxypropan—
2-y1 radical.
If R1 is a n, preference is given to fluorine, chlorine and bromine. Particular preference is
given to chlorine.
The present invention also provides compounds of the general formula (I) in which W represents a
group of the general a (IX) or (X) and R2 represents hydrogen.
Moreover, the present invention provides nds of the general formula (I) in which W
represents a group of the l formula (IX) or (X) and R0 represents hydrogen or methyl.
Moreover, the present invention provides compounds of the general formula (I) in which W
represents a group of the general a (1X) or (X) and R13 represents hydrogen or methyl.
er, the present invention provides compounds of the l formula (I) in which W
ents a group of the general formula (IX) or (X) and n represents 0 or 1.
Moreover, the present invention provides compounds of the l formula (I) in which W
represents a group of the l formula (IX) or (X) and R1 represents hydrogen, cyano,
isopropoxy, trifluoromethoxy, 2,2,2—trifluoroethoxy, isobutoxy, cyclopropylmethoxy, pyridin-Z-
ylmethoxy, benzyloxy, bromine, chlorine, ethoxy, fluorine, hydroxy, methoxy or 2-hydroxypropan—
2-yl.
Moreover, the present invention provides nds of the general formula (I) in which W
represents a group of the general formula (IX)
(1X)
in which m represents 0 or 1, R3 is a C1-C6-alkyl radical which is optionally mono- or
polysubstituted by halogen and/or hydroxy, is halogen, cyano or a Cg—Cb—cycloalkyl radical which
is optionally mono- or polysubstituted by halogen and/or hydroxy and R4 is a C1—C3—alkyl l,
fluorine, chlorine, bromine, cyano or trifluoromethyl.
Moreover, the present invention provides compounds of the general formula (I) in which W
represents a group of the general formula (X)
in which R4 is hydrogen, C1-C3—alkyl, fluorine, chlorine, bromine, cyano or trifluoromethyl and R3
is a C1-C6-alkyl radical which is optionally mono— or bstituted by halogen and/or hydroxy, is
halogen, cyano or a C3-C6-cycloalkyl radical which is optionally mono- or polysubstituted by
halogen and/or hydroxy.
PCT/EPZOl 4/077877
Particular preference is given to compounds in which W represents a group of the general a
(X) in which R4 represents hydrogen and R3 is a C1—C3—alkyl radical which is unsubstituted or
mono- or polysubstituted by hydroxy and/or halogen.
Very particular preference is given here to compounds in which W ents a group of the
general formula (X) in which R4 represents hydrogen and R3 is a Cl—C3—alkyl radical which is
optionally monosubstituted by hydroxy and/or mono- to trisubstituted by fluorine.
Here, special preference is given to compounds in which R4 ents hydrogen and R3 is methyl,
ethyl, ro-C 1-C3-alkyl, hydroxymethyl, l—hydroxyethyl, 2—hydroxypropan—2—yl or 2,2,2—
trifluoro-l -hydroxyethyl.
Especially preferably, R4 is hydrogen and R3 is a trifluoromethyl or a cyclopropyl radical.
Y either represents a radical
*"rN
or represents a group
RaR7 7b
(11).
If Y represents NRSR6 as described above, R5 is ably Cl-CS-alkyl, ularly preferably
methyl or ethyl.
R6 is likewise C1—C6-alkyl which may optionally be mono- or polysubstituted, preferably by C3-Cm-
cycloalkyl.
Particularly preferred for R6 are methyl or ethyl which are optionally substituted by C3-C10-
cycloalkyl. Here, ular preference is given to ropyl.
As an e thereof, mention may be made of cyc10propylmethyl.
Further preferred embodiments for R6 are C3-Cm-cycloalkyl, heterocycloalkyl, 5- or 6-membered
heteroaryl or aryl.
Particular preference is given here to pyridazinyl, phenyl, oxazolyl, piperidinyl and cyclohexyl.
PCT/EP2014/O77877
If Y represents NRSR6 the following radicals may be mentioned as examples for Y: (3-
sulphamoylphenyl)arnino, [(3R)-piperidiny1amino]ethyl, 1,2—oxazol—4-ylamino, [3-
(dimethylsulphamoyl)phenyl]amino, [trans(2-hydr0xypropan—2-yl)cyclohexyl]amino, pyfidazin—
4—ylamino, (cyclopropylmethyl)(methyl)amino.
If Y represents a goup ofthe general a (II)
R7a R717 7c
( o 5
(IN Z
kWRw
R Rm: Rec
(11)
where
0 = 0, l or 2;
p = 0, 1, 2 or 3;
q = 0 or 1,
where the sum ofo, p andq= l, 2 or 3; and
r=00r1;
s=00r1; and
2 ents , NR”, 0, s or S(=O)2,
then 0 or 1 or 2 is preferred for p.
Here, special preference is given to compounds in which Y represents a group of the general
formula (II)
R7a R7bR7c
( o QR7d
*z-N Z
lW 8d
Raa Rel: Recs R
in which
0 = 0,
p = 0 or 1,
q,rands=land
Z represents CRng, NR“, 0, S or S(=O)2.
If Y represents a group of the formula (II) mentioned above, the following groups may be
mentioned by way of e:
4-benzoylpiperazin-l -y1, 4-(py1rolidinyl)piperidin—1 -yl, 4-(3—hydroxy-2,2—
dimethylpropanoyl)piperazin-1 -y1, 4-(methoxyacetyl)piperazin—1 -yl, 4—(2-hydroxypropan—2—
yl)piperidin- l -yl, 4—(cyclopropylmethyl)piperaziny1, 4-methy1piperazinyl, 4-
(cyclopropylcarbonyl)piperazin—l-yl, morpholin-4—y1, 4-(ethoxycarbonyl)piperazinyl, 3-
(dimethylamino)azetidin-1 —yI, 3—(piperidin—1 —yI)azetidin—l —yl, 2—hydroxy—2—
methylpropyl)piperidiny1, oxy-1,4'-bipipen'din-1‘—y1, 4-(dimethylamino)pipexidin-l-yl, 4-
(2,2,2-trifluoroethyl)piperazin—1-yl, 4-ethyloxopipcrazin-1 -y1, 4v(4—fluorobenzoyl)piperazin-1 -
yl. 4-(pyridinyl)piperazinyl, 4~cyclopcnty1-3oxopipcmzinel -y1, 3-oxophenylpiperazin-l-
yl. dime1hylpmpanoyl)piperazin-l-_vl. 4-(2-hydroxymethylpropanoyl)pipcrazin-l-yl. 4-
(! -phcnyle1hy1)pipcrazin-l -yl]ethyl. 4-{p3ridinylcarbonylmipcrazm-I -)'l. 4-
otimylpiperazin-I -)'1. «HIrmrpholinA‘ylcarbmylbipcrazin-l -)'l. 4-[2{m€thylamin0¥2-
oxoethyl]pipemzin—l—yl, 4—(py1'azin—2-yl)piperazin-l-yl, 4—(1—hydroxyethyl)piperidin-l—yl, 2—(2-
mcthyl-2,8-diazaspiro[4.5]dec—8—yl, 6—acetyl—2,6—diazaspiro[3.3]hept—2—yl, 2,8—
diazaspiro[4.5]decyl)ethyl, 6-methyl-2,6-diaza5piro[3.5]non—2-y1, 7-0xaazaspiro[3.5]non
yl, 1,4'—bipiperidin~l'—y1, 2-[2-(hydroxymethyl)piperidiny1, 3-(hydroxymethyl)piperidin-l-y1, 4-
carbamoylpiperidin-l-yl, 3-(dimethylamino)pipcridiny1, 3-(m0rpholiny1mcthyl)piperidin
yl, 4-[(cyclopropylcarbonyl)amino]pipcridinyl, 4- [(5-cyclopr0pyl- l ,2,4-0xadiazol-3 -
yl)methy1]piperidin-l ~yl, 4-(pyrr01idinylcarbonyl)piperidin—1 -y1, ethylpiperazin—l -
yl)piperidin—l -y1, 4—[2—(morpholiny1)ethy1]piperidin-l-yl, 4-[(5-methy1-l ,2,4-oxadiazol
yl)methyl]piperidin-l —yl, 3—(pyrrolidin-l -y1methyl)piperidin-l—y], 4—(methylsulphonyl)piperidin-l —
yl, 4-[2-0x0(pyrrolidin—l hyl]piperazin—1—yl, 4—(phenylsulphonyl)piperidin—1 —yl, 4-
[isonicotinoyl(methyl)amino]piperidin—1-y1, 4-[2-(isoPropylamino)-2—oxocthyl]piperazin—1-yl, 4-
(l ,1 -dioxidotetrahydrothiophen—3—yl)piperazin—1 -yl, 4-[(methoxyacetyl)(methyl)amino]piperidin-1 —
yl, 4-(cyclohexylcarbony1)piperazin-l-yl, 4—[2-(cyclopr0pylamino)—2-oxoethyl]piperazin—l—yl, 2—
hydroxyethyl)piperidin—l—yl, 4-(1H-pyrr01-l-yl)piperidinyl, 4-(3-hydroxypr0pyl)piperazin-l-y1,
4—carbamoylpiperazin-l«yl, 4-(2-0x0py1rolidiny1)piperidin-l-y1, 4-(2-amino-2—
oxoethyl)piperazin-l -y1, 1,1—dioxidothiomorpholinyl, 4-isopropy1piperazin- l -y1, 4-(2-
thienylcarbonyl)piperazin-1—yl, 2-cyclopropyl—2-oxoethy1)piperazin—1—yl, 4—[(1-methy1—lH—pyrazol—
4—yl)methyl]piperazin~l-yl, 4-[(l,5—dimethy1—lH-pyrazol-3—y1)carbonyl]piperazin—l-yl, 4-
(diethylcarbamoyl)piperazin—1-yl, thiomorpholinyl, urylmethyl)piperazin—1-yl, 4—(3-
thienylmethyl)piperazin-1 -y1, 4'-methyl-1 ,4'—bipiperidin—l '-yl, 6-mcthy1-2,6-diazaspiro[3 .3]hept—2—
yl, 4—cyclopentylpiperaziny1, 4—[2-(2-hydroxyethoxy)ethyl]piperazin—l~yl, 4-(pyridin—4—
ylmethyl)piperazin-l-yl, 4{dimethylsulphamoyl)piperazinyl, 4-(pyridinyl)piperazin-l-yl, 4-
(methylsulphony1)piperazinyl, (1H-imidazol-l ~y1)ethyl]piperazin—l -yl, 4-
PCT/EP20l4/077877
(diethylsulphamoyl)piperazin-1 -y1, 4-(py1idiny1)piperaziny1, 4-(piperidin-l -
ylsulphonyl)piperazin-l-yl, 4-[(1,S-dirnethyl-lH-pyrazolyl)sulphonyl, 4-ethylpiperazin-l-yl, 4-
methyl[(4-methylpiperazin-l -yl)carbonyl]piperidinyl, 4-(cyclobutylcarbonyl)piperazin-1 -yl,
4-(cyclopentylcarbonyl)piperazin-l-y1, methylsulphonyl)benzoyl]piperazinyl and 4-[2-
methoxy—S-(methylsulphonyl)benzoyl]piperazin—1 -y1.
Especially preferably, Y is 4-methylpiperazin—1—yl, 4—ethylpiperazin—1 —yl or morpholin—4—y1.
The present invention ably provides compounds of the l formula (I) in which W
represents a group of the general formula (IX)
(TX)
in which
m represents 0 and R2, R0 and R13 all ent hydrogen and R3 represents romethyl, ethyl,
methyl, ropyl, 2,2,2-trifluoro—1—hydroxyethyl or 1—hydroxyethyl; Y represents 4-
methylpiperazin-l-yl, 4-ethylpiperazinyl or morpholiny1, n represents 0 and Rl represents
cyclopropylmethoxy, trifluoromethoxy, trifluoroethoxy, chlorine, ethoxy or methoxy,
Here, Rl particularly preferably represents cyclopropylmethoxy, methoxy or ethoxy.
Here, particular preference is given to compounds in which R3 is a trifluoromethyl or a eyelopropyl
radical.
The present invention also provides the following compounds:
N-{2-[2-(4-benzoylpiperazin—1-yl)-2—oxoethyl]—6-rnethyl-2H—indazol-5—yl}
(tri fluoromethyl)pyridinecarboxarnide
6-ethyl—N—(6—methy1—2—{2—oxo—2—[4-(pyrrolidin-1 -yl)piperidin-l -y1]ethy1} -2H-indazol
yl)pyridine—2-carboxamide
—fluor0—N—(6—methyl{2-oxo[4-(pyrrolidin-l -yl)piperidinyl]ethyl} -2H-indazol-5 -
yl)pyn'dine—2—carboxamide
N—(2- {2—[4—(3 —hydroxy—2,2—dimethylpropanoyl)piperazin-1—y1]—2—oxoethy1} methy1-2H—
indazol—S —yl)—6—(trifluoromethyl)pyridine-2—carboxarnide
2-[4-(methoxyacetyl)piperazin-1~yl]—2-oxoethyl} Inethyl-2H-indazol-5 -yl)
(trifluoromethyl)pyridinecarboxamide
N-(2- {2-[4-(2-hydroxypropanyl)piperidin-1 -y1]oxoethy1} methoxy-2H-indazol-5 -yl)
(trifluoromethyl)pyridine-Z-carboxamide
N—(2—{2—[4-(2-hydroxypropan—2-yl)piperidin—1-y1]oxoethy1}meth0xy—2H-indazol-5—y])
methylpyridine-Z-carboxamide
N—(2- {2-[4—(cyclopropylmethyl)piperazin—1 -y1] -2—oxoethy1} -6 -methoxy—2H-indazol—5—y1)-6—
(trifluoromethyl)pyridine—2-carboxamidc
N-(2-{2-[4-(cyclopropylmethyl)piperaziny1]oxoethy1}methoxy-2H-indazoly1)
methylpyridine-Z-carboxamide
N- {2—[2~(4-benzoylpiperazin— 1 -yl)-2—oxoethyl]—6—methoxy—2H—indazoI—5—yl } —6—
cyclopropylpyfidine-Z{arboxamide
N-{2-[2-(4~benzoylpiperazin—1-yl)—2 -0xoethyl] methoxy.2H-indazoly1} (I -
yethyl)pyridine-E-carboxamide
N-{2-[2-(4~methylpipcrazin—1~yl)oxoethyl](trifluoromethoxy}-2Hvindazol-S-yl }
(trifluoromcthylmyfidine—Zfiarboxamidc
(“y—methyl-N- {2 2—{4-mcthylpipcrazin- l -_\'1)«2-0xocthy11(trifluoromcthoxy}2H-indazol
yl } pyfidine-Z—carboxamide
ten-butyl 3- { [4-( {2—[2—(4—methylpiperazin—1 —yl)—2—oxoethyl]—6—(t1ifluoromethoxy)—2H—indazol—
-y1}carbamoyl)-1,3-thiazoly1]amino}azetidine—l—carboxylate
N~{6~br0mo[2-(4-methy1piperaziny1)0xocthyl]-2H-inda201y1}
oromethy1)pyridine—2—carb0xam ide
N—{6-bromo—2-[2—(4—methylpiperazin—1.-y1)oxoethy1]-2H-indazo1y1}methy1pyridine
carboxamide
N— {6-bromo—2-[2—(4—methy1piperazin—1-y1)0xoethy1]-2H-indazolyl} cyclopropy1—1 ,3-
oxazole—4—carboxamide
tert-bulyl 3- { [4-( {6-br0m0—2-[2-(4—rnethylpiperazin—l —y1)-2—0xoethyl] —2H-indazol—5-
y1}carbamoyl)-1,3-thiazolyl]amin0}azetidine—l—carboxylate
2—(azetidiny1amino)-N—{2-[2-(4-methy1piperazin—1-y1)0xoethyl]—6—(triflu0romethoxy)-
2H—indazol—5-y1}-1,3—thiazole—4-carboxamide
N—{6-cyano~2-[2-(4-methylpiperazin—1 -0xoethyl]—2H-indazoly1}
(trifluoromethyl)pyridine~2-carboxamidc
6'—methy1—N~{2-[2-(4-methylpiperaziny1)0xoethyl]-2H—indazoly1}-2,3'-bipyridine-6—
amide
'—methy1~N-{2-[2-(4-methylpiperaziny1)oxoethyl]~2H—indazol-5 -y1} —2 ,3 '-bipyridine—6-
amide
4'-methyl—N—{2—[2—(4—methylpiperazin—1—y1)—2-oxoethy1]-2H-indazoly1}-2,3'-bipyridine
carboxamide
6'-methoxy-N-{2-[2-(4—methy1piperazin—1-yl)oxoethy1}-2H-indazoIyI}-2,3’-bipyridine
carboxamide
6'-acetamido-N- {2 -[2-(4-methy1piperazin—l -y1)oxoethyl] -2H-indazol-5 -yl} -2,3'-bipyridine-
6-carboxamide
N- (4-methylpiperazin—1 -yl)0xoethy1]-2H-indazoly1}-6'-nitro-2,3‘—bipyridine-6—
carboxamide
6'-amino-N-{2-[2—(4-methy1piperazin—1-y1)-2—oxoethy1]—2H-indazol—5—yl}-2,3'—bipy-ridine-6—
carboxamide
N- {2-[2-(4—benzoylpiperazin-1—y1)oxoethy1]fluoro-2H—indazol-S -yl} —6-
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4{cyclopropylcarbonyl)piperazin—1-yl]—2—oxoethyl}—6—fluoro—2H—indazol-5—yl)—6—
(tn'fluoromethyl)pyridine—2—carb0xamide
N- {6—fluoro[2-(4-methy1piperazin—1 -y])-2.ox0ethyl]—2H-indazol-5 -y1} —6—
(trifluoromethyl)pyn'dine-z-carboxamide
N-{Z- {2-[4-(cyc10propylcarbonyl)piperan'n-l -yI]oxoe1hyl } fluor0.2H-indazoI-5 -y|}
methylpyfidinc-Z-carboxamidc
N- {6-fluor0—2-[34H—mcthylpiperazin—l ayl)—2-oxoexhy1]—2H—indazoly1:#mcthylmfidine-Z-
carboxamjde
N-(2-{2-[4-(cyc10propylcarb0ny1)piperazin—1 —yl]—2—oxoethyl}fluoro—2H-indazol—S-yl)—6-(l -
methyl-1 H-pyrazoly1)pyr1'dinecarhoxamide
N-{2—[2—(4—benzoy1piperazin-1 -y1)oxoethy1]~6-fluoro—2H—indazoI—5-y1}-6—(1-methyl—1 H-
pyrazolyl)pyridine—2—carb0xamide
N- {6-fluoro-2—[2-(4-methylpiperazin—1 -y1)oxoethy1]~2H-indazoly1}(1 -methyl- 1 H-
pyrazolyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazin-1—yl)-2—oxoethyl]fluoro—2H-indazol—S-yl}—5—fluoro—6-(1-
methyl-1H-pyrazoly1)pyridine—2—carboxamide
N-(2- (cyclopropylcarbonyl)piperazin-1 —y1]—2—oxoethy1}~6-fluor0-2H-indazol-S-y1)
fluor0( 1 ~methyl-1H-pyrazolyl)pyridine—B—carboxamide
N—{2—[2-(4—benzoylpiperaziny1)0xoethyl]flu0ro-2H—indazol-5—y1}—6-(morpholin—4-
yl)pyridine—2—carb0xamide
N—(2-{2-[4{cyclopropylcarbonyl)piperazin—1—y1]oxocthy1}fluoro-2H-indazol—5-y1)~6—
(Inorpholiny1)pyridine—2-carboxamide
N- {6—flu0ro[2-(4—methy1piperazin—1 —y1)oxoethyl] -2H-indazol-5~y1} rpholin
yl)pyridine—2—carboxamide
benzy1‘oxy)—2—[2—(4I—methy1piperazin-1—y1)—2-oxoethyl]-2H—indazol—5-y1}-6—
oromethyl)pyridine—2—carb0xamide
sobut0xy-2—[2—(4—methylpiperaziny1)—2—oxoethy]]-2H-indazol-5 -y1} —6-
(trifluoromethyl)pyridine—2-carb0xamide
N- {6-isobutoxy [2-(m0rpholin—4-y1)—2-oxoethy1]-2H-indazol-5 ~yl } -6—
(trifluoromethyl)pyn'dine-Z-carboxamide
N-(2- {2-[4-(2-hydr0xypr0pan—2-y1)piperidin-I -yl]oxoethy1} isobutoxy-ZH-indazol-S-yl)—
fluoromethyl)pyn'dine—2-carboxamide
N—(2—{2-[(cyclopropylmethy1)(methy1)amino]oxoethy1} -6—isobut0xy-2H—indazol—5 -yl)—6—
(trifluoromethyl)pyridine—2-carboxamide
N— {6—(cyclopropylmethoxy)—2-[2-(4-methy1piperazin-1 ~yl) ethyl] -2H-indazoIy1}
(trifluoromethyl)pyfidinecarboxamide
N- {6—(cyc10propylmethoxy)—2-[2-(morpholiny1)-2—oxoethyl]-2H—indazoI—5 -yl}—6-
(tn'fluoromethyl)pyridine-Z-carboxamide
N-[6-(cy010pr0py1methoxy){2-[4-(2—hydroxypropany1)piperidin-1 -yl]—2-0xoethy1}-2H-
indazoI-S-yl](trifluor0methyl)pyridine—2fiarboxamide
N-[6-(cyc10pr0pylmethoxy)—2— {2—{(cyclopropylmethlemethyl)amino]—2-oxoethy1}~2H-
indazoI-S-yl](trifiuoromethyl)pyn‘dine-2—carboxamide
N—{2-[2-(4-methylpipcrazin- l -yl }oxoethyl]Mpmdin-Z—ylmethoxyFZH-indazoI—5-yl } —6—
(trifiuoromethyl)pyridinccarboxamide
N- {2-{2-(morpholinyI)~2-oxoelhyl](p)'ridin-Z-ylmclhoxy}-ZH-indazol-5 -yl }
oromethyl)pyfidine—Z—carboxamidc
N-[2-{2-[4-(2—hydroxypropan—2—yl)piperidinyl]-2 -oxoethy1} ~6-(pyridinylmethoxy)-2H-
indazol—S-y1](trifluoromethyl)pyridinecarboxamide
N-[2— {2—[(cyclopropylmethyl)(methyl)amino] oxoethyl} (pyridiny1methoxy)-2H-
indazol-S-yl](tzifluoromethyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazin—1-y1)—2—0xoethyl]—6—chIoro—2H—indazol—5 -y1} -6—
(trifluoromethy1)pyridinecarboxamidc
N- {6-chloro[2-(morpholiny1)oxocthy1]-2H-indazol—5-y1}(trifluor0methyl)pyridine—
2—carboxamide
ethyl 4— { [6—chloro—5-( { [6-(triflu0romethy1)pyridin—2-yl] carbonyl } amin0)-2H-indazol
yl] acetyl } piperazine—l —carb0xy1ate
N-(6-ch10r0—2- {2-oxo—2—[4—(pyrrolidin— I. -y1)piperidin-1 -y1] ethyl} -2H~indazol-5—y1)-6—
oromethyl)pyridine—Z—carboxamide
N—(6—chlor0 {2-[4-(2-hydroxypropan—2—yi)piperidin-l ~y1]oxoethy1}-2H-indaz01y1)
(trifluoromethy1)pyridinecarboxamide
N—(6—ch10ro {2-[4-(3-hydroxy—2,2-dimethy1pr0pan0y1)piperazin—1-y1]0xoethyl} -2H-
indazol-S-y1)-6~(trifluoromethyl)pyridine-2—carb0xamide
N-(6-chloro{2-[3-(dimelhy1amino)azetidin—1~y1]0xoethyl}-2H-indazoL5—y1)—6—
(trifluoromethy1)pyridine-2—carboxamide
hloro{2—oxo—2—[3-(pipefidin—1-yl)azetidin—1 —yl]ethy1}-2H-indazoly1)
(trifluoromethyl)pyn'dine-Z-carboxamide
N-(6-chloro-2— {2-[4-(2-hydroxymethylpropy1)piperidiny1]oxoethy1} —2H—indazol-S-yl)-
6-(trifluoromethyl)pyn'dine—2-carb0xamide
N—{6-chloro—2-[2-(4-hydroxy-1,4’-bipiperidin-1 '-y1)oxoethy1]-2H-indazol-5 -yI}~
(trifluoromethyl)pyridine-Z-carboxamide
N- {6-methoxy[2-(4-methy1piperaziny1)-2—oxoethyl]—2H—indazol—5 ~yl} —6-
(trifluoromethy1)pyridinecarboxamide
N— {6-methoxy[2—(morpholinyl)—2-0xoethyl]-2H—indazol-5 -yl}
oromethyl)pyridinecarb0xamide
N-(2- {2-[4-(dimethy1amino)piperidinyl]—2-0xoethy1}—6-ethoxy—2H-indazol-5—y1)—6-
(trifluoromethpryridine-2—carboxamide
N-(6—ethoxy{2-0xo-2—[4-(pyrrolidin—1-yl)piperidin—1-yl}ethyl}—2H-indazol—5-yl)—6-
(trifluoromethyl)pyxidinccarboxamide
N- {6—ethoxy[2-(4-methy1piperazin- 1 ~yl)-2axoethyI]-2H-indazol-5 —yI} -6—
(trifluoromethyl)pyn'dine—Z—carboxamide
N- {2-[2—(4—benzoylpipetazin—l ~yI )oxocthyl]ethoxy-2H-indazolyl }
(trifluommethyl)pyridine-Z—carboxamidc
N—(6—cthoxy—2— {2-[4—(2—hydmx3pr0pan-3 -)’l)pipcn'din-l -yI]-2 -oxoethy| } -2 -indazol-5—yl}-6—
(trifluoromcthyl)pyfidine—2—carboxamide
N-{6-ethoxy[2-(morpholin—4—yl)—2—oxoethyl]-2H-indazoly1}-6{trifluoromethpryridine-
2—carboxamide
N- {2—[2-(4-benzoylpiperaziny1)0xoethyl] -3 —methyl—2H-indazol-5 —y1}—6-
(tn' ethyl)pyridine-Z-carboxamide
3—(4—benzoy1piperaziny1)-3—0x0pr0pyl]—2H—indazoI-5—y1}—6-(trifluoromethyl)pyridine-
Z—carboxamide
N—(2-{2—[4—(cyclopropylcarbonyl)piperaziny1]oxoethyl}-2H-indazoly1)—2-(pyridin—3 -
yl)-1 ,3-thiazole—4-carboxamide
N—(2—{2—[4-(cyclopropylcarbonyl)piperazin-1—y1]—2-oxoethyl}-2H-indazoly1)(pyridin
yl)-1,3-thiazolecarboxamidc
N—(2-{2—[4-(cycIopropylcarbonyl)piperaziny1]oxoethy1}—2H-indazolyl)—6-
(tn'fluoromethyl)pyridine-Z-carboxamide
6—(azetidin-3 -ylamino)-N—(2-{2-[4-(cyclopropylcarbonyl)piperazin—1 —y1]—2—oxoethy1}-2H-
indazol—S-y1)pyridine—2-carboxamidc
N— {2—[2—(4—methy1piperazin-1 ~y1)—2-0x06thy1]—2H—indazol—5 —yl} —2—(pyfidin—3 -yl)—I ,3-thiazole—
4—carboxamide
N-{2—[2—(4—methy1piperaziny1)~2—oxoethyl]-2H-indazolyl}(1 -methyl—1H-pyrazoI-4—
idine—2—carboxamide
N— (4—methylpiperazin—1 -yl)oxoethyl] -2H—indazol-5 —y1}—6—(1H—pyrazol—4—yl)pyn'dine—
2-carb0xamide
6-(1 ,3-dimethy1-1H-pyrazoly1)-N—{2-[2-(4-methy1piperaziny1)oxoethy1]-2H—indazol
yl} pyridine-Z-carboxamide
PCT/EP2014/O77877
N- {2-[2-(4-methy1piperazin~ 1 ~y1)—2—oxoethy1]-2H-indazol—5 -y1} —6 rifluoromethy1)- 1 H-
pyrazolyl]pyridine-Z-carboxamide
6-ethyl-N-{2-[2-(4-methy1piperazin—1-yl)oxoethy1]-2H-indazol—5-yl}pyridine
amide
6-(1 -methy1-1 H-pyrazolyl)-N-(2- {2—0x0[4-(2,2,2—trifluoroethyl)piperazin-1 -yl] ethyl} -2H—
indazol-S-y1)pyridinecarboxamide
N-(2—{2-oxo-2—[4-(2,2,2-1;rifluoroethyl)piperazinyl]ethy1}—2H-indazolyl)—6—
(trifluoromethyl)pyridinc-2~carb0xamide
N— {2-[2—(4-ethy1-3—ox0piperaziny1)oxoethyl]-2H-indazoly1} methyl-lH-pyrazol-
yridinecarboxamide
N- {2-[2-(4-benzoy1piperazin- l -y1)oxoethyl]-2H-indazol—5-y1}(trifluoromethyl)pyridine—
2—carboxamide
N- {2—[2-(4-benzoylpiperazin—l -y1)—2—oxoethyI]—2H-indazol-S-y1 } —6-methylpyridine—2-
carboxamidc
N- (4~benzoylpiperazin-l -yl)-2 -0xocthyl}2H—indazoly1: (morpholin-4~yl Wyn-dine-
2-carboxamide
N-{2-[2-(4-benzoy1piperaziny1)oxoethyl]-2H—indazol—S—yl}-2—(pyridinyl)-1,3-thiazole-
4-carboxamide
N- {2—{2-(4-benzoy1piperazin—1 —y1)0xoethy1]-2H—indazo1y1} chlor0pyridine—2-
carboxamide
N- {2—[2—(4-benzoy1piperazin—1 -y1) -2—oxoethyl]—2H—indazo1—5 —y1}—2—methyl—l,3-oxazole—5—
carboxamide
6-amin0-N-{2-[2-(4-benzoy1piperazin—1-y1)0xoethy1]—2H—indazol—5—y1}pyridine-2—
amide
N— {2—[2—(4—benzoy1pipcra2in—1 -y1)oxoethyl]-2H-indazol-5—y1} methy1-1 ,3-oxazolc
carboxamide
N— {2—[2—(4-benzoylpiperazin—1 -y1)oxoethy1] -2H-indazol—5-y1} methoxypyridine
carboxamide
N—{2—[2—(4—benzoylpiperazin—l—yl)—2—0x0ethy1]—2H—indazol-5~y1}—2-cyclopropyl—1,3—oxazole-4—
carboxamide
N-{2-[2—(4-benzoylpiperazin—1—y1)—2—oxoethyl]-2H—indazol—5-y1}—6-(4H-I ,2,4-triazol
yl)pyridine—2—carboxamide
N—{2—[2—(4—benzoylpiperazin-1—y1)oxoethy1]-2H-indazoly1}—2—pheny1-2H-1,2,3-triazole-
4-carboxamide
N-{2—[2-(4—benzoylpiperazin—1—y1)—2-0xoethy1]-2H-indazoly1}(1-methy1-1H-pyrazoI
yl)pyn'dine—2-carboxamide
N-{2-[2-(4-benzoy1piperazin-l-y1)oxoethy1]-2H-indazolyl}(trifluoromethy1)-1,3-
thiazolecarb0xamide
N-{2-[2-(4-benzoy1piperazinyl)oxoethy1]-2H-indazolyl}(1H-pyrazolyI)pyridine-
2-carboxamide
N— {2-[2-(4-benzoylpiperazin—1 -yl)oxoethy1]-2H-indazol-5 -y1} (1-methyl-1H-pyrazol-4—
y1)pyridinecarboxamide
N—{2—[2-(4-benzoylpiperazin-1—yI)-2 hyl] ~2H-indazol-5 -yl} -1 -ethy1—1H-pyrazolc—3 —
carboxamide
N-{2-[2-(4-benzoy1piperazin—1-yl)oxoethyl]—2H—indazol—5 ~yI} —6-(4—Chlor0-1H-pyrazol-l-
yi)pyridinecarboxamide
N- {2-[2-(4-benzoylpiperazin-l -yl)-2—oxoethyl] —2H—indazol—5—yl} —4—(trifluoromethy1)-l ,3-
le—Z-carboxamide
N—{2-[2—(4-benzoylpiperaziny1)oxoethyl]-2H-indazolyl}(1,3-dimethyl-1H-pyrazol-
4-y1)pyridinecarboxamide
N-{Z—{Z-{4-benzoylpipcrazin-l-yl)-2—oxoethyl]-2H—indazol-5—y1}-2,4'-bipyridinc—6—
carboxamidc
N- {2-{2-(4~bcnzoylpiperazin-l -y1)oxoethyl]-2H-indazolyli (1H-p)Tazol—4-yl)p}1‘idinc-
Z—carboxamidc
N-{2~[2-(4—benzoylpiperazin—1-y1)-2—0xoethy1]—2H—indazol—5—y1}—5-fluoro—6—(1-methyl—1H—
pyrazol-4—y1)pyridinecarboxamide
N— {2-[2—(4—benzoylpiperazin-l -y1)-2—0xoethyl]-2H-indazoly1}~6—(3 -methy1—lH—pyraZOI-4—
idine—2—carboxamide
N-{2-[2-(4-benzoylpiperazin—1-y1)-2—oxoethy1]-2H-indazol-S-y1}(1H-1,2,4-triazol
y1)pyridinecarboxamide
N- {2-[2—(4-benzoylpiperazin—1 -y1)—2-0xoethy1]-2H-indazol-5 -y1}[3-(trifluor0mcthy1)-1H-
pyrazo1y1]pyridine-2—carboxamide
2-(4-benzoylpiperazinyl)-2—oxoethy1]-2H-indazol-5 —yl} —6—ethoxypyridine
carboxamide
N— {2-[2—(4—benzoy1piperazin~ 1 -yl)oxoethyl]—2H-indazol-5 -y1}
(cyclopropylmethoxy)pyridine—2—carboxamide
N-{2—[2—(4—benzoy1piperazin—1—yl)oxoethy1]—2H-indazol-5 -y1} ethy1pyridine—2-
carboxamide
N- {2—[2—(4—benzoy1piperazin— 1 —y1)oxoethyl]-2H-indazoI-5 -y1} —2-(4-meth0xypheny1)—1 ,3-
thiazoIe-4—carboxamide
2—(4—benzoylpiperaziny1)oxoethyl]-2H-indaz01y1}brom0-1,3-thiazole—4—
carboxamide
N- {2-[2-(4-benzoy1piperazin—1 —y1)—2-0xoethy1]-2H-indazol-5 -y1} fluoropheny1)—1 ,3-
thiazole-4—carboxamide
N—{2-[2-(4-benzoy1piperazin-1~y1)—2-oxoethyl]~2H-indazol-5 -y1} f‘luoropyridine
carboxamide
N- {2-[2-(4-benzoylpiperazin—l -y1) oxoethy1] -2H-indazol-5 -y1} br0mopyridine
carboxamide
N—(2- {2—[4-(4—flu0robenzoyl)piperazin-1 -yl] oxoethyl } -2H-indazo 1-5 -yl)
(trifluoromethy1)pyridine—Z-carboxamide
N-(2-{2-0x0[4-(pyfidin—Z—yl)piperazin—1-y1]ethy1}—2H-indazol-5 —yl)—6—
(trifluoromethy1)pyridine-Z-carboxamidc
N-(Z-{2-[4-(methoxyacetyl)piperazin—1-y1]oxoethy1}—2H—indazol—5 —yI)
oromethyl)pyridine-2carboxamide
N— {2-[2-(4—cyclopentyI-3 erazin— 1 «y1)oxoethyl] -2H—indazol-5—y1}—6-
(trifluoromethyl)pyridine-2—carboxamidc
N-{2-[2~ox0(3-oxopheny1piperazin—1-y1)ethyl]—2H—indazolyl}
(trifluoromethyl)pyridine-2carboxamide
N42- {2o[4—('2.2-dimethylpmpanoyl )piperazin- I -yl]oxoethyl } -2 H-indazoI-S -yl)-6«
oromethyl)pyfidine—Z-car’ooxamide
N-(Z- {2-{4-{cyclopropylmelhyl azin-l -yl]oxoethyl} -2H-indazol—5 1.1}6.
(Hifiuommcthyl)pyridine—Z-carboxamide
N-{2-[2-oxo(pyridazin—4—y1amino)ethyl]-2H-indazolyl}(trifluoromethyl)pyridine
carboxamide
N-(2-{2-[4-(2-hydroxymclhylpropanoyl)piperazin-1—yl]—2-oxoethy1} —2H-indazol-5 -yI)-6 -
oromethyl)pyridine-Q-carboxamidc
N—(2- {2—0xo—2—[4—(1—phenylethy1)piperazin-1 -y1]ethy1}-2H-indazol—5 —yI)
(trifluoromethyl)pyridinecarboxamide
N-(2— {2—0xo[4—(pyridin-3 -ylcarbonyl)piperazin— 1 —y1] ethyl} —2H-indazol—5 -yl)—6—
(trifluoromethyl)pyridine—2-carb0xamide
N— {2-[2-(4-isonicotinoylpiperazin—1 ~yl)0xoethy1] ~2H—indaZOIyI} -6—
(trifluoromethy1)pyridine—Z—carboxamide
N—(Z—{2-[4-(morpholin—4-ylcarbony1)piperaziny1]—2—oxoethy1}—2H-indazol—5-y1)
(tn'fluoromethyl)pyridine-Z-carboxamide
N—[Z—(Z-{4—[2—(methy1amino)oxoethy1]piperazin— 1 —yI} —2—oxoethy1)-2H—indazo 1-5 —y1]
(Irifluoromethyl)pyridinecarb0xamide
N—(2— {2—oxo[4-(pyrazin—2—y1)piperazin- 1 hy1}-2H-indazol—5-y1)-6—
(m'fluoromethyl)pyridine—2—carboxamide
N—(2—{2—[4—(1~hydroxyethy1)pipen'din-1 -y1]—2-oxoethyl}—2H—indazol-5—y1)-6—
(trifluoromethyl)pyridinecarboxamide
N- {2—[2-(2-methyl-2,8—diazaspiro[4.5 ] dec-8 -y1)—2—oxoethyl] -2H-indazoly1}
(tri ethy1)pyridine—Z-carboxamide
N— {2-[2-(6-acety1-2,6—diazaspiro[3.3]hepty1)oxoethyl]-2H-indazol-5 -y1}
(trifluoromethyl)pyridinecarboxamide
N—{2-[2-0xo(3-0x0-2,8-diazaspir0[4.5]decyl)ethy1]-2H-indazoIy1}
(trifluoromethy1)pyridinecarboxamide
N—{2-[2—(6-methyI-2,6-diazaspiro[3.5]non-2—y1)0xoethy1]-2H-indazoly1}-6—
(trifluoromethyl)pyridine—Z-carboxamide
N— {2-[2-(7-oxaazaspir0[3 .5]n0ny1)-2—oxoethy1]~2H-indazol-5 -yl} —6~
(trifluoromethyl)pyridinecarboxamide
2-(1,4'-bipiperidin-1 '-yl)oxoethyl]-2H-indazol—5-yl}—6-(tn'fluoromethyl)pyridine-2—
carboxamide
2-[2-(hydroxymethyl)pipen'dinyl]—2—oxoethy1} dazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2- {2-[3-(hydr0xymethyl)piperidin—l —yl]—2—oxoethy1}-2H-indazol—5-y1)—6-
(trifluoromcthyl)pyridinecarboxamide
N- { 2-[2-(4-carbamoylpiperidin-I -yl)oxocthyl]-ZH-indazol—5-yl } ~6-
(tri fluoromethylmgridinc-Zcarboxamidc
TH}{2-{3-(dimethylaminowipefidinyl]oxoethyl' -2H-indazoly1)
(mfluoromcthyl)pyridine—Z—carboxamide
N-(Z-{2-[3-(morpholin—4—y1methyl)piperidin—1-y1]oxoethy1}-2H-indazolyl)
(trifluoromethyl)pyfidine—2—carboxamide
N-[2-(2-{4-[(cy010propylcarbonyl)amino]piperidiny1}oxoethy1)-2H-indazol-5—yl]
(tri ethyl)pyridine-2—carboxamide
N-(2-{2-[4-(3-ethyl-l ,2,4-0xadiazol—S—yl)piperidin—1—y1]—2—oxoethy1}-2H—indazol—5—yI)—6—
(trifluoromethyl)pyridinecarboxamide
Z—{4-[(5-cyclopropyl-1,2,4-0xadiazolyl)methy1]piperidin—1—y1}—2-0xoethy1)—2H—
indazol—S—y1]-6—(trifluoromethy1)pyridinecarboxamide
N—(2— {2-oxo-2—[4—(pyrrolidin—l —y1carbonyl)piperidin—1 —yl] ethyl} -2H-indazoly1)—6-
(tn'fluoromethyl)pyridine—2—carb0xamide
N-(Z-{2-[4—(4-methy1piperazin—1-y1)piperidin—1-y1]oxoethyl}-2H-indazoly1)
(trifluoromcthyl)pyridine—Z—carboxamide
N—[2—(2-{4-[2-(morpholin—4-yl)ethyl]piperidin—1-y1}-2—0xoethy1)-2H-indazol-5 -y1]
(trifluoromethyl)pyridine-Z-carboxamide
N—[2-(2—{4-[(5-methyI-1,2,4—0xadiazol—3-y1)methy1]pipen'dinyl}oxoethy1)-2H-indazol-5—
yl](trifluoromethyl)pyridinecarb0xamide
N-(2-{2-oxo[3-(pyrrolidin-1—ylmethy1)pipen'din—1-yl]ethy1}-2H-indazoly1)—6-
(trifluoromethyl)pyridine-Z-carboxamide
N-[2-(2- {[3-(dimethylsulphamoyl)phenyl]amino} —2~oxoethy1)-2H-indazol-5 -y1]
(trifluoromethyl)pyn'dine-Z-carboxamide
N-{2-[2—(1,2—oxazolylamin0)oxoethyl]—2H—indazoly1}(trifluoromethyl)pyridine
carboxamide
N-(2- (methylsu1phonpriperidiny1]oxoethy1}-2H-indazoIyl)
(trifluoromethy1)pyridinecarboxamide
N—[2—(2—oxo-2—{4—[2-0xo(pyITolidinyl)ethy1]piperazin-1—y1}ethy1)-2H—indazoly1]-6—
oromethyl)pyridine—Z-carboxamide
N—(2— {2—0X0[4—(phenylsulphony1)piperidin-1 -y1]ethy1} -2H-indaz01-5 -yl)-6—
(tn'fluoromethyl)pyridinecarboxamide
N-(2- {2—0xo—2—[(3-sulphamoylphenyl)amino] ethyl} dazoly1)
(trifluoromethyl)pyridine-Z-carboxamide
N-[2-(2—{4—[isonicotinoy1(methyl)amino]piperidin-1—y1}-2—oxoethyl)—2H—indazol—5 —yl]
(trifluoromcthyl)pyridine-2—carboxamide
N-{2-(2- {4-{2-(isopropyiamino)-2—oxoethyl]piperazin—1 -y1} oxoethyl)~2H-indazol-5 -yl]
(tfifluoromethyl)pyfidinecarboxamide
N-(2-{ 2-[44 l .1-dioxidoteuahydrothiophen-Ii-yl)piperazin—l—yl}—2-oxoethyl}-2H-indazoly1)—
b—{trifluommcthylmyfidinccarboxamidc
N-[Z—(E- {4~{(mcthoxyacctyl)(mcthylbminflpiperidinyl,' —2-ox0ethyl)-2H—indazolyl]-6—
{trifluororncthylmyn‘dinecarboxamidc
ethyl 4- { [5-( { ifluoromethy1)pyridinyl]carbonyi} amino)—2H—indazol—2—
yl]acetyl}pipcrazinecarboxy1ate
N—(Z-{2-[4-(cyclohcxylcarb0nyl)piperazin—1-yl]—2-oxoethy1}-2H-indazoIyl)
(tfifluoromethyl)pyridjnecarb0xamide
N—[2—(2- {4-[2-(cyclopropylamino)—2—0xoethy1]piperazin-1 -y1} ethy1)-2H-indazoly1]-6—
(trifluoromethyl)pyridine-Z-carboxamide
N—(2—{2-[2-(2-hydroxyethyl)piperidin—1—y1]—2-oxoethy1}-2H—indazol-S -y1)
(trifluoromethyl)pyridinecarboxamide
N—(Z—{2-0x0-2—[4—(pyr'rolidin-l-y1)piperidiny1]ethyl}—2H-indazol—5 —yl)—6—
(trifluoromethyl)pyridine—2-carboxam ide
N—(Z—{Z—oxo-E-[4-(1 H—pyrrol—l -y1)piperidin—1 —y1]ethy1}-2H-indazol—5-y1)-6—
(trifluoromethyl)py1idinecarboxamide
N-(2- {2-[4-(3-hydroxypropy1)piperazin—1 —y1]oxoethyl} -2H—indazolyI)-6—
(trifluoromethyl)pyridine-Z-carboxamide
4— { [5—( { ifluoromcthpryridin—Z—y1] carbonyl } amino)~2H-indazoIyl]acety1} piperazine—
1 -carb0xamide
N-(2- {2-0xo[4—(2-oxopyrr01idin—l —yl)piperidin-1 -y1]ethy1} —2H-indazoly1)—6—
(trifluoromethyl)pyridinecarboxamide
N— {2-[2—(morpholin—4—yl)0xoethyl] -2H—indazol—5 -yl}—6-(trifluor0methy1)pyridine
carboxamide
N-(2- {2—[4-(2-amin0oxoethyl)piperazin—1 -yl]oxoethy1} -2H—indazol-5 -yl)
(trifluoromethyl)pyridine-Z-carboxamide
N-{2-[2-( l ,1-di0xidothiomorpholinyl)—2-oxoethyl]-2H-indazolyl}
oromethyl)pyridinecarboxamide
N—{2-[2—(4—isopropy1piperazinyl)-2—oxoethy1]—2H-indazol-5 -yl} -6—(trifluoromethyl)pyridine-
2—carboxamide
N—(2- {2—0xo-2—[4-(2-thienylcarbony1)piperazin-1 ~yl]ethy1} -2H-indazol-5—y1)—6—
(trifluoromethyl)pyridine-Z-carboxamide
N—(2—{2—[4-(2-cyclopropy1~2—oxoethyl)piperazin~ 1 -y1]oxoethy1} -2H-indazolyl)~6-
(trifluoromethyl)pyridine-2—carboxamide
N-[2—(2-{4—[(1-methy1-1H-pyrazoIyl)methyl]piperazin—1-yl}—2—0xocthy1)—2H—indazoI—5—y1]—
6-(trifluoromethyl)pyridine—2—carb0xamide
N-[Z-(2-{4-[(1,S—dimethyl-lH-pyrazol-IS -y1)carbony1]piperazin-I -yI} —2-0xoethy1)~2H-indazol-
-yl](Irifluoromethyl)pyfidine—2—carboxamide
N.N-dicthyl {[5-( uoromethyl)pyridin-Z-yllcarbonyl } aminoLZH-indazol-Z-
yl]acc1yl i pipcrazinc- 1 {arboxamidc
N- {2 Z-oxo-Z-{thiomorpholin-dr—ylkmyl}-2H ~indazoly1: —6-(tri ethylmyfidine-Z-
carboxamidc
N—(2— {2—[4-(2—fi1ry1methyl)piperazinyl]-2—oxoethy1}—2H—indazol—5-yl)
(trifluoromethyl)pyridine—Z—carboxamide
N-(2- {2-0x0—2-[4-(3-thienylmethyl)piperazin-l -yl] ethyl} -2H-indazol-5 -y1)
(trifluoromethyl)pyridine—2—Carb0xamide
N—{Z-[Z—(4'—methyl—1,4'—bipiperidin-1'-y1)oxoethy1]-2H-indazolyl}-6—
(trifluoromethyl)pyridine-2—Carboxamide
N- {2-[2-(6-methy1—2 ,6—diazaspiro[3 t—2—y1)oxoethyl]-2H-indazol-5 -y1}
(trifluoromethyl)pyridinecarboxamide
N—{2—[2—(4-cyclopentylpiperazinyl)—2-oxoethy1]—2H—indazol—5—y1}-6—
(tfifluoromethyl)pyridine—2—carb0xamide
N—[2—(2—{4—[2-(2—hydroxyethoxy)ethy1]piperazin‘1-y1}-2—oxoethyl)-2H—indazoly1]
(tfifluoromethy1)pyridinecarb0xamide
N—(2—{2—oxo[4—(pyridiny1methyl)piperazin—1-yl]cthy1}—2H-indazolyl)—6-
(trifluoromethyl)pyridine—2-carboxamide
N—(2- {2-[4-(dimethylsu1phamoy1)piperazinyl] 0xoethy1} -2H—indazolyl)
(trifluoromethy1)pyridine—2-carboxamide
N-(2- -2—[4—(pyfidin—4—yl)piperazin—1 ~yl]ethyl} -2H-indazol—5-y1)—6~
(trifluoromethyl)pyridine-Z—carboxamide
N-(2-{2-[4-(methy1sulphonyl)piperazin—1 -y1]oxoethy1} ~2H—indazoly1)
(trifluoromethyl)pyridine—2-carboxamide
formic acid N—[2-(2-{4-[2-(1I-I-imidazol-l-y1)ethyl]piperazin-l-yl}oxoethy1)-2H—indazol—S-
yl](trifluoromethyl)pyridinecarboxarnide (1 : 1)
WO 91426 PCT/EP2014/O77877
N-(2— {2-[4-(diethylsulphamoyl)piperazin~1 -y1]—2-oxoethyl} ~2H-indazol-5 —y1)—6—
(trifluoromethyl)pyridinecarboxamide
N—(2— {2-oxo—2-[4—(pyfidin—3—y1)piperaziny1]ethyl} -2H-indazoly1)
(trifluoromethyl)pyridinecarboxamide
N-(Z— {2-0xo-2—[4-(piperidin- 1 phony1)piperazin—1—y1]ethyl}—2H—indazoly1)
(tn'fluoromethyl)pyridinecarboxamide
N—[2—(2-{4~[(1,S-dimethyl-lH-pyrazolyl)sulphonyl]piperazin—1-y1}—2-oxoethy1)—2H-indazol-
—yl]—6-(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(cyclopropyhnethyl)piperazinyl]oxoethyl}-2H-indazolyl)(1-methyl-1H-
pyrazoly1)pyridinecarboxamide
N-(2-{2-{4-(2-hydroxypropanyl)piperidin-I-y1]—2-oxoethyl}-2H-indazol—5-y1)-6—(l —methyl-
lH-pyrazolyl)pyn'dine-Z-carboxamide
6-(1 methyl-I H-pyrazol-i-yWN-{Z- { 2-0xo-2—[4—{pyrrolidin-l -yl)piperidin-l hyl} -2H-
indazol—S-yl)p}fidinccarboxamidc
N- {4<:thyipipcmzin-l -_\'l}-2 oxoethyILEH—indazol-S-ylj (1-meth_vl-IH-p_\1'az01
y’imyfidinc-Z-carboxamidc
N-(2-{2-[4-(dimethylamino)piperidiny1]oxoethy1}-2H-indazolyl)(1-methyl-1H-
pyrazol—4—yl)pyridine—2—carb0xamide
N—(2— {2-[(cyclopropylmethy1)(methyl)amin0]-2—oxoethyl} methoxy~2H-indazol—5 —y1)-6—
mcthylpyridine—Z-carb0xamide
N-(2- {2-[(cyclopropylmethy1)(methy1)amin0] -2—oxoethyl} -6—ethoxy-2H-indazoly1)—6—
(trifluoromethyl)pyridine—2-carboxamide
N-(2-{2-[(cyclopropy1mcthy1)(methyl)amino]—2—0xoethy1}—6—methoxy—2H-indazol-5 —y1)-6—
(tri fluoromethy1)pyridinccarboxamide
6-cyc10propy1-N-(2-{2-[4-(2—hydroxypropany1)piperidin—1—yl]—2-oxoethy1}mcthoxy-2H-
indazo1—5 —y1)pyridinecarboxamide
6—(1—hydroxyethyl)—N—(2-{2-[4—(2-hydroxypropany1)piperidiny1]—2—oxoethyl}meth0xy—
2H—indazol—5—yl)pyridine—2-carboxamide
6—(azetidin-3—y1amin0)-N- {2-[2-(4—benzoylpiperazin—1 —0xoethyl] —2H—indazol-5 —
yl } pyridine-Z-carboxamide
6-[(azetidin—Z-ylmethyl)amino]—N—{2—[2-(4—benzoylpiperaziny1)-2—oxoethy1]-21—[-indazol
yl}py1idine—2—carboxamide
N— {2-[2—(4—benzoylpiperazin—l —yl)oxoethyl]-2H-indazol-5 -y1}(3 xyazetidin-1 -
yl)pyridine-2—carboxamide
6-[(2R,6S)-2,6-dimethy1morpholin—4—yl]—N—(6-methy1—2—{2-0xo—2-[4—(pyr‘rolidin-1 —
yl)piperidiny1]ethy1}-2H-indazol—5-y1)pyridinecarboxamide
N-[Z-(Z-{4-methyl—4—[(4-Inethylpiperazinyl)carbonyl]piperidinyl}oxoethy1)-2H-
indazol-S -y1](tri fluoromethyl)pyridine—2-carb0xamide
N—(6—chloro {2-oxo[(3R)-piperidin-3 -ylamino] ethyl} -2H—indazol-5 —y1)—6—
(trifluoromethyl)pyridine-2—carboxamide
N—(2— {2-[4-(cyclopropylcarbonyl)piperazin—1 ~y1] ~2-oxoethy1 } isopropoxy-2H~indazoly1)—
6-methylpyridinecarb0xamide
2-[4-(cyclopr0pylcarbonyl)piperazin—1-yl]0xoethy1}«6~130pr0p0xy—2H—indazol—5—y1)-
6-(trifluoromethyl)pyridine-2—carboxamide
N—{2—[2—(4-benzoy1pipcrazinyl)oxoethyl]-6 -isopropoxy—2H-indazoly1}
methylpyridine—Z—carboxamide
N— {2-[2-(4—benzoylpiperazin—1 -yl)oxoethyl] —6-isopropoxy—2H-indazol-S-yl }
(trifluoromethyl)py1idine—2-carboxamide
N-{6-isopropoxy{2-(4-methy1piperazin-1 —yl)—2-oxoethy1]-2H-indazol-S-yl} ~6-
(trifluoromcthyl)pyridinecarboxamide
N- { 6-isopr0poxy[2-{4-methylpi perazin- l -yl )oxoe1hyl]-2H-indazol-S-yl } ~6-
methylpyfidinc—Z-carboxamidc
N-(Z- 1 2-[4-(cyclobutylcarbonyl )pipcmzin)'l]—2 «oxocthyl } dazol-5—yl)—6—
(lrifluoromethylmyfidine~2~carboxamide
N-(2- {2—[4—(cyclopentylcarbonyl)piperazin-I -yl]oxoethyl} dazoly1)
(trifluoromethyl)pyridine-Z—carboxamide
N-[2-(2- {4-[3-(methy1sulphonyl)benzoyl]piperazin-l -yI} oxoethyl)-2H-indazoly1]
(trifluoromethyl)pyridine—Z—carboxamide
N-[2-(2- {4-[2-methoxy-5 -(methylsuIphony1)benzoyl]piperazin-1 -y1} ethy1)-2H-indazol-
-yl]—6-(trifluoromethyl)pyfidinccarboxamide
0—N—(6-methyl {2-oxo[4-(pyrrolidin—1—yl)pipefidin-1 —yl] ethyl} —2H—indazol—5-
y1)pyridine—2—carb0xamide
2-(4-methoxypheny1)-N-(6-methy1—2—{2-ox0[4—(pyrrolidin-1 -yl)piperidin—l-yI]ethy1}-2H—
indazol-S-yl)-1,3-thiazole-4—carboxamide
uor0phenyl)-N—(6—methyl—2— {2—0x0—2— [4-(pyrr01idin-l -y1)piperidin—1 -y1]cthyl } -2H—
indazol—S-y1)-1,3-thiazole—4-carboxamide
N—(6—mcthy1-2—{2-0x0-2—[4—(pyrrolidin—I -y1)piperidin- 1-yl]ethyl} —2H-indazol—5 —y1)—6-
(trifluoromethyl)pyridinc—2-carboxamide
6-bromo-N-{2-[2—(4-mcthylpiperazin—1-y1)—2—0xoethy1]-2H-indazol-5 -y1}pyridine~2-
carboxamide
o-N-{2-[2-(4—methy1pipcrazin—1—y1)-2—oxoethyl]—6—(trifluoromethoxy)—2H-indazol—5 —
yl}pyridine-2—carboxamide
N- {2-[2—(4-methylpiperazin—1 —yl)—2-oxoethy1](trifluor0meth0xy)-2H-indazoly1}—6—(4H—
l,2,4-triazo1y1)pyridinecarboxamide
2—bromo-N- {6-br0mo[2-(4-methy1piperazin—1-y1)~2«oxoethyl]-2H-indazol-5 -yl} -1 ,3-
thiazolecarboxamide
N-{6-hydroxy[2-(4-methy1piperazin-l -yI)oxoethy1]-2H-indazol-5 -y1}
(tdfluoromethy1)pyridinecarboxamide
N-[6—(benzyloxy){2—[4—(2-hydroxypropan-Z-y1)piperidin-1 ~y1]-2—oxoethyl}-2H-indazol-5 -
yl]—6—methylpyridinecarboxamide
6-bromo-N— {6—brom0[2-(4-methylpiperazin—1 -yI)-2—oxoethy1]-2H-i ndazol-S —yl}pyridine—2—
carboxamide
N- {6-(benzyloxy)[2—(4—methy1piperazin—1 -y1)oxoethyl]-2H-indazol-5—y1}—6-
methylpyridine-Z-carboxamide
2-(azetidin-3—ylamino)-N-{2-[2-(4-benzoy1piperazin-l —yl)-2—oxoethyl]—2H—indazoly1} -1 ,3-
thiazole—4—carboxamide
6-acetamid0-N-{6-methoxy~2-[2-(m0rpholinyl)oxoethyl]-2H-indazol-5 -yl }pyridine
carboxamide
Hdimethylamino}N—{2- {2-[4-(2-hydr0xypropanyi)pipcridin-1 -0xoethyl} —6—methoxy-
ZH-imiazol-S-ylmyfidine-Zcarboxamidc
6—(dimcth)'lamino)-N- { 6-mcthoxy—2 -{2—{morpholin—Lyl)—2-oxm hy1]~2H-indazol—5-
yi } ne-Z-carboxamidc
6-acetamido-N-(2- {2-[4-(2-hydroxypropan—2—y1)piperidin-1 -oxoethy1}methoxy-2H-
indazol-S-yl)pyridine-2 -carboxamide
6—(dimethy1amino)-N—{6-methoxy[2—(4-methylpiperaziny1)—2—oxoethy1]—2H-indazol
yl}pyridinecarb0xamide
2-(4—methylpiperazin—1—y1)oxoethyl]-2H—indazoly1}-6—[3-
(methylsulphonyl)pheny1]pyridinecarboxamide
N—{2-[1-(4-benzoylpiperazin—1—y1)—1—0x0propanyl]-2H-indazoIy1}—6—
(trifluoromethyl)pyridine-Z-carboxamide
N-[6-chloro(2-{[trans4-(2-hydroxypropan-2—y1)cyclohexy1]amino}oxoethy1)—2H—
l-S -(trifluoromethyl)pyridine-2—carboxamide
6—(2—hydroxypr0panyl) -N- {6-methoxy-2—[2-(morpholinyl) oxoethyl] -2H-indazol-5 —
yl } pyridine—Z—carboxamide
N- {6-chloro-2—[2—(3 ,3—diflu0ropyrrolidin—1 -yl)-2 -oxoethyl]—2H—indazol-5 —yl} —6—
(trifluoromethyl)pyridine-Z—carboxamide
N- {6-ch10r0[2-0x0-2—(pyrr01idin—1 —y1)ethy1]-2H-indazoly1}(trifluoromethy1)pyn'dine—
2-carboxamide
N— {6—ch10r0—2—[2-(2—oxaazaspiro[3.5]non-7—y1)—2-oxoethyl]—2H-indazol-5 —yI}—6-
(trifluoromethyl)pyridinecarboxamide
N—(6-chlor0—2— {2—[4—(2—hydr0xymethy1propyl)piperazin— 1 -yl] —2-oxoethy1 } -2H—indazol
yl)(trifluoromethyl)pyridinecarb0xamide
N-{6-methoxy-2—[2-ox0(pyrrolidiny1)ethy1]-2H-indazolyl}
(tdfluoromcthyl)pyridinecarboxamide
N-{2-[2-(3,3-difluoropyrrolidin—1 -y1)oxoethyl]—6-meth0xy-2H-indazoly1}
(trifluoromethyl)pyridinecarboxamide
6—(difluoromethy1)-N—{6—methoxy[2—(m0rpholinyl)-2—oxoethy1]-2H—indazol-5 -
idinecarboxamide
N— {2-[2-(3,3—difluoropyrrolidin—1 —yl)—2 -oxoethy1] meth0xy—2H—indazolyl } —6—
methylpyridine—Z-carboxamide
N— {6-methoxy[2-(morpholin—4-yl)oxoethyl]—2H—indazol-5 -y1} methylpyridine~2-
amide
N- {6-meth0xy—2-[2-(m0rpholin—4-yl)oxoethyl]-2H—indazol-S-yl} -2—(tetrahydro—2H—pyTan—4—
yl)-l ,3-0xazole—4—carboxamide
N-{Z-[2-(l ,1—dioxido—1—thia—6—azaspiro[3 '3]hepty1)oxoethyl] ~6-methoxy-2H-indazoi—5—
yl } (1ri fluoromethyl)pyn'dine—Z-carboxamide
N- {6-methoxy{2-(2-oxa-6—aza5piro[3.3]hcpt—6-yl)-2—oxoethyl]-2H —indazoI-5 -yl }
(trifluommethyl)pyfidine-B-carboxamide
N- {6-(3—hydmxy-Zldimethylpropoxy}[2-(mrpholin4-yl}2-oxmthyl]—2H-indazol ~5-y1} -
6—(trifluoromethylmyddine-z-carboxarnide
6-cthyl-N- {6-methoxy[2—(morphol inyI)oxoethyl] -2H-indazol yl} pyn'dine—Z—
carboxamide
6-isobutyl-N— {6—methoxy-2—[2-(m0rpholiny1)0xoethyl]-2H—indazol—5-y1 } ne—2—
carboxamide
methyl 2-[2-(m0rph01inyl)—2-oxoethy1]—5 -( { [6-(trifluoromethyl)pyridin-2—
bony1} amino)—2H-indazoIe-6—carboxylate
methyl 5— {[(6-methylpyridinyl)carbonyl]amino} —2-[2—(m0rpholin—4—y1)—2—0xoethyl]-2H—
indazole—G-carboxylate
N—{6—meth0xy—2—[2~(m0rpholin-4—y1)0xoethyl]—2H—indazol—5—y1}—6-(pyrrolidin—1—
yl)pyridine—2-carboxamide
N— hoxy—2—[2-(1norpholin—4—yl)—2-oxoethy1]-2H-indazol—5 -y1} —6 —(m0rpholin—4—
yl)pyridine—2-carh0xamide
6—(cyc10propy1amino)—N— {6—methoxy-2—[2-(morpholin—4—yl)oxoethy1] -2H-indazol—5 —
yl}pyridinecarboxamide
6—(butylamino)-N- {6-meth0xy[2—(morpholin-4—y1)0xoethy1]-2H-indaz01y1}pyridine
carboxamide
N- {6—methoxy—2-[2—(morpholin-4—yl)—2—0xoethy1]~2H—indazol-5 -y1} (propylamino)pyridine—
2-carboxamidc
butylamino)—N— { 6—methoxy—2—[2-(m0rpholinyl)—2-oxoethyl]-2H-indazol—5 —
yl} pyridine-IZ-carhoxamide
R—N— {6-methoxy[2-(morph01inyl)oxoethyl]-2H—indazol-5 -y1} (2,2,2-trifluoro-l -
hydroxyethy1)pyridinecarb0xamide
PCT/BP2014/O77877
S-N- {6-methoxy-2—[2—(morpholinyl)oxoethyl]-2H-indazol-5 -y1} (2,2,2—trifluoro—1 —
hydroxycthyl)pyridinecarboxamide
6-(1-hydroxyethy1)-N— {6-meth0xy—2-[2-(m0rph01iny1)oxoethy1]-2H—indazoI—5 —
yl}pyTidine-2—carboxamide
6-(cyclopropylamin0)-N—{6-methoxy—2—[2-(4-methy1piperazin-1 -y1)—2—oxoethy1]-2H—indazol-5 —
yl}pyridine—2-carboxamide
N- {6-meth0xy—2-[2-(4-methylpiperazin-l -yl)0xoethyl]-2H—indazol—5—y1 } —6—
lamino)pyfidine—2—carboxamide
buty1amino)-N— {6—methoxy—2-[2-(4—methylpiperazin-I —y1)-2—oxoethyl ] -2H-indazoI
yl}pyfidinccarboxamide
6-(l-hydroxyethyl)-N-{6—meth0xy[2—(4-methylpipcraziny1)oxoethyl]-2H—indazol—5—
y] }pyridine-2carboxamide
N- {6-me1hoxy[2{4-mcthylpipcrazin—l —yI)—2-oxoethy1]-2H—indazol-5 —yl } 4-mcthyl
(trifluoromethyl )pyfidinc-Z-carboxamidc
N— nzyloxy)-2{24 lin4—yl)—2-ox0ethy1}-2H-indazOl-5 ~yl‘. ~6-
(trifluoromethyl)pyfidinc-z-carboxamidc
6-(cyclopr0pylamino)-N-(2— {2-[4-(2-hydr0xypropan—2—y1)piperidin-1 -y1]0xoethy1}
methoxy—ZH-indazol-S—y1)pyridinecarboxamide
6-(buty1amin0)-N-(2— {2—[4-(2—hydroxypropanyl)piperidin—1 -y1]oxoethy1} —6-methoxy—2H—
indazol-S-yl)pyridine-2 -carboxamide
N~(2-{2-[4-(2-hydroxypropan—2—y1)piperidin~1-y1]0xoethy1}methoxy-2H-indazol-5 ~yl)-6 -
[(2-methoxyethyl)amino]pyridine—2—carboxamide
N-(2- {2-[4-(2-hydroxypr0pan—2—yl)piperidiny1]oxoethy1} meth0xy-2H-indazol—5 -y1)
(propylamino)pyridinecarboxamide
N-(2—{2—[4-(2—hydroxypropanyl)piperidin—1—yl]oxoethy1}—6—meth0xy—2H-indazol-5 -yl)—6—
(isobutylamino)pyridine—2—carb0xamide
-fluoro-N—(2- {2-[4-(2—hydroxypropan—2-y1)piperidiny1]-2—oxocthy1}methoxy—2H—
l—S-y1)methylpyfidine—2-carb0xamide
N— {6-hydroxy—2—[2—(morpholin-4—yI)oxoethyl] -2H-indazol—5 —y1}-6—
(tn'fluoromethyl)pyridine—Z—carboxamide
N- {6—(3-cyan0pr0poxy)—2—[2—(m0rpholiny1)~2-oxoethyl]-2H-indazol-S-yl} —6—
(tdfluoromethyl)pyridine-Z—carboxamide
N- {2~[2-(morph01in—4—yl)-2—oxoethy1](2,2,2-trifluoroeth0xy)-2H—indazol-5—yl}—6—
(trifluoromethyl)pyridine—2—carb0xamide
N— {6—(cyclohexylmethoxy)[2-(m0rpholin—4—yl)—2—0xoethy1]-2H-indazoly1}
(trifluoromethy1)pyridine—2—carboxamide
N-{6-(2,2-dimethylprop0xy)[2-(m01ph01inyl)oxoethyl]-2H-indazol-5 -
(trifluoromethyl)pyridine-Z-carboxamide
WO 91426
N—{2—[2—(morpholiny1)0xoethy1](tetrahydrofi1ranylmethoxy)-2H-indazol‘5 —y1}—6 -
(tn'fluoromethyl)pyridinecarboxamide
N- {6-(cyc10pentyloxy)—2-{2-(morpholinyl)oxoethy1] -2H—indazol—5 -y1} —6~
(trifluoromethyl)pyridinecarb0xamide
N— anomethoxy)—2~[2~(morpholin-4—y1)oxoethyl] -2H—indazolyl} -6—
(trifluoromethy1)pyridine—2—carb0xamide
({2-[2-(morpholinyl)—2—oxoethy1]( {[6 -(t1'ifluoromethyl)pyridinyl]carbonyl} amino)-2H-
indazol-é—yl}oxy)acetic acid
N— {6—(cyclobutylmethoxy)-2—[2-(morpholin—4—yl)oxoethyl]-2H-indazol-5—yl} ~6-
oromethyl)pyridine-Z-carboxamide
N-{2-[2—(morph01in—4-yl)0xoethyl] [2-(pyrrolidin—l —y1)ethoxy]—2H—indazol—5—yl} —6—
(tn’fluoromethyl)pyridine-2—carboxamide
N- {6-[2-(morpholin-4—yl)ethoxyI-Q-{Z-(morpholinA-yl}oxocthyl]-2H—indazolyl }
oromethyl)pyridinc-E-carboxamidc
N-{2-[2{morpholin—i-yl)oxoethyl1-6—[2-(pipcddin_vl)cthoxy}-2H-indazolyl2
(trifiuoromcthy!)pyfidinc—2—caxboxamide
N- {6-(3-hydroxypropoxy)—2-[2-(m0rpholin—4—yl)—2—oxoethyl]~2H—indazol-5 -yl}
(trifluoromethyl)pyridinecarboxamide
N- {6-(2—hydr0xypropoxy)—2-[2-(m0rpholiny1)oxoethyl]-2H—indazol—5—yl} —6—
(tn'fluoromethyl)pyridine—2—carboxamide
N—{6—(2—hydroxyethoxy)—2-[2-(morpholiny1)0xocthy1]-2H-indazoly1}-6—
(trifluoromethyl)pyridine—2—carboxamide
N— {6—(2-methoxyethoxy)—2-[2—(morpholiny1)oxocthyl] -2H-indazol-5 -y1}
(trifluoromcthyl)pyridine-2—carboxamide
ethyl ({2-[2-(morph011'nyl)oxoethyl]-5 —( { [6—(trifluoromethyl)pyridin~2~
yl]carb0nyl}amino)-2H—indazoly1}oxy)acetate
methyl 4-( {2—[2—(morpholin-4—yl)oxoethyl] -5 ~( { [6-(triflu0romcthyl)pyridin—2 -
yl]carbonyl}amino)—2H-indazolyl} oxy)butan0ate
ethyl 2—( {2—[2—(morpholinyl)—2-oxoethyl] —5 —( { [6—(tfifluoromethyl)pyridin—2-
yl]carbony1} amino)-2H-indazolyl} oxy)propanoate
ethyl 3—methy1—2—( {2—[2-(morpholin—4-yl)oxoethy1]( { [6-(trifluoromethyl)pyridin
yl]carbony1} amino)-2H-indazol-6—yl} oxy)butanoate
2—( (morph01in—4~yl)0xoethyl]-5 —( {[6-(triflu0r0methyl)pyridin—2—y1]carbony1}amino)-
2H—indazolyl} oxy)propanoic acid
2—hydroxypropan—2 -yl)-2— [2—(m0rpholin—4-yl)—2—0x0ethyl]-2H—indazolyl} —6—
(trifluoromethyl)pyn'dine—2-carboxamide
N—{6-chloro[2-(4-methylpiperazin-1~y1)0xoethyl]-2H—indazo1-5 -yl}
(difiuoromethyl)pyridinecarb0xamide
PCT/EP2014/O77877
N-{6-chloro[2-(morpholin-4—yl)—2-oxoethyl]-2H-indazol-5 -(difluoromethyl)pyridine-
2-carboxamide.
The present invention further provides a process for preparing intermediates of the general formula
(III) from the compound of the formula (II)
/ /
F F
F \ O F \ 0
N N
F HN F HN
\ 14 \
H3C\ N/N R
O HO NIN
H H
0 R14
(II) (III)
in which R“ is either methyl or ethyl.
The conversion of the intermediate of the formula (II) into the intermediates of the formula (III) is
carried out by a Grignard reaction. Preferably, the Grignard on is carried out using
alkylmagnesium e. To this end, preference is given to using either magnesium
bromide 0r ethylmagnesiurn bromide.
Thus, the invention also provides intermediates of the general formula (II).
The invention furthermore es intermediates of the general formula (III) in which R";
represents either methyl or ethyl.
The compounds of the formula (I) according to the invention act as inhibitors of IRAK4 kinase and
have an unforeseeable useful pharmacological activity spectrum.
Thus, in addition to the subject matter ned above, the present invention also provides the use
of the nds according to the invention for the treatment and/or prophylaxis of diseases in
man and animals.
The compounds according to the ion are suitable for the prophylaxis and/or treatment of
various disorders and disease—related states, in particular ers mediated by TLR (except for
TLR3) and/or the IL—l receptor family and/or disorders whose pathology is mediated directly by
IRAK4. IRAK4—associated ‘ disorders which may be mentioned are multiple sclerosis,
sclerosis, myocardial infarction, Alzheimer's disease, virus-induced myocarditis, gout,
psoriasis and arthritis.
The nds ing to the invention can furthermore be used for the prophylaxis and/or
treatment of disorders mediated by MyD88 and TLR (except for TLR3). This includes multiple
sclerosis, toid arthritis, lic syndrome, es, osteoarthritis, Sjogren syndrome,
sepsis, skin disorders such as psoriasis, atopic itis and acne vulgaris, pulmonary disorders
such as pulmonary fibrosis, chronic ctive pulmonary e (COPD), acute respiratory
distress syndrome (ARDS), acute lung injury (ALI), interstitial lung disease (ILD), sarcoidosis and
pulmonary hypertension.
By virtue of the mechanism of action of the compounds according to the invention, they are
le for the prophylaxis and/or treatment of the TLR-mediated disorders Behcet‘s e, gout,
endometfiosis, graft rejection, lupus erythematosus, adult—onset Still‘s disease and chronic
inflammatory bowel disorders such as ulcerative colitis and Crohn's disease.
In addition to the disorders already listed. the use of the compounck according to the invention is
also suitable for the treatment and/or prevention of the following disorders: eye disorders such as
ceratitis, allergic conjunctivitis, kemtoconjunctivitis sicca, macular degeneration and uveitis;
cardiovascular disorders such as arteriosclerosis, myocardial reperfusion damage, myocardial
infarction, hypertension and neurological disorders such as Alzheimer's disease, stroke and
Parkinson's disease.
Furthermore, the compounds according to the invention can be used for the prophylaxis and/or
treatment of pruritus and pain. By virtue of the mechanism of action of the nds according to
the invention, they are suitable for the prophylaxis and/or treatment of oncological ers such
as lymphomas, chronic lymphatic leukaemia, melanomas and liver cell carcinoma and Ras-
dependent tumours.
Moreover, the compounds according to the invention are le for the treatment andfor
prevention of disorders mediated via the IL-1 receptor family. These disorders comprise CAPS
(cryopyrin-associated periodic syndromes) including FCAS ial cold autoinflammatory
syndrome), MWS (Muckle-Wells syndrome), NOMID (neonatal-onset multisystem inflammatory
disease) and CONCA (chronic infantile, neurological, cutaneous, and lar) me, FMF
(familial mediterranean fever), HlDS (hyper-IgD syndrome), TRAPS (tumour necrosis factor
receptor l—associated periodic syndrome), juvenile idiopathic arthritis, adult-onset Still‘s disease,
Adamantiades—Behcet‘s disease, rheumatoid arthritis, osteoarthritis, keratoconjunctivitis sicca und
Sjogren syndrome, multiple sclerosis, lupus erythematosus, type-l diabetes, type-2 diabetes and the
ae of myocardial infarction. Pulmonary disorders such as asthma, COPD, idiopathic
interstitial pneumonia and ARDS, endometriosis, chronic-inflammatory bowel disorders such as
Crohn's disease and tive colitis are ated with dysregulation of the IL—1 reptor family
and suitable for therapeutic and/or prophylactic use of the compounds according to the invention.
The compounds according to the invention can furthermore be employed for the treatment and/or
prevention of neurological ers mediated by the IL-1 receptor family, such as stroke,
Alzheimer's disease, stroke, skull—brain trauma, pain disorders such as cancer pain, erative
pain, inflammation-induced and chronic pain and ological ers such as psoriasis, atopic
dermatitis, allergic contact dermatitis.
The treatment and/or prophylaxis of inflammatory skin disorders, cardiovascular disorders, lung
disorders, eye disorders, autoimmune disorders and neoplastic disorders with the IRAK4 inhibitors
according to the invention is particularly preferred.
The present invention further also provides a method for treatment and/or prevention of disorders,
in particular the disorders mentioned above, using an effective amount of at least one of the
compounds according to the invention.
In the context of the present invention, the term "treatment" or "treating" includes inhibition,
retardation, ng, alleviating, ating, restricting, reducing, suppressing, repelling or
healing of a disease, a condition, a disorder, an injury or a health problem, or the development, the
course or the progression of such states and/or the symptoms of such . The term "therapy" is
understood here to be synonymous with the term ment".
The terms "prevention '1 H
, prophylaxis" or "preclusion" are used synonymously in the context ofthe
present invention and refer to the avoidance or reduction of the risk of contracting, encing,
suffering from or having a disease, a ion, a disorder, an injury or a health problem, or a
development or ement of such states and/or the symptoms of such states.
The treatment or prevention of a disease, a condition, a disorder, an injury or a health m may
be partial or complete.
The compounds ing to the invention can be used alone or, if required, in combination with
other active compounds. The present invention therefore further provides medicaments sing
at least one of the ive compounds and one or more further active ingredients, especially for
treatment and/or prevention of the aforementioned disorders. Preferred examples of active
compounds suitable for combinations include:
in general, mention may be made of active compounds such as antibacterial (cg. penicillins,
vancomycin, ciprofloxacin), antiviral (cg. aciclovir, oseltamivir) and antimycotic (eg. naftifin,
nystatin) substances and gamma globulins, immunomodulatory and immunosuppressive
compounds such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons,
corticosteroids (e.g. prcdnisone, prednisolone, methylprednisolone, hydrocortisone,
betamethasone), cyclophosphamide, azathioprine and sulfasalazine; paracetamol, eroidal
anti-inflammatory substances S) (aspirin, ibuprofen, naproxen, etodolac, celecoxib,
cine).
For tumour therapy, mention may be made of immunotherapy, antiproliferative substances such as,
by way of example but not by way of limitation, trastuzumab, rituximab, tositumomab, aromatase
inhibitors (e.g. letrozole, anastrozole), antiestrogens (eg. tamoxifen), topoisomerase I inhibitors
(cg. in'notecan, tepotecan), topoisomerase II inhibitors (cg. daunorubicin, idarubicin,
mitoxantrone), microtubuli—active substances (eg. vinblastine, vincristine), erase tors
(eg. imetelstat), alkylating nces and histone deacctylase tors (eg. vorinostat,
romidepsin, panobinostat); substances which modulate cell differentiation processes such as MMP
inhibitors (peptide mimetics, non-peptide mimetics and tetracyclins such as, for example,
marimastat, BAY 12-9566, EMS—275291, clodronate, prinomastat, doxycycline), mTOR tors
(c.g. sirolimns. cvcrolimus, olimus. zotamiimus). antimctaboiites (eg. methotrexate. 5-
fluorouracil, cladribine, fludarabine), platinum compounds (eg. carboplatin, cisplatin.
cisplatinum); anti—angiogenic compounds (e.g.. bevacizumab). drogenic compounds (eg.
flutamide, nilutamidc, bicalutamide, cyproterone e), proteasome inhibitors (eg. bortezomib,
carfilzomib, oprozomib, ONYX0914), gonadoliberin agonists and onists (eg. goserelin,
triptorelin, degarelix), methionine aminopeptidase inhibitors (cg. bengamide derivatives, TNP—470,
I’M—2458), heparanase inhibitors (eg. SSTOOOl, PI-88); inhibitors of cally modified ras
protein (cg. famesyl transferase inhibitors such as lonafamib, tipifarnib), HSP90 inhibitors (e.g.:
geldamycin derivatives such as l7-allylaminogeldanamycin, 17—demethoxygeldanamycin
(17AAG), l7-DMAG, retaSpimycin hydrochloride, [Pl-493, AUY922, BIIBOZS, STA-9090, KW-
2478), kinesin spindle protein inhibitors (cg. SB715992, SB743921,
pentamidinc/chlorpromazinc), MEK (mitogen-activated protein kinase kinase) inhibitors (eg.
trametinib, BAY 86-9766, AZD6244,), kinase inhibitors (e.g.: sorafenib, regorafenib, lapatinib,
sutent, dasatinib, cetuximab EMS-908662, 8436, AMG 706), hedgehog signal inhibitors
(eg. cyclopamine, vismodegib), BTK. (Bruton’s tyrosine ) inhibitors (cg. ibrutinib),
JAK/pan-JAK (janus kinase) inhibitor (e.g. 88-1578, baricitinib, tofacitinib, pacritinib,
momelotinib, ruxolitinib, VX—509, AZD-l480, TG-101348), PBK inhibitor (cg. BAY 1082439,
3O BAY 80-6946, ATU—027, 6, DS—7423, GSK—2126458, buparlisib, PF-4691502, BYL—7l9,
XL-147, XL—765, idelalisib), SYK (spleen tyrosine kinase) inhibitor (eg. fostamatinib, Excellair,
PRT—062607), sphonates (cg. etridonate, clodronate, tiludronate, pamidronate, alcndronic
acid, onate, risedronate, zoledronate), rituximab, cyclophosphamide, doxorubicin,
vincristine, mbucil, fludarabine, dexamethasone, bine, prednisone.
Also suitable for tumour y is a combination of a non-drug therapy such as chemotherapy,
herapy or phototherapy which is anied by a drug treatment with the IRAK4 inhibitors
according to the invention or which, after the non-drug tumour therapy such as chemotherapy,
radiotherapy or photothcrapy has ended, are supplemented by a drug treatment with the IRAK4
inhibitors according to the invention.
In addition to those mentioned above, the IRAK4 tors according to the invention can also be
combined with the following active compounds:
active nds for Alzheimer therapy such as, for example, acetylcholinesterase inhibitors (e.g.
donepezil, rivastigmine, galantamine, tacrine), NMDA (N-methyl—D—aspartate) or antagonists
(e.g. memantine); L—DOPA/carbidopa (L-3,4-dihydroxyphenylalanine), COMT hol-O—methyl
erase) inhibitors (e.g. entacapone), ne agonists (e.g. ropinrol, pramipexol,
bromocriptine), MAO—B (monoaminooxidase—B) inhibitors (e.g. selegiline), anticholinergics (e.g.
trihexyphenidyl) and NMDA antagonists (e.g. amantadin) for the treatment of Parkinson's disease;
nterferon (lFN-beta) (e.g. IFN beta-1b, IFN a Avonex® and Betaferon®), glatiramer
acetate. immunoglobulins. natalizumab. fingolimod and immunosuppressive drugs such as
mitoxantrone, azathioprine and cyclophosphamidc for the treatment of le sclerosis;
substances for the treatment of ary disorders such as, for example. beta
sympathomimetics (e.g. salbutamol), olinergics (e.g. glycopyrronium), methylxanthines (e.g.
theophylline), leukotriene receptor antagonists (e.g. montelukast), PDE-4 (phosphodiesterase type
4) inhibitors (e.g. roflumilast), methotrexate, IgE antibodies, azathioprine and cyclophosphamide,
cortisol-containing ations; substances for treating osteoarthritis such as non—steroidal anti-
inflammatory substances (NSAle). In addition to the two therapies mentioned, rexate and
biologics for B—cell and T-cell therapy (e.g. rituximab, abatacept) may be mentioned for
rheumatoid disorders such as rheumatoid arthritis and juvenile idiopathic arthritis. Neurotrophic
substances such as acetylcholinesterase inhibitors (e.g. donepezil), MAO (monoaminooxidase)
inhibitors (e.g. selegiline), interferons and anticonvulsive drugs (e.g. ntin); active
compounds for the treatment of vascular disorders such as beta-blockers (e.g. metoprolol),
ACE inhibitors (e.g. benazepril), diuretics (e.g. hydrochlorothiazide), calcium channel rs
(e.g. nifedipine), statins (e.g. tatin); anti—diabetics such as, for example, metformin and
glibenclamide, nylureas (e.g. tolbutamide) and insulin therapy for the treatment of diabetes
and metabolic syndrome. Active compounds such as mesalazine, sulfasalazine, azathioprine, 6—
mercaptopurine or rexate, probiotic bacteria (Mutaflor, VSL#3®, Lactobacillus GG,
Lactobacillus plantarum, L. acidophilus, L. casei, Bifidobacterium infantis 35624, Enterococcus
fecium SF68, Bifidobacterium longum, Escherichia coli Nissle 1917), antibiotics such as, for
example, ciprofloxacin and metronidazole, anti-diarrhoeal drugs such as, for example, loperamide,
or laxatives (bisacodyl) for the treatment of chronic-inflammatory bowel disorders.
Immunosuppressives such as glucocorticoids and non—steroidale anti-inflammatory substances
(NSAIDS), cortisone, chloroquin, cyclosporine, azathioprine, belimumab, rituximab,
cyclophosphamide for the treatment of lupus erythematosus. By way of example, but not by way of
limitation, calcineurin inhibitors (e.g. tacrolimus and ciclosporin), cell division inhibitors (e.g.
azathioprine, mycophcnolate mofetil, mycophenolic acid, everolimus or sirolimus), rapamycin,
basiliximab, daclizumab, anti-CD3 antibodies, anti-T-lymphocyte globulin/anti-lymphocyte
globulin for organ transplants. Vitamin D3 analogues such as, for example, calcipotriol, tacalcitol
or calcitriol, salicylic acid, urea, ciclosporine, methotrexate, efalizumab for dermatological
disorders.
The present invention r provides medicaments which comprise at least one compound
according to the invention, typically together with one or more inert, nontoxic, pharmaceutically
le excipients, and the use thereof for the aforementioned purposes.
The compounds ing to the invention can act systemically and/or locally. For this e,
they can be administered in a suitable manner, for example by the oral, parenteral, pulmonal, nasal,
gual, lingual. buccal. rectal. dermal. transdermal, conjunctiva] or otic route, or as an implant
01' stem.
The compounds according to the invention can be administered in suitable stration forms for
these administration routes.
Suitable administration forms for oral administration are those which work according to the prior
art and release the compounds according to the invention rapidly and/or in a modified manner and
which contain the compounds according to the invention in crystalline and/or amorphized and/or
ved form, for example tablets (uncoated or coated tablets, for example with gastric juice-
resistant or retarded-dissolution or insoluble coatings which control the release of the compound
ing to the invention), tablets or films/oblates which disintegrate rapidly in the oral cavity,
films/lyophilizates, capsules (for example hard or soft gelatin capsules), sugar—coated tablets,
granules, pellets, powders, ons, suspensions, aerosols or solutions.
Parenteral administration can be accomplished with avoidance of an absorption step (for example
by an enous, intraarterial, intracardiac, intraspinal or intralumbar route) or with inclusion of
an absorption (for example by an intramuscular, subcutaneous, intracutaneous, aneous or
intraperitoneal route). Suitable administration forms for parenteral administration include injection
and on formulations in the form of solutions, suspensions, emulsions, lyophilizatcs or e
powders.
For the other administration routes, suitable es are inhalable medicament forms (including
powder inhalers, nebulizers), nasal drops, solutions or sprays, s, films/oblates or capsules for
lingual, sublingual or buccal administration, suppositories, ear or eye preparations, vaginal
capsules, aqueous suspensions (lotions, g mixtures), lipophilic suspensions, ointments,
WO 91426 PCT/EP2014/O77877
creams, transdermal therapeutic s (eg. patches), milk, pastes, foams, sprinkling powders,
ts or stents.
Preference is given to oral or parenteral administration, especially oral administration.
The compounds ing to the invention can be converted to the administration forms
mentioned. This can be accomplished in a manner known per 36 by mixing with inert, non-toxic,
pharmaceutically suitable excipients. These excipients include carriers (for example
microcrystalline cellulose, lactose, ol), solvents (cg. liquid polyethylene glycols),
emulsifiers and dispersing or wetting agents (for example sodium dodecylsulphate,
polyoxysorbitan oleate), binders (for e polyvinylpyrrolidone), synthetic and natural
polymers (for example n), stabilizers (e.g. antioxidants, for example ic acid),
colorants (cg. inorganic pigments. for example iron ) and flavour and/or odour tants.
in general. it has been found to be advantageous in the case of parenteral administration to
administer amounts of from about 0.001 to 1 mg/kg. preferably about 0.01 to 0.5 rug/kg, of body
weight to achieve efToctivc results. In the case of oral administration the dosage is about 0.01 to
100 mg/kg, preferably about 0.01 to 20 mg/kg and most preferably 0.1 to 10 mg/kg ofbody weight.
It may nevertheless be necessary where appropriate to deviate from the stated amounts, specifically
as a function of the body weight, route of administration, individual response to the active
compound, nature of the preparation and time or interval over which administration takes place.
Thus, in some cases less than the abovementioned minimum amount may be sufficient, while in
other cases the upper limit mentioned must be exceeded. In the case of stration of greater
amounts, it may be advisable to divide them into several individual doses over the day.
The working examples which follow illustrate the invention. The invention is not restricted to the
examples.
Unless stated otherwise, the percentages in the tests and examples which follow are percentages by
weight; parts are parts by weight. Solvent ratios, dilution ratios and concentration data for the
liquid/liquid solutions are in each case based on volume.
Preparation of the compounds according to the invention
The preparation of the compounds according to the invention is rated by the following
synthesis schemes:
The ediates 0 shown in Synthesis Scheme 1 can be prepared analogously to ture and
patent procedures, for example from 4-substituted 2-fluoronitrobenzaldehydes or 2—chloro-5—
nitrobenzaldchydes, or they are commercially available. For the preparation, 4-substituted Z—fluoro—
-nitrobenzaldehydes are reacted with hydrazine (J. Med. Chem, 2013, 56, 4343). The resulting 5-
nitroindazoles (Intermediates 0) can be reduced, for example, with palladium on carbon by
hydrogenation (U8201228984, W020067l940, 153596, EP2045253) or transfer
hydrogenation (Eur. J. Med. Chem. 2010. 45. 5520) or by reaction with iron (J. Chem. Soc., 1955.
2412) or tintII) chloride {Bioorg. Med. Chem. 2004. 12. 2115. U3201215962) to give the
corresponding S-aminoindazoles. The Intermediates la can be converted into Intermediates 1b. The
radical R: can be introduced by various routes, for e via aIkylation with alkyl halides
(Bioorg. Med. Chem, 2010, 18, 4801) or alkylsulphonates or via reductive amination by reaction
with aldehydes (W02009102498) or ketones (EP140325). le for use as reducing agents are
various hyride donors such as, for example, sodium borohydride, sodium cyanoborohydride or
sodium trisacetoxyborohydride. Alternatively, it is also possible to e the anilinic nitrogen of
the Intermediates la first using an acyl halide or a carboxylic ide, and then to reduce the
amide using a suitable reducing agent to give the ponding amine, which also s
Intermediates lb. Suitable for use as reducing agents are, for example, lithium aluminium hydride
(J. Am. Chem. Soc, 1954, 76, 1384), borane as complex with dimethyl sulphide etic
Communications, 1991, 21, 1579) or tetrahydrofuran (Org. and Biomol. Chem, 2012, 10, 8692) or
sodium bis(2-methoxyethoxy)aluminium hydride (WO200873461).
The Intermediates la and 1b can be ed at the ic nitrogen with a known protective group
described in the literature (Protecting Groups, Philip J. Kocienski, 3rd Revised Edition (9th
February 2005), Thieme, Chapter 8; Greene's Protective Groups in Organic Synthesis, Peter G. M.
Wuts, Theodora W. , 4th Edition (8th er 2006), Wiley—Interscience, Chapter 7),
giving the Intermediates 2. The preferred protective group is the tert-butyloxycarbonyl group (BOC
protective group). The BOC protective group is ably introduced with di-teIt-butyl dicarbonate
in the presence of a base such as, for example, N,N—diisopropylethylamine or triethylamine.
The Intermediates 2 can be reacted with carboxylic esters halogenated in the carboxylic acid
moiety such as, for example, methyl bromoacetate, ethyl bromoacetate, tert—butyl bromoacetate,
benzyl bromoacetate, ethyl 3-brom0propanoate or ethyl 2-bromopropanoate under basic conditions
to give a mixture of the corresponding regioisomeric 1— and 2-a1kylated le compounds
(Organic Letters, 2009, 11, 5054; WO200474284; USZOO9286800; WO200919167;
W0201297744; J. Med. Chem, 2007, 50, 3101; Molecules, 2006, 11, 86). Here, preference is
given to the reaction with N,N—dicyclohexylmethylamine in ydrofuran or N,N-
dimethylformamide between 25°C and 100°C (J. Org. Chem. 2006, 71, 5392). Likewise preferred
is the reaction in the presence of potassium carbonate in N,N-dimethylformamide. The mixtures of
the regioisomeric l— and lated indazole compounds can be separated by column
chromatography or preparative HPLC, which gives access to the 2-alkylated indazole compounds
(Intermediates 3).
The sion of the Intermediates 3 into the Intermediates 4 can be carried out under known
conditions (Protecting Groups, Philip J. Kocienski, 3rd Revised n (9th February 2005),
Thieme, Chapter 6; Greene's Protective Groups in Organic Synthesis, Peter G. M. Wuts, Theodora
W. Greene, 4th Edition (8th December 2006), Wiley—Interscience, Chapter 5; W02009l9l67 Al).
Here, preference is given to ysis with lithium hydroxide or lithium hydroxide monohydrate
in a mixture of tetrahydrofiiran and water (J. Med. Chem.. 2012. 55. 1318, Bioorg. Med. Chem,
2009. 17. 7] l3). Optionally. ethanol or methanol may also be added.
The Intermediates 4 can be reacted with amines to give the corresponding Intermediates 5. Here,
use may be made of various coupling rugents known from the literature (Amino Acids. Peptides
and Proteins in Organic Chemistry. Vol.3 * ng Blocks, Catalysis and Coupling Chemistry,
Andrew B. Hughes, Wiley, Chapter 12 - Peptide-Coupling Reagents, 407—442; Chem. Soc. Rev.,
2009, 38, 606). The use of l-(3-dimethylarninopropyl)—3—ethylcarbodiimide hydrochloride in
combination with l—hydroxy-1H—benzotriazole hydrate is preferred 2107475; Bioorg. Med.
Chem. Let., 2008, 18, 2093).
The Intermediates 5 obtained in this manner can be converted into Intermediates 6. The removal of
the protective group at the anilinic nitrogen can be carried out under known reaction ions
(Protecting Groups, Philip J. Kocienski, 3rd Revised Edition (9th February 2005), Thieme, Chapter
8; 's Protective Groups in Organic Synthesis, Peter G. M. Wuts, ra W. Greene, 4th
Edition (8th December 2006), Wiley-Interscience, Chapter 7). Preferred is the removal of the tert—
butyloxycarbonyl protective group with trifluoroacetic acid in romethane g. Med.
Chem. Lett, 2011, 21, 6274; J, Med. Chem, 2008, 51, 1904; WO201353051).
Using the coupling reagents known from the ture which were already mentioned for the
preparation of the Intermediates 5, the Intermediates 6 can be reacted with heterocyclic carboxylic
acids to give compounds of the general formula (I). Here, too, preference is given to using 1—(3-
dimethylaminopropyl)ethylcarbodiimide hydrochloride in combination with oxy—1H-
benzotriazole hydrate (U82006194801).
R0 o
R R2 c
fim'—'- -—)- —>-
N N N
/ / /
1 N 1
R R N 1
H H R H
Intermediate 0 Intermediate 1a Intermediate 1!:
Br O—R 2
i RD i‘ R”
( n N
N R13 .
PG’ /
a __
O—R \ fN
Ni n1 N
R‘ n
Intermediate 2 Intermediate 3
1“ R: i“ R“
IN '3
R ,N R”
PG / P’s / I
N CH N Y '
\ l \. l
R1 N _
l. L,. RI N ( ..-.
intent-radiate 4 Intermediate 5
IR R" WOH i2 R“
W N R13
./ O T /
N Y Y
\I \ [N 0
R1 N M R1 N ( n
0 0
Intermediate 6 (I)
Synthesis Scheme 1:
(PG means protective group; RCl represents C1-C6-alkyl or benzyl.)
Alternatively, the Intermediates 5 can also be obtained ly from Intermediates 2, as rated
in Synthesis Scheme la. The reagents used are halogenated carboxamides. The reaction ions
are identical to those of the preparation of Intermediate 3 from Intermediate 2. ence is given
to the reaction with 2—bromoacetarnides in the presence of the base N,N—dicyclohexylrnethylamine.
Particular preference is given to the reaction with 2~br0m0-1~(morpholinyl)ethanone.
B! Y
R2 0 2
I I R°
n i
0 N 13
PG \N PG/ /
_—”'
/ [N Y
R N I
R \N
H n
Intermediate 2 0
Intermediate 5
sis Scheme 1a:
As illustrated in Synthesis Scheme 2, the Intermediates 3 can also be converted first into the
Intermediates 7 (J. Am. Chem. Soc, 2009, 131, 3342; EP2522657). If PG denotes tert-
butyloxycarbonyl, it is preferred to use trifluoroacetic acid in dichloromethane (W0201062171).
The Intermediates 7 can be reacted with heterocyclic ylic acids to give the Intermediates 8.
Here, as in Synthesis Scheme 1, coupling reagents are used. The preferred coupling t used is
1-(3-dimethylaminopropy1)ethy1carbodiim.ide hydrochloride in combination with 1-hydroxy-1H-
benzotriazole hydrate.
The Intermediates 8 can be hydrolysed analogously to Synthesis Scheme 1, the hydrolysis with
lithium hydroxide or m hydroxide monohydrate in a mixture of tetrahydrofiuan and water
being preferred. Optionally. ethanol or methanol may also be added.
The Intermediates 9 formed in this manner can be converted into the compounds of the l
formula (I). The coupling with amines is carried out analogously to Synthesis Scheme 1 using
ng reagents known from the ture. The use of l—(3—dimethy1aminopropyl)—3—
ethylcarbodiimide hydrochloride in combination with 1-hydroxy-1H-benzotriazole hydrate is
preferred.
r 2 W OH
R° t r
N 13 HN 4 13 if
R R
PG’ / 0
d d
N —'R M N O—R
R \N/ 3 \N/
n n
O O
intermediate 3 Intermediate 7
2 2
II; R0 l? R“
W N Rta W N R13
El: / {NM —Rd I]: / H Y
" IN OH W
\ \
R N R] N
ll n
O 0
Intermediate 8 Intermediate 9
'32 R”
W N R13
\[Cf _/
\ INMY
R‘ N
(I) 0
S nthesis Scheme 2:
(PG means protective group; Rd represents C1-C5-alky1 or benzyl.)
The Intermediates 2b can be prepared as illustrated in Synthesis Scheme 3. Reaction of the
Intermediates la with an excess of di-tert-butyl dicarbonate gives a mixture of Intermediates 10 and
11 which can be hydrolysed selectively at positions 1 and 2, respectively, thereby giving the
Intermediates 2b. The hydrolysis is preferably carried out using sodium ate in a mixture of
methylfonnamide and water between 50°C and 100°C for 12 - 36 hours (Tet. Lett., 2006, 47,
8575).
RD |-L_,C>( \n/ \ Ra
HQN H3. c o n
CH? 0 N, >]/ T O
\ 8090 R: /
N )Q HC
+ N
3 CH,
I CF 0 \ I
R1 0 ‘3 '
u N 0—6043.
\ CH;
'“temd'a‘e ‘3
Intermediate1D age/£13 ‘ Intermediate“
1 “3.032
,' 1-5.5:
H R'
a; c n.
rgc>r Y- \N\
CH3 0
at N]
Intermediate 2b
Synthesis Scheme 3:
The Intermediates 83 can be prepared as described in Synthesis Scheme 4 from Intermediates 1a
for example with the g Rl = C1 in a multistep synthesis sequence. To this end, initially one
of the nitrogen atoms in the indazole ring is protected, preferably the nitrogen atom in position 1
(WO200958924). The preferred protective group is the tcrt-butyloxycarbonyl group (BOC
protective group). The BOC tive group is preferably introduced with t-butyl dicarbonate
in the presence of a base such as, for example, N,N—diisopropylethylamine or triethylamine.
Under the coupling ions mentioned above, the Intermediates 12 can be ed with
heterocyclic carboxylic acids, thus giving the ediates 13. The use of l—(3-
dimethylaminopropyl)—3—ethylcarbodiimide hydrochloride in combination with l-hydroxy—IH—
riazole hydrate is preferred.
The protective group of the Intermediates 13 at the indazole ring can be removed under reaction
conditions known from the literature cting Groups, Philip J. Kocienski, 3rd Revised Edition
(9th February 2005), Thieme, Chapter 8; Greene's Protective Groups in Organic Synthesis, Peter G.
M. Wuts, Theodora W. Greene, 4th Edition (8th December 2006), Wiley-Interscience, Chapter 7).
Preferred is the use of trifluoroacetic acid in dichloromethane for the removal of a BOC protective
group. The Intermediates 14 can be converted into a mixture of the corresponding regioisomeric 1—
and 2-alkylated indazole compounds. Separation of the regioisomers gives the desired 2-alky1ated
indazole derivatives mediates 821) (J. Org. Chem. 2006, 71, 5392). Here, the same reaction
conditions as for the preparation of the Intermediates 3 from the Intermediates 2 are ed
(Synthesis Scheme 1). The use of N,N-dicyclohexylmethylamine in tetrahydrofuran or N,N-
dimethylformamide is preferred.
R° R“ W
HN HzN
2 O
\N ————- NH
R1 51’ R‘ g PG -
Intermediate 12
Intermediate 1a
Br o—R"
H R0
w H (n
it (Idle—e t if ———~W N 0
3 N
R PG _
H R a;
ediate 13 lntermedrate 14
\H/ N o—Rd
R1 \N/ M
Intermediate Ba
S nthesis Scheme 4:
(PG means protective group; Rd represents a1ky1 or benzyl.)
In some cases, the Intermediates 14 can also be prepared as described in Synthesis Scheme 5. The
Intermediates 1a are acylated regioselectively at the anilic nitrogen with heterocyclic carboxylic
acids. Here, the coupling reagents mentioned above are employed. Preference is given to the
combination of l-(3-dimethylaminopropyl)—3-ethylcarb0diimide hloride and l-hydroxy—IH—
benzotriazole hydrate using the base triethylarnine (EP1403255; W02005 82890; USZOO6194801;
Bioorg. Med. Chem. Lett, 2007, 17, 3550).
R \H/ RD
H2N O W N
\ # T \
IN [N
I N O
R 1 N
H R
Intermediate 1a Intermediate 14
W0 9] 426
Synthesis Scheme 5:
According to Synthesis Scheme 5-1, it is possible to obtain, from ediates 14a where R10 = —
COzMe or —C02Et, preferably —C02Me, in a Grignard reaction (Organikum, 19th Edition, Johann
ius Barth Leipzig, pp. 515 — 520) by using methylmagnesium bromide, methylmagnesium
chloride, ethylmagnesium bromide or agnesium chloride, Intermediates 14b where R1d = -
C(CH3)ZOH or —C(CH2CH3)ZOH. The reaction with methylmagnesium bromide is preferred to
obtain Intermediates where R1d : -C(CH3)3OH. The intermediates of the formula 14b can then be
converted analogously to Sythesis Scheme 4 and then according to Synthesis Schema 2 into
compounds according to the invention where RI = -C(CH3)30H or —C(CH2CH3)30H. Alternatively
and preferably, the Intermediates 14b can also be converted by reaction with 2-chloroacetamides or
2-bromoacetamides into compounds of the a (I) according to the invention where Rl = -
C(CH;)3OH or —C(CH3CH3);OH. Here. the same reaction conditions as in Synthesis Scheme la
may be employed. The use of N.N—dicyclohexylmethylamine in ydrofuran or KN-
dimethylformamide is preferred. Particular preference is given to the use of 2—bromo—l {morpholin-
4—yl)ethanone.
W O
Ro \( R
H HN
w N
\n/ \
\ ,. HO
N IN
E N/ Rld N
R H
Intermediate 143 Intermediate 14b
Synthesis Scheme 5—1:
(Rlc represents —C02Me 0r -C02Et
RId represents methyl or ethyl)
A subset of the compounds according to the invention can be prepared as illustrated in Scheme 6.
The starting materials of the l formula (Ia) are reacted in the presence of a palladium catalyst
with an organometallic compound which transfers the radical R”. The l R'b ents C1-C6-
alkyl, C3—C8-cycloalkyl, heterocycloalkyl, C3-C3-cycloalkyl-C1—C4-alkyl, heterocycloalkyl—Cl-C4—
alkyl, alkenyl, C2-C6—alkynyl, aryl, 5- to lO-membered heteroaryl, aryl-CI-C4-alkyl or 5— or
6-membered heteroaryl—Cl—C4-alkyl which may optionally be mono- or polysubstituted by cal
or different substituents from the group consisting of protected hydroxy, halogen, cyano,
C(=O)OR3, S(=O)2-C1-C6-alkyl, protected NHZ, protected NHR“ or N(Ra)Rb. Suitable for the
W0 2015/09] 426
reaction are the known coupling reactions using organomagnesium compounds (Kumada reaction:
J. Organomet. Chem, 2002, 653, 288; Handbook of Organopalladium Chemistry for Organic
Synthesis, 2002, 1, 335; Top. Curr. Chem, 2002, 219, l), organoboron nds (Suzuki
reaction: Pure Appl. Chem, 1985, 57, 1749; Chem. Rev., 1995, 95, 2457; Advances in Metal-
Organic Chemistry, 1998, 6, 187; Angew. Chem, Int. Ed. Engl., 2004, 43, 2201, Top. Curr.
Chem, 2002, Vol. 219, 248), tin compounds (Stille reaction: Angew. Chem, 1986, 98, 504;
Synthesis, 1992, 803; Org. React, 1997, 50, 1; Angew. Chem, Int. Ed. Engl, 2004, 43, 4704; J.
Organomet. Chem, 2002, 653, 50) or organozinc compounds (Negishi reaction: Acc. Chem. Res,
1982, 15, 340; Metal-Catalyzed coupling Reactions, F. Diedrich, P. J. Stang, Wiley—VCH,
1998, 1; Aust. J. Chem. 2004, 57, 107; Handbook of Organopalladium Chemistry for Organic
Synthesis, E.—I. Negishi, Y. Dumond, 2002, Vol. I, 767) in the presence of a ium compound
(e.g. palladiumfll) e, tetrakis(triphenylphosphine)palladium, allylchloro(1.3-bis(2.6~di—
isopropylphenyl)imidazol-Z—ylidene)palladium. tristdibenzylideneacetoneJdipalladium(0). a ligand
(cg. 2.2‘-bis(diphenylphosphino)— l .l '-binaphthyl, triphenylphosphine. 1.1 '-
bis(dipheny1phosphino)fenocene, 3-dicyclohexy1phosphino—214'.6'-triisopropylbiphenyl. 4.5-
bis(diphenylphosphino)—9,9-dimethylxanthene, 2{dicyelohexylphosphino)3,6—dimethoxy-2',4’,6‘-
triis0propyl-l,1’-biphenyl, 1,1’-bis(di-o-tolylphosphino)ferrocene) in a solvent (eg. N,N-
dimethylformamide, toluene, xylene, tetrahydrofuran, dioxane, dimethoxyethane, tert-butyl methyl
other) using a base (eg. sodium tert-butoxide, potassium tert-butoxide, sodium e, potassium
hydride, potassium hexamethyldisilazide, tripotassium phosphate, caesium ate) at a
temperature of 40-200°C. The temperature depends inter alia on the solvent. Alternatively to the
palladium compounds mentioned above, it is also possible to use other palladium compounds
which are so-called pre-catalysts (eg. chloro[2—(dicyclohexylphosphino)—3,6-dimethoxy-Z’,4’,6'-
tn'isopropyl—l ,l ’—biphenyl] [2-(2-aminoethyl)phenyl]palladium(II) or yclohexylphosphino—
2’,4’,6’—tni30propyl—l,l’—bipheny1)[2-(2-aminoethy1)phenyl)]palladium(II) chloride). Preferred for
use in the reactions are tetrakis(triphenylphosphine)palladium, palladium(II) acetate with 2,2’—
phenylphosphino)-l,l’—binaphthyl or 4,5-bis(dipheny1phosphino)-9,9-dimethylxanthene or
allylehloro(1 ,3—bis(2,6—di—isopropy1phenyl) i midazolylidene)palladium. The use of
tetrakis(tripheny1phosphine)palladium is particularly preferred. Here, the radicals Ra and Rb can
assume the ions bed for the general formula (I). In the case that the electrophiles carry
protected hydroxyl functions or protected NH; or NHR", this protective group can be removed
again in an additional synthesis step by a customary ture s (Protecting Groups, Philip J.
Kocienski, 3rd Revised Edition (9th February 2005), Thieme; Greene‘s Protective Groups in
Organic Synthesis, Peter G. M. Wuts, Theodora W. Greene, 4th Edition (8th December 2006),
Wiley-Interscience).
[n the case that Rlb ents cyanide, the on of the starting materials of the general formula
(Ia) can be carried out in the presence of one of the palladium compounds described above and in
the presence of zinc cyanide in one of the solvents described above at a temperature of 40 — 200°C.
Here, g of the on mixture may be either by thermal heating or in the microwave.
Particular preference is given here to using tetrakis(triphenylphosphine)palladium in MN-
dimethylformamide at a temperature of 150°C in the microwave.
In addition, the starting materials of the general formula (Ia) can also be reacted with primary or
secondary amines or with alkoxides ald-Hartwig on: Chemtracts: Inorg. Chem, 1996,
8, 1; Chem. Org. Chem. 1997, 1, 287; Synlett 1997, 329; Angew. Chem, Int. Ed. Engl, 1998, 37,
2046; Pure Appl. Chem. 1999, 71, 1425; Top. Curr. Chem. 2002, 219, 131), which allows
compounds of the general formula (Ib) where Rib = NHR“, NRaRb, NHC(=0)Ra or on3 to be
obtained. The reaction is carried out in the presence of a palladium compound (eg. ium(II)
acetate, tris(dibenzy|ideneacetone)dipalIadium(0)), a ligand (eg. 2,2’-bis(diphenylphosphino)~1,1’-
binaphthyl, triphenylphosphine, 1,1‘—bis(diphenylphosphino)ferroeene, clohexylphosphino-
2'.4',6’-triisopropylbiphenyl, 4,5-bi5(diphenylphosphino)—9,9-dimethylxanthene, 2-
(dicyclohexylphosphino)3,6-dimethoxy-2'.4',6‘-triisopropyl-l ,1 '-biphenyl. l .1 di—o—
tolylphosphino)ferrocen) in a solvent (cg. rV,A-'-dimethylfonnamide, toluene, ,
tetrahydmfilran. e, dimethoxyethanc, tert-butyl methyl ether) using a bat: {e.g. sodium ten-
butoxide, potassium ten-butoxide, lithium hexamethyldisilazide, sodium hexamethyldisilazide,
potassium hexamethyldisilazide, potassium carbonate, caesium carbonate) at a temperature of 40-
200°C. The temperature depends inter alia on the solvent. Alternatively to the palladium
compounds mentioned above, it is also possible to use other palladium compounds which are so-
called pre-catalysts (cg. chloro[2-(dicyclohexylphosphino)—3,6—dimethoxy—2',4’,6'—triisopropyl—
1,l'-biphenyl][2-(2-aminoethyl)phenyl]palladiumfll) or (2—dicyclohexylphosphino—Z',4 ',6’-
triisopropyl-l,l’-biphenyl)[2-(2-aminoethyl)phenyl)]pailadiumfll) chloride). Here, the reaction
with the last-mentioned pre—catalysts is preferred.
$2 R° $2 R“
W N R13 W N R13
T / /
Y \n/ /N Y
ORia \ OR‘lb \ /N
N ( N
n ( n
O 0
(la)
(lb)
Synthesis Scheme 6:
(RIa represents chlorine, bromine, iodine, [(t1‘ifluoromethyl)sulphonyl]oxy or
[(nonafluorobutyl)sulphony1]oxy.
Rlb represents a) C1-C6-alkyl, C3—C3—cycloalkyl, heterocycloalkyl, C3-Cg-cycloalkyl-C1-C4-alky1,
heterocycloalkyl—C;-C4-alkyl, C2—C6-alkenyl, alkynyl, aryl, 5- to lO-membered heteroaryl,
l-C4-alkyl or 5- or 6-membered heteroaryl-CI-Crt-alkyl which may optionally be mono- or
polysubstituted by identical or different substituents from the group consisting of protected
hydroxy, halogen, cyano, C(=O)0Ra, S(=O)2-C.-C5-alkyl, protected NHz, protected NHR“ or
N(R")Rb,
b) cyanide, c) NHR“, NRaRb, NHC(=O)R"’ or OR“)
A subset of the compounds according to the invention can be prepared as shown in Synthesis
Scheme 7 by reacting starting materials of the general formula (Ic) with electrophiles Re-X such as
alkyl halides, ulphonates, aryl halides, arylsulphonates, hetaryl halides or hetarylsulphonates.
X has the meaning chlorine, e, , O(S=O)3CH3, O(S=O)2C6H4CH3 or O(S=O)2CF3,
with X preferably being chlorine, bromine or iodine and particularly preferably bromine.
Re represents C1-C5—alkyl, C3-Cg-cycloalkyl, heterocycloalkyl, C3-C3—cycloalkyl—Ci—C4-alkyl,
heterocycloalkyl—C1—C4-alkyl, C3-C5-alkenyl, C3-C5-alkynyl, aryl, 5— to 10—membered heteroaryl,
aryl-C 1-C4-alkyl or 5— or 6-membered aryl-Ci-C4-alkyl which may optionally be mono- or
bstituted by cal or different substituents from the group consisting of hydroxy
(optionally protected), halogen, cyano, C(=O)OR', S{=O)z-C,-Cb-alkyl, protected NH}, protected
NHR‘ or NR‘R”. Here, the radicals R3 and Rb can assume the definitions described for the general
formula (I). In the case that the electrophiles carry protected hydroxyl functions or protected NH;
or NHR‘, this protective group can be d again in an additional synthesis step by a customary
literature s cting Groups, Philip J. Kocienski, 3rd d Edition (9th February 2005),
Thieme; Greene's Protective Groups in Organic Synthesis, Peter G. M. Wuts, Theodora W. Greene,
4th n (8th December 2006), Wiley-Interscience). If Rc—X has the meaning alkyl halide or
alkylsulphonate, it is possible to use suitable bases such as, for example, sodium tert—butoxide,
potassium utoxide, sodium hydride, potassium hydride, potassium hexamethyldisilazide,
tripotassium phosphate, sodium carbonate, potassium carbonate, caesium carbonate
(W02003101379 A2; Bioor. Med. Chem, 2008, 16, 1966; J. Med. Chem, 2012, 55, 7141).
Furthermore, it is possible to use further additives such as, for example, sodium iodide, potassium
iodide, caesium iodide for the alkylation. The reaction with activated aryl s, arylsulphonates,
l halides or hetarylsulphonates (electron-withdrawing radicals or heteroatoms in the ortho-
and/or osition to the halide or sulphonate) can take place by nucleophilic aromatic
substitution at the activated aryl halide, arylsulphonate, hetaryl halide or hetarylsulphonate, it being
likewise possible to employ suitable bases such as, for example, sodium tert-butoxide, potassium
tert-butoxide, sodium hydride, potassium hydride, potassium hexamethyldisilazide, tripotassium
phosphate, sodium carbonate, ium carbonate or caesium carbonate for the reaction
(WO200795124 A2, EP2103620 A1). Furthermore, the ion or heteroarylation of the starting
materials of the general formula (10) in Synthesis Scheme 7 can be carried out by reaction with aryl
halides, lphonates, hetaryl halides or hetarylsulphonates using a copper—based transition
metal catalyst known from the literature (e.g. copper(l) iodide, copper(l) oxide, (II) acetate)
(Russ. Chem. Rev., 1974, 43, 1.443; Tetrahedron, 2000, 56, 5054; t, 2003, 2428; Angew.
Chem, Int. Ed. Engl., 2003, 42, 5400; Angew. Chem, Int. Ed. Engl, 2004, 43, 1043) or palladium
(e.g. palladium(ll) acetate, ibenzylideneacetone)dipalladium(0)) (Acc. Chem. Res, 1998, 31,
852; Angew. Chem, Int. Ed. Engl., 1998, 37, 2046; Top. Cur. Chem, 2002, 219, 131) in the
presence of a suitable base (cg. sodium ten-butoxide, ium tert—butoxide, sodium hydride,
potassium hydride, potassium hexamethyldisilazide, tripotassium ate, sodium carbonate,
potassium ate, caesium carbonate) and a ligand (e.g. 2,2’-bis(diphenylphosphino)—l,1’—
binaphthyl, 4,5-bis(dipheny1phosphino)~9, 9—dimethylxanthene, triphenylphOSphine, l 1'-
bis(diphenylphOSphino)ferrocene, 1,1 ’—bis(di-o-tolylphosphino)ferrocene, 1,3 —dirtert-butyl
chloro-l,3,2-diazaphospholidine, 2'-(dicyclohexylphosphino)—N,N—dimethylbiphenyl-2—amine) in a
solvent (eg. N,N—dimethylfonnamide, toluene, xylene, tetrahydrofuran, dioxane, dimethoxyethane,
tert—butyl methyl ether) at a temperature of °C. Preferably, the oxyindazoles are
reacted with alkyl halides using the base ium carbonate and the solvent N,N—
dimethylformamide. The ons are preferably canied out at 70 - 150°C in the microwave over a
period of l - 24 hours.
R2 RD R0
| $
13 W N 13
W” R R
N Y “——’ r Y
\ ,N
O \ / .. O
N ' N
HO (
n n
.. _
"N w (l3
O - Re 0
(167* '
* ~
, (Id)
Sypthesis Scheme 7:
(Re ents C1-C6-alkyl, C3-Cg-eycloalkyl, heterocycloalkyl, Cg—Cg—cycloalkyl—C1-C4-alkyl,
cycloalkyl-C]-C4-alky1, C2-C6-alkenyl, C2—C6—alkynyl, aryl, 5- to bered heteroaryl,
aryl-Cl-C4-alkyl or 5— or 6—membered aryl—Cl—C4-alky1 which may optionally be mono- or
polysubstituted by identical or different substituents from the group consisting of hydroxy
(optionally protected), halogen, cyano, C(=O)ORa, S(=O)2—C1-C(,-alkyl, protected NHZ, protected
NHRa or NRaRh.)
The pyridinecarboxylic acids (Intermediate 19) used as starting material for the synthesis of a
subset of the compounds according to the invention are commercially available or can be prepared
by routes known from the literature in accordance with Synthesis Scheme 8. Some of the
Intermediates 19 can be prepared from carboxylic esters (Intermediate 17) by hydrolysis or — in the
case that it is a tert—butyl ester - by reaction with an acid such as, for example, hydrogen chloride or
trifluoroacetic acid, The Intermediates 19 may optionally be produced as salts (for example as
potassium salt). The Intermediates 17 are commercially available, can be prepared by routes known
from the literature or are available from the Intermediates 16 which, as X], carry chlorine, bromine
W0 2015/09 1 426
or iodine, by reaction in a carbon monoxide here, optionally under superatmospheric
pressure in the presence of a phosphine ligand such as, for example, 1,3-
bis(diphenylphoshino)propane, a palladium compound such as, for example, palladiumfll) acetate
and a base such as, for example, triethylamine with addition of ethanol or methanol in a solvent
such as, for example, dimethyl sulphoxide.
Here, the radical R3 represents cyano, substituted or unsubstituted C1-C6-alkyl, tuted or
tituted C1-C6-alkoxy, substituted or unsubstituted C3—C6—cycloa1ky1, heterocycloalkyl, C5—
Cn-spirocycloalkyl, substituted or unsubstituted C3—Cficycloalkyl-Ct—C,—alkyl, substituted or
unsubstituted aryl, 5- to 10-membered heteroaryl, NHZ, NHR", b or N(H)C(=O)Ra.
In the special case that R3 has the meaning substituted or tituted C1-C5-alkoxy, NHZ, NHRa
or b, R3 can be introduced by heating the corresponding bishalogenated Intermediates 15 in
which x‘ and x2 independently of one another represent chlorine, bromine or iodine with alcohols
or amines, which yields the ediates 16.
If R‘ represents substituted or unsubstituted Cl-Cb-alkyl (Eur. J. of Org. Chern., 2002, 327),
substituted or unsubstituted C3-Cb-cycloalkyl. ycloalkyl, C5-Cl.-5pirocycloalkyl or
substituted or unsubstituted C3—C6-cycloa1kyl-C]-C4-all<yl, R'1 can be introduced by reacting the
Intermediates 15 with the appropriate organometal compounds. Suitable for this purpose are
lithium compounds (Green Chemistry, 2011, 13, 1110), organomagnesium compounds or
organocopper compounds . Chem, 2013 , 125, 6397). In the case of amino- or y-
substituted radicals R3, the fimctional group in the organometal compound-carries a protective
group which is known in the literature and, according to the opinion of the person skilled in the art,
suitable (Protecting Groups, Philip J. ski, 3rd Revised Edition (9th February 2005), Thieme;
Greene’s Protective Groups in Organic Synthesis, Peter G. M. Wuts, Theodora W. Greene, 4th
Edition (8th December 2006), Wiley-Interscience). This tive group can be removed again in
an additional synthesis step by a customary literature process (Protecting Groups, Philip J.
Kocienski, 3rd d Edition (9th February 2005), Thieme; Greene's Protective Groups in
Organic Synthesis, Peter G. M. Wuts, Theodora W. Greene, 4th Edition (8th December 2006),
Wiley-Interscience). Alternatively, the radical R3 can also be introduced Via a palladium-catalysed
Suzuki coupling (Pure Appl. Chem, 1985, 57, 1749; Chem. Rev., 1995, 95, 2457; Advances in
Metal-Organic Chemistry, 1998, 6, 187; Angew. Chem, Int. Ed. Eng]., 2004, 43, 2201, Top. Curr.
Chem, 2002, Vol. 219, 248) if R3 is tuted or unsubstituted aryl or a 5— to 10-membered
heteroaryl. Here, R3 is introduced via a corresponding organoboron compound in the presence of a
palladium compound (e.g. palladiumfll) acetate, tris(dibenzy1ideneacetone)dipalladium(0),
is(triphenylphosphine)pailadium), a ligand (eg. 2,2’-bis(diphenylphosphino)-l,1’-binaphthyl,
triphenylphOSphine, 1,1'-bis(diphenylphosphino)ferrocene, 2—dicyclohexy1phosphino-2',4',6’-
triisoprOpylbiphenyl, 4,5—bis(diphenylphosphino)—9,9-dimethylxanthene, 2-
(dicyclohexylphosphino)3,6-dimethoxy-2’,4’,6’-triisopropyl-1,l’-biphenyl, 1,1 di-o-
tolylphosphino)ferrocene) in a solvent (eg. methylformamide, acetonitrile, toluene, xylene,
tetrahydrofuran, e, dimethoxyethane, methanol, ethanol, water) using a base (eg. sodium
carbonate, potassium carbonate, caesium carbonate, tripotassium phosphate, potassium fluoride,
sodium hydroxide) and optionally added lithium chloride at a temperature of 25 - 200°C. The use
of tetrakis(triphenylphosphine)palladium is red.
Alternatively, the Intermediates 17 can also be prepared from Intermediates 18. To introduce the
radical R3, the above-described Suzuki reacktion with appropriate organoboron compounds is
employed.
, (12‘) (mm
(R . m
(R4 )m
I l
1 \ O
. h R'
, \N 0‘R“ x' N \Rd
X‘ N X' R' N X
0 0
Intermediate 15 lntermedcatete Intermediate” |ntermeduate13
Intermediate 19
Synthesis Scheme 8:
(X1 ents chlorine, bromine or iodine.
X2 represents chlorine, bromine or .
Rd represents C1—C6—alkyl or benzyl.
R3, R4 and m have the definitions described in the general formula (1).)
In ance with Synthesis Scheme 9, Intermediates 20, which can be prepared ing to
Synthesis Scheme 2, can be reacted in a Negishi reaction (Acc. Chem. Res, 1982, 15, 340; Metal-
Catalyzed coupling Reactions, F. Diedrich, P. J. Stang, Wiley-VCH, 1998, 1; Aust. J. Chem.
2004, 57, 107; ok of Organopalladium Chemistry for Organic Synthesis, E.-I. Negishi, Y.
Dumond, 2002, V01. 1, 767) with primary and secondary alkylzinc reagents in the presence of a
palladium catalyst, which allows the preparation of a subset (Ie) of the compounds according to the
invention where Rg = primary or secondary C1-Cé-alky1. Preference is given to the reaction with
diethylzinc or 2—methylpropylzinc bromide.
WO 91426 PCT/EP2014/O77877
/ /
I 1'22 R0 I IR? RD
\N N 13
R \ N is
Br / R9 N /
N Y ——-———> N Y
O \ ’ O
R1 N 1 \N/
n R n
O 0
ediate 20 (Ie)
Smthesis Scheme 9:
(Rs represents primary or secondary alkyl)
Further intermediates can be obtained according to Synthesis Scheme 10: The Intermediates 9 can
be reacted in an amide coupling as described in Synthesis Scheme 1 to give the Intermediates 21.
The use of i{Ts-dimethyiaminopmpylH{thyicarbodiimide hloride in combination with I-
hydroxy-I iI-bcuzotriamle hydrate is preferred. Intermediates 21 can then be com-med by reaction
with triiluoroacetic acid into Intermediates 22 which, in an amide coupling reaction, can be reacted
analogously to the methods described in Synthesis Scheme l to afford Exemplary Compounds.
is CH;
0 CH3 <23 0 Ci-i3
R2 Ru rNJ $2 Rn N CH3
I ‘3
13 N W N
W\n/N R
R < > H C
/ 3
/ H Y N N
N OH
O \ /
O \ ’ R1 N
Intermediate 21
ediate 9
R2 R“ g
Wrmiwi R13 (
intermediate 22
Smthesis Scheme 10:
Intermediates of type 2b can be obtained according to Synthesis Scheme 11: Intermediates 12b are
reacted with benzyl carbonochloridate and N-ethy].-N-isopropylpropane-Z-amine in THF to give
Intermediates 23. The reaction with roacetic acid in dichloromethane then leads to the
Intermediates 2b which are reacted further according to Synthesis Scheme 1 to give the compounds
according to the invention.
2014/077877
H2N o Q/OYO o
/ R
CH3 _ HN
\ /N_< 0
H30 CH3
CI \N/ 0
Intermediate 12b
Intermediate 23 H30 3
Q/0 0 Y R“
intennedsate 2:)
Sflthesis Scheme 11:
WO 91426 PCT/EP2014/O77877
Abbreviations
MN—dimethylformamide
high-performance liquid tography
1 -hydroxy—1H—benzotriazole hydrate
ultra-performance liquid chromatography
diode array detector
FIFE
, E polytetrafluorocthylcnc
CV l column volume(s)
l BOC l ten-butyloxycarbonyl
protecting group
Methods
Analytical HPLC methods:
Method A1: UPLC (ACN—HCOOH):
ment: Waters y UPLC-MS SQD 3001; column: Acquity UPLC BEH C18 1.7 50x21
mm; mobile phase A: water + 0.1% by volume of formic acid (99%), mobile phase B: acetonitiile;
gradient: 0-l.6 min 1—99% B, 1.6-2.0 min 99% B; flow rate 0.8 ml/min; temperature: 60°C;
injection: 2 ul; DAD scan: 210-400 nm; ELSD.
Method A2: UPLC (ACN-NH3):
Instrument: Waters Acquity UPLC—MS SQD 3001; column: Acquity UPLC BEH C18 1.7 50x2.1
mm; mobile phase A: water + 0.2% by volume of ammonia (32%), mobile phase B: acetonitrile;
gradient: 0—1.6 min 1—99% B, 1.62.0 min 99% B; flow rate 0.8 ml/min; temperature: 60°C;
injection: 2 ul; DAD scan: 210-400 nm; ELSD.
Method A3: (LC-MS)
Instrument: Agilent 1290 Infinity LC; : Acquity UPLC BEH C18 1.7 50x21 mm; mobile
phase A: water + 0.05% by volume of formic acid, mobile phase B: acetonitn'le + 0.05% by
2014/077877
volume of formic acid; gradient: 0-1.7 min 2-90% B, 1.7—2.0 min 90% B; flow rate 1.2 ml/min;
temperature: 60°C; injection: 2 pl; DAD scan: 190-390 nm; MS: Agilent TOF 6230.
Method A4: (LC—MS)
Instrument: Waters Acquity; column: x (Phenomenex), 50x2 mm; mobile phase A: water +
0.05% by volume of formic acid, mobile phase B: acetonitrile + 0.05% by volume of formic acid;
gradient: 0-1.9 min 199% B, 1.9-2.1 min 99% B; flow rate 1.5 ml/min; temperature: 60°C;
injection: 0.5 pl; DAD scan: 200-400 mm.
Preparative HPLC methods:
Method PI: System: Waters autopurification system: Pump 2545. Sample Manager 2767. CFO.
DAD 3996. ELSD 2424. SOD; column: e C18 5pm 100x30 mm: mobile phase: A: water +
0.1% by volume of formic acid. mobile phase B: acetonitn'le; gradient: 08 min 10-10096 8. 8-10
min 100% B: flow rate: 50 : temperature: room temp; solution: mm 250 mg 1’ max. 2.5 m1
DMSO or DMF; injection: 1 x 2.5 ml; detection: DAD scan range 210—400 nm; MS ESI+, 1351-,
scan range 160—1000 m/z.
Method P2: System: Waters autopurification system: Pump 254, Sample Manager 2767, CFO,
DAD 2996, ELSD 2424, SQD 3100; column: XBridge C18 5pm 100x30 mm; mobile phase: A:
water + 0.2% by volume of ammonia (32%), mobile phase Bz'methanol; gradient: 0-8 min 30-70%
B; flow rate: 50 mllmin; temperature: room temp.; detection: DAD scan range 210—400 nm; MS
ESl+, ESL, scan range 160-1000 m/z; BLSD.
Method P3: : Labomatic, pump: HD-5000, fraction collector: LABOCOL Vario—4000, UV
detector: Knauer UVD 2.18; column: XBridge C18 5pm 100x30 mm; mobile phase A: water +
0.2% by volume of ammonia (25%), mobile phase B: acetonittile; nt: 0-1 min 15% B, 1—6.3
min 15-55% B, 6.3—6.4min 55—100% B, 6.4-7.4min 100% B; flow rate: 60 ml/min; temperature:
room temp; solution: max. 250 mg / 2 m1 DMSO; injection: 2 x 2 m1; detection: UV 218 nm;
software: SCPA PrepConS.
Method P4: System: Agilent: Prep 1200, 2xPrep Pump, DLA, MWD, Prep FC; column: Chiralpak
[A 5pm 250x20 mm; mobile phase A: ol, mobile phase B: ethanol; gradient: isocratic 50%
B; flow rate: 15 ml/min; temperature: room temp; detection: UV 254 nm
Method P5: System: Labomatic, pump: HD-SOOO, fraction collector: LABOCOL Vario-4000, UV
detector: Knauer UVD 2.18; column: : torex RP C18 10pm 125x30 mm, mobile
phase: A: water + 0.1% by volume of formic acid, mobile phase B: acetonitrile; gradient: 0 - 15
PCT/EP2014/O77877
min 65 — 100% B; flow rate: 60 mI/min; temperature: room temp; solution: max. 250 mg / 2 ml
DMSO; injection: 2 x 2 ml; detection: UV 254 nm; software: SCPA PrepConS.
Microwave
CEM Discover S-Class; autosampler: CEM Explorer; software: CEM Synergy; : Dynamic
heating mode, 300 W, 18 bar max.
Intermediates
2-F1uoronitro—4-(trifluoromethoxy)benzaldehyde
('3 1°
0*”N
0 F
.9 g (100.4 mmol) of 2-fluoro(trifluoromethoxy)benmldehyde were dissolved in 100 ml of
sulphuric acid (“729690) and, in a three-necked flask fitted with mechanical stirrer, dropping funnel
and internal thermometer, cooled to -15°C. Over a period of 60 min, the nitrating acid (28 ml of
sulphuric acid (w=96%) in 14 ml of nitric acid )), which had been prepared and cooled
beforehand, was added dr0pwise to this solution. During the addition, the internal ature
fluctuated between -15°C and -12°C. After the end of the dropwise addition, stirring was continued
for another hour (internal temperature -13°C). The reaction mixture was added to ice and extracted
three times with in each case 150 ml of ethyl acetate. The combined org. phases were washed with
saturated sodium chloride solution, dried over sodium sulphate, filtered and concentrated. This
gave 25.4 g (100% of theory) of the title compound.
1H NMR (400 MHz, CHLOROFORM—d) 5 = 7.34 (dd, 1 H), 8.57 (d, 1 H), 10.34 (s, 1. H).
Intermediate 0-2
o(trifluoromethoxy)-lH-indazole
0 \
/(|)\ H
.4 g (100.4 mmol) of 2-fluoro—5-nitro(trifluoromethoxy)benzaldehyde were lly charged
in 200 ml of absolute ethanol, and 25 m1 (513.6 mmol) of hydrazine hydrate were added. The
colour of the solution darkened. The reaction mixture was heated under reflux for 2 h. The reaction
mixture was then added to 1.4 l of water and stirred usly for 10 minutes. The precipitate
formed was filtered off with suction and washed three times with in each case 40 ml of water. The
ing solid was dried in a vacuum drying cabinet at +50°C ovemight. This gave 19.4 g (78% of
theory) of the title compound.
UPLC—MS (Method Al): R1: 1.03min
MS (ESIpos): m/z = 248 (M+H)+
1H NMR (400 MHz, DMSO-d6) 5 = 7.86 (s, 1 H), 8.46 (s, 1 H), 8.82 (s, 1 H), 1387 (br. s., 1 H).
Intermediate 0—3
6—(Benzyloxy)nitro-1 H-indazole
0 3:2
.0 g (111.6 mmol) of —l H—indazolol (CAS No. 1082041662) were initially charged in
750 ml oftetrahydrofuran, and 13.9 ml (134.0 mmol) ofbenzyl alcohol and 35.1 g (134.0 mmol) of
triphenylphosphine were added. The solution was cooled to 0°C, and 26.03 ml (134.0 mmol) of
diisopropylazo dicarboxylate were added. The on mixture was stirred at 0°C for 1 h and then
at 25°C for 24 h. Water was then added, and the reaction mixture was extracted with ethyl e.
The combined c phases were washed with saturated sodium chloride solution and
concentrated. The residue was taken up in dichloromethane, Isolute® HM-N (Biotage) was added
and during concentration the residue was adsorbed on Isolute. The Isolute was applied to a
cartridge (750 g; KP-Sil) pre—equilibrated with hexane and chromatography was carried out using
the Isolera® flash purification system ge) (mobile phase: /ethyl acetate; flow rate: 200
m1/min; gradient: isocratic 88:12 (1 CV), 88:12—>20:80 (10 CV), isocratic 20:80 (2 CV)). The
ed product fractions were concentrated and dried. This gave 18.908 g (63% of theory) of the
title compound.
UPLC—MS (Method Al): Rt = 1.09 min
MS (ESIpos): m/z = 270 (M+H)+
1“ NMR (300 MHz, DMSO-d6) 6 : 5.35 (s, 2 H), 7.25 — 7.57 (m, 6 H), 8.20 (s, 1 H), 8.45 (s, 1 H),
13.38 (br. 5., 1 H).
Intermediate 0-4
6-Ethoxy—5—nitro—lH—indazole
WO 91426 2014/077877
I |+
O,.N
Han/\o H
100 mg (0.56 mmol) of 5—nitr0-1H-indazolol (CAS No. 1082041—56—2) were initially charged in
668 pl of N,N—dimethylformamide, and 93 mg (0.67 mmol) of potassium carbonate and 54 pl (0.67
mmol) of iodoethane were added. The solution was heated in a microwave at 60°C for 1 h. Water
was then added, and the reaction mixture was extracted with ethyl acetate. The combined organic
phases were washed with saturated sodium chloride solution, filtered through a hydrophobic filter
and concentrated. The residue was taken up in dichloromethane, lsolute® HM-N (Biotage) was
added and during concentration the residue was adsorbed on Isolute. The Isolute was applied to a
cartridge (25 g; KP~Sil) pre-equilibrated with hexane and tography was carried out using
the lsolera® flash purification system (Biotage) (mobile phase: hexane’ethyl acetate: flow rate: 25
ml/min; gradient: isocratic 88:12 (1 CV), 83:12->0:100 (10 CV), isocratic 0:100 (2 CV)). The
combined product ons were concentrated and dried. This gave 89 mg (77% of theory) of the
title compound.
S (Method A1): R[ = 0.89 min
MS (ESIpos): mfz = 208 (M+H)‘
1H NMR (300 MHz, DMSO-d6) 5 = 1.37 (t, 3 H), 4.23 (q, 2 H), 7.19 (s, 1 H), 8.17 (s, 1 H), 8.40 (s,
1 H), 13.31 (br. 5., 1 H).
ediate 0—5
Methyl o-1H-indazolc-é-carboxylate
' N+
O \
H3C’ fl
4.60 g (26.1 mmol) of methyl 1H—indazole-é-carboxylate were ved in 120 m1 of sulphuric
acid (W=96%) and, in a three—necked flask fitted with mechanical stirrer, dropping funnel and
internal thermometer, cooled to —15°C. Over a period of 15 minutes, the nitrating acid (9.2 m1 of
sulphuric acid (w=96%) in 4 ml of nitric acid (w=65%)), which had been prepared and cooled
beforehand, was added dropwise to this solution. During the addition, the internal temperature
fluctuated between -15°C and —12°C. After the end of the dropwise addition, stirring was continued
for another hour (internal temperature 6°C). The reaction e was added to ice, and the
precipitate formed was filtered off with suction, washed with water and dried in a drying cabinet at
50°C under reduced pressure. This gave 5.49 g (91% of theory) of the title compound.
UPLC-MS (Method A1): Rt = 1.21 min
MS s): m/z = 471 (M+H)+
1H NMR (400 MHz, DMSO—dé): 6 = 3.85 (s, 3 H) 6.01 (s, 2 H) 6.98 (s, 1 H) 7.79 - 7.91 (m, 1 H)
7.99 (s, 1 H) 12.84 (br. s., 1 H).
Intermediate 1-1
fluoromethoxy)-1H-indazole-S-amine
/T\ H
F F
.0 g {40.5 mmol) of 5-nitro(trifluoromethox3-HH—indazole mediate 0.2) were dissolved
in 400 ml of methanol. The solution was then ed and flushed with nitrogen (this was
repeated twice). 2.48 g (2.0 mmol) of palladium on activated carbon were added. The flask was
evacuated and flushed with hydrogen. The reaction mixture was hydrogenated under standard
hydrogen pressure at room temperature for 5 hours. The reaction mixture was filtered through a
PTFE filter with Celite and concentrated. This gave 7.2 g (74% of theory) of the title compound.
UPLC-MS (Method A1): R[ = 0.75 min
MS (ESIpos): m/z = 218 (M+H)+
1H NMR (400 MHz, DMSO-d6) 6 = 4.91 (s, 2 H), 7.04 (s, 1 H), 7.32 (s, 1 H), 7.83 (s, 1 H), 12.72
(br. 5., 1 H).
Intermediate 1—2
-Amino—1H-indazol—6—ol
HO NI
Analogously to Intermediate 1—1, 6.5 g (36.3 mmol) of 5-nitro-1H—indazolol (CAS No. 1082041—
56-2) were dissolved in 1.5 1 of methanol and hydrogenated with 193 mg (1.8 mmol) of palladium
on activated carbon under standard hydrogen pressure at 25°C for 5 h. This gave 5.28 g (98% of
theory) of the title compound.
UPLC—MS d A1): Rt = 0.26 min
MS (ESIpos): m/z = 150 (M+H)+
]H NMR (400 MHz, DMSO-d6): 6 = 4.37 (br. s., 2 H) 6.71 — 6.78 (m, 2 H) 7.59 (s, 1 H) 12.17 (br.
s., l H).
Intermediate 1-3
6-(Benzyloxy)-lH-indazole-S-amine
18.5 g (68.7 mmol) of zyloxy)-5—nitro-lH—indazole (Intermediate 0-3) were dissolved in 500
ml of ethanol and initially charged in a 1 l three-necked flask with mechanical stirrer and reflux
ser, and 100 ml of water were added. 192 g (343.5 mmol) of iron powder and 1.84 g (34.35
mmol) of ammonium chloride were then added- The brown suspension was heated at reflux fer 4 h.
The reaction mixture was cooled to 25°C using a water bath and filtered through Celite (clear
filtrate). The filter cake was washed with ethanol. The filtrate was concentrated until about 200 ml
of soivent were left. The reaction e was added to 2 l of water. The suspension was cooled
and the resulting precipitate was then filtered off with suction. The filter cake was washed twice
with in each case 150 ml of water and twice with in each case 100 ml of diethyl ether. The
itate was dried in a vacuum drying cabinet at 50°C for 5 h and then rogenated for 5 h
using 193 mg (1.81 mmol) of palladium on activated carbon at 25°C under standard hydrogen
pressure. This gave 15.28 g (92% of theory) of the title compound.
UPLC-MS (Method A1): R1: 0.66 min
MS (ESIpos): m/z = 240 (M+H)+
1H NMR (300 MHz, DMSO—d6): 8 = 4.54 (s, 2 H), 5.19 (s, 2 H), 6.84 (s, 1 H), 6.91 (s, 1 H), 7.22 -
7.45 (m, 3 H), 7.48 - 7.57 (m, 2 H), 7.66 (s, 1 H), 12.43 (br. s., l H).
Intermediate 1-4
6-Isopropoxy-1 H—indazole-S-amine
i H
H30 CH3
10 g (45.2 mmol) of 6-isopropoxy-5—nitro-lH—indazole (CAS No. 1082041—56-2) were dissolved in
200 ml of ethanol and hydrogenated with 1.20 g (1.13 mmol) of palladium on activated carbon
under standard en pressure at 25°C for 24 h. The reaction e was filtered off through
Celite, the filter cake was washed with ethanol and the filtrate was concentrated. The residue was
subjected to incipient dissolution with a little ethanol in an ultrasonic bath, diethyl ether was added
and the e was digested r in the ultrasonic bath. The solid was filtered off with suction
and washed with a little diethyl ether and hexane, giving 4.69 g (54%) of product. The filtrate was
concentrated and applied to a Biotage SNAP cartridge (100 g; KP-Sil) pre—equilibrated with hexane
and chromatography was carried out using the Isolera® flash purification system (Biotage) (mobile
phase: hexane/ethyl acetate; gradient: 90:10—>35:65 (9.2 CV), isocratic 35:65 (1 CV)). The
combined product fractions were concentrated and the residue was digested with a mixture of
hexane and dichloromethane (2:1) in an ultrasonic bath. The solid formed was filtered off. This
gave an additional 2.36 g (27% of theory) of the title compound.
UPLC-MS (Method A1): 1% = 0.75 min
MS (ESIpos): m/z = 192 (M+H)T
'H NMR (400 MHz, 6): 6 = 1.31 (s, 3 H), 1.33 (s, 3 H), 4.43 (s, 2 H), 4.57 - 4.68 (m, 1 H),
6.81 (s, l H). 6.83 (s, l H). 7.64(s, 1 H), 12.34 (br. s., 1 H).
Intermediate [-5
6-Ethoxy—l H-indazole—5~amine
Analogously to Intermediate 1-1, 65 mg (0.31 mmol) of 6—ethoxy—5-nitro—IH-indazole
(Intermediate 0—4) were dissolved in 4.1 ml of ol and hydrogenated with 33 mg (0.03 mmol)
of palladium on activated carbon under standard en re at 25°C for 5 h. This gave 54
mg (97% of theory) of the title compound.
UPLC—MS (Method A1): R[ = 0.64 min
MS s): m/z = 178 (M+H)+
1H NMR (400 MHz, DMSO—d6): 8 = 1.40 (t, 3 H), 4.07 (q, 2 H), 4.47 (br. s., 2 H), 6.81 (s, 2 H),
7.65 (s, 1 H), 12.39 (br. s., 1 H).
Intermediate 1-6
Methyl S-amino-1H—indazolecarboxylate
H30 H
Analogously to Intermediate 1-1, 5.48 g (24.8 mmol) of methyl 5-nitro-lH-indazolecarboxylate
(Intermediate 0-9) were dissolved in 293 m1 of methanol and enated with 1.32 g (1.24
mmol) of palladium on activated carbon under standard hydrogen pressure at 25°C for 3 h. This
gave 4.52 g (91% of theory) of the title compound.
UPLC-MS (Method A1): R = 0.75 min
MS (ESIpos): m/z = 222 (M+H)'
lFl NMR (500 MHz, DMSO—d6): 5 = 3.85 (s, 3 H), 6.05 (br. 5., 2 H), 6.99 (d, 1 H), 7.85 (d, 1 H),
8.00 (s, l H), 1283 (br. s., 1 H).
Intermediate 2-1
tert-Butyl (6—methyl-1H-indazol-S-ylkarbamate
HCX3 Y \/N
HC N
.3 g (70.0 mmol) of 6—rnethy1—lH—indazole-S-amine (CAS No: 811159) were suspended in
150 ml of tetrahydrofuran, 13.4 ml (80.0 mmol) of N,N-diisopropylethylamine were added and the
mixture was cooled to 0°C. After addition of 5.52 g (25.3 mmol) of di—tert-butyl dicarbonate at
0°C, the mixture was then stirred at 25°C for 18 h. The mixture was concentrated, giving 17.6 g of
a crude product which was used t purification.
S (Method A1): Rl = 1.01 min
MS (ESIpos): m/z = 248 (M+H)+‘
Intermediate 2—2
tert—Butyl (6-methoxy— 1 H-indazol—S -yl)carbamate
0 I2
4.0 g (24.5 mmol) of 0xy-1H-indazol-S—amine (CAS No. -61—8) were dissolved in 30
m1 of tetrahydrofiiran, and 5.35 g (24.5 mmol) of di-tert—butyl dicarbonate were added. The
reaction mixture was stirred at 25°C for 18 h. The mixture was then concentrated and the residue
was suspended in 20 m1 of dichloromethanc. 200 m1 of hexane were added and the resulting
suspension was stirred with ice bath cooling for 25 s. The precipitate was filtered off with
n, washed twice with 25 ml of hexane and dried. This gave 4.83 g (75% of theory) of the title
compound.
UPLC-MS (Method A2): R = 1.08 min
MS (ESIpos): m/z = 264 (M+H)F
1H NMR (400 MHz, CHLOROFORM-d) 6 = 1.56 (s, 9 H), 3.95 (s, 3 H), 6.88 (s, 1 H), 7.12 (br. 3.,
1 H), 7.94 (d, 1 H), 8.40 (br. s., 1 H).
Intermediate 2-3
utyl [6—(tn'fluor0methoxy)- 1 H-indazol-S-yl]carbamate
H30 0 N
”ca/T \
3 N
CH3 0
O N
A H
F F
.0 g (23.0 mmol) of 6—(trifluoromethoxy)—1H-indazole—S-amine (Intermediate 1-1) were
suspended in 100 ml of tetrahydrofuran, 4.81 ml (27.6 mmol) of NJV—diisopropylethylamine were
added and the mixture was cooled to 0°C. After addition of 5.52 g (25.3 mmol) of di-tert-butyl
dicarbonate at 0°C, the mixture was then stirred at 25°C for 18 h. A further 3.52 g (16.1 mmol) of
di-tert—butyl dicarbonate were added, and the mixture was stirred at 25°C for a further 24 h. The
reaction mixture was heated at reflux for a r 24 h. The reaction mixture was then
concentrated, taken up in ethyl acetate and washed with 0.5 M hydrochloric acid, saturated sodium
bicarbonate solution and saturated sodium chloride solution. The combined organic phases were
dried over sodium sulphate and the solution was, after filtration, concentrated. The residue was
taken up in dichloromethane, Isolute® HM-N (Biotage) was added and during concentration the
residue was ed on Isolute. The Isolute was applied to a Biotage SNAP cartridge (340 g; KP—
Sil) pre-equilibrated with hexane and tography was carried out using the Isolera® flash
purification system (Biotage) (mobile phase: /ethyl acetate; gradient: isocratic 90:10 (3 CV),
90:10->80:2O (2 CV), isocratic 80:20 (7 CV), 80:20->75:25 (1 CV), isocratic 75:25 (7 CV)). The
combined product fractions were concentrated and the sh solid was dried under reduced
pressure. This gave 3.48 g (48% of theory) of the title compound.
UPLC-MS d A2): Rt= 1.15 min
MS s): m/z = 318 (M+H)+
1H NMR (300 MHz, DMSO-d6) 8 =1.44 (s, 9 H), 7.51 (s, l H), 7.83 (s, 1 H), 8.11 (s, 1 H), 8.80 (s,
1 H).
Intermediate 2-4
tert-Butyl (6-hydroxy-1 H-indazol-S -y1)carbamate
H30 0 N
H3C>l/ Y \N
CH3 0
8.05 g (36.8 mmol) of t-butyl dicarbonate were suspended in 125 ml of drofiiran and
.0 g (33.5 mmol) of 5-amino-1H—indazol—6-ol (Intermediate 1-2) were added a little at a time with
stirring. The reaction mixture was stirred at 25°C for 24 h. The reaction mixture was subsequently
concentrated, the residue was taken up in methanol and 2 m1 of 1 M aqueous sodium hydroxide
solution and 2 m1 of water were added. The mixture was stirred for another 30 min and the
methanol was then distilled off. 1 M hloric acid was added to the residue until a pH of 7 had
been reached. The mixture was then extracted with dichlommethane and the combined org. phases
wen: dried oxer sodium te. filtered and concentrated. This gave 7.50 g (90% of theory) of the
title compound.
UPLC-MS (Method A2): R: 0.95 min
MS (ESIpos): m/z = 250 (M+H)+
lH NMR (300 MHz, DMSO—dé): 6 = 1.47 (s, 9 H) 6.88 (s, 1 H) 7.66 (s, 1 H) 7.82 (s, 1 H) 7.91 (s, 1
H) 10.19 (br. s., 1 H) 12.50 (s, 1 H).
ediate 2-5
tert—Butyl (6—fluoro-1H—indazol-S-yl)carbamate
H30 0 H
H3C>CrH T \
F N
ously to Intermediate 2-2, 4.96 g (32.8 mmol) of 6—fluor0-1H—indazole-S-amine (CAS No.:
7090460), 7.16 g (32.8 mmol) of di-teIt-butyl dicarbonate and 6.28 ml (36 mmol) of N,N—
diisopropylethylamine were dissolved in 51 m1 of tetrahydrofuran and stirred at 25°C for 20 h. This
gives 5.72 g (69% of theory) of the title compound.
UPLC-MS (Method A1): K = 1.01 min
MS (ESIpos): m/z = 252 (M+H)+
1H-NMR (300 MHz, DMSO-d6): 5 = 1.45 (s, 9H), 7.35 (d, 1H), 7.81 (m, 1H), 8.03 (s, 1H), 8.80 (s,
1H), 13.08 (s, 1H).
Intermediate 2-6
tert—Butyl mo-1H-indazolyl)carbamate
H3C o N
H3c>r Y \N
CH3 0
7.05 g (17.1 mmol) of the mixture of tert-butyl 6-bromo—5-[(tert-butoxycarbony])amino]—1H-
indazole—l—carboxylate and tert-butyl 6-bromo[(tert-but0xycarb0nyl)amino]—2H—indazole-2—
carboxylate (Intermediates 10 and 11) were dissolved in 141 ml of dimethylformamide, and with
2.17 g (20.5 mmol) of sodium carbonate in 71 m1 of water. The reaction mixture was heated at
85°C for 24 h. Dichloromcthane was added and the reaction mixture was washed with 0.5 M
hydrochloric acid and saturated sodium chloride on. dried over sodium sulphate and
concentrated. The t was dried under reduced pressure. This gave 5.35 g (98% of theory) of
product.
UPLC-MS (Method A2): R. = [.09 min
MS (ESIneg): m/z = 310 (M(7°Br)-H)‘
'H NMR (400 MHz, CHLOROFORM-cfl 5 = 1.57 (s, 9 H) 7.01 (br. 5., 1 H) 7.83 (s, 1 H) 8.07 (s, 1
1-1)8.5{)(s, 1 H).
Intermediate 2-7
tert-Butyl [6—(henzyloxy)—1H—indazol-S-y1]carbamate
H30 0 N
H3c>r T \N
CH3 0
0 I2
7.50 g (30.1 mmol) of tert-butyl (6-hydroxy—1H-indazol—S—yl)carbamate (Intermediate 2-4) were
dissolved in 150 m1 of NJV-dimcthylformamide, and 5.66 g (33.1 mmol) of benzyl e and
8.32 g (60.2 mmol) of potassium carbonate were added with stirring. The reaction mixture was
stirred at 25°C for 24 h. The reaction mixture was then diluted with water and extracted with ethyl
acetate. The combined c phases were washed with saturated sodium chloride solution, the
phases were separated and filtered through a hydrophobic filter. The residue was taken up in
dichloromethane and during concentration adsorbed on Isolute. The Isolute was applied to a
e SNAP cartridge (340 g; KP-Sil) pre-equilibrated with hexane and chromatography was
carried out using the a® flash purification system (Biotage) (mobile phase: hexane/ethyl
acetate; gradient 100:0->60:40 (10 CV), isoratic 60:40 (9 CV)). The combined product fractions
were concentrated and dried under reduced pressure. This gave 3.46 g (34% of theory) of product.
UPLC—MS (Method A2): R = 1.27 min
MS (ESIpos): m/z = 340 (M+I-I)+
1H NMR (300 MHz, CHLOROFORM-d): 5 = 1.55 (s, 9 H) 5.20 (s, 2 H) 6.92 (s, 1 H) 7.14 (s, 1 H)
7.36 — 7.49 (m, 5 H) 7.94 (d, J=0.75 Hz, 1 H) 844 (5,1 H).
Intermediate 2-8
tert-Butyl-l H—indazol-S-y1carbamate
H3C>r0 N
H3C T N
CH3 0
.5 g (191.5 mmol) of lH-indazole-S-amine (CAS No. 19335—11-6) were lly charged in 300
m1 of ydrofilran, 37 m1 of N,N-diisopropylethylamine were added, 41.8 g (191.5 mmol) of di—
tert-butyl dicarbonatc were added a little at a time and the mixture was stirred at 25°C for 24 h. The
mixture was concentrated, giving 44.6 g (95% of theory) of the title compound.
UPLC-MS (METHOD A1): R[ = 0.96 min
MS (ESIpos): m/z = 234 V
1H-NMR (300 MHz, DMSO—dé): 8 = 1.44 (s, 911), 7.24 - 7.46 (m, 211), 7.84 (5, 11-1), 7.92 (s, 1H),
9.24 (br. s., 1H), 12.86 (br. s., 1H).
Intermediate 2-9
tert—Butyl hy1—1H-indazol—5 —y1)carbarnate
H3C CH
H3C O O
Y CH3
1.00 g (6.8 mmol) of 3-methy1-1H—indazole-S—amine were reacted analogously with 1.48 g (6.8
mmol) of di—tert—butyl carbonate and 1.3 ml (7.5 mmol) of N,N—diisopropylethylamine in 15 ml of
THF overnight. tration gave 1.70 g of the title compound as a crude product.
UPLC-MS (METHOD A1): Rt = 1.01 min
MS (ESIpos): m/z = 248 (M+H)+.
Intermediate 2—10
tert-Butyl (6-isopropoxy—1H—indazolyl)carbamate
0 N
H30>r TH30 \N
CH3 0
o N/
A ”
HO OH
ously to intermediate 2-2, 2.2 g (11.6 mmol) of 6-isopropoxy-IH—indazole-5—amjne
(Intermediate 1-4) were reacted with 2-52 g {11.6 mmol] of di-tc-n—butyl dicarbonate and 2.21 mi
(12.7 mmol) of NN-diisopropylethylamine. This gave 2.72 g (81% of theory) of the title
compound.
UPLC—MS (Method AI): Rt = 1.20
MS (ESIpos): m/z = 292 (M+I‘I)r
lH-NMR (300 MHz, DMSO-dé): 6 = 1.34 (d, 6H), 1.47 (s, 9H), 4.63- 4.74 (m, 1H), 6.98 (s, 1H),
7.68 (s, 1H), 7.88 (s, 1H), 7.94 (s, 1H), 12.68 (s, 1H).
Intermediate 2-11
Benzyl oro—1H—indazol—S-yl)carbamate
Cl N
6.1 ml of trifluoroacetic acid were added to 4.61 g of tert-butyl-S- {[(benzyloxy)carb0nyl]amino}
ch10r0-2H—indazole—2-carboxylate (Intermediate 23—1, crude product) in 40 m1 of dichloromethane,
and the e was stirred at room ature overnight. Saturated aqueous sodium bicarbonate
solution was added and the solid was filtered off with suction, washed with water and diethyl ether
and dried. This gave 2.11 g of a light-brown solid (crude product).
1H-NMR (400 MHz, DMSO-dg, selected signals): 6 [ppm]: 5.13 (s, 2H), 7.69 (s, 1H), 7.83
(s, 1H), 8.07 (s, 1H), 9.13 (br. s., 1H), 13.15 (br. s., 1H).
Intermediate 3-1
Ethyl {5-[(tett—butoxycarbonyl)amino]—6~methyl-2H-indazolyl}acetate
H o
H3C>1/O\n/N / )0
HC \—
3 CH3
CH3 0 \/N
H3C N
.0 g (40.4 mmol) of tert-butyl (6—methy1—1H—indazol-S-yl)carbamate (Intermediate 2-1) were
stirred with 9.00 ml (80.9 mmol) of ethyl bromoacetate in 75 ml of tetrahydmfilran in the presence
of 17.1 ml (80.9 mmol) of N..\’-dic_vclohcxylmethylamine at 70°C for 24 h. The itated solid
was filtered off and washed twice with ethyl acetate, Water was added to the filtrate and the
organic phase was separated off and ted twice with ethyl acetate. The combined organic
phases were washed with 1 M hydrochloric acid solution, saturated sodium bicarbonate solution
and saturated sodium chloride solution and trated. The residue was taken up in
dichloromethane, Isolute® HM—N (Biotage) was added and during concentration the residue was
adsorbed on Isolute. The Isolute was d to a Biotage SNAP cartridge (340 g; KP-Sil) pre-
brated with hexane and chromatography was carried out using the Isolera® flash purification
system (Biotage) (mobile phase: hexane/ethyl acetate; flow rate: 100 mI/min; nt: isocratic
100210 (1 CV), 100:0—>50:50 (20 CV), isocratic 50:50 (0.2 CV)). The combined t fractions
were concentrated and dried. This gave 8.90 g (42% of theory) of the title compound.
In a second experiment, 213 mg of the title compound were obtained analogously from 2.00 g of
tert-butyl (6-methyl-1H-indazoI—S-yl)carbamate using 2.24 g of potassium ate instead of
N,N-dicyclohexylmethylaminc at 80°C in N,N—dimethylformamide, with two successive
ations on silica gel (hexane/ethyl acetate).
UPLC—MS (Method A1): K = 1.14 min
MS (ESIpos): m/z : 334 (M+H)+
'1l-NMR (600 MHz, DMSO-d6): 5 : 1.21 (t, 3H), 1.46 (s, 9H), 2.28 (s, 3H), 4.16 (q, 2H), 5.34 (s,
2H), 7.38 (d, 1H), 7.57 (s, 1H), 8.25 (d, 1H), 8.40 (s, 1H).
Intermediate 3-2
Benzyl {5—[(tert—butoxycarbony1)amino]meth0xy-2H-indazolyl}acetate
HcXW/m}\_©
Analogously to ediate 3-1, 4.17 g (15.8 mmol) of tert-butyl (6-mcthoxy-1H-indazol
yl)carbamate (Intermediate 2-2) in 50 m1 of THF were stirred with 2.51 ml (15.8 mmol) of benzyl
bromoacetate and 3.36 ml (15.8 mmol) of NJV-dicyclohexylmethylamine at 65°C for 4 h, 2.51 ml
(15.8 mmol) of benzyl cetate and 3.36 ml (15.8 mmol) of N,N—dicyclohexylmethylamine
were then added and the mixture was stirred at 65°C for a further 18 h. p and ation
by column chromatography using the Isolera® flash purification system (Biotage) (mobile phase:
hexane/ethyl acetate: flow rate: 100 ml/min: gradient: tic 100:10 (5 min). 100:0->75:25 (20
min). isocmtic 75:25 [5 min). 75:25->50:50 (15 min). isocratic 50:50 (5 min), 50:50->20:80 (6
min))gave 322g (47% of theory) of the title compound.
UPLC-MS (Method AI): R‘ = 1.37 min
MS (ESIpos): m/z = 412 (M+H)’
2H—NMR (500 MHz, DMSO—d6): 6 = 1.47 (s, 9H), 3.86 (s, 3H), 5.20 (s, 2H), 5.37 (s, 2H), 6.97 (s,
1H), 7.28 - 7.42 (m), 7.79 (s, 1H), 7.94 (br. 5., 1H), 8.21 (s, 1H).
Intermediate 3-3
Ethyl {5—[(tert—butoxycarbony1)amin0]~6-(trifluoromethoxy)-2H-indazolyl} e
H3C o N
(130* \H/ / _>—o
N \—CH3
CH3 0 \l
O N
Analogously to Intermediate 3—1, 3.17 g (10.0 mmol) of tert-butyl [6-(trif1uoromethoxy)-1H—
indazol—S—yl]carbamate (Intermediate 2-3), 5.54 ml (50 mmol) of ethyl bromoacetate and 10.7 ml
(50 mmol) of N,N—dicyclohexylmethylamine in 20 m1 of tetrahydrofuran were heated at 70°C for
24 h. Work—up and purification by column chromatography using the Isolera® flash purification
system (Biotage) (mobile phase: hexane/dichloromethane/ethyl acetate; gradient: isocratic 902525
(5 CV), 90:5:5->85:7.5:7.5 (5 CV), isocratic 85:75:75 (11 CV), 85:7.5:7.5->80:10:710 (3 CV),
isocratic 80:10:10 (9 CV)) gave 512 mg (13% of theory) of product.
UPLC-MS (Method A2): R = 1.29 min
MS (ESIpos): m/z = 404 (M+H)+
‘H NMR (400 MHz, DMSO-d6) 5 = 1.22 (t, 3 H), 1.44 (s, 9 H), 4.18 (q, 2 H), 5.42 (s, 2 H), 7.58 (s,
1 H), 7.82 (s, 1 H), 8.44 (d, 1 H), 8.75 (s, 1 1-1).
Intermediate 3-4
Ethyl {6—(benzyloxy)—5-[(tert—butoxycarbonyl)amino]-2H-indazol—2—yl}acetate
Analogously to Intermediate 3-]. 3.46 g (10.2 mmol) of tyl nzyloxy)—lH-indazol-S—
yl]carbamate mediate 2-7). 2.26 ml (20.3 mmol) of ethyl bromoacetate and 4.36 1111 (20.3
mmol) of N,N{licyclohexylmethylamine in 50 ml of Ietmhydmfuran were heated at 70°C for 2 h.
Another 2.26 ml (20.3 mmol) of ethyl bromoacetate and 4.36 ml (20.3 mmol) of N,N-
dicyclohexylamine were added, and the mixture was stirred at 70°C for a further 22 h. Work-up
and purification by column chromatography using the Isolera® flash purification system (Biotage)
(mobile phase: hexane/ethyl e; gradient 90:10->65:35 (10 CV), isoratic 65:35 (5 CV), 65:35-
>50:50 (5 CV), isocratic 50:50 (5 CV)) gave 2.37 g (55% of theory) of the title compound.
UPLC-MS (Method Al): R1: 1.43 min
MS (ESlpos): m/z = 426 (M+H)+
1H NMR (400 MHz, CHLOROFORM-d): 6 = 1.28 (t, 3 H), 1.54 (s, 9 H), 4.25 (q, 2 H), 5.09 (s, 2
H), 5.19 (s, 2 H), 7.03 (s, 1 H), 7.25 (s, 1 H), 7.32 - 7.49 (m, 5 1-1), 7.82 (s, 1 II), 8.30 (s, 1 H).
Intermediate 3-5
Ethyl {5-[(tert—butoxycarbonyl)amino]—6—fluoro—2H-indazol-2—yl}acetate
H O x—CH3
H3C O N
HGCX Y / )0
CH3 0 ml“\
F N
Analogously to Intermediate 3-1, 5.44 g (21.6 mmol) of utyl (6-fluoro—lH—indazol—5—
yl)carbamate (Intermediate 2-5), 4.80 ml (43.3 mmol) of ethyl bromoacetate and 9.18 ml (43.3
mmol) of N,N—dicyclohexylmethylamine in 30 m1 of tetrahydrofuran were stirred for 72 h, with an
additional 0.96 ml (8.6 mmol) of ethyl bromoacetate and 1.84 ml (8.6 mmol) of MN-
dicyclohexylmethylamine being added after 24 h and 48 h, respectively. The mixture was
concentrated, taken up in romethanc, washed with water, dried and trated. Work-up
and purification by column chromatography using the Isolera® flash purification system (Biotage)
(mobile phase: hexane/dichloromethane/ethyl e; isocratie 40:48:12 (8 CV)) gave 375 g (47%
of theory) of the title compound.
UPLC—MS (Method A1): Rt = 1.15 min
MS (ESIpos): m/z = 338 l
1H-NMR (300 MHz, DMSO-d6): 6 = 1.21 (t, 3H), 1.46 (s, 9H), 4.17 (q, 2H), 5.36 (s, 2H), 7.37 (d,
1H), 7.84 (d, 1H), 8.36 (s, 1H), 8.80 (s, 1H).
Intermediate 3—6
Ethyl {6—bromo[(tert—butoxycarbonyl)amino]-2H-indazolyl} acetate
H 0
H30 0 N
H3C>r Y /
N—>—oLa“.
CH3 0 \ I
Br N
Analogously to Intermediate 3—1, 4.85 g (15.5 mmol) of ten-butyl (6-bromo-lH-indazoI—5—
yl)carbamate (Intermediate 2-6), 6.89 ml (62.1 mmol) of ethyl bromoacetate and 13.3 ml (62.1
mmol) of N,N-dicyclohexylmethylamine in 50 m1 of tetrahydrofuran were d at 70°C for 24 h.
Work-up and purification by column chromatography using the Isolera® flash ation system
(Biotage) (mobile phase: hexane/dichloromethane/ethyl acetate; gradient: isocratic 80:10:10 (16
CV), 80:10:10->75:12.5:12.5 (1 CV), isocratic 75:12.5:12.5 (8 CV)) gave 2.01 g (32% of theory)
of the title compound.
UPLC~MS (Method A2): R = 1.27 min
MS (ESIpos): m/z = 398 (M(79Br)+H)+
l"H NMR (400 MHz, DMSO-d6): 5 = 1.21 (t, 3H), 1.45 (s, 9H), 4.17 (q, 2H), 5.40 (s, 2H), 7.78 (s,
1H), 7.96 (s, 1H), 8.41 (d, 1H), 8.54 (s, 1H).
Intermediate 3-7
Ethyl {5-[(tert-but0xycarbonyl)amino]—2H~indazol—2-y1}acetate
HSCH302:CH3
.5 g (76.3 mmol) of potassium carbonate and 4.67 ml (42.0 mmol) of ethyl bromoacetate were
added to 8.90 g (38.1 mmol) of tert-butyl lH-indazol-S-ylcarbamate (Intermediate 2—8) in 80 m1 of
N,N-dimethylformamide and the mixture was stirred at 80°C for 24 h. The mixture was diluted
with water and extracted with ethyl e, the c phase was washed with water and saturated
sodium chloride solution, dried and concentrated and the residue was purified by column
chromatography on silica gel (hexane/ethyl acetate). This gave 2.4 g of the title compound as main
component as a mixture with tert-butyl lH—indazol-S-ylcarbamate (starting material).
1H—NMR (500 MHZ, CHLOROFORM-d, selected signals): 5 = 1.28 (t, 3H), 4.25 (q, 1H), 5.16 (s,
2H), 7.03 (dd, 1H), 7.62 (d, 1H).
Intermediate 3—8
Ethyl {5-{(ten-butoxycarbonyl}amino]—3-methyl-2H-indazolylEacetate
H3C CH3
¥CH3
o 0
Y CH3
N 3/20
0 CH3
A mixture of 1.70 g of tert-butyl (3-methy1-1H-indazol-S-yl)carbamate (Intermediate 2-9) (crude
t) and 842 ill (7.6 mmol) of ethyl bromoacetate and 1.90 g (13.7 mmol) of potassium
carbonate in 10 ml of N,N-dimethy1formamide was stirred at 80°C for 5 h. The mixture was diluted
with water and extracted three times with ethyl acetate and the extract was washed with water and
saturated sodium chloride solution, dried and concentrated. The residue was purified by column
chromatography purification on silica gel (hexane/ethyl e). This gave 436 mg of the title
nd as a crude product.
UPLC-MS (METHOD A1): R, = 1.12 min
MS (ESIpos): m/z = 334 (M+H)+.
Intermediate 3-9
Ethyl 3- {5-[(tert—butoxycarbonyl)amino]—2H-indazolyl}propanoate
>r '
L 04 3
HSC O N
1.0 g (4.3 mmol) of tert-butyl dazol-S-ylcarbamale (Intermediate 2-8), 656 pl (5.1 mmol) of
ethyl bromopropionate and 1.30 g (9.4 mmol) of potassium ate in 6.4 m1 of MN-
dirnethylformamide were heated at 80°C for 90 min. Work—up and purification by column
tography using the Isolera® flash purification system (Biotage) (mobile phase: hexane/ethyl
e; gradient 100:0->80:20 (5 CV), 80:20—>70:30 (5 CV), 70:30—>60:40 (5 CV)) gave 640 mg
(45% of theory) of the product.
UPLC-MS (Method A1): K = 1.12 min
MS (ESIpos): m/z = 334 (M~I~H)+
lI-l—NMR (300 MHz, DMSO-d6): 5 = 1.13 (t, 3H), 1.48 (s, 9H), 3.00 (t, 2H), 4.04 (q, 2H), 4.60 (t,
2H), 7.17 — 7.24 (m, 1H), 7.43 -7.50 (m, 1H), 7.82 (s, 1H), 8.21 (s, 1H), 9.23 (s, 1H).
Intermediate 3-10
Ethyl {S-[(ten.hutoxycarbonyl)amino]—6—isopropoxy—2H-indazolyl}acetate
H 0 CH3
H30 0 N
Y / )4;
H3C N
H3C CH3
Analogously to Intermediate 3—5, 2.72 g (9.3 mmol) of tert-butyl (6-isopropoxy-lH-indazol-S—
yl)carbamate (Intermediate 2-10) were reacted with 3.10 ml (28.0 mmol) of ethyl bromoacetate.
This gave 1.84 g (52% of theory) ofthc title compound.
UPLC-MS (Method A1): Rt = 1.32 min
MS (ESIpos): m/z = 378 (M+H)+
IH NMR (600 MHz, DMSO—dé): 5 = 1.21 (t, 3H), 1.34(d, 6H), 1.48 (s, 9H), 4.16 (q, 2H), 4.68 —
4.75 (m, 1H), 5.27 (3,2H), 6.98 (s, 1H), 7.63 (s, 1H), 7.97 (s, 1H), 8.17 (s, 1H).
Intermediate 3-1 1
Ethyl (teIt—butoxycarbonyl)amino]-2H-indazol—2—yl}propanoate
H O
H3C O N
>5. 1: <13? c...O/
3 N CH3
A mixture of 15.0 g (64.3 mmol) of tert-butyl lH-indazol-S-ylcarbamate (Intermediate 2—8), 9.21
ml (70.7 mmol) of ethyl 2-bromopropanoate and 17.8 g (128.6 mmol) of potassium carbonate in
100 ml of methylfonnamide was stirred at 80°C for 24 h. The mixture was diluted with
2014/077877
water and extracted with ethyl acetate, and the extract was washed with saturated sodium chloride
solution and concentrated. The residue was purified by column chromatography on silica gel
e/ethyl acetate). This gave 6.10 g (28% of theory) of the title compound.
1H NMR (400 MHz, DMSO-d6): 6 = 1.14 (t, 3H), 1.49(s, 9H), 1.77 (d, 3H), 4.07 — 4.17 (m, 2H),
.52 (q, 1H), 7.23 (dd, 1H), 7.49 (d, 1H), 7.85 (br. 5., 1H), 8.32 (s, 1H), 9.22 (s, 1H).
Intermediate 3-12
tert-Butyl (5 - { [(benzyloxy)carbonyl]amino} -6—chlor0a2H-indazol—2iy1)acetate
Cl N 3—0 CH3
0 >LCH3
2.1 1 g of benzyl (6-ch10ro-1H-indazol-S-yl)carbamate (Intermediate 2-11) were initially charged in
ml of THF, 1.5 ml of ten—butyl bromoacetate and 2.2 m1 ofN,N-dicyclohexylmethylamine were
added and the mixture was stirred at 65°C overnight. Another 0.75 ml of tert—butyl cetate
and 1.1 m1 of N,N-dicyclohexylmethylamine were added, and the mixture was stirred at 70°C
overnight. The solid was filtered off, the filter cake was washed with ethyl acetate, water was
added to the filtrate, the mixture was ted with ethyl acetate and the extract was washed with
1M aqueous hydrochloric acid solution, saturated sodium bicarbonate solution and sodium chloride
solution, filtered through a hydrophobic filter and concentrated. The e was purified by
column chromatography on silica gel. This gave 950 mg of the title compound as a yellow foam.
1H NMR (400 MHz, DMSO-dé): 5 = 1.43 (s, 9H), 5.14 (s, 2H), 5.29 (s, 2H), 7.29 — 7.47 (m, 5H),
7.80 (s, 1H), 7.84 (s, 1H), 8.41 (s, 1H), 9.09 (s, 1H).
Intermediate 4—1
{5-[(tert-Butoxycarbonyl)amino]—6—methyl—2H-indazolyl} acetic acid
H 0
HC 0 N
HBCX \l‘r / 4>~OH
3 N
CH3 0 \/
H3C N
.7 g (254 mmol) of m hydroxide monohydrate dissolved in 50 ml of water were added to
.6 g (25.4 mmol, 80%) of ethyl {5-[(tert—butoxycarbonyl)amino]methy1-2H-indazol
yl}acetate (Intermediate 3—1) in 100 ml of tetrahydrofuran and 10 ml of ethanol, and the mixture
was d. This resulted in the precipitation of a solid. After 18 h, the reaction mixture was diluted
with water and acidified to pH 4 using 2M hloric acid, and the solid was filtered off, washed
with water and diethyl ether and dried. This gave 698 g (87% of theory) of the title compound.
UPLC-MS (Method A1): R1: 0.92 min
MS (ESIpos): m/z : 306 (M+H)+
'H-WR (300 MHz, DMSO—d6): 5 = 1.44 (s, 9H), 2.25 (s, 3H), 4.78 (s, 2H), 7.32 (s, 1H), 7.49 (s,
1H), 8.10 (s, 1H), 8.35 (s, 1H).
Intermediate 4~2
{5—[(tert-Butoxycarbonyl)aminolmethoxy-2H-indazolyl} acetic acid
Sji><jjr02):):f“
H3
Analogously to Intermediate 4—1, 3.2 g of benzyl {5-[(tcit—butoxyearbonyl)amino]methoxy-2H-
indazol—Z—yl}acetate (Intermediate 3-2) gave 1.91 g of the title compound.
UPLC-MS (Method A1): R[ = 1.04 min
MS (ESIpos): m/z = 322 (M+H)+
1H-NMR (500 MHz, DMSO—d6): 6 = 1.47 (s, 9H), 3.86 (s, 3H), 5.16 (s, 2H), 6.96 (s, 1H), 7.78 (s,
1H), 7.93 (br. s., 1H), 8.16 (d, 1H),13.13(br.s., 1H).
Intermediate 4-3
{5-[(tert-Butoxycarbonyl)amino]—6—(trifluoromethoxy)-2H-indazol-2—yl} acetic acid
22*T31):}0H
Analogously to Intermediate 4-1, 530 mg (1.31 mmol) of ethyl ext-butoxycarbonyl)amino]-6—
(trifluoromethoxy)-2H-indazolyl}acetate (Intermediate 3-3) were suspended in 20 ml of
tetrahydrofiiran, a solution of 157 mg (6.57 mmol) of m hydroxide monohydrate in 2.4 ml of
water was then added and the mixture was stirred at 25°C for 24 h. Work-up gave 437 mg (81% of
theory) of the title compound.
UPLC~MS (Method AI): R, = 1.10 min
MS (ESIpos): m/z = 376 (M+H)+
1H NMR (400 MHz, DMSO-d6): 6 = 1.44 (s, 9 H), 5.29 (s, 2 H), 7.57 (s, 1 H), 7.81 (s, 1 H), 8.41
(d, l H), 8.74 (s, l H).
Intermediate 4—4
{6-Bromo[(tert-butoxycarbonyl)amino]-2H-indazol~2-y1} acetic acid
Analogously to Intermediate 4-1. 1.00 g (2.5 mmol) of ethyl mo—5—[(ten-
butoxycarbonyl)amino]-2H-indazol—Z-yl}acetate (Intermediate 3-6) was dissolved in 50 ml of
tetrahydrofuran, a solution of 301 mg (12.6 mmol) of lithium hydroxide monohydrate in 4.5 ml of
water was then added and the mixture was stifled at 25°C for 24 h. Work-up gave 844 mg (82% of
theory) of the title compound.
S (Method AI): R = 0.64 min
MS (ESIpos): m/z = 370 (M(7913r)+H)+
1H NMR (300 MHz, DMSO-d6): 6 = 1.45 (s, 9 H), 3.35 (5 br, 1 H), 5.28 (s, 2 H), 7.76 (s, 1 H),
7.95 (s, l H), 8.38 (s, l H), 8.52 (s, l H).
Intermediate 4-5
{5-[(tert-Butoxyearbonyl)amino]-2H-indazoly1}acetic acid
H3C CH3
H30 0 H
T@N/
O \
N —>70H
ously to Intermediate 4-1, 5.00 g (15.6 mmol) of ethyl {5—[(tert-butoxycarbonyl)amino]-2H-
l-2—yl}acetate (Intermediate 3-7) were dissolved in 50 m1 of tetrahydrofuran and 5 m1 of
ethanol, 21 on of 6.57 g (15.6 mmol) of lithium hydroxide monohydrate in 20 m1 of water was
then added and the mixture was stirred at 25°C for 24 h. Work-up gave 4.1 g (89% of theory) of the
title compound.
UPLC—MS (Method A1): R = 0.90 min
MS (ESIpos): m/z = 292 (M+H)+.
Intermediate 4-6
{5-[(tert-Butoxycarbonyl)amino]-3—methy1—2H—indazol-Z—yl} acetic acid
3 W<CH3CH3
O O
Y CH3
”“CE‘/ N \ /
N VOH
Analogously to intermediate 4—l, 436 mg (1.3 mmol) of ethyl {5-[(tert-butoxycarbonyl)amino]
methyl—2H«indazol_vlMedal: (Immediate 3—8) were dissolved in 5 ml oftetrahydrofinan and 1
ml ol‘ethanol, a on of 549 mg (13.1 mmol) of lithium hydroxide monohydrate in 2.5 ml of
water was then added and the mixture was stirred at 25°C for 24 h. This gave, after addition of
citric acid, a solid which was filtered off, washed with water and diethyl ether and dried. This gave
320 mg (70% of theory) of the title compound.
UPLC-MS (Method A1): Rt = 0.92 min
MS (ESIpos): m/z = 306 (M+H)+.
Intermediate 4-7
(tert—Butoxycarbonyl)amino]-2H-indazoly1}pr0panoic acid
H O
H C O N
3 X r 0“
H3C N
CH O \ ’
3 N
CH3
Analogously to Intermediate 4-1, 5.77 g (17.3 mmol) of ethyl (tert—butoxycarbonyDamino]-
2H-indazoly1}propanoate (Intermediate 3-8) were dissolved in 50 ml of tetrahydrofuran and 5
ml of l, 21 solution of 7.26 g (17.3 mmol) of lithium hydroxide monohydrate in 40 ml of
water was then added and the mixture was stirred at 25°C for 24 h. Acidification with l M
hydrochloric acid solution gave a solid which was filtered off, washed with water and diethyl ether
and dried. This gave 4.2 (79% of theory) of the title nd.
IH-NMR (300 MHz, DMSO—d6): 5 = 1.45 (s, 9H), 1.72 (d, 3H), 5.33 - 5.41 (m, 1H), 7.18 (dd, 1H),
7.45 (d, 1H), 7.82 (s, 1H), 8.26 (s, 1H), 9.20 (s, 1H), 13.13 (br. s., 1H).
Intermediate 4-8
{6-(Benzyloxy)[(tcrt-butoxycarbony1)amino]-2H-indazoly1}acetic acid
HC 0 o
HjoXY 0
Analogously to Intermediate 4-1, 14.15 g (33.3 mmol) of ethyl {6—(benzyloxy)-5—[(tert—
carbonyl)amino]~2H~indazol—2-yl}acetate (Intermediate 3—4) were dissolved in 250 ml of
tenahydmfuran and 25 ml of ethanol, 21 on of 3.98 g [166.3 mmol) of lithium hydroxide
monohydrate in 30 ml ot'water was then fitted and the e was stirred at 25°C for 72 h. After
acidification with l M hydrochloric acid solution to pH 3 the reaction mixture was concentrated.
water WE added and the ing solid was d off, washed with water and diethyl ether and
dried. This gave 13.05 g (33% of theory) of the title compound.
UPLC-MS (Method A1): Rt = 1.25 min
MS (ESIpos): m/z = 398 (MM-I)+
lI-l—NMR (300 MHz, DMSO—d6): 5 = 1.45 (s, 9 H), 4.93 (s, 2 H), 5.20 (s, 2 H), 7.01 (s, 1 H), 7.26 —
7.45 (m, 3 H), 7.53 (d, 2 H), 7.80 — 7.91 (m, 2 H), 8.11 (s, 1 H).
Intermediate 4-9
(5, { [(Benzyloxy)carbonyl]amino} chloro-2H-indazolyl)acetic acid
CI N fi>70H
1.7 ml of trifluoroacetic acid were added to a mixture of 940 g of tert-butyl (5—
{[(benzyloxy)carbony1]amino}—6-ch10r0-2H-indazoly1)acetate (Intermediate 3—12) in 10 m1 of
dichloromethane, and the mixture was stirred at room temperature overnight. Saturated aqueous
sodium bicarbonate solution was added and the precipitate was filtered off with suction, washed
with water and ethyl acetate and dried. This gave 766 mg of the title compound.
‘H-NMR (400 MHz, DMSO-dé): 5 [ppm]: 4.66 (s, 2H), 5.12 (s, 2H), 7.26 - 7.45 (m, 5H),
7.69 (s, 1H), 7.75 (s, 1H), 8.22 (s, 1H), 9.01 (s, 1H).
Intermediate 5-]
tert-Butyl {2—[2-(4-benzoylpiperazin—1-y1)oxoethyl]methy1-2H—indazol—5 -yl} carbamate
H 0 /—\ 0
/ }N\_/
H3OH3CXOTN N
CH3 0 \ /
H30 N
181 mg (0.59 mmol) of {5-[(ten-butoxycarbonyl)amino]methyl-2H-indazolyl}acetic acid
(Intermediate 43-!) and 169 mg (0.89 mmol) of phenyl(piperazin~l-yl)methanone were initially
charged in 5 ml of tetrahydrofuran and 0.5 ml of NN—dimethylformamide. 91 mg (0.59 mmoll of 1—
hydroxy-lH-benzotriazole hydrate. 227 mg (1.19 mmol) of l-(3—dimethylaminopropyly3—
ethylcarbodiimide hydrochloride and 0.25 ml (1.79 mmol) of triethylamine were added and the
mixture was stirred at 25°C for 18 h. The mixture was diluted with water and ethyl acetate and the
precipitated solid was d off, washed with water and diethyl ether and dried under reduced
pressure. This gave 248 mg (85% of theory) of the title compound.
UPLC—MS d A1): Rt = 1.07 min
MS (ESIpos): m/z = 478 (MH—l)+
1H NMR (400 MHz, DMSO—dé): 5 = 1.42 (s, 9H), 2.24 (s, 3H), 3.32 - 3.82 (m, 8H). 5.41 (br. s.,
2H), 7.33 (s, 1H), 7.38 - 7.48 (m, 5H), 7.52 (s, 1H), 8.12 - 8.16 (m, 1H), 8.35 (s, 1H).
Intermediate 5-2
utyl hy1—2—{2—oxo—2—[4-(pyrr01idin—1-y1)piperidin—1—y1}ethyl}—2H-indazol-5—
yl)carbamate
Analogously to Intermediate 5-1, 2.00 g (6.55 mmol) of {5—[(tert-butoxycarbonyl)amino]
methyl-2H-indazolyl}acetic acid (Intermediate 4-1) were reacted with 1.31 g (8.52 mmol) of4-
(pyrrolidin-l-y1)pipeiidine. This gave 2.59 g (90% of theory) of the title compound.
UPLC-MS (Method A1): K = 0.77 min
MS (ESIpos): m/z = 442 (M+H)+
]H-NMR (300 MHz, DMSO—d6): 5 = 1.18 - 1.52 (m, 11H, contains singlet at 1.45 ppm), 1.66 (br.
s., 4H), 1.83 (t, 2H), 2.16 — 2.30 (m, 4H), 2.76 - 2.90 (m, 1H), 3.08 - 3.22 (m, 1H), 3.80 - 3.92 (m,
1H), 4.01 -4.14 (m, 1H), 5.31 - 5.46 (m, 2H), 7.35 (s, 1H), 7.53 (s, 1H), 8.15 (s, 1H), 8.39 (s, 1H).
Intermediate 5-3
tert-Butyl (2—{2-[4—(3~hydroxy-2,2-dimethylpr0panoyl)piperazin-1—y1]—2—oxoethy1} hy1—2H—
indazol-S-y1)carbamate
H o /_\ 0
H30 0 N
Hc>l/ 41/ / ‘>_N N
0 m” “2.0
H30 N CH30H
Analogously 10 Intermediate 5-1, 300 mg (0.98 mmol) of {S-[Uen—butoxycarbonylkminol-év
methyl-ZH-indazof-Z-yl}acetic acid (Intermediate 4—1) were reacted with 238 mg (1.28 mmol) 01‘3-
hydroxy-ZJ-dimethyI-l{piperazin-l-ylmmpan-l«me. This gas: 216 mg (46% of theory) of the
title compound.
UPLC-MS (Method A2): R. = 0.96 min
MS s): m/z = 474 (M+H)'
1H NMR (400 MHz, DMSO-dé): 6 = 1.16 (s, 6H), 1.45 (s, 9H), 2.26 (s, 3H), 3.39 - 3.68 (m, 10H),
4.59 (t, 1H), 5.42 (s, 2H), 7.35 (s, 1H), 7.54 (s, 1H), 8.15 (s, 1H), 8.37 (s, 1H).
ediate 5—4
utyl (2- {2-[4-(meth0xyacety1)piperazin—1 —yl]—2-oxoethyl}—6—methy1-2H—indazol—5—
yl)carbamate
H O 0
H30 0 N
H3c>f T /
Nfit\_/11—“0
CH3 0 \ / \
H30 N CH3
Analogously to Intermediate 5-1, 300 mg (0.98 mmol) of {5—[(tert-butoxycarbonyl)amino]—6—
methyleH—indazoly1} acetic acid (Intermediate 4—1) were reacted with 248 mg (1.28 mmol) of 2—
methoxy-l-(piperazin~l—yl)ethanone hydrochloride (1:1). This gave 144 mg of the title compound
as a crude product.
UPLC-MS (Method A2): R‘ = 0.93 min
MS (ESIpos): m/z = 446 (M+H)+.
Intermediate 5-5
ten-Butyl (2-{2-[4-(2-hydr0xypropany1)piperidiny1]oxoethyl} methoxy-2H-indazol
yl)carbamate
H CH3
HacXOTN OH
H C N—>'N CH3
Analogously to Intermediate 5-1, 266 mg (0.83 mmol) of {5-[(ten-butoxycarbonyl)amino]-6—
methoxy—ZH—indazol-Z—yl}acetic acid (Intermediate 42) were reacted with 154 mg (1.08 mmol) of
2-(piperidinyl)propanol in 10 m1 of tetrahydrofuran. This gave 382 mg of the title compound
as a crude product.
UPLC-MS (Method A1): K = 1.10 min
MS (ESIpos): ml = 447 (MTHY.
Intermediate 5—6
tert-Butyl (2-{2-[4-(cyclopropy1methy1)piperazin-1—y1]oxoethy1}-6—methoxy-2H-indazol—5-
yl)carbamate
3 o N
CH1]: :C:N3 N N
/ \ I
O N
Analogously t0 Intermediate 5—1, 250 mg (0.78 mmol) of {5-[(tert—butoxycarbonyl)amino]-6—
methoxy-2H-indazol—2—yl}acetic acid (Intermediate 4—2) were reacted with 164 mg (1.17 mmol) of
lopropy1methy1)piperazine. This gave 402 mg of the title compound as a crude product.
S (Method A1): Rt 2 0.85 min
MS (ESIpos): m/z = 444 (M+H)+.
ediate 5—7
tert-Butyl {2-[2-(4-benzoy1piperazin—1-yl)oxoethy1]methoxy-2H—indazol—5-y1}carbamate
O O
H / \
H30 0 N
X. Xm N
/ f“;w
O N
Analogously to Intermediate 5—1, 548 mg (1.71 mmol) of {5-[(tert—butoxycarbonyl)amin0]~6-
methoxy—ZH—indazol-Z—yl}acetic acid (Intermediate 4—2) were d with 389 mg (2.05 mmol) of
phenyl(piperazinyl)methanone. This gave 808 mg of the title compound as a crude product.
UPLC-MS (Method A1): Rt = 1.14 min
MS s): m/z = 494 (M+H)"_
Intermediate 5.8
lert-Butyl {2-{2-(4-mcthylpipcrazin-l -yl)—2 -oxoethyl](tritluoromethoxy+2H-indazol
yl } carbamate
H /—\
HSCXOYN / 4>—N N‘“CH3
CH 0 \ IN
O N
F F
350 mg (0.85 mmol) of tert-butyl {2-[2-(4-methylpiperaziny1)ox0ethy1]
(trifluoromethoxy)-2H-indazoly1}carbamate (Intermediate 4-3), 130 mg (0.85 mmol) of 1-
hydroxy—lH—benzotriazole hydrate and 325 mg (1.70 mmol) of 1-(3-dimethy1aminopropy1)-3—
ethylcarbodiimide hydrochloride in 3.5 m1 of N,N-dimethy1formamide and 473 pl (340 mmol) of
tfiethylamine were stirred at 25°C for 30 min. 103 }J.1 (0.93 mmol) of y1p1'perazine (CAS
No: -3) were then added and the mixture was stirred at 25°C for 24 h. The mixture was
poured into 50 m1 of water, filtered h suction, washed with water and dried. This gave 305
mg (78% of theory) of the title compound.
UPLC-MS (Method A2): R[ = 1.12 min
MS (ESIpos): m/z = 376 (M+H)+
1H NMR (400 MHz, DMSO—d6): 6 = 1.44 (s, 9 H), 2.23 (s, 3 H), 2.28 - 2.38 (m, 2 H), 2.41 (br. s.,
2 H), 3.47 (br. s., 2 H), 3.55 (br. s., 2 H), 5.49 (s, 2 H), 7.54 (s, 1 H), 7.80 (s, 1 H), 8.34 (d, 1 H),
8.73 (s, 1 H), 9.93 (br. s., 1 H).
Intermediate 5-9
tert-Butyl {6-br0mo[2-(4-methy1piperazin-1 -y1)oxoethy1] -2H-indazol-5~y1 } carbamate
H30>r0 N N
/ N—CH3
H30 T N \___/
CH3 0 \ /
Br N
Analogously to Intermediate 5-8, 800 mg (1.97 mmol) of {6—bromo—5—[(tert—
butoxycarbonyl)amino]-2H-indazolyl}acetic acid (Intermediate 4-4) were reacted with 246 pl
(2.17 mmol) of l-methylpiperazine. This gave 824 mg (93% of theory) of the title compound.
UPLC-MS (Method A2): K = 1.07 min
MS (ESIpos): m/z = 452 (M(79Br)+H)’
lH NMR (300 MHz, DMSO—d6): 5 = 1.45 (s, 9 H), 2.20 (s, 3 H), 2.25 — 2.34 (m, 2 H), 2.34 — 2.40
(m, 2 H), 3.43 - 3.49 (In, 2 H), 3.50 - 3.55 (m, 2 H), 5.47 (s, 2 H), 7.75 (s, 1 H), 7.93 (s, 1 H), 8.31
(s, I H). 8.54 (s, 1 H).
Intermediate 5-10
ten-Butyl (2— {2—{4-(cyclopropylcarbonyl)piperazin- I -yl]—2—oxoethyl} ~21'I—indazolylkarbamaxe
H30 CH3
T@N/
/——\ O
O \N N
o \__/N4€>
Analogously to Intermediate 5—1, 2.00 g (4.3 mmol, 62%) of {5-[(tert-butoxycarbonyl)amino]—2H-
indazol—Z-yl}acetic acid (Intermediate 4—5) were reacted with 1.14 g (6.0 mmol) of
cyclopropyl(piperazin—1—y1)methanone hydrochloride (1:1). This gave 2.3 g of the title nd
as a crude product.
UPLC-MS (Method AI): R = 0.97 min
MS s): m/z = 428 (M+H)‘.
ediate 5—] 1
tert-Butyl {2—[2—(4-benzoy1piperaziny1)oxoethyl]-2H-indazoly1}carbamate
Analogously to Intermediate 5-1, 2.53 mg (8.7 mmol) of ert-but0xycarbony1)amino]-2H-
indazol—Z-y1}acetic acid (Intermediate 4-5) were reacted with 1.98 g (10.4 mmol) of
pheny1(piperazin—1~y1)methanone to give 3.8 g (93% of theory) of the title compound.
UPLC—MS (Method AI): R = 1.05 min
MS (ESIpos): m/z = 464 (M+H)+.
1H-NMR (400 MHz, DMSO-dé): 5 = 1.45 (5, 91-1), 3.30 — 3.78 (m, 8H), 5.41 (br. s., 2H), 7.18 (dd,
1H), 7.35 - 7.50 (m, 6H), 7.82 (br. s., 1H), 8.11 (s, 1H), 9.18 (s, 1H).
Intermediate 5-12
tert-Butyl {2-[2-(4-methylpiperazin—1 -y1)—2—oxoethyl] -2H—indam1—5—yl } earbamate
Analogously to Intermediate 5-1, 1.00 g (3.4 mmol) of i5-[(ten-butoxycarbonylkminol-ZH-
indazol-Z-y1}acetic acid (Intermediate 4-5) was reacted with 0.41 g (4.1 mmol) of 1-
methylpiperazine to give 916 mg (71% of theory) of the title compound.
S (Method Al): Rt = 0.73 min
MS (ESIpos): m/z = 374 (M+H)+.
Intermediate 5—13
text-Butyl (2-{2-0x0—2-[4-(2,2,2—trifluoroethyl)piperazin—1—yl]ethy1}—2H—indazol—5 -yl)carbamate
H O r‘“\
H30 0 N
X. If WC?f,“ N F
/ w 31.
3 N F
Analogously to Intermediate 5—1, 1.01 g (3.5 mmol) of ert—butoxycarbonyl)amino]-2H-
lyl}acetie acid (Intermediate 4-5) were reacted with 1.00 g (4.2 mmol) of 1-(2,2,2—
trifluoroethyl)piperazine dihydrochloride to give 634 g (42% of theory) of the title nd.
UPLC—MS (Method Al): Rt = 1.11 min
MS (ESIpos): m/z = 442 (M+H)+.
Intermediate 5-14
tert-Butyl {2-[2-(4—ethy1—3—oxopiperazin—l —y1)—2-oxoethy1]-2H-indazol-5—yl}carbamate
H 0 /*<
H30 O N
N N—t
CH3 0 \N/
Analogously to Intermediate 5-1, 2.38 g (3.5 mmol, 62%) of {5—[(tert-butoxycarbonyl)amino]-2H—
indazolyl}acetic acid (Intermediate 4-5) were reacted with 1.00 g (6.1 mmol) of 1-
ethylpiperazin-Z—one hydrochloride (1:1) to give 1.92 g (71% of theory) of the title compound as a
crude product.
UPLC—MS (Method A1): R, = 0.92 min
MS s): m/z = 402 (M+H)+.
Intermediate 5—15
tyl {2-{2-(4-benzoy1piperazin-l -yI)—2-oxoethyl]—3-methyiQH-indazoLSfi'l : carbamate
3 \FCHSCH3
TN©:}Ca?)
Analogously to Intermediate 5-1,160 mg (0.52 mmol) of {5- [(tcrt—butoxycarbonyl)amino]
methyl—ZH-indazol—Z—yl}acetic acid (crude product) (Intermediate 4-6) were reacted with 150 mg
(0.79 mmol) of phenyl(piperazin—1-y1)rnethanone. Addition of water and ethyl acetate resulted in
the precipitation of a solid which was washed with water and l ether and dried. This gave 130
mg (52% of theory) of the title compound.
S (Method A1): R[ = 1.07 min
MS (ESIpos): m/z = 478 (M+H)+.
Intermediate 5—16
tert-Butyl {6-methoxy[2-(morpholiny1)oxoethy1]-2H—indazoly1}carbamate
H fl
H30 0 N
H3C>( \11/ O
N_>—N U
CH3 0 \ /
O N
Analogously to ediate 5—1, 1.00 g (3.11 mmol) of {5-[(tert-butoxycarbonyl)amino]—6—
methoxy—ZH—indazol—Z-yl}acetic acid (Intermediate 4-2) was reacted with 407 1.1.1 (4.67 mmol) of 1—
methylpiperazine. The on mixture was added to water and extracted with ethyl acetate. The
combined organic phases were washed with saturated sodium chloride solution, dried over sodium
sulphate, filtered, concentrated and dried. This gave 1.16 g (95% of theory) of the title compound.
UPLC-MS (Method A2): R. = 1.03 min
MS (ESIpos): m/z = 391 (M+H)‘
'H NMR (300 MHZ. CHLOROFORM-d): 5 = 1.55 (s. 9 H). 3.58 (s. 4 H). 3.66 (s. 4 H). 3.93 (s. 3
H), 5.18 (s, 2 H), 6.94 (s, 1 H), 7.22 (s, 1 H), 7.81 - 7.90 (m, l H), 3.25 (s, l 11).
Intermediate 5-17
tert—Butyl {6—methoxy[2-(4-methy1piperazin-1—yl)-2—oxoethyl]—2H—indazol-5—yl}carbamate
0 fix:/ \
H30 N
/ NwCH3
CH3 0
o N
3
Analogously to Intermediate 5—16, 1.00 g (3.11 mmol) of ert-butoxycarbonyl)amino]~6-
methoxy-2H-indazoI—2—yl}acetic acid (Intermediate 4-2) was reacted with 530 pl (4.67 mmol) of 1—
methylpiperazine. Work-up gave 1.21 g (96% of theory) of the title compound.
UPLC-MS (Method A1): R. = 0.82 min
MS (BSIpos): m/z = 404 (M+H)+
'H NMR (300 MHZ, CHLOROFORM-d): 5 = 1.55 (s, 9 11), 2.28 (s, 3 H), 2.30 - 2.34 (m, 2 H),
2.34 - 2.41 (m, 3 H), 3.52 - 3.61 (m, 2 H), 3.62 - 3.71 (m, 2 H), 3.93 (s, 3 H), 5.18 (5,2 H), 6.94 (s,
1 H), 7.22 (s, 1 H), 7.85 (s, 1 H), 8.24 (s, 1 H).
Intermediate 5-18
utyl (2—{2—[(cyclopropylmethyl)(methy1)amino]42-oxoethyl} —6—methoxy—2H—indazol—5—
yl)carbamate
HC CH
Analogously to Intetmediate 5—1, 250 mg (0.78 mmol) of {5-[(tert-butoxycarbonyl)amin0]
methoxy-ZH-indazol-z—yl}acetic acid (Intermediate 4-2) were d with 86 mg (1.01 mmol) of 1—
cyclopropyl-N-methylmethanamine at 25°C for 24 h. The mixture was diluted with water and
extracted three times with ethyl acetate, and the extracts were washed with saturated sodium
chloride solution and concentrated. This gave 353 mg of a crude product.
UPLCvMS (Method A1): K = 1.19 min
MS (ESIpos): m/z = 389 (M+H)’.
Intermediate 5-19
tert-Butyl 2-[1 —(4—benzoy1piperazin—1 —y1)—1 —oxopropan—2-yl]-2H-indazol-5 -y1}carbamate
H3C>r U 0
CH 0 \NN
Analogously to Intermediate 5-1, 2.00 g (6.55 mmol) of {5-[(tert-butoxycarbonyl)amino]-2H-
indazol—Z—yl}propanoic acid mediate 4-6) and 1.50 g (7.86 mmol) of phenyl(piperazin-l-
yl)methanone were stirred at 25°C for 24 h. This gave 3.7 g of the title compound as a crude
product.
UPLC—MS (Method A1): Rt: 1.11 min
MS (ESIpos): m/z = 448 (M+H)V'.
Intermediate 5-20
ten-Butyl {6-(benzyloxy)-2—[2—(m0rpholin~4-y1)oxoethy1]—2H-indazoly1}carbamate
we 0 o
wc>r 0 /—W
3*_/__;>_N o
Analogously to Intermediate 5-1, 3.50 g (8.81 mmol) of {6-(benzyloxy)~5—[(tert—
butoxycarbonyl)amino]-2H-indazol-2—yl}acetic acid (Intermediate 4-8) and 1.14 m] (13.2 mmol) of
morpholine were reacted at 25°C for 24 h. Work-up gave 3.67 g (89% of theory) of the title
compound.
UPLC-MS (Method AI): R. = 1.25 min
MS (ESIpos): m/z = 467 (M+H)'
1H NMR (400 MHz, DMSO-dé): 6 = 1.45 (s, 9 H), 3.41 - 3.48 (m, 2 H), 3.51 - 3.60 (m, 4 H), 3.61
- 3.66 (m. 2 H). 5.31 (s. 2 H). 5.35 (s. 2 H). 7.01 (s. l H), 7.29 - 7.37 (m. I H). 7.38 - 7.44 (m. 2 H).
7.50 - 7.57 (In, 2 H), 7.87 (s, 2 H), 8.11 (s, l H).
Intermediate 5-21
Benzyl {6-chloro—2—[2—(4—methylpiperazin—l —yl)—2—ox0ethy1]-2H—indazol-5 -yl} carbamate
0\T§o
\\/N /——\
C' N N N—CH
o \__/
387 mg of (5—{[(benzyloxy)carbonyl]amino}-6—ch10ro-2H-indazolyl)acetic acid (Intermediate 4-
9) were reacted. analogously to the preparation of Intermediate 5—1 with 140 mg of 1-
piperazine. After the reaction, the mixture was diluted with water and ethyl acetate and
saturated sodium chloride solution were added. The precipitated solid was filtered off, washed with
water and diethyl ether and dried. This gave 302 mg of the title compound.
PCT/EP2014/O77877
'H-NMR (400 MHz, DMSO—dfi): 5 [ppm]= 2.19 (s, 3H), 2.23 — 2.41 (m, 4H), 3.41 — 3.48 (m, 2H),
3.48 — 3.56 (m, 2H), 5.13 (s, 2H), 5.46 (s, 2H), 7.28 - 7.45 (m, 5H), 7.75 (s, 1H), 7.81 (s, 1H), 8.32
(d, 1H), 9.07 (s, 1H).
Intermediate 5-22
Benzyl {6-chloro[2-(Inorpholiny1)-2—0xoethy1]—21indazol—5-y1}carbamate
O O
m20/N
400 mg of benzyl (6—chlor0~1H—indazol-S-yl)carbamate (Intermediate 2-11) were initially charged
in 5.0 ml of cyclopentyl methyl ether. 265 mg of 2-br0mo-l-(morpholinyl)ethanone and 0.22 ml
of Niethyl-N—isopropylpropane—2—arnine were added and the mixture was stirred at 100°C for 20 h.
Water was added and a solid was obtained by removing oily es from the rim of the flask by
scratching. The solid was d off with suction, washed with water and diethyl ether, triturated
with ethyl acetate and dried. This gave 254 mg of the title compound.
lH-NMR (500 MHz, DMSO-d6): 5[ppm] = 3.47 (d, 2H), 3.56 (d, 2H),3.58 - 3.61 (m, 2H), 3.65 (d,
2H), 5.15 (s, 2H), 5.49 (s, 2H), 7.28-7.48 (m, 5H), 7.76 (s, 1H), 7.83 (s, 1H), 8.33 (s, 1H), 9.07 (s,
111).
ediate 6—1
2-(5-Amino—6—methy1—2H—indazolyl)—1 -(4-benzoylpiperazin—1 —y1)ethanone
O /—\ 0
“IfJ“ ” N \_/
H30 N
0.3 ml (3.89 mmol) of trifluoroacetic acid was added to 247 mg (0.52 mmol) of tert—butyl {2-[2—(4-
benzoylpiperazin-l-yl)0xoethy1]—6-methy1-2H-indazolyl}carbamate (Intermediate 5—1) in 5
ml of dichloromethane and the mixture was stirred at 25°C for 18 h. Another 0.3 ml (3.89 mmol) of
trifluoroacetic acid was then added and the e was stirred for 18 h, poured into saturated
sodium bicarbonate solution and extracted times with dichloromethane. Concentration gave 223 mg
of the title compound as a crude product.
UPLC-MS (Method AI): R = 0.61 min
MS (ESIpos): m/z = 378 (M+H)+
]H NMR (400 MHz, DMSO-d6): 6 = 2.15 (s, 3H), 3.29 — 3.75 (m, 8H), 4.53 (s, 2H), 5.28 (br. 5.,
2H), 6.63 (s, 1H), 7.17 (s, 1H), 7.37 - 7.47 (m, 511), 7.75 - 7.79 (m, 1H).
Intermediate 6-2
2-(5-Aminomethyl-2H-indazolyl)-l -[4—(pyrrolidin- 1 ~y1)piperidin- l han0ne
2 KIA )LNG'O
H3C N
2.59 g (5.37 mmol) of ten-butyl (6—methyl-2—{Z-oxo—Z-[44p31mlidin-l-y1)piperidin-l-yl]ethy1}-
Zli—indazol-S-ylkarbamate (Intermediate 5-2) were initially charged in 30 m1 of dichloromethane,
4.5 ml (58.7 mmol) of trifluoroaeetic acid were added and the mixture was stirred at 25°C for 78 h.
The reaction e was concentrated and twice toluene was added and in each case the mixture
was concentrated again. The residue was purified by HPLC according to Method P2 (gradient: 0—
0.5 min 25 mI/min to 70 ml/min 25% B; 0.5-5.5 min 25-55% B; flow rate: 70 ml/min). This gave
1.04 g (52% of theory) of the title nd.
UPLC-MS (Method A2): R1 = 0.81 min
MS (ESIpos): m/z = 342 (M+H)+
IH-NMR (300 MHz, 6): 8 = 1.16 - 1.47 (m, 2H), 1.66 (br. s., 4H), 1.82 (br. 3., 2H), 2.12 -
2.28 (m, 4H), 2.74 — 2.89 (m, 1H), 3.05 — 3.20 (m, 1H), 3.79 — 3.92 (m, 1H), 4.02 — 4.14 (m, 1H),
4.58 (br. 5., 2H), 5.18 — 5.33 (m, 2H), 6.65 (s, 1H), 7.19 (s, 1H), 7.78 (d, 1H).
Intermediate 6—3
1- -Amino—6-methyl—2H-indazol—2-y1)acetyl]piperazinyl} -3 -hydroxy—2,2-dimethylpropan—
1 -one
0 h 0
2 :©:/\ N N
N \—/H C
\ / 3
H3C N CHSOH
0.34 ml (4.37 mmol) of trifluoroacetic acid was added to 207 mg (0.44 mmol) of tert—butyl (2—{2—
[4-(3-hydroxy-2 ,2-dimethylpropanoyl)piperazin-1 -yl] oxoethyl} —6 -methyl-2H-indazol-5 -
yl)carbamate (Intermediate 5-3) in 5 m1 of dichloromethane, and the mixture was stirred at 25°C
WO 91426
for 2 days. The mixture was poured into saturated sodium bicarbonate solution and extracted three
times with dichloromethane, and the ts were concentrated. This gave 184 mg of the title
compound as a crude product.
UPLC-MS (Method A1): R = 0.52 min
MS (ESIpos): m/z = 374 ,
Intermediate 6-4
2-(5-Amino-6—rnethyl—2H-indazol-2—yl)-1 —[4—(methoxyacetyl)piperazin—1 —yl]ethanone
O /—\ O
/ m m
\ [N 0\
H30 N CH3
0.25 ml (3.23 mmol) of trifluoroacetic acid were added to 144 mg (0.32 mmol) of ten-butyl (2-{2-
{Hmhoxyaecqbpiperazin-l -)’l]—2-oxoethyl} methyl—2H-indazol-5 ~yl)carbamate (Intermediate
—4) in 3 ml of dichloromethane, and the mixture was stirred at 25°C for 24 h. The mixture was
concentrated, giving 219 mg of the title compound as a crude product.
UPLC—MS (Method A1): K = 0.46 min
MS (ESIpos): m/z = 346 (M+H)+_
Intermediate 6-5
2—(5-Aminomethoxy-2H—indazol—2~yl)~1-[4-(2-hydroxypropany1)piperidin—I —yl]ethanone
woe0 CH3
/ CH3
0 N
261 111 (3.38 mmol) of trifluoroacetic acid were added to 382 mg (0.86 mmol) of tert-butyl (2-{2-
[4-(2-hydroxypropan—2-yl)pipe1idin—1 -yl] oxoethyl} methoxy-2H-indazolyl)carbamate
(Intermediate 5—5) in 5 m of romethane, and the mixture was stirred at 25°C for 18 h.
Another 609 pl (7.90 mmol) of trifluoroacetic acid were added, and stirring was continued at 25°C
until the reaction had gone to completion. The mixture was concentrated and three times toluene
was added and in each case removed again under reduced re. This gave 735 mg of the title
compound as a crude product.
S (Method A1): R1= 0.57 min
MS (ESIpos): m/z = 347 (M+H)+..
2014/077877
Intermediate 6-6
2-(5~Amino—6-methoxy-2H-indazoly1)-1 -[4-(eyelopropylmethy1)piperazin-1 -y1]ethan0ne
O /—\
HZNICTNNM>
O \N/
(IJH
Analogously to Intermediate 6—5, 402 mg (0.86 mmol) of tert-butyl (2—{2—[4—
propylmethyl)piperazin—l—y1]—2—oxoethy1}methoxy~2H-indazoly1)carbamate
(Intermediate 5—6) were reacted with 663 pl (8.61 mmol) of trifluoroacetic acid in 5 m1 of
dichloromethane. This gave 822 mg of the title compound as a crude product.
Intermediate 6-7
2-(5-Amino—6—melhoxy-2H-indazol~2-yl)-l {4—benzoy1pipemzin-l -yl)ethanone
O /—\ O
13?J” N N \_/
(I) N
Analogously to Intermediate 6—3, 808 mg (1.64 mmol) of tert-butyl {2-[2—(4-benzoylpiperazin—1-
yl)-2—oxoethyl]methoxy-2H-indazo1—5-yl}carbamateflntermediate 5-7) were stirred with 1.26 ml
(16.37 mmoi) of trifluoroacetic acid in 10 m1 of dichloromethane at 25°C for 18 h. Work-up gave
649 mg (99% of ) of the title compound.
UPLC-MS (Method A1): K = 0.63 min
MS (ESIpos): m/z = 394 (M+H)+
1H NMR (400 MHz, DMSO-d6): 5 = 3.33 — 3.79 (8H), 3.81 (s, 3H), 4.60 (s, 2H), 5.27 (br. 5., 2H),
6.62 (s, 1H), 6.78 (s, 1H), 7.39 - 7.50 (m, 5H), 7.76 (s, 1H).
Intermediate 6-8
2—[5—Amino—6-(trifluoromethoxy)-2H—indazol—2—y1]—1—(4—methy1piperaziny1)ethanone
0 /—\
U / fr) N—CH3
O133 N
Analogously to Intermediate 6-4, 484 mg (1.06 rnmol) of utyl {2-[2-(4-methy1piperazinyl)-
thyl]—6—(trifluoromethoxy)-2H-indazoly1}carbamate (Intermediate 5-8) were reacted with
815 pl of tn’fluoroacetic acid in 5 m1 of dichloromethane. Work-up gave 320 mg (85% of theory) of
the title compound.
UPLC-MS d A2): K = 0.79 min
MS (ESIpos): m/z = 357 (M+H)+
1H NMR (400 MHz. DMSO—dfi): 5 = 2.16 — 2.24 (m. 3 H). 2.28 (t. 2 H). 2.32 — 2.40 (m, 2 H). 3.41 -
3.49 (m, 2 H), 3.49 — 3.56 (m, 2 H), 4.95 (s, 2 H), 5.36 (s, 2 H), 6.88 (s, 1 H), 7.39 (s, 1 H), 7.98 (s,
1 H).
Intermediate 6-9
minobr0m0-2H-indazoI—2—yl)—l —(4—methylpiperazin—1 —yl)ethan0ne
N \_/
Br N
Analogously to Intermediate 6-4, 293 mg (0.65 mmol) of tert-butyl {6-bromo[2-(4—
methylpiperazin—l-y1)oxoethy1]-2H—indazolyl}carbamate (Intermediate 5-9) were reacted
with 499 pl (6.48 mmol) of trifluoroacetic acid in 3 ml of dichloromethane. Work-up gave 210 mg
(92% of theory) of the title compound.
UPLC—MS (Method A2): R[ = 0.70 min
MS (ESIpos): m/z : 352 (M(79Br)+H)+
1H NMR (400 MHz, DMSO—d6): 5 = 2.20 (s, 3 H), 2.27 (t, 2 H), 2.31 - 2.40 (m, 2 H), 3.41 — 3.48
(m, 2 H), 3.49 - 3.56 (m, 2 H), 4.91 (s, 2 H), 5.34 (s, 2 H), 6.92 (s, 1 H), 7.77 (s, 1 H), 7.95 (d, 1 H).
Intermediate 6—10
2-(5-Amino—2H—indazol-2—yl)—1 —[4—(cyclopropylcarbony1)piperazin-1 -y1] ethanone
Analogously t0 ediate 6-4, 2.3 g (5.38 mmol) of tert-butyl (2— {2-[4-
(cyCIOpIOpylcarbonyl)piperaziny1]oxoethyl}-2H-indazoly1)carbamate (Intermediate 5—10)
were reacted with 4.1 ml (53.8 mmol) of trifluoroacetic acid in 25 ml of dichloromethaue to give
1.09 g (62% of theory) of the title compound as a crude product.
UPLC-MS (Method A1): Rt = 0.47 min
MS (ESIpos): m/z = 328 (M+H)+.
lntermedinte 6-1!
2-{5-1Xmino-2H-indazol—2-yl}1{4-bcnzoylpiperazin-l -yl)ethanonc
Analogously to ediate 6—4, 4 20 g (906 mmol) of tert-butyl {2-[[-2(4—benzoylpiperazin— l—yl)—
2-oxoethy1]-2H—indazol—5—yl}carbamate (Intermediate 5-11) were reacted with 6.98 ml (90.6
mmol) of trifluoroacetic acid to give 3.27 g (99% of theory) of the title compound.
UPLC-MS (Method A1): R = 0.57 min
MS (ESIpos): m/z = 364 (M+H)+
1H—NMR (300 MHz, fi): 5 = 3.36 — 3.80 (m, 8H), 4.78 (s, 2H), 5.33 (br. 5., 2H),
6.55 (d, 1H), 6.74 (dd, 1H), 7.30 (d, 1H), 7.38 - 7.53 (m, 5H), 7.81 (s, 1H).
Intermediate 6-12
2-(5-Amino—2H—indazol~2-yl)- l -(4~methylpiperazin-1 -y1)ethanone
HZNm
/ \
N _
Analogously to Intermediate 6-4, 916 mg (2.45 mmol) of tert-butyl {2-[2-(4-methylpiperazinyl)-
2-oxoethyI]-2H-indazol-5—yl} ate (Intermediate 5-12) were stirred with 1.89 ml (245 mmol)
2014/077877
of trifluoroacetic acid in dichloromethane at 25°C for 24 h. The mixture was concentrated and the
crude product was dissolved in 10 m1 of tetrahydrofuran and 1 m1 of N,N-dimethy1formamide. The
precipitated solid was filtered off and washed with diethyl ether. The solid was dissolved in
methanol and the solution was concentrated to dryness. This gave 1.2 g of the title compound as a
crude product.
Intermediate 6-13
2—(5-Amino-2H-indazolyl)[4-(2,2,2-trifluoroethy1)piperazin-I -y1]ethanone
\N/N Q}
ously to Intermediate 6-4, 1.1 mi (14.4 mmol) of trifluoroacetic acid were added to 634 mg
(1.43 mmol) of tert-buty] (2-{l-oxo-z-[4-(2,2,2-trifluomethylmiperazinyl]cth)1;-2H--indazol
yl)carbamate (Intermediate 5—13) in 5 m1 of dichloromethane and the mixture was stirred at 25°C
for 24 h. The e was concentrated and twice toluene was added and evaporated. This gave 1.0
g of a crude product.
UPLC-MS (Method Al): R = 0.59 min
Ms (ESIpos): m/z = 342 (M+H)+.
Intermediate 6-14
4—[(5—Arnino—2H—indazolyl)acety1] -l -ethy1piperazinone
\N/NnyiN\—/ —\CH
Analogously to ediate 6—4, 2.8 ml (35.9 mmol) of trifluoroacetic acid were added to 1.92 g
(3.59 mmol, 75%) of tert-butyl {2-[2—(4-ethyloxopiperazin-1—yl)oxoethyl]-2H-indazol—5-
yl}carbamate (Intermediate 5-14) in 15 ml of dichloromethane and the mixture was stirred at 25°C
for 24 h. Saturated sodium bicarbonate solution was added, the mixture was filtered, the organic
phase was separated off and the aqueous phase was extracted with romethane. A precipitate
formed in the s phase; this precipitate was filtered off with suction and washed with water
and diethyl ether. Drying gave 636 mg (44% of theory) of the title compound as a crude product.
W0 2015/09’1426
Intermediate 6-15
2-(5-Aminomethyl—2H-indazolyl)(4-benzoylpiperazin-l-yl)ethanone
3:50
0.21 ml (2.72 mmol) of trifluoroacetic acid was added to 130 mg (0.27 mmol) of tert~butyl {2-[2-
(4—benzoylpiperazin—1-yl)-2oxoethyl]methyl—2H—indazol—S—yl}carbama'te in 3 ml of
romethane, and the mixture was stirred at 25°C for 24 h and concentrated. This gave 204 mg
of the title compound as a crude product.
UPLC—MS d A1): K = 0.61 min
MS (ESlpos): mfz = 378 (M+H)'.
Intermediate 6-16
2-(5—Amino-6—rnethoxy-2H-indazoly1)—1—(morpholin—4-yl)ethanone
H3
Analogously to Intermediate 6—4, 1.16 g (2.97 mmol) of tert-butyl {6—methoxy[2-(morpholin—4—
yl)oxoethyl]~2H—indazol-5—yl}carbamate (Intermediate 5—16) were stirred with 2.29 ml (29.7
mmol) of roacetic acid in 20 ml of dichloromethane at 25°C for 24 h. A further 1.15 ml (14.9
mmol) of trifluoroacetic acid were added, and the mixture was stirred at 25°C for a further 24 h.
Three times, the reaction e was concentrated with toluene. The residue was dissolved in
tetrahydrofirran and diethyl ether was added. The resulting precipitate was filtered off with suction,
washed with diethyl ether and dried. This gave 759 mg (88% of theory) of the title compound.
S (Method A2): Rz = 0.60 min
MS (ESIpos): m/z = 291 (M+H)+
1H NMR (400 MHz, DMSO-d6): 5 = 3.45 (br. s., 2 H), 3.51 — 3.71 (m, 6 H), 3.93 (s, 3 H), 5.40 (s,
2 H), 7.10 (s, 1 H), 7.52 (s, 1 H), 8.21 (s, 1 H).
Intermediate 6—17
2-(5-Aminomethoxy—2H-indazolyl)(4-methylpiperazin-l-yl)ethanone
H2Nfih‘\ / —>rN N—CH3
O N
Analogously to Intermediate 6-16, 1.25 g (3.10 mmol) of tert-butyl {6—methoxy—2-[2-(4-
piperazin-l—y1)oxoethy1]-2H-indazolyl}carbamate mediate 5—17) were stirred
with 2.39 mi (31.0 mmol) of trifluoroacetic acid in 25 m1 of dichloromethane at 25°C for 5 h.
Work-up gave 534 mg (57% of theory) of the title compound.
UPLC-MS (Method A2): R. = 0.61 min
MS (ESIpos): m/z = 304 (M+H)’
'H NMR (400 MHz, DMSO-dé): 6 = 2.19 (s, 3 H), 2.34 - 2.30 (m, 2 H). 2.30 - 2.37 (m. 2 H), 3.41
— 3.48 (m, 2 H), 3.49 - 3.54 (m, 2 H), 3.82 (s, 3 H), 4.61 (br. s., 2 H), 5.23 (s, 2 H), 6.63 (s, I H),
6.79 (s, 1 H), 7.76 (s, 1 H).
Intermediate 6-18
2-(5-Amino-6—methoxy-2H-indazol—2—yl)—N—(cyc1opropylmethyl)-N-methylacetamide
Analogously to Intermediate 6-4, 353 mg (0.86 mmol, 95%) of tert—butyl (2—{2—
[(cyclopropylmethyl)(methyl)amino]-2—oxoethy1}methoxy—2H-indazol-5—y1)carbamate
(Intermediate 5-18) were initially d in 10 ml of dichloromethane. 665 pl (8.63 mmol) of
trifluoroacetic acid were added, the mixture was stirred at 25°C for 24 h, another 200 ul of
trifluoroacetic acid were added and the mixture was stirred for 3 h. The mixture was concentrated
and twice toluene was added and in each case the mixture was concentrated again. This gave 750
mg of a crude product.
UPLC—MS (Method A1): K = 0.61 min
MS (ESIpos): m/z = 289 (M+H)+,
ediate 6-19
2-(5 -Amino-2H—indazol~2-y1)-l -(4-benzoylpiperazin-1 -yl)propan-1 -one
H2N\©f\ ‘2‘N \—/N—:
N o
N CH3
Analogously to Intermediate 6-4, 3.70 g (7.75 mmol) of tert-butyl (4-benzoylpiperazin—l—yl)—
l-0xopropan-2—yl]-2H-indazol-5—yl}carbamate (Intermediate 5-19) (crude product) were initially
charged in 40 ml of dichlommethane. 6.0 m1 (77.4 mmol) of trifluoroacetic acid were added and
the mixture was stirred at 25°C for 24 h. The mixture was carefully poured into saturated sodium
bicarbonate solution. extracted with dichloromethane and concentrated. The crude product was
triturated with l ether. This gave 2.4 g (75% of theory) of the title compound as a light-brown
solid.
IH—NMR (300 MHz, DMSO-dé): 6 = 1.59 (d, 3H), 2.9 — 3.7 (broad signals, superimposed), 4.78 (s,
2H), 5.74 (br. s, 1H), 6.52 (s, 1H), 6.71 (dd, 1H), 7.25 - 7.47 (m), 7.91 (s, 1H).
Intermediate 6-20
2-[5-Amino(benzyloxy)-2H—indazol—2—yl]-1 —(morpholin—4—y1)ethanone
H2N130 / fl”; ‘0
0 N
Analogously to Intermediate 6-4, 3.65 g (7.82 mmol) of tert-butyl {6-(benzyloxy)-2—[2—(morpholin-
2—oxoethy1]—2H~indazoly1} carbamate (Intermediate 5-20) were initially charged in 50 m1
of dichloromethane. 6.0 m1 (78.2 mmol) of trifluoroacetic acid were added and the mixture was
stirred at 25°C for 24 h. The mixture was carefully poured into saturated sodium bicarbonate
solution and extracted with dichloromethane, and the combined organic phases were washed with
saturated sodium de solution and concentrated. This gave 2.72 g (95% of theory) of the title
nd.
UPLC—MS (Method Al): R = 0.85 min
MS (ESIpos): m/z = 312 (M+H)‘
1H-NMR (400 MHz, FORM—d): 5 = 3.59 (s, 4 H), 3.65 (d, 4 H), 5.15 (s, 4 H), 6.78 (s, 1
H), 6.98 (s, 1 H), 7.34 - 7.44 (m, 3 H), 7.46 — 7.50 (m, 2 H), 7.71 - 7.74 (m, 1 H).
Intermediate 6-21
2-(5-Aminochloro—2H-indazol-2—yl)-1 —(4-methy1piperazin—1—y1)ethanone
0'Ir N —>—N
N—CH
o \__/
.0 m1 of ice-cold trifluoroacetic acid were added to 299 mg of benzyl {6-chloro[2-(4-
methylpiperazin—l-y1)—2-oxoethyl]-2H-indazol-5~yl}carbamate (Intermediate 5-21}, and the
mixture was stirred at room temperature for 3 days. The mixture was poured into saturated aqueous
sodium bicarbonate solution and extracted with ethyl acetate and the extract was washed with
sodium chloride on, filtered through a hydrophobic filter and concentrated. Purification by
preparative HPLC (Method P2) gave a solid which was triturated with diethyl ether. Drying gave
101 mg of the title compound.
1H-NMR (300 MHz, fi): 5 [ppm]: 2.18 (s, 3H), 2.22 — 2.39 (m, 4H), 3.38 — 3.56
(m), 4.96 (s, 2H), 5.33 (s, 2H), 6.88 (s, 1H), 7.57 (s, 1H), 7.94 (d, 1H).
ediate 6-22
minoch10r0-2H—indazolyl)—1-(morpholin—4—yl)ethanone
H2NK)?
\/ 074N /—\
.. o
O \_/
Analogously to the preparation of Intermediate 6—21, 254 mg of benzyl {6—chloro—2-[2—(morph01in—
4-y1)0xoethyl]-2H-indazol-5—yl}carbamate (Intermediate 5-22) were stirred with 3 m1 of
trifluoroacetic acid at room temperature for 6 days. Analogous aqueous work-up gave 137 mg of
the title compound as a crude product.
UPLC-MS (Method A1): Rt = 0.60 min (UV detector: TIC). Mass found 294.00.
Intermediate 7-1
Ethyl (5-amino-6—fluoro-2H—indazol—2-yl)acetate
PCT/EPZO] 4/077877
NO CH
F N
Analogously to Intermediate 6-4, 1.1 g (3.3 mmol) of ethyl {5-[(tert—butoxycarbonyl)amino]
fluoro-ZH—indazol-Z-yl}acetate (Intermediate 3-5) were d with 1.92 ml (24.9 mmol) of
trifluoroacetie acid in 11 ml of dichloromethane. Work-up gave 790 mg (100% of theory) of the
title compound.
UPLC-MS (Method AI): R, = 0.67 min
MS s): m/z = 238 (M+H)+
lH—NMR (300 MHz, DMSOd6): 5 = 1.21 (t, 3H), 4.16 (q, 2H), 4.93 (s, 2H), 5.24 (s, 2H), 6.81 (d,
1H), 7.21 (d, 1H), 8.80 (s, 18).
ediate 7-2
Ethyl [S—amino(benzyloxy)-2H-indazol-2—yl}acetate
HZNJib
/ )0LC.
O N
Analogously to Intermediate 6-4, 2.37 g (5.56 mmol) of ethyl {6-(benzyloxy)-5—[(tert—
butoxycarbonyl)amino]—2I-1—indazoly1}acetate (Intermediate 3-4) were reacted with 3.24 ml
(41.8 mmol) of trifluoroacetic acid in 25 ml of dichloromethane. Work-up gave 1.79 g (99% of
theory) of the title compound.
UPLC-MS (Method A1): R, = 0.91 min
MS (ESIpos): m/z = 326 (M+H)+
1H NMR (400 MHz, CHLOROFORM-d): 6 = 1.29 (t, 3 H), 4.25 (q, 2 H), 5.07 (s, 2 H), 5.15 (s, 2
H), 6.81 (s, 1 H), 7.01 (s, 1 H), 7.31 - 7.45 (m, 3 H), 7.45 - 7.52 (m, 2 H), 7.67 (s, 1 H).
Intermediate 7-3
Ethyl (5—amino-2H-indazoly1)acetate
N 370
0 \—CH3
Analogously to Intermediate 6-4, 9.0 m1 (117.4 mmol) of trifluoroacetic acid were added to 5.00 g
(15.7 mmol) of tert-butyl {5-[(tert-butoxycarbonyl)amino]-2H—indazolyl}acetate (Intermediate
3-7) in 75 ml of romethane and the e was stirred at 25°C for 24 h. The mixture was
poured into saturated sodium bicarbonate solution, the organic phase was separated off and the
s phase was extracted three times with dichloromethane. The combined organic phases were
washed with sodium chloride solution, dried and concentrated. This gave 3.4 g of the title
compound as a brown solid.
UPLC-MS (METHOD A1): Rt = 0.47 min
MS (ESIpos): m/z = 220 (M+H)'
'H-NMR (400 MHz, DMSO—db): 6 = 1.18 (t, 3H), 2.49 (br. 5., 1H), 4.12 (q, 2H), 4.80 (s, 2H), 5.20
(s. 2H), 6.52 (dd, 1H), 6.73 (dd. 1H). 7.26 — 7.32 (m, 1H), 7.87 (d, 1H).
Intermediate 7-4
Ethyl 3—(5-amino—2H-indazol-Z-yl)propanoate
Analogously to Intermediate 7-1, 640 mg (1.92 mmol) of ethyl 3—{5—[(tert—butoxycarbonyl)amino]—
ZH—indazol—Z-yl}propanoate (Intermediate 3-9) were reacted with 1.1 ml (14.4 mmol) of
roacetic acid. This gave 391 mg (87% of theory) of the title compound.
UPLC—MS (Method A1): Rt = 0.50 min
MS (ESIpos): m/z = 234 (M+H)+r
Intermediate 7—5
Ethyl (5—aminoisopropoxy—2H—indazol—2—yl)acetate
Analogously to Intermediate 7-1, 1.8 g (4.84 mmol) of ethyl {5—[(tert-butoxycarbonyl)amino]~6-
isopropoxy-ZH-indazol-Z-yl}acetate (Intermediate 3-10) were reacted with 2.8 ml (36.3 mmol) of
trifluoroacetic acid. This gave 1.3 g (100% of theory) of the title compound.
UPLC—MS (Method A1): R{ = 0.69 min
MS (ESIpos): m/z = 278 (M+H)+
1H—NMR (300 MHz, DMSO-d6): 6 = 1.21 (t, 3H), 1.32 (d, 6H), 4.15 (q, 2H), 4.59 (s, 1H), 4.60 —
4.69 (m, 1H), 5.16 (s, 2H), 6.64 (s, 1H), 6.81 (d, 1H), 7.83 (s, 1H).
Intermediate 7—6
Benzyl (5-aminomethoxy—2H—indazol—2-yl)acetate
9 N _>—0
OH 0
Analogously to Intermediate 7-1. 25.7 g (60.1 mmol) of benzyl ert-butoxycarbonyl)amino]~6-
methoxy-ZH—indazoI-Z-yl}acetate (Intermediate 3-2) were reacted with 23.1 ml (300.3 mmol) of
trifluoroacetic acid. This gave 20.5 g (98% of theory) of the title compound.
UPLC-MS (Method A1): Rt = 0.85 min
MS (ESIpos): m/z = 312 (Mi—H)‘
Intermediate 8-1
Ethyl [6-fluoro—5-( { [6—(trifluoromethyl)pyridin~2-yl]earbonyl} amino)—2H-indazol-2—yl]acetate
I H o CH
F / N 0’
N /
F o \ /N
F N
221 mg (1.16 mmol) of fluoromethyl)pyridinecarboxylic acid, 177 mg (1.16 mmel) of 1-
hydroxy—lH—benzotriazole e and 444 mg (2.32 mmol) of 1-(3—dimethy1aminopr0py1)—3-
arbodiimide hydrochloride in 5.5 ml of dimethylformamide were stirred at 25°C for 30 min.
250 mg (1.05 mmol) of ethyl (5—aminofluoro-2H—indazolyl)acetate mediate 7—1) were
added and the mixture was stirred at 25°C for 30 min. The mixture was poured into 150 m1 of
water, filtered off with suction, washed with water and dried. This gave 366 mg (84% of theory) of
the title compound.
UPLC-MS (Method A1): R = 1.23 min
MS (ESIpos): m/z = 411 (M+H)"
‘H-NMR (300 MHz, DMSO-dé): 5 = 1.22 (t, 3H), 4.18 (q, 2H), 5.41 (s, 2H), 7.55 (d, 1H), 8.21 (m,
1H), 8.36- 3.51 (m, 4H), 10.27 (m, 1H).
Intermediate 8-2
Ethyl (6—fluoro-5 - { [(6-mcthylpyr1dinyl)carbony1]amino } —2H-indazol-2—y1)acetate
| H 0
/ CH
/ N
HBO N /
O \ /N
F N
ously to Intermediate 8—], 159 mg (1.16 mmol) of 6-methy1pyridine-2—carboxy1ie acid were
meted with 250 mg (1.05 mmol) of ethyl (S-aminofluoro-ZH-indazol-Z-yl)acetate (Intermediate
7-1). Work-up gave 316 mg {84% of ) of the title compound.
UPLC-MS (Method Al): R. = 1.17 min
MS s): ml‘z = 357 (M+H)‘.
Intermediate 8-3
Ethyl [6-flu0r0({[6-(1-methy1-1H-pyrazol-4—yl)pyridin—2—yl]carbonyl}amino)—2H—indazol—2-
yl] acetate
Analogously to Intermediate 8—1, 235 mg (1.16 mmol) of ethyl-1H-pyrazoly1)py‘ridine-2—
carboxylic acid were reacted with 250 mg (1.05 mmol) of ethyl (S—aminc-6rfluoro-ZH—indazol
yl)acetate (Intermediate 7-1). Work—up gave 364 mg (82% of theory) of the title compound.
UPLC~MS (Method A1): R, = 1.05 min
MS (ESIpos): m/z = 423 (M+H)+.
Intermediate 8-4
Ethyl [6-flu0ro-S-( {[5-fluoro-6—(1 —methy1-1 H—pyrazolyl)pyn'din—2—yl] carbonyl} amino)—2H—
indazol—Z—yl]acetate
PCT/EP2014/O77877
)0/—-CH3 /
/ F N
Analogously to Intermediate 8-1, 235 mg (1.0 mmol) of 5-fluoro-6—(l-methyl—lH—pyrazol
yl)pyridine-2—carboxylic acid (Intermediate 19—5) were reacted with 250 mg (1.05 mmol) of ethyl
(5-amino—6-fluoro—2H-indazol—2-yl)acetate (Intermediate 7-1). Work-up gave 326 mg (76% of
theory) of the title nd.
UPLC-MS (Method AI): R[ z 1.13 min
MS (ESIpos): m/z = 442 (M+H)".
Intermediate 8-5
Ethyl [6-tluoro-5{{[6-(morpholin-4—y1)pyridin—2-yl]carbony1}amino)~2H-indazol-Z-yl]acetate
l H O CH
l/\N / N 0/—
N /
Q o \ /N
F N
Analogously to Intermediate 8-1, 222 mg (0.97 mmol) of 6-(morpholin—4-yl)pyridinecarboxylic
acid were reacted with 230 mg (0.97 mmol) of ethyl (S-aminofluoro-2H-indazoly1)acetate
(Intermediate 7—1). Work—up gave 414 mg (100% of theory) of the title compound.
UPLC-MS (Method A1): R, = 1.12 min
MS (ESIpos): rn/z = 428 (M+H)'.
Intermediate 8-6
Ethyl [6-(benzyloxy)—5 —( { ifluoromethyl)pyridiny1]carbonyl} —2H-indazol
y]]acetate
F \N N333
. )0LC.
F O \ /
O N
1.79 g (5.5 mmol) of ethyl [5—amino(benzyloxy)-2H-indazol—2-yl]acetate (Intermediate 7-2),
1.26 g (6.6 mmol) of 6-(trifluoromethyl)pyridine-2—carboxylic acid, 842 mg (5.5 mmol) of l-
hydroxy—lH-benzotriazole hydrate, 2.11 g (11.0 mmol) of 1-(3—dimethylaminopropyl)—3—
ethylcarbodiimide hydrochloride and 2.3 m1 (16.5 mmol) of triethylarnine were in 75 m1 of
tetrahydrofuran at 25°C for 24 h. The reaction mixture was concentrated and water was added to
the residue. The ing solid was filtered off with suction and washed twice with water and twice
with diethyl ether. The yellow solid was dried under reduced pressure. This gave 2.44 g (89% of
theory) of product.
S (Method AI): R = 1.42 min
MS (ESIpos): m/z = 499 (M-tH)+
IH NMR (400 MHz, DMSO—d6): 5 = 1.23 (t, 3 H), 4.18 (q, 2 H), 5.31 (s, 2 H), 5.33 (s, 2 H), 7.32
(s. 1 H), 7.34 - 7.47 (m, 3 H), 7.54 - 7.61 (m. 2 H). 8.18 (d. 1 H), 8-32 - 8.42 (m, 2 H). 8.43 - 8.52
(m, I H), 8.81 (s, 1 H). 10.47 (s. l H).
Intermediate 8—7
Ethyl [6-hydroxy( {[6-(trifluoromethpryridin-Z-yl]carbonyl}amino)-2H-indazoIyl]acetate
| O
F o \ /
HO N
1.0 g (2.01 mmol) of ethyl [6-(benzyloxy)—5—({[6—(trifluorornethyl)pyridiny1]carbonyl}amino)-
azol—2—yl]acetate (Intermediate 8-6) was dissolved in 40 ml of ethanol, and the flask was
evacuated and then flushed with nitrogen (this procedure was repeated two more times). 213 mg
(0.2 mmol) of ium on carbon were added and the flask was evacuated and flushed with
hydrogen. The reaction mixture was hydrogenated under standard hydrogen pressure at 25°C for 6
h. The reaction mixture was then filtered through a PTFE filter with Celite and trated. This
gave 783 mg (96% of theory) of product.
S (Method A1): Rt = 1.08 min
MS (ESIpos): m/z = 409 (M+H)+
1H NMR (400 MHz, DMSO-d6): 8 = 1.22 (1, 3 H), 4.17 (q, 2 H), 5.28
, (s, 2 H) 6.92 (s, 1 H) 8.21
(d, 1 H), 8.27 (s, 1 H), 8.40 (t, 1 H), 8.47 (d, 1 H), 8.70 (s, 1 H), 10.55 (s, 1 H), 10.72 (s, 1 H).
Intermediate 8-8
Ethyl [6—isobutoxy—5-( {[6-(triflu0romethyl)pyridin—2—y1]carbonyl}amino)—2H—indazolyl]acetate
PCT/EP2014/O77877
| O
F \ N
N / f0
F N \—CH3
F 0 \ /
O N
H30%
200 mg (0.49 mmol) of ethyl [6-hydroxy({[6-(trifluoromethyl)pyfidin—2—yl]carbony1}amino)-
azol-2—yl]acetate (Intermediate 8-7) were dissolved in 1.5 ml of NJV—dimethylformamide,
and 203 mg (1.47 mmol) of potassium carbonate were added with stirring. The suSpension was
d at 25°C for 10 minutes, and 80 pl (0.73 mmol) of 1—bromomethylpropane were then
added. The reaction mixture was stirred in the microwave at 100°C for 1 h. The reaction mixture
was then diluted with water, and ethyl acetate was added- A solid was , which was filtered
off with suction and washed twice with water and twice with diethyl ether. The greenish solid was
dried in a drying cabinet for 3 h. This gave 200 mg (88% of ) of product.
UPLC—MS (Method AI): R. = 1.45 min
MS (ESIpos): m/z = 465 (M+H)T
1H NMR (300 MHz, DMSO-dé): 5 = 1.12 (d, 6 H), 1.22 (t, 3 H), 2.19 (dt, 1 H), 3.96 (d, 2 H), 4.17
(q, 2 H), 5.32 (s, 2 H), 7.09 (s, 1 H), 8.22 (d, 1 H), 8.32 (s, 1 H), 8.37 - 8.45 (m, 1 H), 8.46 - 8.51
(m, 1 H), 8.78 (s, I H), 10.58 (s, 1 H).
Intermediate 8-9
Ethyl {6—(cyclopropylm.ethoxy)—5 -( { [6-(trifluoromethyl)pyridin~2—yl]carbonyl}amino)-2H-indazol—
cetate
F O \ /
O1::0 W N
Analogously to Intermediate 8—5, 200 mg (0.49 mmol) of ethyl [6—hydroxy({[6-
(trifluoromethyl)pyridin—2—yl]carbony1}amino)-2H—indazolyl]acetate (Intermediate 8-7) were
reacted with 71 ul (0.73 mmol) of (bromomethyl)cyclopropane. Work—up gave 223 mg (99% of
theory) ofthe title compound.
UPLC-MS (Method A1): R1= 1.38 min
MS (ESIpos): m/z = 463 (M+H)+
1H NMR (300 MHz, CHLOROFORM—d): 5 = 0.38 - 0.50 (m, 2 H), 0.69 - 0.84 (m, 2 H), 1.30 (t, 3
H), 1.45 (br. s., 1 H), 3.98 (d, 2 H), 4.27 (q, 2 1-1), 5.15 (s, 2 H), 6.98 (s, 1 H), 7.87 (d, 1 H), 7.93 (s,
1 H), 8.13 (t, 1 H), 8.51 (d, 1 H), 8.88 (s, 1 H), 10.91 (s, 1 H).
Intermediate 8—10
Ethyl [6-(pyridinylmethoxy)-5 —( {[6-(trifluoromethyl)pyridiny1]carbonyl}amin0)-2H-indazol—
2-yl]acetate
200 mg (0.49 mmol) of ethyl [6-hydroxy({[6-(tn'fluoromethyl)pyridin—2-y1]carbonyl}amino)-
2H—indazoly1]acetate (Intermediate 8—7) were dissolved in 6.6 m1 of N,N—dimethylformamide,
and 270 mg (1.96 mmol) of potassium ate were added with stirring. The suspension was
stirred at 25°C for 10 minutes, and 185 mg (0.73 mmol) of 2—(bromomethyl)pyridine hydrobromide
were then added. The reaction mixture was stirred in the microwave at 100°C for 1 h. The reaction
mixture was then diluted with water, and ethyl e was added. A solid was formed, which was
filtered off with suction and washed twice with water and twice with diethyl ether. The greenish
solid was dried in a drying cabinet for 3 h. This gave 160 mg (65% of theory) of the title
compound.
UPLC—MS (Method Al): R: 1.24 min
MS s): m/z = 500 (M+H)+
1H NMR (400 MHz, DMSO-d6): 5 = 1.23 (1, 3 H), 4.18 (q, 2 H), 5.34 (s, 2 H), 5.36 (s, 2 H), 7.70
(d, 1 H), 7.82 — 7.91 (m, 1 H), 8.15 — 8.21 (111,1 H), 8.36 (s, 1 H), 8.37 — 8.43 (m, 1 H), 8.45 - 8.50
(m, 1 H), 8.62 (d, 1 H), 8.82 (s, 1 H), 10.50 (s, 1 H).
ediate 8-1 I
Ethyl [5-( { [6-(1 -methyl— 1 H—pyrazol—4-yl)pyridiny1]carb0ny1 } amino)-2H—indazol—2—yl]acetate
O ‘—CH
Analogously to Intermediate 8-1, 1.00 g of 6—(1 —methy1—1H—pyrazo1-4—y1)pyridine-2—carboxylic acid
(Intermediate 19-2) (crude product) and 961 mg (4.39 mmol) of ethyl (5-amino-2H-indazol
y1)acetate mediate 7-3) were stirred in 10 ml of tetrahydrofman at 25°C for 24 h. Water was
added, the mixture was concentrated and the precipitated solid was filtered off with suction,
washed with water and diethyl ether and dried under reduced pressure. This gave 1.45 g (80% of
theory) ofthe title compound.
UPLC-MS (Method AI): Rt: [.01 min
MS s): m/z = 405 (M+H)‘.
Intermediate 8—12
Ethyl [6—ethoxy—5-( { [6-(trifluoromethy1)pyridinyl]carbonyl } amino)—2H-indazol—2-yl]acetate
F I O
F \N N
/ )0\
F o \ /
o N
Analogously to Intermediate 3—1, 1.30 g (3.71 mmol) of N—(6—ethoxy—1H—indazol-S-yl)—6—
(trifluoromethyl)pyridine—Z—carboxamide (Intermediate 14—3), 826 pl (7.42 mmol) of ethyl
bromoacetate and 1.54 ml (7.42 mmol) of NJV—dicyclohexylmethylamine in 20 ml of
tetrahydrofuran were stirred at 65°C for 18 h. Another 413 pl (3.71 mmol) of ethyl bromoacetate
and 770 1.11 (3.71 mmol) of N,N—dicyclohexylmethylamine were added were added, and the mixture
was stirred at 65°C for a further 6 h. Work-up gave 143 mg of the title compound as a crude
product.
A r 637 mg of the title compound were ed by addition of water to the on filtrate,
extraction with ethyl acetate, g the organic phase with 1M hydrochloric acid solution,
saturated sodium bicarbonate solution, saturated sodium chloride solution, drying, concentration
and ation of the residue with ethyl acetate.
UPLC—MS (Method A1): Rt = 1.31 min
MS (ESIpos): m/z = 437 (M+H)+
2014/077877
'H NMR (400 MHz, DMSO-d6): 5 = 1.23 (t, 3H), 1.51 (t, 3H), 4.14 - 4.27 (m, 4H), 5.31 (s, 2H),
7.10 (s, 1H), 8.18 — 8.23 (m, 1H), 8.31 (s, 1H), 8.37 - 8.44 (m, 1H), 8.45 - 8.49 (m, 1H), 8.73 (s,
1H), 10.74 (s, 1H).
Intermediate 8-13
Ethyl 3-[5-( { [6-(trifluoromethy1)pyridinyl]carbonyl } amino)-2H-indazolyl]propanoate
F o \N/
Analogously to Intermediate 8-1, 194 mg (0.83 mmol) of ethyl 3—(5—amino—2H-indazol-2—
yl)propanoate (Intermediate 7-4) were reacted with 175 mg (0.91 mmol) of 6
oromcthylwyridinca~carboxy1ic acid. This gave 285 mg (84% of theory) of the title
compound.
UPLC-MS (Method A1): K: 1.17 min
MS (ESIpos): m/z = 407 (M+H)".
Intermediate 8~14
utyl [6-Chlor0( {[6-(trifluoromethyl)pyridin—2—yl]carbony1}amino)—2H—indazol—2—yl]acetate
H3C CH3
ZI $0143
N /
F N‘>—0
F 0 \/
Cl N
4.48 g (12.2 mmol) of N—(6-chloro-1H-indazol-S—yl)(trifluoromethyl)pyridine-2—carboxamide
(Intermediate 14-1) were initially d in 40 m1 of tetrahydrofuran. 3.61 ml (24.5 mmol) of tert-
butyl bromoacetate and 5.19 ml (24.5 mmol) of N,N—dicyclohexylmethylamine were added and the
e was stirred at 70°C for 5.5 h. Another 3.61 1111 (24.5 mmol) of tert-butyl bromoacetate and
.19 ml (24.5 mmol) of N,N—dicyclohexylmethylamine were added, the mixture was stirred at 65°C
for 18 h, another 1.81 mi (12.3 mmol) of tert-butyl bromoacetate and 2.60 ml (12.3 mmol) ofMN—
dicyclohexylmethylamine were added and the mixture was stirred at 65°C for a further 6 h. The
mixture was filtered, water was added to the filtrate, the mixture was extracted three times with
ethyl aCetate and the combined organic phases were washed with 1M hydrochloric acid, saturated
sodium bicarbonate solution and saturated sodium chloride solution and concentrated. Trituration
of the crude product with ethyl acetate gave, after drying, 1.45 g (26% of theory) of the title
compound.
UPLC-MS (Method Al): R. = 1.43 min
MS (ESIpos): m/z = 455 (M+H)*
lH-NMR (400 MHz, 6): 5 = 1.45 (s, 9H), 5.32 (s, 2H), 7.95 (s, 1H), 8.23 (d, 1H), 8.38 —
8.44 (m, 1H), 8.45 — 8.49 (m, 1H), 8.49 (s, 1H), 8.66 (s, 1H), 10.5 (s, 1H).
Intermediate 8-15
tert-Butyl [6~methoxy-5 -( { [6-(trifluoromethyl)pyridin—2—yl] carbonyl} amino)—2H-indazol
yl]acetate
/ H3C CH3
H >LCH3
F \ N
N / f0
F O \ /N
O N
2.00 g (5.95 mmol) of N—(é—methoxy—IH—indazol-S-yl)(trifluoromethyl)pyridine-Z—carboxamide
(Intermediate 14—2) were dissolved in 40 ml of tetrahydrofuran and 4.39 ml (29.7 mmol) of tert-
butyl bromoacetate and 6.37 ml (29.7 mmol) of NJV-dicyclohexylmethylamine were added at
°C. The solution was stirred at 70°C for 3 h. Another 0.87 ml (5.95 mmol) of tert-butyl
bromoacetate and 1.27 ml (5.95 mmol) of NJV—dicyclohexylmethylamine were added, and the
mixture was stirred at 70°C for a further 24 h. The solid in the reaction mixture was filtered off and
washed twice with ydrofuran. The regioisomerically pure crystals are dried in a vacuum
drying cabinet at 50°C for 3 h. This gave 1.58 g (59% of theory) of product.
UPLC-MS d AI): R: 1.36 min
MS (ESIpos): mfz = 451 (M+H)+
1H NMR (400 MHz, CHLOROFORM-d): 5 = 1.50 (s, 9 H), 4.04 (s, 3 H), 5.04 (s, 2 H), 7.06 (s, l
H), 7.86 (d, 1 H), 7.92 (s, l H), 8.12 (t, l H), 8.50 (d, 1H), 8.84 (s, 1 H), 10.72 (s, l H).
Intermediate 8-16
tert-Butyl [5 —( {[6-(trifluoromethyl)pyridinyl] carbonyl} amino)—2H—indazolyl] acetate
2014/077877
525 mg (3.80 mmol) of potassium carbonate were added to a solution of 582 mg (1.90 mmol) of N-
(1H-indazolyl)(trifluoromethyl)pyridine-Z-carboxamide (Intermediate 14-4) and 309 pl (2.09
mmol) of tert-butyl bromoacetate in 5 m1 of N,N-dimethylfom1amide, and the mixture was stirred
at 80°C for 24 h. Water was added, and the mixture was extracted three times with ethyl acetate. A
solid precipitated from the ethyl acetate phase; this solid was filtered off with suction and washed
with ethyl acetate. Drying under d pressure gave 72 mg (8% of theory) of the title
compound. The ethyl acetate phase was concentrated and the residue was purified by preparative
HPLC. This gave a fiirther 151 g (19% of theory) of the title compound.
1H—NMR (500 MHz, DMSO—d6): 6 = 1.45 (s, 9H), 5.27 (s, 2H), 7.56 — 7.61 (m, 1H), 7.61 - 7.64 (m,
1H), 8.17 (dd, 1H), 8.30 - 8.39 (m), 8.39 - 8.43 (m,lH), 10.38 (s, 111).
Intermediate 8-17
Ethyl [6—isopropoxy—5—( { [6—(trifluoromethyl)pyfidin—2—yl]carbonyl } amino}2H-indazol yl]acetate
I H 0 / CH
F / N
N /
F o \ IN
0 N
H CXCH
Analogously to ediate 8-1, 300 mg (1.08 mmol) of ethyl (5-aminoisopropoxy-ZH-indazol-
2-yl)acetate (Intermediate 7-5) were reacted with 227 mg (1.19 mmol) of 6—
(trifluoromethyl)pyridinecarboxylic acid. This gave 487 mg (100% of theory) of the title
compound.
UPLC—MS (Method A1): Rt: 1.34 min
MS s): m/z = 451 (M+H)+
1H-NMR (300 MHz, DMSO-dé): 5 = 1.23 (t, 3H), 1.41 (d, 6H), 4.18 (q, 2H), 4.79 — 4.92 (m, 1H),
.32 (s, 2H), 7.18 (s, 1H), 8.22 (d, 1H), 8.33 (s, 1H), 8.37 — 8.50 (m, 2H), 8.75 (s, 111), 10.75 (s,
1H).
Intermediate 8—18
Ethyl propoxy-5 — { [(6-methylpyridinyl)carbonyl]amin0} -2H-indazol-2—yl)acetate
H O / CH
/ N
H30 N /
O \ /
i N
H3C CH3
Analogously to Intermediate 8-2, 0.3 g (1 mmol) of ethyl (5-aminoisopropoxy-2H-indazol-Z-
yl)acetate (Intermediate 7—5) were reacted with 137 mg (1.2 mmol) of 6-methylpyridine—2-
carboxylic acid. This gave 380 mg (89% of theory) of the title compound.
UPLC-MS (Method A1): R. = 1.28 min
MS (ESIpos): m/z = 397 (M+H)+
'H-NMR (300 MHz, DMSO-d6): 5 = 1.22 (t, 3H), 1.45 (d, 6H), 2.62 (s, 3H), 4.18 (q. 2H), 4.78 —
4.89 (m, 1H), 5.31 (s, 2H), 7.15 (s, 1H). 7.52 —- 7.60 (m. 1H). 7.95 — 8.01 (m, 2H). 8.29 (s. 1H}.
8.72 (s, 111), 10.99 (s, 1H).
Intermediate 8-19
tert—Butyl [6-(benzyloxy){[(6-methy1pyridin—2—yl)carbonyl]amino}~2H—indazolyl]acetate
HBC CH3
l O
H >L-CH3
\ N O
H3C N /
0 \ IN
O N
Analogously to Intermediate 8-15, 1.00 g (2.79 mmol) of N—[6—(benzyloxy)—lH—indazol—S-y1]—6—
methylpyridine—Z—carboxamide mediate 14-5) was ved in 20 ml of tetrahydrofuran and
1.64 ml (11.2 mmol) of tert—butyl bromoacetate and 2.39 ml (11.2 mmol) of MN-
ohexylmethylarnine were added at 25°C. After 3 h at 70°C, another 1.64 ml (11.2 mmol) of
tert-butyl bromoacetate and 2.39 ml (11.2 mmol) of cyclohexylmethylamine were added,
and the mixture was stirred at 70°C for a further 24 h. The solid in the reaction mixture was filtered
off and washed twice with tetrahydrofuran. The regioisomerically pure crystals are dried in a
vacuum drying cabinet at 50°C for 3 h. This gave 971 mg (74% of theory) of product.
UPLC-MS (Method A1): K = 1.47 min
MS (ESIpos): m/z = 473 (M+H)+
lH-NMR (500 MHz, DMSO-dé): 8 = 1.45 (s, 9H), 2.43 (s, 3H), 5.20 (s, 2H), 5.31 (s, 2H), 7.29 (s,
1H), 7.39 - 7.43 (m, 1H), 7.45 - 7.53 (m, 3H), 7.63 - 7.68 (m, 2H), 7.93 — 7.97 (m, 1H), 7.97 - 8.00
(m, 1H), 8.29 (d, 1H), 8.78 (s, 1H), 10.87 (s, 1H).
Intermediate 8-20
Methyl 3-[6-methoxy-5 -( { [6-(trifluoromethyl)pyridiny1]carbonyl} amino)—2H—indazol—2—y1]—2-
propanoate
H o
F N/ N
/ CH
9 N CH3
164 mg (1.19 mmol) of potassium carbonate and 83 1.11 (0.65 mmol) of methyl (2R)~3-bromo
methylpropanoate were added to 200 mg (0.60 mmol) of N-(é-methoxy-lH-indazol-S-yl)—6—
oromethyl)pyridine—2-carboxamide mediate 14-2) in 5 m1 of acetonitrile, and then
mixture was stirred at 85°C for 24 h. The mixture was diluted with water and extracted with ethyl
acetate and the extract was washed with saturated sodium chloride solution, filtered through a
hydrophobic filter and concentrated. The crude product was dissolved in 2.0 m1 of dimethyl
sulphoxide and purified by preparative HPLC. The product fraction was lyophilized. This gave 25
mg (56% of theory) of the title compound.
,UPLC-MS d A1): R( = 1.23 min
MS (ESIpos): m/z = 437 (M+H)+
2O 1H—NMR(300 MHZ, DMSO-d6): 5 = 1.08 (d, 3 H), 3.13 (q, l H), 3.55 (S, 3 H), 4.04 (s, 3 H), 4.48
(dd, 1 H), 4.62 (dd, 1 H), 7.40 (s, 1 H), 8.02 (s, 1 H), 8.17 - 8.26 (m, 1 H), 8.40 (1, 1 H), 8.47 (d, 1
H), 8.71 (S, 1 H), 10.42 (s, l H).
Intermediate 8—21
Benzyl [5-({[6-(difluoromethyl)pyridin—2-yl]carbonyl}amino)Inethoxy-2H-indazol-2—y1]acetate
| H
F \ N
N /
F o m” /—©
0 N )0
WO 91426
Analogously to Intermediate 8-6, 400 mg (1.29 mmol) of benzyl (5-amino1nethoxy-2H-indazol-
2-yl)acetate (Intermediate 7-6) were stirred with 245 mg (1.41 mmol) of 6-
(difluoromethyl)pyridinecarb0xylic acid (CAS No: 1256824—41—5), 197 mg (1.29 mmol) of 1-
hydroxy-lH-benzotriazole hydrate and 493 mg (2.57 mmol) of 1-(3-dimethylaminopropy1)—3-
ethylcarbodiimide hydrochloride and 537 pl (3.85 mmol) of triethylamine in 10 m1 of
tetrahydrofuran at 25°C for 24 h. The reaction mixture was diluted with water and extracted three
times with ethyl acetate. The combined organic phases were washed with saturated sodium chloride
on and concentrated. The crude product was taken up in diethyl ether and a little water and
stirred for 30 minutes. The solid was filtered off with suction, washed three times with diethyl ether
and dried in a drying cabinet. This gave 401 mg (48% of theory) of the title nd.
S (Method AI): R = 1.29 min
MS (ESIpos): m/z = 467 (M+H)'.
Intermediate 8-22
Benzyl [S—( l[6-(2hydroxypmpan-Z-ylmyfidin—Z-yl]carbonyl} aminoM-methoxy-BH -indazo|
yllacetate
| H
H3C / N
N /
CH3 0
Analogously to Intermediate 8—6, 300 mg (0.96 mmol) of benzyl (5-aminomethoxy—2H—indazol—
2—yl)acetate (Intermediate 7-6), 295 mg (1.16 mmol) of ium 6-(2-hydroxypropan—2—
yl)pyridinecarboxylate (Intermediate 19-11), 148 mg (0.96 mmol) of l-hydroxy-IH-
benzotriazole hydrate, 277 mg (1.45 mmol) of 1-(3-dimethy1aminopropyl)ethylcarbodiimide
hydrochloride and 403 pl (2.89 mmol) of ylamine in 10 m1 of tetrahydrofuran were stirred at
°C for 24 h. The on mixture was diluted with water and extracted three times with ethyl
acetate. The combined organic phases were washed with saturated sodium chloride solution and
concentrated. The crude product was dissolved in 4 ml of dimethyl sulphoxide and purified by
preparative HPLC according to Method P5 (gradient: 0 - 15 min 30 — 70% B; flow rate: 150
ml/min). The product fraction were lyophilized. This gave 209 mg (46% of ) of the title
compound.
UPLC-MS (Method A1): R. = 1.19 min
MS (ESIpos): m/z = 475 (M+H)‘
1H-NMR (300 MHz, DMSO-d6): 5 1.57 (s, 6 H), 4.00 (s, 3 H), 5.21 (s, 2 H), 5.41 (s, 2 H), 5.47 (s,
1 H), 7.13 (s, 1 H), 7.34 - 7.41 (m, 5 H), 7.94 (dd, 1 H), 7.99 - 8.12 (m, 2 H), 8.33 (s, 1 H), 8.69 (s,
l H), 10.94 (s, 1 H).
Intermediate 8-23
Benzyl (6-methoxy—5- {[(6—methylpyridinyl)carbonyl]amino } -2H-indazoly1)acetate
fl n 0
~ fiePfi
00 N
7.57 g (19.0 mmol) of N-(6-methoxy-lH-indazo1y1)methylpyridine-2carboxamide
(Intermediate 14-6) were stirred with 6.03 ml (38.1 mmol) of benzyl cetate in 100 ml of
tetrahydrofiuan in the presence of 8.01 mi (38.1 mmol) of cyclohexylmethylamine at 70°C
for 2.5 h and at 60°C for 17 h. Another 3.02 ml (19.1 mmol) of benzyl bromoacetate and 4.01 m]
(19.1 mmol) of N,N—dicyclohexylmethylamine were added and the mixture was stirred at 70°C for
a further 24 h. The solid was filtered off with n and washed with ethyl acetate. The filtrate
was filtered once more and washed twice with ethyl acetate and the solid was dried. Water was
added to the filtrate, and after phase separation the aqueous phase was washed once more with
ethyl acetate. The combined organic phases were washed with saturated sodium chloride solution,
filtered through a hydrophobic filter and concentrated. Ethyl acetate was added to the crude
product, and the mixture was stirred for 15 minutes. The solid was filtered off with suction, washed
three times with ethyl acetate and dried in a drying cabinet. This gave a total of 6.02 g (63% of
) of the title compound.
LC-MS (Method A3): R: 1.25 min
MS (ESIpos): m/z = 431 (M+H)+
1H—NMR (500 MHZ, DMSO-d6): 6 = 2.63 (s, 3 H), 4.01 (s, 3 H), 5.21 (s, 2 H), 5.40 (s, 2 H), 7.11
(s, 1 H), 7.34 - 7.40 (m, 5 H), 7.55 (dd, 1 H), 7.93 - 8.02 (In, 2 H), 8.30 - 8.33 (m, 1 H), 8.73 (s, 1
H), 10.72 (s, l H).
Intermediate 8-24
tert—Butyl [6—rneth0xy-5—( { [2-(tetrahydro-2H-pyran-4~y1)-1 ,3 -oxazol-4—y1]carbonyl} —2H-
indazol—2—yl}acetate
1.19 g (1.77 mmol) of N-(6-methoxy-1H—indazolyl)(tetrahydro-2H-pyi~anyl)-1,3-oxazole-
4—carboxamide (Intermediate 14-7) were stirred with 524 til (3.55 mmol) of tert-butyl bromoacetate
in 10 m1 of tetrahydrofuran in the ce of 752 pl (3.55 mmol) of N,N—
dicyclohexylmethylamine at 70°C for 2.5 h and at 60°C for 17 h. r 1.51 ml (9.5 mmol) of
tert—butyl bromoacetate and 2.00 ml (9.5 mmol) of N,N—dicyclohexylmethylamine were added and
the mixture was stirred at 70°C for a further 6 h. The solid was filtered off with suction and washed
three times with ethyl acetate. Water was added to the e, and after phase separation the
aqueous phase was washed once more with ethyl acetate. The combined organic phases were
washed with saturated sodium chloride on, filtered h a hydrophobic filter and
concentrated. Ethyl acetate was added to the crude product and the solid was filtered off with
suction, washed three times with ethyl acetate and dried in a drying cabinet. This gave a total of
330 mg (41% of theory) of the title compound.
UPLC—MS (Method AI): R. = 1.23 min
MS (ESlpos): m/z = 457 (M+H)‘
'H—NMR (500 MHz. DMSO-d6): 6 = 1.44 (s. 9 H), 1.72 - 1.86 (m, 2 H). 1.91 - 2.02 (m, 2 H), 3.17
- 3.27 (m, I H), 3.48 (rd, 2 H), 3.92 (dt, 2 H), 3.97 (s, 3 H), 5.18 (s, 2 H), 7.10 (s, 1 H), 8.26 (d, 1
H), 8.57 (s, 1 H), 8.74 (s, 1 H), 9.41 (s, 1 H).
Intermediate 8-25
tert—Butyl (5—{[(6—bromopyridiny1)carbonyl]amino}—6—rnethoxy-2H—indazoly1)acetate
H30 CH3
| O
H >Z'CH3
4.20 g (12.10 mmol) of 6-bromo-N-(6—methoxy—1H—indazol—S—yl)pyridinecarboxamide
(Intermediate 14-8) were stirred with 3.57 ml (24.20 mmol) of tert-butyl bromoacetate in 50 ml of
tetrahydrofuran in the ce of 5.18 ml (24.20 mmol) of N,N-dicyclohexylmethylarnine at 70°C
for 2 h and at 60°C for 17 h. Another 3.57 ml (24.20 mmol) of tert-butyl bromoacetate and 5.18 ml
(24.20 mmol) ofNJWdicyclohexylmethylamine were added and the mixture was stirred at 70°C for
a further 24 h. The reaction mixture was cooled using an ice bath and the resulting solid was
filtered off with suction, washed with water and diethyl ether and dried under reduced pressure.
This gave 3.67 g (66% of theory) of the title compound.
S (Method Al): Rt = 1.33 min
MS (ESIpos): m/z = 461 (M+H)+
‘H—NMR (500 MHz, DMSO-d6): 5 = 1.44 (s, 9 H) 4.00 (s, 3 H) 5.20 (s, 2 H) 7.14 (s, 1 H) 7.90 -
8.10 (m, 2 H) 8.20 (dd, 1 H) 8.29 (3,1 H) 8.68 (s, 1 H) 10.31 (s, 1 H). -
Intermediate 9—1
[6-F1uoro-5 -( { [6-(trifluoromethyl)pyridiny1]carbony1 } amino)-2H—indazoly1] acetic acid
F oF \N/
381 mg (0.93 mmol) of ethyl [6-fluoro({[6—(trifluoromethyl)pyIidin—Z—yl]carbonyl}amino)—2H—
indazolyl]acetate nediate 8-1) were suspended in 9.2 ml of tetrahydrofuran and 0.45 ml of
ethanol, and a solution of 222 mg (9.3 mmol) of lithium hydroxide in 2.3 ml of water was then
added. The mixture was stirred at 25°C for 30 min and then ed to pH 2 with ice cooling
using 2N hydrochloric acid. 10 ml of water were added and the itate was filtered off with
suction. This gave 332 mg (93% of theory) of the title compoand.
UPLC~MS (Method A1): Rt = 1.04 min
MS (ESIpos): m/z = 383 (M+H)’
1H~NMR (300 MHz, DMSO-dé): 6 = 5.30 (s, 2H), 7.55 (d, 1H), 8.22 (m, 1H), 8.34 - 8.54 (m, 4H),
.26 (m, 1H), 13.30 (5 br, 1H).
Intermediate 9-2
(6—Flu0r0—5— { [(6—methy1pyridinyl)carbonyl]amino} —2H-indazol—2—yl)acetic acid
\ z
“IO z
oF \N/
Analogously to ediate 9—1, 316 mg (0.89 mmol) of ethyl (6-fluor0{[(6-methylpyridin—2-
yl)carbonyl]amino}-2H—indazol-2—yl)acetate (Intermediate 8-2) were reacted with 212 mg (8.87
mmol) of lithium hydroxide in 2.2 m1 of water, 8.8 m1 of tetrahydrofuran and 0.44 ml of l.
Work—up gave 302 mg of the title compound as a crude product.
UPLC-MS (Method A1): Rt = 0.99 min
MS (ESIpos): m/z = 329 (M+H)+
1H NMR (400 MHz, DMSO-d6) 5 = 2.62 (s, 3 H), 5.28 (s, 2 H), 7.44 - 7.63 (m, 2 H), 7.90 - 8.06
(m, 2 H), 8.45 (s, 1 H), 8.56 (d, 1 H), 10.38 (d, J=1 H).
PCT/EP20l4/077877
Intermediate 9-3
[6-Fluoro-5—( {[6 —(1 methyl—1 H-pyrazolyl)pyridinyl]carbonyl}amino)-2H—indazoly1]acetic
acid
Analogously to Intermediate 9—1. 364 mg (0.86 mmol) of ethyl ro( {[6-(1-methyl-1H-
pymzol—4-yl)pyridin—2-yl]carbonyl}amino)—2H-indazolyl)acetate (Intermediate 8—3) were
meted with 206 mg (8.6 mmol) of lithium hydroxide in 2.1 ml of water, 8.5 m] of teu'ahydmfiiran
and 0.42 ml of ethanol. p gave 302 mg (89% of theory) of the title compound as a crude
product-
UPLC-MS (Method A1): K = 0.87 min
MS (ESIpos): m/z = 395 (M+H)"
lH-NMR (300 MHz, DMSO-d6): 5 = 3.93 (s, 3H), 5.30 (s, 2H), 7.55 (d, 1H), 7.92 (t, 2H), 8.03 (t,
1H), 8.21 (3, 11-1), 8.39 (d, 1H), 8.46 (s, 1H), 8.52 (s, 1H), 10.51 (s, 1H), 13.26 (5 br, 1H).
Intermediate 9-4
[6-Fluor0-5 -( { [S-fluoro( 1 -methyl- 1 H—pyrazol—4—yl)pyridin—2—yl] carbonyl } amin0)—2H—indazol-2—
yl}acetic acid
Analogously to Intermediate 9—1, 326 mg (0.74 mmol) of ethyl [6-fluoro({[5-fluoro—6—(1—
methyl-lH—pyrazol—4-yl)pyridinyl]carbonyl}amino)-2H—indazol—2-y1]acetate (Intermediate 8-4)
were reacted with 177 mg (7.4 mmol) of lithium hydroxide in 1.8 m1 of water, 7.3 m1 of
tetrahydrofuran and 0.36 ml of ethanol. Work-up gave 305 mg (100% of theory) of the title
compound as a crude t.
UPLC-MS (Method AI): R = 0.95 min
MS (ESIpos): m/z = 413 (M+H)+
PCT/EP20l4/077877
IH~NMR (300 MHz, DMSO-d6): 6 = 3.96 (s, 3H), 5.30 (s, 2H), 7.54 (d, 1H), 7.98 (m, 21-1), 8.27
(m, 2H), 8.46 (s, 1H), 8.53 (s, 1H), 10.42 (s, 1H), 13.29 (3 br, 1H).
Intermediate 9-5
0r0( orpholin—4—yl)pyridiny1] carbonyl } amino)-2H—indazolyl] acetic acid
| n O
(\N /
N / )0“
0d O
F \N/N
Analogously to Intermediate 9-], 436 mg (1.02 mmol) of ethyl [6-fluoro—5—({[6—(morpholin—4-
yl)pytidinyl]carbonyl}amino)-2H-indazolyl]aeetate (Intermediate 8-5) were reacted with 244
mg (10.2 mmol) of lithium hydroxide in 2.5 ml of water, 10 ml of tenahydmfimm and 0.5 ml of
ethanol. Work—up gave 295 mg (72% of theory) of the title compound as a crude product.
UPLC-MS (Method Al): R. = 0.95 min
MS (ESIpos): m/z = 400 (M+H)'
1H—NMR (300 MHz, DMSO-d6): 6 = 3.59 (m, 4H), 3.75 (m, 4H), 5.26 (s, 2H), 7.15 (d, 1H), 7.42
—7.59 (m, 2H), 7.82 (t, 1H), 8.40 ~ 8.51 (m, 2H), 10.28 (m, 1H).
Intermediate 9-6
[6—(Benzyloxy)({[6-(triflu0romethyl)pyridiny1]carbonyl}amino)—2H—indazol—2—yl]acetic acid
l O
F \ n
F I)? f”N F O \N/ O
Analogously to Intermediate 9-1, 75 mg (0.15 mmol) of ethyl [6-(benzyloxy)—5-({[6—
(trifluoromethyl)pyridinyl]carbonyl}amino)—2H—indazol—2-yl]acetate (Intermediate 8-6) were
reacted with 18 mg (0.75 mmol) of m hydroxide in 271 pl of water and 2.5 ml of
tetrahydrofuran. Work-up gave 59 mg (83% of theory) of the title nd.
UPLC-MS (Method A1): Rt = 1.26 min
MS (ESIpos): m/z = 471 (M+H)+
1H NMR (400 MHz, DMSO-d6): 8 = 7.31 (s, 1 H), 7.33 - 7.47 (m, 3 H), 7.54 — 7.63 (m, 2 H), 8.12
- 8.22 (m, 1 H), 8.31 (s, 1 H), 8.39 (s, 1 H), 8.46 — 8.51 (m, 1 H), 8.80 (s, 1 H), 10.47 (s, 1 H).
Intermediate 9-7
[6-Isobutoxy—5-( {[6-(trifluoromethyl)pyiidin-2—yl] yl} amino)—2H-indazolyl]acetic acid
| O
O N
mew/l
Analogously to ediate 9-], 200 mg (0.43 mmol) of ethyl [6—isobutoxys5—({[6—
(trifluoromethyl)pyridin—2-yl]carbonyl}amino)-2H-indazol~2-yl]acctate (Intermediate 8-8) were
reacted with 51 mg (2.15 mmol) of lithium hydroxide in 776 p1 of water and 10 ml of
tetrahydrofilran. Work-up gave 64 mg (87% of theory) of the title compound.
UPLC-MS (Method A1): R, = 1.22 min
MS (ESIpos): m/z = 437 (M+H)+
'H NMR (300 MHz, DMSO-d6): 6 = 1.11 (s, 3 H), 1.13 (s, 3 H), 2.19 (dt, 1 H), 3.96 (d, 2 H), 5.21
(s, 2 H), 7.09 (s, 1 H), 8.22 (dd, 1 H), 8.31 (s, 1 H), 8.37 - 8.46 (m, 1 H), 8.46 - 8.52 (m, 1 H), 8.78
(s, l H), 10.58 (s, 1 H).
ediate 9-8
[6—(Cyclopropylmethoxy)—5-({[6-(trifluoromethyl)pyridin—2—yl]carbonyl}amino)~2H—indazol
yl]acetic acid
v40)“/ O
/ f“
F 0 ml“
0 N
Analogously to Intermediate 9-], 220 mg (0.48 mmol) of ethyl [6—(cyclopropylmethoxy)({[6-
(trifluoromethyl)pyridin~2-yl]carbonyl}amino)—2H-indazolyl]acetate (Intermediate 239) were
reacted with 57 mg (2.38 mmol) of lithium hydroxide in 857 ill of water and 10 ml of
tetrahydrofuran. Work-up gave 18] mg (88% of theory) of the title compound.
UPLC—MS (Method A1): R[ = 1.21 min
MS (ESIpos): m/z = 435 (M+H)+
1H NMR (400 MHz, DMSO-d6): 6 = 0.42 - 0.48 (m, 2 H), 0.63 - 0.69 (m, 2 H), 1.29 — 1.41 (m, 1
H), 4.03 (d, 2 H), 5.20 (s, 2 H), 7.07 (s, 1 H), 8.21 (dd, 1 H), 8.29 (s, 1 H), 8.37 - 8.44 (m, 1 H),
8.46 - 8.50 (m, 1 H), 8.76 (s, 1 H), 10.71 (s, 1 H).
Intermediate 9—9
[6-(Pyridin—2-ylmethoxy)—5—({[6-(trifluoromethyl)pyridinyl]carbony1}amino)—2H-indazol-2—
yl]acetic acid
YOY”/ O
/ 2°“
0 N
Analogously t0 Intermediate 9—1, 160 mg (0.32 mmol) of ethyl [6—(pyfidin—2—ylmethoxy)—5-({[6-
(trifluoromethyl)pyridinyl]carbonyl}amino)-2H-indazoly1]acetate (Intermediate 8-10) were
d with 38 mg (1.60 mmol) of lithium hydroxide in 577 p1 of water and 6.7 m1 of
tetrahydrofuran. p gave 129 mg (85% of theory) of the title compound.
UPLC—MS (Method A1): R = 1.02 min
MS (ESIpos): m/z = 472 (M+H)+
1H NMR (300 MHz, DMSO-d6): 5 = 5.02 (s, 2 H), 5.34 (s, 2 H), 7.30 (s, 1 H), 7.42 (dd, 1 H), 7.70
(d, 1 H), 7.80 - 7.92 (m, 1 H), 8.18 (d, 1 H), 8.27 (s, 1 H), 8.39 (t, 1 H), 8.44 - 8.53 (m, l H), 8.62
(d, 1 H), 8.80 (s, 1 H), 10.49 (s, 1 H).
Intermediate 9-10
[5—({[6-(1 l-1H-pyrazoly1)pyridin—2~yl]carb0r1yl} amino)-2H-indazol-2 -y1] acetic acid
Analogously to Intermediate 9—1, 1.2 g (3.11 mmol) of ethyl [5-({[6-(1-methyl-lH-pyrazol
y1)pyridiny1]carbonyl}amino)-2H-indazoly1]acetate (Intermediate 8-11) (crude product) were
initially charged in 10 m1 of ydrofuran, and 1.25 g (29.7 mmol) of lithium hydroxide
monohydrate in 3 ml of water and 2 m1 of ethanol were added. The mixture was stirred at 25°C for
h. Water was added, followed by 10% strength citric acid down to a pH of 4. The mixture was
ted three times with ethyl acetate, and saturated sodium chloride solution was added to the
aqueous phase. A solid precipitated from the aqueous phase; this solid was filtered off with suction,
washed with water and ethyl e and dried. This gave 850 mg (54% of theory) of the title
compound as a brown solid.
UPLC-MS (Method A1): R, = 0.82 min
MS (ESIpos): m/z = 37 (M+H)+.
§H-NMR (300 MHZ, DMSO—dé): 5 = 3.93 (s), 4.98 (s, 2H), 7.60 (s, 2H), 7.83 — 8.05 (m,
3H), 8.23 - 8.40 (m. 311). 8-67 (5. 1H), 10.42 (s. 1H).
Intermediate 9-11
([6—Chloro—5~({[6-(trifluoromethyl)pyridiny1]carbonyl}amino)-2H—indazol-Z-yl}acetic acid
2/ I
1.45 g (3.19 mmol) of teI't-butyl [6-chlor0—5—({[6—(trifluoromethyl)pyridin—2—yl]carbonyl}amino)-
azol—2—yl]acetate (Intermediate 8-14) were dissolved in 15 ml of dichloromethane, and 2.46
ml (31.9 mmol) of trifluoroacetic acid were added at 25°C. The solution was stirred at 25°C for 18
h. Water was added, the resulting precipitate was filtered off with suction, washed three times with
water and twice with diethyl ether and the solid was dried under reduced re. This gave 1.28 g
(98% of theory) of the title compound.
S (Method A1): Rt: 1.11 min
MS (ESIpos): m/z = 399 (M+H)+
lH—NMR (400 MHz, DMSO—d6): 8 = 5.31 (s, 2H), 7.93 (s, 1H), 8.22 (dd, 1H), 8.37 - 8.50 (rn, 3H),
8.64 (s, 1H), 10.52 (s, 1H), 13.28 (br. 5., 1H).
Intermediate 9-12
[6—Methoxy—5—( { [6—(trifluoromethyl)pyridin—2—yl] carbonyl} amino)-2H—indazoly1]acetic acid
11'” 2/ 0:I:
\ if
Analogously to Intermediate 9-11, 1.1 g (2.44 mmol) of tert-butyl [6-methoxy({[6-
(trifluoromethyl)pyridiny1]carbonyl}amino)-2H-indazoIyl]acetate (Intermediate 8-15) were
stirred with 3.76 ml (48.8 mmol) of trifluoroacetic acid in 20 ml of dichloromethane at 25°C for 24
h. Work—up gave 1.20 g (96% of theory) of the title nd.
UPLC-MS (Method A1): R[ = 1.09 min
MS (ESIpos): m/z = 395 (M+H)+
1H NMR (300 MHz. DMSO-dé): 8 = 3.99 (5. 3 H). 5.22 (s, 2 H), 7.14 (s, l H), 8.22 (dd. 1 H), 8.31
(s, 1 H), 8.42 (d, l H), 8.46 (s, l H), 8.71 (s, 1 H), 10.51 (s, l H).
Intermediate 9-13
[6—Ethoxy—5—( { [6—(trifluoromethyl)pyridin—2—yl]carbony1 } —2H-indazol—2—y1] acetic acid
F l H
F \ N
N / fopl
F O \ IN
O N
H C)
Analogously to Intermediate 9-1, 774 mg (1.77 mmol) of ethyl {[6-ethoxy({[6-
(trifluoromethyl)pyridinyl]carbonyl}amino)—2H-indazol-2—yl]acetate (Intermediate 8—12) were
initially charged in 1 m1 of ethanol and 25 ml of tetrahydrofuran, a solution of 745 mg (17.74
mmol) of lithium hydroxide monohydrate dissolved in 5 m1 of water was then added and the
mixture was stirred at 25°C for 3 days. Work-up gave 698 mg (94% of theory) of the title
nd.
UPLC-MS (Method AI): R = 1.13 min
MS (ESIpos): m/z = 409 (M+H)+
lH-NMR (300 MHZ, 6): 5 = 1.49 (t, 3H), 4.20 (q, 2H), 5.17 (s, 2H), 7.09 (s, 1H), 8.21 (dd,
1H), 8.28 (s, 1H), 8.36 - 8.48 (m, 2H), 8.71 (s, 1H), 10.73 (s, 1H).
Intermediate 9-14
[5-({[6-(Trifluoromethyl)pyridiny1]carbony1}amino)-2H-indazo1—2-yl]acetic acid
F \ ZI
N /
197 {ii (2.57 mmol) of tfifluoroacetic acid were added to a mixture of 216 mg (2.02 mmol) of text-
butyl [5-({ [6-(trifluoromethyl)pyridinyl]carbonyl}amino)—2H—indazol—2—yl]acetate (Intermediate
8-16) in 3 ml of dichloromethane. The mixture was stifled at 25°C for 3 days, another 197 iii (2.57
mmol) of trifluoroacetic acid were added and the mixture was stirred at 25°C. Water was added to
the on mixture. The mixture was stirred for 10 min and the solid was filtered off with suction,
washed with water and dried. This gave 142 mg (76% of theory) of the title nd-
IH—NMR (300 MHz. DMSO—db): 6 = 5.25 (s. 2H). 7.52 - 7.62 (m, 2H). 8.14 (dd. IR), 826 - 8.41
(m, 4H), 10.37 (s, 1H).
Intermediate 9-15
3—[5-({[6-(Trifluormethyl)pyridin—2-yl]carbonyl}amino)-2H-indazolyl]propanoic acid
F O \/
Analogously to Intermediate SM, 285 mg (0.70 mmol) of ethyl 3-[5—({[6—(triflu0romethyl)pyridin—
2—yl]carbonyl}amino)—2ll-indazol—2-y1]propanoate (Intermediate 8-13) were reacted with 168 mg
(7.0 mmol) of lithium hydroxide. This gave 253 mg (95% of theory) of the title compound.
UPLC-MS d A1): R1 = 0.99 min
MS (ESIpos): m/z = 379 (M+H)+.
Intermediate 9-16
[6-Isopr0poxy( { ifluoromethyl)pyn'din-2—yl]carbonyl} amino)—2H-indazoly1]acetic acid
H O
F N/ N
/ )—OH
F N
F O /
O \N
H30 CH3
Analogously to Intermediate 9-1, 490 mg (1.1 mmol) of ethyl [6-isopropoxy({{6-
(tn'fluoromethyl)pyridin—2-y1]carbonyl}amin0)—2H—indazol-2—y1]acetate (Intermediate 8-17) were
reacted with 260 mg (11 mmol) of lithium hydroxide. This gave 367 mg (80% of theory) of the title
compound.
UPLC-MS (Method A1): Rt = 1.17 min
MS (ESIpos): mfz = 423 (M+H)+
lH-NMR (300 MHz, DMSO-dé): 6 = 1.45 (d, 6H), 4.80 — 4.92 (m. 1H). 5.21 (s. 2H). 7.17 (s. 1H).
8.19 — 8.25 (m, 1H), 8.30 (s, 1H), 8.36 — 8.49 (m, 2H), 8.74 (s, 1H), 10.75 (s, 1H), 13.21 (s, 1H).
Intermediate 9—17
(6-Isopropoxy{[(6-methy1pyridin—2—y1)carbony1]amino}-2H—indazolyl)acetic acid
\ 21
I 0 Z
(,0 2k?0I
O \l
H30 CH3
Analogously to Intermediate 9—1, 370 mg (0.93 mmol) of ethyl (6-isopropoxy{[(6-
methylpyridiny1)carb0nyl]amin0}-2H-indazol—2—yl)acetate (Intermediate 8—18) were reacted
with 223 mg (9.33 mmol) of lithium hydroxide. This gave 280 mg (81% of ) of the title
compound.
UPLC-MS d A1): Rt = 1.11 min
MS (ESIpos): m/z : 369 (M+H)+
1H—NMR (300 MHZ, DMSO-d6): 5 = 1.45 (d, 6H), 2.62 (s, 3H), 4.78 — 4.89 (m, 1H), 5.19 (s, 2H),
7.14 (s, 1H), 7.52 — 7.60 (m, 11-1), 7.93 -8.02 (m, 2H), 8.27 (s, 1H), 8.72 (s, 1H), 10.99 (s, 1H),
13.19 (sbr, 1H).
Intermediate 9-18
nzyloxy) { [(6-methy1pyridiny1)carbony1] amino } -2H-indazoly1] acetic acid
\ N
H30 N / )0”
O \ /N
O N
Analogously to Intermediate 9-14, 100 mg (0.21 mmol) of tert-butyl [6-(benzyloxy)—5—{[(6—
methy1pyridinyl)carbonyl]amino}-2H-indazolyl]acetate mediate 8-19) were dissolved in
6.7 m1 of romethane and stirred with 326 1.11 (4.23 mmol) of roacetic acid at 25°C for
24 h. Work-up gave 67 mg (76% of theory) of the title compound.
UPLC-MS (Method AI): R. = 1.20 min
MS (ESIpos): m/z = 417 (M+H)'
IH NMR (400 MHz. DMSO-dé): 6 = 2.43 (s. 3 H), 512 (s, 2 H), 5.31 (s, 2 H). 7.29 (s. l H). 7.42
(d, 1 H), 7.44 - 7.54011, 3 H), 7.65 (d, 2 H), 7.91 - 8.02 (m, 2 H), 8.30 (s, l H), 8.78 (s, l H), 10.87
(s, 1 H).
Intermediate 9—19
(6—Methoxy {[(6-methylpyridin—2—yl)carbonyl]amino}—2H—indazol—2—yl)acetic acid
:I H 0
H30 N flfm
00 N
Analogously t0 Intermediate 9-1, 2.28 g (3.92 mmol, 74%) of benzyl hoxy—5—{[(6-
methylpyridin—2—yl)carbony1]amino}-2H—indazolyl)acetate (Intermediate 8-23) were dissolved in
m1 of tetrahydrofiiran and 3.0 m1 of methanol, a solution of 1.65 g (39.2 mmol) of lithium
hydroxide monohydrate in 3.0 ml of water was then added. The mixture was diluted with water and
ed to pH 4 using 10% strength citric acid. The precipitated solid was filtered off, washed
three times with water and three times with diethyl ether and dried under reduced pressure. This
gave 243 g of the title compound as a crude product.
UPLC—MS (Method A1): Rt = 1.00 min
MS (ESIpos): m/z = 341 (M+H)+.
Intermediate 9-20
h0xy-5—({[2-(tetrahydr0-2H-pyranyl)-1,3-0xazoly1]carbonyl}amino)-2H-indazol
yl]acetic acid
Nijm fmNo o
Analogously to Intermediate 9-11, 325 mg (0.71 mmol) of tett-butyl [6-methoxy-S-({[2-
(tetrahydro—2H-pyran—4-yl)-l ,3-0xazol-4—yl]carbonyl } amino)—2H—indazol—2—yl]acetate
(Intermediate 8-24) were dissolved in 5 ml of dichloromethane and stirred with 549 pl (7.12 mmol)
of trifluoroacetic acid at 25°C for 21 h. Another 275 111 (3.56 mmol) of roacetic acid were
added and the mixture was stirred at 25°C for a further 70 h. Water was added, the resulting
precipitate was filtered off with suction, washed three times with water and three times with diethyl
ether and the solid was dried under reduced re. This gave 3| 3 mg of the title compound as a
crude product.
UPLC-MS (Method A1): R[ = 0.91 min
MS (ESIpos): mfz = 401 (M+H)+
‘H-NMR (300 MHz, DMSO—d6): 5 = 1.67 — 1.90 (m, 2 H), 1.98 (d, 2 H), 3.22 (ddd, 1 H), 3.40 -
3.54 (111,2 H), 3.87 — 4.01 (m, 6 H), 5.20 (s, 2 H), 7.10 (s, 1 H), 8.27 (s, 1 H), 8.56 (s, 1 H), 8.75 (s,
1 H), 9.42 (s, 1 H).
Intermediate 9-21
(5- { [(6-Bromopyridinyl)carbony1]amino} —6—methoxy—2H-indazol—2-yl)acetic acid
I : O
mN OH O
O N
Analogously to Intermediate 9-11, 3.50 g (7.59 mmol) of tert-hutyl (5—{[(6-bromopyridin-2—
yl)carbonyl]amino}—6—methoxy—2H-indazolyl)acetate (Intermediate 8—25) were dissolved in 100
ml of dichloromethane and stirred with 11.7 ml (15.54 mmol) of trifluoroacetic acid at 25°C for 24
h. The reaction mixture was carefully added to saturated sodium bicarbonate solution and d
briefly, and the resulting precipitate was filtered off with suction and dried at 50°C in a vacuum
drying cabinet. This gave 3.10 g of the title nd as a crude product.
UPLC-MS (Method A1): R1: 1.02 min
MS (ESIpos): m/z = 405 (M+H)'
‘H-NMR (300 MHz, é): 8 = 4.00 (s, 3 H) 5.21 (s, 2 H) 7.13 (s, 1 H) 7.95 (dd, 1 H) 8.04 (t,
1 H) 8.20 (dd, 1 H) 8.28 — 8.31 (m, 1 H) 8.68 (s, 1 H) 10.30 (s, 1 H).
Intermediate 9~22
3—[6—Mcthoxy-5 -( { [6-(trifluoromethyl)pyridin-2—yl] carbonyl} amino)-2H—indazoly1]
methylpropanoic acid
l H o
F / N
N /
F N OH
F o \ '
o N CH3
Analogously to Intermediate 4-1, 37 mg (0.09 mmol) of methyl 3-[6-methoxy—5-({[6-
(trifluoromethyl)pyridinyl]carbonyl}amino)-2H—indazol—2—yl] —2—methylpropanoate (Intermediate
8-20) were dissolved in 2 ml of tetrahydrofuran and 0.1 m1 of methanol, :1 solution of 36 mg (0.85
mmol) of lithium hydroxide monohydrate in 0.1 m1 of water was then added and the mixture was
stirred at 25°C for 23.5 h. The mixture was diluted with water, acidified to pH 4 using 10%
strength citric acid and ted three times with ethyl e. The combined organic phases were
washed with saturated sodium chloride solution, filtered through a hydrophobic filter, concentrated
and dried under reduced pressure. This gave 34 mg (94% of ) of the title compound.
UPLC-MS (Method AI): R = 1.13 min
MS (ESIpos): rn/z = 423 CM+H)+
'H—NMR (300 MHz, DMSO-d6): 5 = 1.04 (d, 3 H), 3.00 - 3.13 (m, 2 H), 3.98 (s, 3 H), 4.37 (dd, 1
H), 4.59 (dd, 1 H), 7.15 (s, 1 H), 8.22 (dd, 1 H), 8.29 (s, 1 H), 8.35 - 8.44 (In, 1 H), 8.44 - 8.49 (In,
1 H), 8.68 (s, 1 H), 10.49 (s, 1 H).
Intermediate 9—23
3-[6-Methoxy—5-( { [6-(trifluoromethyl)pyn'dinyl]carb0ny1 } -2H-indazolyl] ~2—
methylpropanoic acid
| H
H3C / N
N /
CHOH 0 fl”\I
3 9 N ”-0“
CH O
Analogously to ediate 4-1, 206 mg (0.43 mmol) of benzyl [5-({[6-(2-hydroxypropan
yl)pyridin—2-yl]carbonyl}amino)methoxy-2H-indazolyl]acetate (Intermediate 8-22) were
suspended in 10 ml of tetrahydrofuran and 1.0 ml of methanol, 3 solution of 182 mg (4.33 mmol)
of lithium hydroxide drate in 1.5 ml of water was then added and the mixture was stirred at
°C for 24 h. The mixture was diluted with water, acidified to pH 4 using 10% strength citric acid
and concentrated. The precipitated solid was filtered off, washed once with water and three times
with diethyl ether and dried under reduced pressure. This gave 155 mg (93% of ) of the title
compound.
UPLC-MS d A1): Rt = 1.20 min
MS (ESIpos): m/z = 421 (M+H)+
IH NMR (400 MHZ, DMSO-dé): 5 = 1.57 (s, 6 H), 3.99 (s, 3 H), 5.20 (s, 2 H), 5.47 (s, 1 H), 7.12
(s. l H). 7.93 (dd. J=7.5, 1.3 Hz, 1 H), 7.98 - 8.1] (m, 2 H), 3.28 (s, 1 H), 8.68 (s, I H), 10.93 (s, 1
Intermediate 9-24
[5—( { [6—(Difluoromethyl)pyridin—2~yl]carbony1}amino)—6-methoxy-ZH-indazol-Z-yl]acetic acid
| H
F / N
F O 1:)?N\N VOH
CH3 0
Analogously to Intermediate 4—1, 613 mg of benzyl [5—({[6-(difluoromethyl)pyridiii—2—
yl]carbonyl}amino)meth0xy~2H—indazol-2—yl]acetate (Intermediate 8—21) were stirred at room
temperature with 469 mg of lithium hydroxide monohydrate in 3 ml of water, 15 m1 of THF and 1
ml ofmethanol for 3 h. This gave, after analogous work—up, 378 mg of the title compound.
UPLC-MS (Method A1): Rt = 0.98 min, mass found (UV Detector TIC) 376.00.
Intermediate 10 and ediate 11
tert-Butyl 6-bromo—5-[(tert—butoxycarbonyl)amino}-lH—indazole—l-carboxylate tert-butyl 6—br0mo-
-{(tert—butoxycarbonyl)amino]—2H—indazol—2—carboxylate
H30 0 N
HSCX Y \N H
CH3 0 / H3C O N
>l/ \n/ 0
Br N /
27.5 g (126.1 mmol) of di-tert-butyl dicarbonate were dissolved in 53.5 ml of tetrahydrofuran and
cooled to 0°C. After addition of 5.35 g (25.2 mmol) of 6-bromo-lH-indazoIe-S-amine (CAS No:
1360928-41—1) at 0°C, the mixture was then d at 80°C for 24 h. The reaction mixture was
concentrated, dichloromethaue was added and the reaction mixture was washed with 0.5 M
hydrochloric acid and saturated soditun de solution, dried over sodium te and, during
concentxation. adsorbed on lsolute® HM-N (Biotage). The Isolate was applied to a e SNAP
cartridge (340 g; KP-Sil) pre—equilibrated with hexane and chromatography was carried out using
the lsolemi flash purification system (Biotage) (mobile phase: hexandethyl acetate; gradient:
isocratic 80:20 (9 CV)). This gave 7.07 g (68% of ) of the regioisomeric product e.
(Ratio: l—isomer/Z—isomer: 85%/15%)
UPLC-MS (Method A2): R1: 1.48 min
MS (ESIncg): m/z = 410 (M(79Br)—H)7
Intermediate 12-1
tert—Butyl 5—amino—6-chloro-1H-indazolecarboxy1ate
Cl N
HaC 7) “CH3
2.1 m1 (11.8 mmol) of NJV—diisopropylethylamine and 2.34 g (10.7 mmol) of di-tert-butyl
dicarbonate were added to 1.80 g (10.7 mmol) of 6—chloro—1H-indazole—S—amine (CAS No.
2216810) in 18 m1 of tetrahydrofuran, and the mixture was stirred at 25°C for 18 h. The
e was concentrated and the residue was taken up in ethyl acetate and, during concentration,
adsorbed on Isolute. The Isolute was applied to a Biotage SNAP cartridge (100 g; KP—Sil) pre-
equilibrated with hexane and chromatography was carried out using the Isolera® flash purification
system (Biotage) (mobile phase: /ethyl acetate; flow rate: 50 ml/min; gradient: isocratic
100:0 (5 min), 100:0->75r25 (20 min), isocratic 75:25 (5min), 75:25->50:50 (15 min), isocratic
50:50 (5 min), 50:50->0:100 (15 min». The combined product fractions were concentrated and
dried under d pressure. This gave 1.23 g (43% of theory) of the title compound.
UPLC-MS d A1): R = 1.16 min
MS (ESIpos): m/z = 268 (M+H)+
Intermediate 12-2
tert-Butyl 5-arninochloro-2H-indazole-Z-carboxylate
HZN1:04O
C] N O
H3C_€CH3
7.5 g of Mhlom-lli—indazolc-S-amine (CAS No. 221681-750) were converted analogously to the
preparation of Intermediate l2-1. Purification by column—chromatographic purification on silica gel
(hexane/ethyl acetate) gave 1.0 g of the title compound.
'H—NMR (500 MHz, DMSO-dé): 5 = 1.62 (5, 9H), 5.33 (s, 2H), 6.79 (s, 1H), 7.74 (s, 1H), 8.50 (d,
1H).
ediate 13
tett—Butyl 6-Ch101‘0—5-( { [6-(trifluoromethyl)pyridin—2—yl]carbonyl}amino)—1H—indazole- 1 —
carboxylate
F \N N
F o /N
CI N
1"3C37\\CH3
H30
Analogously to Intermediate 5-1, 1.23 g (4.59 mmol) of utyl 5-amino-6—chlor0-1H-indazole-
1-carboxylate (Intermediate 12—1) in 20 ml of MN—dimethylformamide were stirred with 1.14 g
(5.97 mmol) of fluoromethyl)pyridinecarb0xy1ic acid at 25°C for 72 h. Water was added,
the mixture was stirred for 15 min and the solid was filtered off with suction, washed three times
with water and dried under reduced pressure. This gave 202 g (98% of theory) of the title
compound.
UPLC-MS (Method A1): R( = 1.57 min
MS (ESIpos): m/z = 441 (M+H)+
1H—NMR (300 MHz, DMSO-d6): 6 = 1.65 (s, 9H), 8.19 — 8.27 (m, 2H), 8.37 — 8.53 (m, 3H), 8.75 (s,
1H), 10.59 (s, 1H).
Intermediate 14—1
N-(6-Chloro-1H-indazol-S-yl)(trifluoromethyl)pyridine-2 —carboxamide
I H
F \N N
F 0 IN
ously to Intermediate 6-1, 6.7 ml (8.73 mmol) of trifluoroacetic acid were added to 3.85 g
(8.73 mmol) of tert-butyl 6-ch10ro-5—({[6-(trifluoromethyl)py1idin—2—yl]carbonyl}amino)-1H-
indazole-l-carboxylate (Intermediate 13) in 40 m1 of dichloromethane, and the mixture was stirred
at 25°C for 18 h. Work-up gave 2.98 g (100% of theory) of the title nd.
UPLC-MS d A1): R‘ = 1.18 min
MS (ESIpos): m/z = 341 (M+H)+
1H—NMR (300 MHz, 6): 6 = 7.83 (s, 1H), 8.14 — 8.27 (m, 2H), 8.36 - 8.49 (m, 2H), 8.60 (s,
1H), 1050 (br. s., 1H), 13.25 (br. s., 1H).
Intermediate 14-2
N-(6—Methoxy—1H-indazol—S~y1)—6—(trifluoromethyl)pyridine—2—carb0xamide
F \ n
O \/N
Cl) N
3.84 g (23.5 mmol) of 6-methoxy—lH-indazole-S-amine (CAS No.: 7492238) and 4.95 g (25.9
mmol) of 6-(trifluoromethy1)pyridine—2—earboxylic acid were dissolved in 150 m1 of
tetrahydrofuran, and mit 3.60 g (23.5 mmol) of 1-hydr0xy—1H-benzotriazole hydrate, 9.02 g (47.1
mmol) of 1-(3-dimethy1aminopropy1)—3-ethylearb0diimide hydrochloride and 9.84 ml (70.6 mmol)
of triethylamine were added at 25°C. The solution was stirred at 25°C for 24 h. After concentration
of the solution, the residue was taken up in ethyl acetate, water was added and the aqueous phase
was extracted three times with ethyl acetate. The combined organic phases were washed with
saturated sodium chloride solution and dried over sodium sulphate and, after filtration, the solution
was concentrated. The residue was taken up in romethane, [solute® HM—N (Biotage) was
added and during concentration the residue was ed on e. The Isolute was d to a
e SNAP cartridge (340 g; KP—Sil) pre-equilibrated with hexane and chromatography was
earned out using the Isolera® flash purification system (Biotage) (mobile phase: hexane/ethyl
acetate; gradient 100:0->50:50 (9 CV), isocratic 50:50 (4 CV)). The combined product fractions
were concentrated and the beige solid was dried under reduced pressure. This gave 3.75 g (47% of
theory) of the title compound.
UPLC-MS (Method A1):K = 1.12 min
MS (ESIpos): m/z = 337 (M+H)‘
'H-NMR (400 MHz, DMSO-do): 5 = 4.01 (s, 3 H). 7.13 (s, l H), 8.02 (s, 1 H), 8.21 (dd, 1 H), 8.40
(I, 1 H), 8.47 (d, 1 H), 8.74 (s, 1 H), 10.42 (s, 1 H), 12.91 (s, 1 H).
Intermediate 14-3
N—(6—Ethoxy—1 H—indazol-S -yl)(trifluoromethyl)pyridine—2-carboxarnide
F I H
F \N N
F o \/N
j) N
Analogously to Intermediate 5-1, 1.00 g (5.64 mmol) of 6—ethoxy—l H—indazole—S—amine and 1.29 g
(6.77 mmol) of 6-(trifluoromethy1)pyridine—2-carboxylic acid were reacted in 50 ml of
tetrahydrofuran at room temperature for 18 h. Work-up and purification by column
chromatography using the a® flash purification system ge) (SNAP cartridge (100 g;
KP-Sil), mobile phase: hexane/ethyl acetate; gradient: isocratic 100:0 (1 CV), 100:0->50:50 (10
CV), isocratic 50:50 (4.7 CV), 50:50->3:97 (9.4 CV)) gave 1.30 g (64% of theory) of the title
compound.
UPLC-MS (Method A1): Rt = 1.18 min
MS (ESIpos): m/z = 351 (M+H)'
1H—NMR (500 MHz, DMSO-d6): 5 = 1.51 (t, 3H), 4.24 (q, 2H), 7.10 (s, 1H), 8.00 (s, 1H), 8.20 (dd,
1H), 8.39 - 8.43 (m, 1H), 8.46 - 8.48 (m, 111), 8.79 (s, 1H), 10.67 (s, 1H), 12.87 (s, 1H).
Intermediate 14-4
N—( 1 H-Indazol-S-y1)(trifluoromethyl)pyridinecarboxamide
F o /
Analogously to Intermediate 5—1, 4.43 g (33.3 mmol) of lH-indazole-S-amine (CAS No.: 19335—
11—6) were reacted analogously with 7.00 g (36.6 mmol) of 6~(trifluoromethyl)pyridine—2-
carboxylic acid. This gave, after ation by column chromatography on silica gel (hexane/ethyl
acetate), 7.8 g (73% of theory) of the title nd.
'H-NMR (300 MHz, DMSO-dé): 6 = 7.51 (d, 1H), 7.68 (dd. 1H), 8.05 (s. 1H). 8.14 (dd, 1H), 8.25 -
8.41 (m, 3H). 10.42 (s, 1H), 13.04 (hr. 5., 1H).
Intermediate 14-5
N—[6—(Benzyloxy)—l H—indazol—S-y1]methylpyridine-2carboxamide
Analogously t0 Intermediate 14—2, 1.00 g (4.18 mmol) of 6-(benzyloxy)—lH-indazole—S—amine
(Intermediate 1-3) and 688 mg (5.02 mmol) of 6-methylpyridinecarboxylic acid were dissolved
in 50 ml of tetrahydrofuran and stirred with 640 mg (4.18 mmol) of 1-hydroxy-1H-benzotriazole
hydrate, 1.60 g (8.36 mmol) of 1-(3-dimethylaminopropyl)—3—ethylcarb0dii1nide hydrochloride and
1.75 ml (12.54 mmol) of triethylamin at 25°C for 24 h. After concentration of the solution, water
was added to the precipitate formed and the precipitate was d off with n, washed with
water and diethyl ether and dried under reduced re. This gave 1.13 g (76% of theory) of the
title compound.
UPLC-MS (Method A1): K = 1.26 min
MS (ESIpos): m/z = 359 (Ml—H)+
1H NMR (300 MHz, DMSO-d6): 5 = 2.43 (s, 3 H), 5.34 (s, 2 H), 7.29 (s, l H), 7.35 — 7.57 (In, 4 H),
7.65 (d, 2 H), 7.86 - 8.07 (m, 3 H), 8.84 (s, 1 H), 10.82 (s, 1 H), 12.95 (s, 1 H).
Intermediate 14-6
N—(6-Methoxy—1H-indazo1y1)-6—methylpyridinecarboxamide
| H
\N N
HC \
9 N
Analogously to ediate 14-2, 5.00 g (30.64 mmol) of 6-methoxy-lH-indazole-S-amine (CAS
No. 7492238) and 4.62 g (33.70 mmol) of 6-methylpyridine—Zearboxylic acid were dissolved
in 100 ml of tetrahydrofiiran and stirred with 4.69 g (30.64 mmol) of l-hydroxy-lH-benzotriazole
hydrate. 11.74 g (61.28 mmol) of l-(3-dimethylaminopropyl)~3ethylcarbodiimide hydrochloride
and 21.35 ml (153.2 mmol) of triethylamine at 25°C for 20 h. Water was added1 and the reaction
mixture was concentrated. The resulting precipitate was filtered off with suction. washed three
times with water and three times with diethyl ether and dried in a drying cabinet. This gave 7.89 g
(65% oftheory) of the title compound.
UPLC-MS (Method Al): Rt = 0.49 min
MS (ESIpos): m/z = 283 (M+H)+,
Intermediate 14-7
N-(6-Methoxy—1H—indazol—S—yl)—2-(tetrahydro-2H—pyranyl)-1,3-oxazolecarboxamide
Analogously to Intermediate 14—2, 782 mg (4.80 mmol) of 6«rnethoxy-1H-indazole-S-amine (CAS
No. 8) and 1.04 g (5.27 mmol) of 2-(tetrahydro-ZH-pyrany1)—1,3-oxazole
carboxylic acid (CAS No. 955401-82—8) were dissolved in 15 m1 of ydrofilran and d
with 734 mg (4.80 mmol) of oxy—1H—benzotriazole hydrate, 1.84 g (9.59 mmol) of 1-(3-
dimethylaminopropyl)—3—ethylcarbodiimide hydrochloride and 3.34 ml (24.0 mmol) of
triethylamine at 25°C for 26 h. Water was added, and the reaction mixture was concentrated. The
resulting precipitate was filtered off with suction, washed three times with water and three times
with diethyl ether and dried in a drying cabinet. This gave 1.19 g (37% of theory) of the title
compound.
S (Method A1): Rt = 0.94 min
2014/077877
MS (ESlpos): m/z = 343 (M+II)'I
Intermediate 14—8
o-N-(6-methoxy-lH-indazol-S -yl)pyridinecarboxamide
| H
N/ N
Br \
(.3 N
2.0 g (12.26 mmol) of 6-methoxy—1H—indazole-S—amine (CAS No. 7492238) were dissolved in
50 ml of tetrahydrofuran. 4.72 g (14.71 mmol) of 0-(benzotriazol-I-yl)-N,N,N’,N'-
teuamethyluronium telrafluoroborale and 2.56 mi (14.7! mmol) of N,N-diisopropylethylamine
were added and the mixture was stirred at 25°C for 30 minutes. 2.56 ml (14.7] mmol) of 6—
bromopyridine~2—carboxylic acid (CAS No. 21 1904) were added. and the e was stirred at
°C for a further 24 h. The reaction mixture was concentrated and the residue was added to 400
ml of water. The resulting precipitate was filtered off with suction, washed twice with water and
twice with diethyl ether and dried at 50°C in a vacuum drying cabinet for 4 h. This gave 4.18 g
(98% of theory) of the title compound.
UPLC-MS d A1): R = 0.93 min
MS (ESIpos): m/z = 347 (M+H)’
lH NMR (300 MHZ, DMSO-d6): 5 = 4.02 (s, 3 H) 7.13 (s, l H) 7.89 - 8.10 (In, 3 H) 8.20 (dd, 1 H)
8.71 (s, 1 H) 10.22 (s, 1 H) 12.90 (br. 5., 1 H).
ediate 14—9
Methyl 5—( {[6—(trifluoromethyl)pyridin-2—yl] carbonyl} amino)— 1 H-indazolecarboxylate
F |
/ o
F HN
H30’ fl
4.5 g (23.53 mmol) of methyl 5-amino-1H-indazolecarboxylate (Intermediate 1—6) were
dissolved in 45 ml of tetrahydrofuran, 9.07 g (28.24 mmol) of O—(benzotriazol-l-yl)-N,N,N',N'-
tetramethyluronium tetrafluoroborate and 4.92 ml (28.24 mmol) of N,N-diisopropylethylamine
were added and the mixture was stirred at 25°C for 30 minutes. 4.95 g (25.89 mmol) of 6-
(trifluoromethyl)pyridinecarboxy1ic acid (CAS No. 211904) were added, and the mixture
was stirred at 25°C for a further 24 h. The reaction mixture was d off with suction through a
membrane filter, washed with tetrahydrofuran and water and dried at 50°C in a vacuum drying
cabinet for 24 h. The filtrate was concentrated with acetonitrile and the ing prccipitate was
d off with suction, washed and dried. This gave 8.60 g (84% of theory) of the title compound.
UPLC—MS d A1): R = 1.21 min
MS (ESIpos): m/z = 365 (M+H)+
lH NMR (300 MHz, DMSO-d6): 6 = 3.97 (s, 3 H), 8.13 — 8.27 (m, 2 H), 8.30 (s, 1 H), 8.33 - 8.45
(m, 1 H), 8.45 - 8.51 (m, 1 H), 9.15 (s, 1 H), 12.57 (s, 1 H), 13.44 (s, 1 H).
Intermediate 14-10
Methyl 5- {[(6-methy1pyridinyl)carbonyl]amino}-1 H—indazole—6—carboxylate
/ 0
H30 N
H3C’O fl
500 mg (2.62 mmol) of methyl S-amino-lH—indazole-6—carboxylate (Intermediate 1—6) were
ved in 5 ml of tetrahydrofuran, 1.01 g (3.14 mmol) of O—(benzotriazol—l—yl)—N,N,N’,N'—
tetramethyluronium tetrafluoroborate and 547 pl (3.14 mmol) of N,N‘-diisopropylethylamine were
added and the mixture was stirred at 25°C for 30 minutes. 395 mg (2.88 mmol) of 6-
methylpyridinecarboxylic acid (CAS No. 21190-87—4) were added, and the mixture was stirred
at 25°C for a further 8 h. The reaction mixture was added to water and stirred vigorously for 10
minutes and the precipitate was filtered off with suction through a nylon filter. The precipitate was
washed twice with water and twice with diethyl ether. The solid was dried in a vacuum drying
cabinet at 50°C for 3 h. This gave 790 mg (92% of theory) of the title compound.
UPLC-MS (Method A1): Rt = 1.05 min
MS s): m/z = 31 1 (M+H)+
1H NMR (300 MHz, DMSO-d6): 5 = 2.65 (s, 3 H), 4.00 (s, 3 H), 7.55 (dd, 1 H), 7.91 — 7.99 (m, 1
H), 7.99 - 8.04 (m, 1 H), 8.23 (s, 1 H), 8.29 (s, 1 H), 9.18 (s, 1 H), 12.65 (s, 1 H), 13.41 (s, 1 H).
Intermediate 14-11
N—[6—(2-Hydroxypropan—2—yl)—lH—indazol—S -yl]-6—(trifluoromethyl)pyridine-Z-carboxamide
F \ O
F HN
H30 /N
HO fl
6.9 ml (5 equiv.) of a 3M methylmagnesium bromide solution in diethyl ether were added
carefullyto an ice-cold solution of 1.50 g (4.12 mmol) of methyl S—({[6—(trifluoromethy1)pyridin—2-
yl]carbony1}amino)-lH-indazole-é-carboxylate (Intermediate 14-9) in 20 ml of THF. The mixture
was stirred with ice bath cooling for 1 h and at room temperature for 19.5 h. Another 2 equiv. of
methylmagnesium bromide solution were added and the e was stirred at room temperature
for a r 24 h. Saturated aqueous ammonium chloride on was added and the mixture was
stirred and extracted three times with ethyl acetate. The combined organic phases were washed
with sodium chloride on. filtered through a hydrophobic filter and concentrated. The residue
was purified by column tography on silica gel (hexane/ethyl acetate gradient). This gave
763 mg (45% of theory) of the title compound.
]H—NMR (400 MHz, DMSO-dfi): 8 [ppm]= 1.63 (s, 6H), 5.99 (s, 1H), 7.49 (s, 1H), 8.06 (s, 1H),
814 ~ 8.19 (m, 1H), 8.37 (t, 11-1), 8.46 (d, 1H), 8.78 (5, 11-1), 12.32 (s, 1H), 12.97 (s, 1H).
Intermediate 16-1
6—Bromo—N—isobuty1pyridine—2—amine
H30WAN /
N Br
In a pressure reactor, 1.0 g of 2,6-dibromopyridine and 340 mg of 2-methy1propane—1—amine and
1.43 ml of 2,2,6,6-tetramethylpiperidine were stirred at 190°C for 16 h. The mixture was poured
into saturated sodium bicarbonate solution, extracted with dichloromethane, washed with saturated
sodium chloride solution, dried over sodium sulphate and trated. The residue was purified
by column chromatography on silica gel. This gave 920 mg of the title compound.
1H—NMR (300 MHz, CHLOROFORM-d): 8 = [ppm]= 1.00 (d, 6H), 1.81 — 1.98 (m, 1H), 3.05 (t,
2H), 4.76 (br. s., 1H), 6.29 (d, 1H), 6.72 (d, 1H), 7.22 — 7.35 (m, 2H).
Intermediate 17-1
Methyl 6—(1—hydroxyethy1)pyridine-2—carboxy1ate
H C / O.‘
N CH
OH O
2.00 g of l —(6—bromopyridinyl)ethanol (Telfer, Shane G.; Kuroda, Reiko, Chemistry A European
Journal, 2005, 11, 57 - 68) were suspended in 20 ml of methanol and 30 ml of dimethyl
sulphoxide. 265 mg of 1,3.bis(diphcnylphoshino)propane, 140 mg adium(11) acetate and 3.2
ml of triethylamine were added, the mixture was flushed three times with carbon de and
stirred in a carbon monoxide atmosphere (12 bar 0.5 h, then at 16 bar overnight). Water was added,
the mixture was extracted with ethyl acetate and the extract was concentrated. This gave 1.7 g of
methyl 6-(1-hydroxyethyl)pyridine-2~carboxy1ate as an oil (crude product).
1H—NMR (400 MHz, FORM-d): 8 = 1.57 (d. 3H). 4.02 (s. 3H). 5.03 (q. 1H). 7.56 (d, 1H),
7.88 (t, 1H), 8.05 (d, 1H).
Intermediate 17-2
Methyl 6-(2,2,2-tn'fluoro- l -hydroxyethyl)pyridine-Z-carboxyl ate
HO / 0‘
N CH3
F F
1.04 g (4.06 mmol) of 1-(6-brornopyridiny1)-2,2,2-trifluoroethanol (CAS 10938807) were
reacted analogously to Intermediate 17-1 in a carbon de atmosphere. Afier analogous work-
up, the crude product was d by preparative HPLC. This gave 696 mg of the title compound.
1H-NMR (300 MHz, DMSO—dfi): 5 = 3.89 (s, 3H), 5.15 — 5.28 (m, 1H), 7.18 — 7.25 (m, 1H), 7.86
(dd, 1H), 8.05 - 8.14 (m, 2H).
Intermediate 17—3
Methyl 6-(2—hydroxypropany1)py1idinecarboxylate
H30 I
H30 / o\
N CH3
OH 0
1.00 g of 2—(6—bromopyridin-2—yl)propan—2-ol was reacted analogously to Intermediate 17-1 in a
carbon monoxide atmosphere. After analogous work-up, the crude product was purified by
preparative HPLC. This gave 540 mg of the title compound.
]H-NMR (400 MHZ, DMSO'dg): 6 [ppm]= 1.44 (s, 6H), 3.86 (s, 3H), 5.34 (s, 1H), 7.86 - 7.99 (m,
3H).
Intermediate 17-4
Methyl 6— {[1{text-butt)xycarbonyl)azetidinyl]amino}pyridine-Z-carboxylate
CH O
A A3 \
H30 0 N
CH3 l
/ o\
N N CHa
A mixture of 250 mg of methyl ropyridine-Z—carboxylate, 361 mg of tert—butyl 3-
aminoazetidine-l-carboxylate (1.3 equivalents) and 0.84 ml of N-ethyl—N-i50propylpropane—2—
amine in 3.0 m1 of l-methylpyrrolidinone was stirred at 80°C. Another 0.5 equivalent of tert-
butyl 3-aminoazetidine-l-carboxylate was added and the mixture was stirred at 100°C ght.
Another 0.5 equivalent of ten-butyl 3-aminoazetidine-1«carboxylate was added and the mixture
was d at room temperature for 3 days. Water was added, the mixture was extracted with ethyl
acetate, the organic phases were trated and the residue was purified by preparative HPLC.
This gave 230 mg of the title compound.
UPLC-MS (Method A1): Rt = 1.07 min (UV detector TIC), mass found 307.15.
Intermediate 17-5
Methyl 6-( {[1-(tert-butoxycarb0nyl)azetidinyl]methyl} amino)pyridine—2—carboxylate
/ O
A mixture of 500 mg of methyl 6-flu0ropyridinecarboxy1ate, 720 mg of tert-butyl 2-
(aminomethyl)azetidinecarboxylate and 2.2 m1 of N—ethyl-N—isopropylprOpane-Z-amine in 7.5
ml of 1-methy1pyrrolidinone was d at 100°C for 30 min, at 120°C for 4 h and at 140°C for
3 h. The mixture was concentrated and the product was purified by preparative HPLC (column:
Reprospher C18—DE Sum 125x30 mm, solvent system: A = water + 0.1% by volume of formic acid
(99%), B = itrile, gradient 0 - 5.5 min 40-80% B). This gave 230 mg of the title nd as
a crude t. Mass found (UV detector TIC) 321.17.
Intermediate 17-6
Methyl ,6S)-2,6—dimethylmorpholinyl]pyridme—2—carb0xylate
H C \ O
N \CH3
300 mg of methyl 6-fluoropyridine—2—carboxy1ate were reacted analogously with 334 mg of
(2R,6$)-2,6-dimethy1morpholine analogously to Intermediate 17—4 at 80°C overnight. Another 0.5
equivalent of (2R,6S)—2,6-dimethylmorpholine was added and the mixture was stirred at 100°C for
7 h. Aqueous work-up gave 875 mg of a crude product which still contained 1—methylpyrrolidin
one. UPLC-MS (Method A1): Rt = 1.05 min (UV detector TIC), mass found 25000.
Intermediate 17-7
Methyl 6-(isobutylamino)pyridine-2—carboxy1ate
H C / O
3 Y\N
N \CH3
CH3
900 mg of 6-bromo—N-isobutylpyridine-Z-amine mediate 16-1) were reacted analogously to
Intermediate 17—1 in a carbon monoxide atmosphere. The crude product was purified by column
chromatographic purification on silica gel. This gave 796 mg of the title compound.
1H—NMR (300 MHz, CHLOROFORM-d): d [ppm]= 1.02 (d, 3H), 1.83 — 1.98 (m, 1H), 3.08 (1, 2H),
3.97 (s, 3H), 4.97 (br. s., 1H), 6.58 (d, 1H), 7.42 (d, 1H), 7.58 (t, 1H).
Intermediate 19-1
ium 6-(1~hydroxyethyl)pyridine—Z—carboxylate
OH O
541 mg of methyl 6-(1-hydroxyethy1)pyridine—2-earboxylate (Intermediate 17-1, crude product)
were initially charged in 5 ml of methanol, 120 mg of potassium hydroxide were added and the
mixture was stirred at 50°C overnight. More potassium hydroxide was added and the mixture was
stirred at 50°C for 5 h. The mixture was concentrated, giving 625 mg of potassium 6—(1—
hydroxyethyl)pyridine—Z-carboxylate as a crude product-
Intermediate 19—2
6-(1-Methyl-IH-pyrazoly1)pyridine-Z-carboxylic acid
OH N’
500 mg (2.31 mmol) of methyl 6-br0rnopyridinecarb0xylate, 578 mg (1.2 equiv.) of l—methyl
(4,4,5,5—tetramethyl-1,3,2-dioxah0rolan—2—y1)—1H-pyrazole and 192 mg of lithium chloride were
initially charged in 5 ml of toluene and 3 ml of ethanol. 162 mg of
iphenylphosphine)palladium(II) chloride and 3.5 ml of aqueous sodium carbonate solution (2
M) were added and the mixture was heated in the microwave at 120°C. The mixture was acidified
to pH 5 with 10% strength citric acid solution and extracted three times with ethyl acetate, and the
extract was washed with sodium chloride solution, filtered and concentrated. The residue was
d by preparative HPLC (column XBridge C18 5pm 100x30 mm). This gave 70 mg (15% of
theory) of the title compound.
1H-NMR (400 MHZ, é): 5 = 3.89 (s, 3H), 7.79 - 7.94 (m, 3H), 8.09 (s, 1H), 8.39 (s, 1H),
(12.9 br. s, 1H).
Intermediate 19-3
ethyl-1H—pyrazol—5 —yl)pyridine—2-carboxylic acid
OH ,N‘N
Analogously to the synthesis of Intermediate 19—2, 500 mg (2.31 moi) of methyl 6—
bromopyn'dine-Z-carboxylate were reacted with 1-methy1(4,4,5,5-tetramethyl—1,3,2—
dioxaborolan—Z-yl)-lH-pyrazole in the microwave at 120°C for 90 min. Purification by preparative
HPLC according to Method P1 gave 34 mg (15% of theory) of the title compound.
1H-NMR (400 MHz, DMSO-dfi): 6 = 4.22 (s, 3H), 6.89 (d, 1H), 7.50 (d, 1H), 7.96 — 8.10 (m, 3H),
13.29 (br. s., 1H).
cdixte 19-4
6-(1H-Pymzolyl)pyridine—2—carboxylic acid
ously to the synthesis of Intermediate 19—2, 1 g (2.31 mmol) of 6-bromopyridine
carboxylic acid and 1.15 g of 4—(4,4,5,S—tetramethyl—l,3,2—dioxaborolan—2-y1)~1H—pyrazole were
reacted in the microwave at 120°C for 90 min. Ethyl acetate and water were added, the mixture was
filtered and the organic phase was separated off and extracted twice with ethyl acetate. The ethyl
acetate phases were discarded. 10% strength citric acid solution was added to the aqueous phase
until a pH of 4 was d, the mixture was extracted three times with ethyl acetate and the ethyl
acetate phases were concentrated. This gave a residue which was purified by preparative HPLC
(column XBridge C18). This gave 110 mg (12% of ) of the title compound.
1H—NMR (300 MHz, DMSO—dé): 5 = 7.77 - 7.98 (m, 3H), 8.31 (s, 2H), 13.03 (br. s., 2H).
Intermediate 19—5
-Fluoro(l -Inethyl-1H—pyrazol—4—yl)pyridine—2-carboxylic acid
500 mg of methyl 6-bromofluoropyridinecarboxylate were reacted analogously with 533 mg
(1.2 equiv.) of l—methyl—4-(4,4,5,5-tctramethyl-1,3,2-di0xaborolanyl)-lH-pyrazole in the
microwave at 120°C for 90 min. This gave 380 mg (80% of ) of the title compound as a
crude product.
UPLC—MS (Method Al): Rt = 0.72 min
MS (ESIpos): m/z = 222 (M+H)+
Intermediate 19-6
6—(1,3—DimethyI—1H—pyrazol—4-yl)pyridinecarb0xylic acid
[CH3
OH N\
l N
N /
o /
\ CH3
Analogously to the sis of Intermediate 19-2, 500 mg (2.31 mmol) of methyl 6—
bromopyridine-Z—carboxylate were reacted with 617 mg of 1,3-dimethyl(4,4,S,5-tetramethyl-
1,3,2-dioxaborolan—2—yl)—1H—pyrazole in the microwave at 120°C for 90 min. ation by
HPLC gave 66 mg (13% of theory) of the title compound. “ '
1H-NMR (400 MHZ, DMSO-dé): 6 = 2.47 (s), 3.80 (s, 3H), 7.71 - 7.81 (m, 2H), 7.88 — 7.94 (m,
1H), 8.27 (s, 1H), 1295 (br. s., 1H).
Intermediate 19-7
6-(3 —Methyl-1H—pyrazol—4—yl)pyridinecarboxylic acid
/ E:
Q /N /N
\ CH3
Analogously to the synthesis of Intermediate 19-2, 216 mg of methyl 6-bromopyridine
carboxylate were d with 250 mg of 3—methyl-4—(4,4,5,5-tetramethyl-l,3,2—dioxaborolan-2—yl)—
lH-pyrazole in the microwave at 120°C for 90 min. This gave, after purification by HPLC, 68 mg
(33% of theory) of the title compound mixed with methyl 6—(3—methy1—1H-pyrazol
y1)pyridinecarboxylate.
UPLC-MS (Method Al): Rt = 0.50 min
MS (ESIpos): m/z = 204 (M+H)’
2014/077877
Intermediate 19-8
6-[3-(Methylsulphonyl)phenyl]pyridine-Z-carboxylic acid
500 mg (2.31 mmol) of methyl 6—bromopyridine—Z-carboxylate, 694 mg (1.5 equiv.) of [3—
(methylsulphonyl)phenyl]boronic acid and were initially charged in 10 ml of DMSO. 267 mg of
tetrakis(triphenylphosphine)pa11adium(0), 736 mg of sodium carbonate and 2 ml of water were
added and the e was heated in the microwave at 110°C for 2 h. The mixture was diluted with
water and acidified to pH 4 with 10% strength citric acid solution, ethyl acetate was added, the
mixture was filtered, the phases of the filtrate were separated, the aqueous phase was extracted with
ethyl e and the extract was washed with sodium chloride solution and concentrated 2.5 ml of
methanol and 917 mg of m hydroxide monohydrate in 10 ml of water were added and the
mixture was stirred at room temperature for 5 h. The mixture was diluted with water, acidified to
pH 4 with 10% strength citric acid solution and extracted with ethyl acetate and the extracts were
washed with sodium chloride solution and concentrated. This gave 776 mg of the title compound as
a crude t.
UPLC-MS (Method Al): K = 0.75 min
MS (ESIpos): m/z = 278 (M+H)+
Intermediate 19-9
Trifluoromethy1)~1H-pyrazolyl]pyridine—Z—carboxylic acid
Analogously to the preparation of Intermediate 19-8, 250 mg of methyl 6-br0mopyridine-2—
carboxylate were reacted with 394 mg of 4-(4,4,5,5~tetramethyl-1,3,2-dioxaborolan—2—yl)—3—
(trifluoromethyl)-lH-pyrazole. This gave 442 mg of the title compound as a crude product.
UPLC-MS (Method A1): R1: 0.82 min
MS (ESIpos): m/z = 258 (M+H)+
Intermediate 19-10
Potassium ,2-trifluoro-l -hydroxyethyl)pyridinecarboxy1ate
165 mg of potassium ide were added to 693 mg of methyl 6-(2,2,2—trifluoro—1-
hydroxyethyl)pyridinecarboxylate (Intermediate 17-2) in 5.0 ml of methanol, and the mixture
was stirred at 50°C for 20 h. Concentration gave 787 mg of a solid which was processed r
without any filrther purification.
Intermediate 19-1 1
Potassium 6—(2—hydroxypmpan—3 -yl)pyridinecarboxylatc
H3C I _
H30 / O
OH O
ously to Intermediate 19—10, 535 mg of methyl 6—(2—hydroxypropan—2—yl)pyridinc
carboxylate (Intermediate 17-3) were reacted with 0.28 g of potassium hydroxide in 6.0 ml of
methanol at 50°C. This gave, after concentration, 876 mg of the title nd as a crude product.
Intermediate 19-12
6- { [l -(tert-Butoxycarbonyl)azetidin—3 -yl]amino} pyridine—Z—carboxylic acid
CH3 )1
CH3 ND\ gr/ OH
N N
0.31 g of lithium hydroxide monohydrate dissolved in 1.0 m1 of water and 0.5 ml of ethanol was
added to a mixture of 230 mg of methyl 6-{[l-(tert-butoxycarbonyl)azetidin-3—yl]amino}pyridine—
2-carboxylate (Intermediate 17—4) in 4.0 m] of THF, and the mixture was stirred at room
temperature overnight. The mixture was diluted with water, acidified to pH 6 with citric acid
solution and extracted with ethyl acetate, and the extract was washed with saturated sodium
chloride solution, filtered through a hydrophobic filter and concentrated. This gave 202 mg of an
oil which was used without r purification.
Intermediate 19-13
Potassium 6-( {[ l -(tert-butoxycarbonyl)azetidinyl]methyl } amino)pyridineearboxylate
BAH / O K
N N
H30 0
H30 CH3
24 mg of potassium hydroxide were added to 230 mg of methyl 6—({[1—(tert~
butoxycarbonyl)azetidin~2-yl]methyl}amino)pyridine—Z-earboxylate mediate 17—5) in 3.0 ml
of ethanol, and the e was stirred at 50°C overnight. The mixture was concentrated, giving
265 mg of a crude product which was used further without purification.
Intermediate 19-14
6-[(2R,6S)—2,6-Dimcthylmorpholinyl]pyridinecarboxylic acid
H30Q \ OH
875 mg of methyl 6-[(2R,6S)-2,6-dimethylmorpholin—4-yl]pyridine-2—carboxylate (Intermediate
17—6) were initially d in 5 m1 of THF and 1 ml of methanol, 698 mg of lithium hydroxide
monohydrate in 2.5 ml of water were added and the mixture was stirred at room temperature
overnight. Twice, toluene was added and the mixture was in each case concentrated again.
Methanol was added, the mixture was stirred, the solid was filtered off and washed with l
ether and the filtrate was concentrated and purified by ative HPLC (Method P1). This gave
224 mg of the title compound.
UPLC-MS (Method Al): Rt = 0.66 min (UV detector TIC), mass found 236.12.
Intermediate 19-15
Potassium 6-(isobutylamino)pyridine-Z-earboxylate
PCT/EPZO 14/077877
\ O
HN N
HC 0
454 mg of lithium hydroxide were added to a solution of 790 mg of methyl 6—
(isobutylarnino)pyridine—2—carboxylate mediate 17-7) in 3.4 m1 of water, 32 m1 of THF and
3.2 ml of methanol, and the mixture was stirred at room ature overnight. This gave, after
concentration, 1.15 g of a solid which was used without further purification.
UPLC-MS (Method A1): Rt = 0.58 min (UV detector TIC), mass found 194.00.
ediate 20-1
6—Bromo—N-{6-methoxy[2-{morpholiny1)oxoethy1]—2H-indazolyl }pyridine-2—
amide
| o
H /"'\
/ N
Br ”
N 0
001:)“ka \N'
Analogously to Intermediate 8—6, 1.00 g (2.47 mmol) of (5-{[(6~bromopyridin
yl)carbonyl]amino}methoxy—2H—indazol—2—yl)acetic acid (Intermediate 9-21), 258 pl (2.96
mmol) of morpholinc, 378 mg (2.47 mmol) of 1—hydroxy-l.H—benzotriazole hydrate, 946 mg (4.94
mmol) of l-(3-dimethylaminopropyl)-3—ethylcarbodiimide hydrochloride and 1.03 ml (7.40 mmol)
of ylarnine in 35 ml of. tetrahydrofuran were stirred at 25°C for 24 h. The reaction mixture
was concentrated, water was added and the resulting precipitate was d off with suction,
washed with water and diethyl ether and concentrated under reduced pressure. This gave 586 mg
(50% of theory) of the title compound.
UPLC-MS (Method A1): R1 = 1.07 min
MS (ESIpos): m/z = 474 (M+H)f
1H NMR (400 MHz, DMSO-d6): 5 = 3.47 (d, 2 H), 3.58 (br. s., 4 H), 3.64 (d, 2 H), 4.00 (s, 3 H),
5.40 (s, 2 H), 7.93 - 7.99 (m, 1 H), 8.05 (t, 1 H), 8.14 — 8.29 (m, 2 H), 8.68 (s, 1 H), 10.31 (s, l H).
Intermediate 21—1
tert-Butyl 4- {[5 -({ [6-(trifluoromethyl)pyridinyl]carbonyl} amino)-2H-indazol
yl]acetyl}piperazine-1 -carboxylate
FYawH\ N
N /
/_\ O
F o
N »N CH3
\—/N4<
0 0 CH3
1.30 g (3.57 mmol) of [5—({[6-(trifluoromethyl)pyridinyl]carbonyl}amino)-2H-indazol
y1]acetic acid (Intermediate 9-14) was in 50 m1 of tetrahydrofuran and 5.4 m1 of MN—
dimethylformamide, and the mixture was stirred at 25°C for 30 minutes. 997 mg (5.35 mmol) of
tert-butyl piperazine-l-carboxylate, 546 mg (3.57 mmol) of l—hydroxy—lH—benzotn'azole hydrate
and 1.37 g (7.14 mmol) of 1-{3-dimethylaminopmpyl)—3—ethylcarbodiimide hydrochloride were
then added. and the mixture was stined at 25°C for a further 24 h. The metion mixture was added
to water. The resulting solid was filtered off with suction and washed twice with water. The solid
was taken up in dichloromethane and the solution was dried over sodium sulphate. filtered and
concentrated. The yellow solid was dried under reduced pressure. This gave 1.78 g (94% of theory)
of tert-butyl 4- { [5 -( { [6—(trifluoromethyl)pyridin—2—y1]carbonyl } amino)—2H-indazol—2—
y1]acety1}piperazine-1~carb0xy1ate.
UPLC-MS (Method Al): R = 1.21 min
MS (ESIpos): m/z = 533 (Mel-H)+
ediate 22-1
N-{2-[2-Oxo(piperaziny1)ethy1]-2H-indazol-5 -yl} ifluoromethyl)pyridine
carboxamide
2:]:
N N NH
1.93 ml (25.08 mmol) of trifluoroacetic acid were added to 1.78 g (3.34 mmol) of utyl 4-{[5-
( { [6—(trifluorornethyl)pyridin-2—y1]carbonyl} -2H—indazoly1]aeety1}piperazine—l —
carboxylateflntermediate 21-1) in 11 m1 of diehloromethane, and the e was stirred at 25°C
for 24 h. The mixture was then poured into saturated sodium bicarbonate on. The resulting
suspension was filtered and the filter cake was washed with 30 m1 of water and 10 m1 of diethyl
ether. Drying under reduced pressure gave 1.41 g (97% of theory) of N—{2—[2-ox0—2-(piperazin
yl)ethyl]—2H-indazol-5 -y1} (trifluoromethyl)pyridinecarboxamide as a crude product.
UPLC-MS (Method Al): R1= 0.80 min
MS s): m/z = 433 (M+H)+
'H NMR (400 MHz, DMSO-d6): 5 = 2.66 (br. 5., 2 H), 2.73 (br. s., 2 H), 3.39 (br. s., 2 H), 3.47 (br.
s., 2 H), 5.44 (s, 2 H), 7.47 - 7.68 (m, 2 H), 8.17 (d, J=7.1 Hz, 1 H), 8.30 (s, 2 H), 8.33 — 8.43 (m, 2
H), 10.37 (s, 1 H).
Intermediate 23-1
utyl 5- { [(benzyloxy)carbony1]amino } chloro—2H-indazole—2—carboxylate
\ /19%
CI N O+CH3
1.0 1.50 ml of N-ethyl-N-isoprOpylpropane—Z—amine and 1.11 ml of benzyl carbonochloridate were
added to 2.09 g of tert-butyl 5—amino—6—eh10ro-2I‘[-indazole—2-carboxylate (Intermediate 12-2) in
m1 of THF, and the mixture was stirred at room temperature overnight. Another 1.50 ml of N-
ethyl—N—isopropylpropaneamine and 1.11 ml of benzyl earbonochloridate were added, and the
mixture was stirred at room temperature for 3 days. Another 1.50 ml of N—ethyl-N—
isopropylpropane—Z-amine and 1.11 ml of benzyl carbonochloridate were added, and the mixture
was d at room temperature overnight. Water was added, the mixture was extracted with ethyl
e and the extract was washed with sodium chloride solution and concentrated. This gave 4.61
mg of a crude product which was processed further t further purification.
UPLC-MS (Method A1): Rt = 1.40 min (UV-TIC), mass found 401.00.
The chemical names of the examples were ted using the ACD / LABS (Batch Version
) software.
Examples
General Procedure la
1.0 equivalent of the respective intermediate, 1.0 equivalent of l-hydroxy-lH-benzotriazole
hydrate, 2.0 equivalents of 1—(3—dimethylaminopropyl)-3—ethy1carbodiimide hydrochloride, 5.0
lents of triethylamine and 1.5 equivalents of the ylic acid in question were stirred in
tetrahydrofuran at 25°C for 24 h. Water and ethyl e were added to the reaction mixture. The
resulting precipitate was filtered off, washed with water and l ether and dried.
General Procedure lb
1.0 equivalent of the respective intermediate, 1.0 equivalent of l-hydroxy-lH-benzotriazole
e, 2.0 equivalents of imethylaminopropyl)—3-ethy1carbodiimide hydrochloride, 3.0
equivalents of triethylamine and 1.5 equivalents of the carboxylic acid in question were stirred in
NJV-dimethylformamide at 25°C for 24 h, giving a suspension. The resulting precipitate was
filtered off, washed twice with N,N-dimcthylformamide and diethyl ether and dried.
General Procedure 1c
1.0 equivalent of the respective intermediate, 1.0 lent of l—hydroxy-lH~benzotriazole
hydrate, 2.0 equivalents of 1-(3—dimethy1aminopropyl)ethylcarbodiimide hydrochloride, 5.0
equivalents of triethylamine and 1.3 equivalents of the carboxylic acid in question were stirred in
tetrahydrofuran at 25°C for 24 h. Water was added and the reaction mixture was extracted
repeatedly with ethyl acetate. The combined organic phases were concentrated and the residue was
purified by preparative HPLC according to Method P1.
General Procedure 1d
1.0 equivalent of the respective intermediate, 1.0 equivalent of 1-hydroxy-1H-benzotriazole
hydrate, 2.0 equivalents of 1~(3—dimethy1aminopropyl)—3-ethylcarbodiimide hydrochloride, 3.0
equivalents of triethylamine and 1.2 equivalents of the carboxylic acid in question were stirred in 1
ml ofNJV—dimethylforrnamide at 25°C for 24 h. The reaction mixture was d with a further 1.5
ml ofNJV-dimethylfonnamide and purified by preparative HPLC according to Method P1.
PCT/EP2014/O77877
General Procedure 1e
1.0 equivalent of the respective intermediate, 1.0 lent of 1-hydroxy-1H-benzot1iazole
hydrate, 2.0 equivalents of 1-(3-dimethy1aminopropy1)—3—ethylcarbodiimide hydrochloride, 4.0
equivalents of triethylamine and 1.2 equivalents of the yhc acid in question were stirred in 1
ml of tetrahydrofuran at 25°C for 24 h. The reaction mixture was poured into 25 ml of water. The
precipitate formed was filtered off, washed twice with diethyl ether and dried in a drying cabinet.
Table 1: es 1-18
The exemplary compounds were ed by the general experimental procedures la - le from the
appropriate intermediates and carboxylic acids.
Prepared *
Structure/Name 1H-NMR / LC-MS
from
1 OKOY':33:)—~©~ Q Intermediat 1a (400 MHZ, DMSO—d6)16=238
e61 and 6-
0 [a] (s, 3H), 3.32 - 3.77 (8H), 5.45
(trifluorom (68%) (br. 5., 2H), 7.39 - 7.49 (m, 6H),
N-{2-[2-(4-benzoylpiperazin-
pyr1d1 8.15 - 8.21 (m, 2H), 8.24 (s,
1-yl)oxoethyl] ~6-methy1-
ne 1H), 8.33 - 8.43 (m. 2H), 10.11
ZH-indazol-S-yl }
yllc, (5, 1H)_
(trifluoromethyl)pyridine
801d_ UPLC-MS (Method A1): R1 =
carboxamide
1 1.16 mm
MS (ESIpos): m/z = 551
(M+H)+
2 “fl“ 0 Intermediat 1a (300 MHz, DMSO-dé): 5 = 1.21
3 \N mjLNON
e 6-2 and 6— (91%) - 1.49 (m, 5H), 1.67 (br. 5., 4H),
6—ethy1—N-(6-methyl{2-oxo- ethylpy‘idi 1-84 (t, 2H), 2.14 - 2-31 (In, 1H),
119-2”
2—[4-(pyrrolidin 2.79 - 2.95 (m, 3H), 3.17 (t, 1H),
yl)pipefidin—1 —yl] ethyl} ~2H- carboxylic 3.80 — 3.93 (m, 1H), 4.03 — 4.16
acid
indazol-S-y1)pyridine—2— (m, 11-1), 5.34 - 5.49 (m, 2H),
carboxamide 7.49 (s, 1H), 7.53 — 7.59 (m,
1H), 7.94 _ 8.01 (m, 2H), 8.24
(s, 1H), 8.39 (s, 1H), 10.37 (s,
1H).
UPLC-MS (Method A2): Rt =
1.18 min
MS (ESIpos): m/z = 475
(M+H)+
PCT/EP2014/O77877
Intermediat 1b (400 MHz, DMSO-d6): 8 = 1.18
6 6-2 and 5— (36%) - 1.37 (m, 1 H), 1.37 — 1.51 (m,1
fluoropyrid H), 1.68 (br. 8., 4 H), 1.76 - 1.94
—fluoro—N—(6-methy1—2 - {2-
ine-Z- (m, 2 H), 2.14 — 2.30 (m, 1 H),
oxo—Z—[4-(pyrrolidin-l -
carboxylic 2.39 (s, 3 H), 2.78 - 2.94 (In, 1
yl)pipen'din-1—y1]ethy1}-2H-
acid H), 3.18 (t, 1 H), 3.82 - 3.95 (m,
l-S-y1)pyridine
1 H), 4.03 — 4.16 (m, 1 H), 5.44
carboxamide
(d, 1 H), 5.39 (d, 1 H), 7.44 —
7.50 (m, 1 H), 7.99 (td, 1 H),
8.12 (s, 1 H), 8.20 — 8.29 (m, 2
H), 8.75 (d, 1 H), 10.15 (s, 1 H).
LC-MS d A3): Rt = 0.79
I MS (ESIpos): m/z = 465
(M+H)+
I Intermediat 1a
” o m o (300 MHz, DMSO—d6); 5 = 1.16
.= \ N .
N / )flL/N
F N n c
F O \ I 3 6 6-3 and 6-
me N cap (53%) (s, 6H), 2.40 (s, 3H), 3.39 - 3.52
N—(2— {2—[4—(3—hydroxy—2,2— (trifluorom (m, 4H), 3.52 — 3.70 (m, 6H),
dimethylpropanoyl)piperazin— ethy1)pyridi 4.62 (t, 1H), 5.47 (s, 2H), 7.49
1-y1]0xoethy1} methy1- ne-2— (s, 1H), 8.17 - 8.29 (m, 3H),
2H-indazoly1) ylic 8.34 - 8.45 (m, 2H), 10.15 (s,
(trifluoromethy1)pyridine acid 1H).
carboxamide UPLC-MS (Method A1): Rt =
1.06 min
MS (ESIpos): m/z = 547
(M+H)+
| o o Intermediat 1a
l (400 MHz, DMSO-d6): 6 = 2.40
F ‘
\ H
_/\ N N
.: \_/
N O
F 0 \l \
14,6 N 6 6-4 and 6-
cH3 (12%) (s, 3H), 3.36 — 3.64 (m, 8H),
N—(Z—{Z—[4‘ (trifluorom 4.12 (br. 8., 2H), 5.47 (s, 2H),
(methoxyacety1)piperazin-1 - ethy1)pyn'di 7.49 (s, 1H), 8.18 — 8.28 (m,
yl]—2—oxoethy1}—6-methy1-2H- 116 3H), 8.35 - 8.45 (m, 2H), 10.13
indazol—S—y1)—6— carboxylic (8, 11—1),
(tn'fluoromethyl)pyfidine-2— acid UPLC—MS d Al): Rt =
carboxamidc 1.02 min
MS (ESIpos): m/z = 519
(M+H)+
O C Intermediat 1::
H: (300 MHz, DMSO-dé): 6 = 0.94
F \ N N
N / F601
‘ e 6-5 and 6—
F o KIN—>— (51%) - 1.29 (m, 8H, contains singlet at
011’ fluorom 1.04 ppm), 1.35 - 1.51 (m, 1H),
N—(2—{2—[4-(2—hydroxypr0pan- ethy1)pyridi 1.74 (t, 2H), 2.53 (s, 1H), 2.98
2—yl)pipen'diny1] ne (t, 1H), 3.91 — 4.10 (m, 4H),
oxoethy1}-6—methoxy-2H- carboxylic 4.17 (s, 1H), 4.41 (d, 1H), 5.28 —
indazol—S-y1) acid 5.44 (m, 2H), 7.10 (s, 1H), 8.18
oromcthyl)pyridine—2— - 8.27 (m, 2H), 8.35 - 8.50 (m,
carboxamide
2H), 8.69 (s, 1H), 10.50 (s, 1H).
UPLC—MS (Method A1): Rt =
1.13 min
I (ESIpos): m/z=
(M+H}F
I !
1 7 "
o Intermediat 1c
H at, (300 MHZ, DMSO-dfi): 6 = 0.97
\ N W
we :1
‘ W”)
a SVK/k" ’ c 6-5 and 6- (41%) - 1.29 (m, 8H, contains t at
01') melhylpyn' 1.04 ppm), 1.36 - 1.50 (m, 1H),
N-(2-{2-[4-(2-hydroxypropan— dine 1.74 (t, 2H), 2.53 (s, 1H), 2.61
2-y1)piperidiny1]—2- ylic (5, 3H), 2.98 (t, 1H), 3.95 — 4.08
oxoethyl}methoxy-2H— acid (m, 4H), 4.17 (s, 1H), 4.41 (d,
indazol-S-yl) 1H), 5.28 - 5.42 (m, 2H), 7.08
methylpyridine-Z-carb0xamide (s, 1H), 7.51 — 7.59 (m, 1H),
7.92 — 8.02 (m, 2H), 8.20 (s,
1H), 8.70 (s, 1H), 10.70 (s, 1H).
UPLC-MS (Method A1): Rt =
1.06 min
MS (ESIpos): m/z = 466
(M+H)+
8 : o Intermediat 1a
l (400 MHz, 6): 8 = 0.41
o £5)”ny 66-6 and 6- (17%) (br. s., 2H), 0.66 (d, 2H), 1.12
(trifluorom [b] (br. s., 1H), 2.89 - 3.26 (m, SH),
N—(2— {2-[4—
ethyl)pyn'di 3.60 (br. 3., 3H), 4.00 (s, 3H),
(cyclopropylmethyl)piperazin— ne—2— 4.21 (d, 1H), 4.42 (d, 1H), 5.48
1 ~y1]—2—oxoethy1}methoxy-
carboxylic (d, 2H), 7.11 (s, 1H), 8.19 — 8.25
2H-indazol—5—y1) acid (m, 2H), 8.36 — 8.49 (m, 2H),
(tfifluoromethyl)pyridine
8.72 (s, 1H), 10.5 (s, 1H), 10.7
carboxamide hydrochloride
(3).
UPLC-MS (Method A1): Rt =
0.94 min
MS (ESIpos): m/z = 517
. (M+H)+
l 9 ”Icfiknw}~©" Intermediat MHz, 6, felected
or) I (800
‘ A M", 66-6 and 6- Slgnals, sample contamcd a
3“: methyipyn' proportion of formic acid): 5 =
N'(2‘{2‘[4‘ dine-Z— 0.27 (br. 5., 2H), 0.59 (br. 3.,
(eye10pr013y1methy1)piperazin- carboxylic 2H), 0.97 (br. 5., 1H), 2.62 (s),
1-y1]oxoethy1}methoxy- acid 3.05 (br. 5.), 3.53 (br. 3.), 4.00
2H-indazolyl) (s, 3H), 5.43 (br. 5., 2H), 7.03 (s,
methylpyridinecarboxamide 1H), 7.55 (dd, 1H), 7.93 _ 3.01
(m, 2H), 8.19 (s, 1H), 8.72 (s,
1H), 10.71 .
UPLC-MS (Method Al): Rt =
0.85 min
MS (ESIpos): mfz = 463
(M+I’I)+
«(EYE }/—\ o Intermediat la (300 MHZ, DMSO-d6): 5 = 1.04
0 ?:©: U5 66—7 and 6- (50%) - 1,15 (m, 4H), 2.21 - 2.33 (m,
cyclopropyl [d] 1H), 3.39 — 3.37 (8H), 4.00 (s,
N-{2-[2—(4—benzoy1piperazin-
e. ,
3H), 5.41 (br. s., 2H), 7.09 (s,
1-y1)oxoethy1]methoxy-
yhc_ 1H), 7.41 - 7.52 (m, 5H), 7.58 -
2H-indazol—5 —yl} —6-
ac1d_ 7.65 (m, 1H), 7.87 - 7.96 (m,
cyclopropylpyridine-Z-
2H), 8.20 (s, 1H), 8.66 (s, 1H),
carboxamide
.80 (s, 1H).
UPLC-MS (Method A1): Rt =
1.18 min
MS (ESIpos): m/z = 539
(M+H1+
n A (300 MHz, DMSO-d6): 6 = 1.51
(d, 3H), 3.38 — 3.91 (8H), 3.99
I N- (4—benmy1piperazin— Intermediat (s, 3H), 4.81 - 4.90 (m, 1H),
e19-1 5.41 (br. 5., 2H), 5.60 (d, 1H),
1 —y1)—2—oxoethy1]—6—methoxy—
7.09 (s, 1H), 7.35 - 7.56 (m,
2H—indazol—5-yl} —6-(1 -
5H), 7.76 — 7.82 (m, 1H), 8.01 -
hydroxyethy1)pyridine-2—
8.11 (m, 2H), 8.21 (s, 1H), 8.68
carboxamide
(s, 111), 10.78 (s, 1H).
UPLC—MS (Method A1): Rt =
0.93 min
MS (ESIpos): m/z = 534
(M+H)+
12 |\ Intermediat 1d
F o
H /—\ (400 MHz, DMSO-d6) 5 = 2.22
N/ N / _>—N N—CH
F «N C 6-8 and 6- —
F o (47%) (s, 3 H) 2.27 2.36 (m, 2 H)
FjiF (trifluorom 2.37 — 2.44 (m, 2 H) 3.44 — 3.52
N-{2—[2—(4-methy1piperazin—l— ethy1)pyridi (m, 2 H) 3.52 — 3.60 (m, 2 H)
yl)—2—oxoethyl]—6- ne 5.52 (s, 2 H) 7.75 (s, 1 11) 8.23
(trifluoromethoxy)—2H— carboxylic (dd, 1 H) 8.38 — 8.50 (m, 3 H)
indazol—S—yl} —6— acid 8.71 (s, 1 H) 10.40 (s, 1 H).
(trifluoromethy1)pyridine UPLC-MS (Method A1): Rt =
carboxamide 0.96 min
MS (ESIpos): m/z = 531
(M+H)+
D, Intermediat 1d
o (300 MHz, DMSO-d6) 8 = 2.21
/ n _>—N/—\N—CH C 6-8 and 6- (s, 3 H), 2.25 - 2.34 (m, 2 H), o (49%)
0 \N/
+; methylpyri 2.39 (br. 5., 2 H), 2.61 (s, 3 H),
6-methy1—N— {2—[2—(4— dine 3.44 - 3.51 (m, 2 H), 3.51 - 3.61
methylpiperaziny1)—2- carboxylic (m, 2 H), 5.52 (s, 2 H), 7.59 (dd,
oxoethyl] acid 1 H), 7.76 (s, 1 H), 7.96 - 8.04
(trifluoromcthoxy)—2H- (m, 2 H), 8.45 (s, 1 H), 8.72 (s, 1
indazol—S-y1 } pyn'dine-Z- H), 10.65 (s, 1 H).
carboxamide UPLC-MS (Method A1): Rt 2
0.92 min
MS (ESIpos): m/z = 477
(M+H)+
[ntermediat (300 MHz, DMSO-dé) 5 = 1.39
C 6-8 and 2- (39%) (s, 9 H), 2.21 (s, 3 H), 2.26 -
{[1-(tcn- 2.34 (m, 2 H), 2.38 (br. 5., 2 H),
butoxycarb 3.46 (br. 5., 2 H), 3.54 (br. 5., 2
ten-butyl 3~{[4—({2(4- onyl)azetidi H), 3.77 (dd, 2 H), 4.20 (t, 2 H),
methylpiperazin— 1 -y1) 11 4.46 (d, 1 H), 5.50 (s, 2 H), 7.56
oxoethy1]—6- y1]amino}— (s, 1 H), 7.73 (s, 1 H), 8.42 (s, 1
(trifluoromethoxy)-2H- 1,3- H), 8.57 (d, 1 H), 8.62 (s, 1 H),
indazo1—5-yl} carbamoyl)- 1 ,3 - thiazole—4— 9.54 (s, 1 H).
l—Z—yl]amino } azetidine— carboxylic S d A1): Rt =
1 -carb0xy1ate acid“ 0.63 min
MS (ESIpos): m/z = 639
(M+1.-1)+
Intermedia 16 (300 MHz, DMSO-d6) 5 = 2.21
N 0mm,
;ijfir“ Lyra.L/
F Intermediat (76%) (s, 3 H), 2.29 (br. s., 2 H), 2.38
N- mo—2—[2—(4- 6 6-9 and 6— (br. s., 2 H), 3.47 (br. s., 2 H),
methylpiperazin—l — (trifluorom 3.54 (br. s., 2 H), 5.50 (s, 2 H),
oxoethyl]—2H—indazoly1} ethyl)pyridi 8.09 (s, 1 H), 8.24 (d, l H), 8.35
(trifluoromethyl)pyridine ne—2- — 8.50 (m, 3 H), 8.64 (s, 1 H),
carboxamide carboxylic 10.54 (s, 1 H).
acid LC—MS (Method A3): Rt = 0.93
MS (ESIpos): m/z = 525
(M(79Br)+H)+
WO 91426 2014/077877
Intermediat lie—m
e6-9 and 6— (93%) (s, 3 H), 2.25 - 2.35
N (m, 2 H),
N-{6-bromo[2-(4- methylpyri 2.38 (br. 5., 2 H), 2.64 (s, 3 [-I),
methylpiperazin-l-y1) dine-2— 3.47 (br. s., 2 H), 3.54 (br. 5., 2
oxoethyl]-2H-indazol-5—y1}—6- carboxylic H), 5.49 (S, 2 H), 7.58 (dd, 1 H),
methylpyridine-Z-carboxamide acid 7.97 - 8.04 (m, 2 H), 8.08 (s, 1
H), 8.39 (s, 1 H), 8.71 (s, 1 H),
.77 (s, 1 H).
LC—MS (Method A3): Rt = 0.88
MS (ESIpos): m/z = 471
(M(79Br)+H)+
0 /—\ [mermcdiax Ie (300 MHz, DMSO-dé) a = 1.01
| fl N—O‘ I
D \l 66-9 and 2— (55%) — 1.07 (m, 2 H), 1.07 — l.16(m, 2
8r N
N-{G-bromo—Z-[Z-{4- Cyclopmpyl H), 2.17 - 2.26 (111,4 H), 2.27 -
methylpiperazin-l -y1) -1,3- 2.34011, 2 H), 2.37 (br. s., 2 H),
oxoethyl]~2H-indazolyl} oxazole 3.46 (br. s., 2 H), 3.54 (br. 5., 2
cyclopropyl-l,3-oxazole carboxylic H), 5.49 (s, 2 H), 8.03 (s, 1 H),
carboxamlde acid 8.29 (s, 1 H), 8,37 (s, 1 H), 8.63
(s, 1 H), 9.61 (s, 1 H).
LC—MS (Method A3): Rt = 0.33
MS (ESIpos): m/z = 487
(M(79Br)+H)+
18 f4“ o \/—\. Interrnediat 1e (300 MHz, DMSO-d6) 5: 1.39
.4' 66-9 and 2- (41%) (s, 9 H), 2.21 (s, 3 H), 2.25 —
ert- 2.33 (m, 2 H), 2.37 (br. s., 2 H),
tert-butyl 3-{[4-({6-bromo
butoxycarb 3.46 (br. s., 2 H), 3.54 (br. s., 2
[2—(4-methylpiperazin-1 —y1)
onyl)azetidi H), 3.79 (dd, J=8.6, 5.4 Hz, 2
oxoethyl]-2H—indazol
11—3- H), 4.23 (t, 2 H), 4.50 (d, 1 H),
y1}carbamoyl)~1,3—thiazol
yl]amino}— 5.47 (s, 2 H), 7.54 (s, 1 H), 8.05
no}azetidine-l -
1,3- (5, 1 H), 8.31 - 8.41 (m, 1 H),
carboxylme
thiazole 3.54 (d, 1 H), 8.64 (s, 1 H), 9.82
ylic (s, 1 H).
acid** UPLC-MS d A2): Rt =
1.09 min
1 iMS (ESlpos): m/z = 633
i i (M179Br)+H)+
* Prepared according to the stated procedure, the yield in % is indicated in ts
[a]: The reaction was carried out in a mixture of tetrahydrofuran/N,N—dimethylformamide (5:1). 3
equivalents of triethylamine were used.
fl .
[b]: 1.3 equivalents of the pyridineearboxylic acid were used.
[c]: 1.5 equivalents of the pyridinecarboxylic acid were used. The product was in the aqueous
phase.
[d]: Preparative HPLC was carried out according to Method P1.
[e]: The product precipitated directly from the reaction mixture, was filtered off, washed repeatedly
with water and dried in a drying cabinet.
** 2—{[1-(tert-Butoxycarbony1)azetidinyl]amino}~1,3-thiazolecarboxylic acid was prepared
from 3—bromo—2—oxopropanoic acid and tert—bu’tyl 3—arninoazetidine-l—carboxylate analogously to
Bioorgam'c and Medicinal Chemistry Letters, 1996, 6, 12, 1409 — 1414 and Chemical and
Pharmaceutical Bulletin, 2005
, 53, 4, 437 — 440.
Example 19
tidinylamino)-N- {2~[2-(4-methylpiperazinyl)oxoethyl]-6—(trifluoromethoxy)—2H-
indazol-S -yl} -1,3—thiazole—4—carboxamide
HANkfnfiN—yNCN—CmO O \N/
F—i—F
21 mg (0.03 mmol) of utyl 3-{[4-( {2-[2-(4-rnethylpiperazin—1~yl)-2—ox0ethyl}—6—
(trifluoromethoxy)-2H-indazoly1 } carbamoy1)—l ,3—thiazol-2—y1]amino } azetidine-l -carboxylate
(Example 18) were dissolved in 1 ml of romethane, and 25 1,11 (0.03 mmol) of trifluoroacetic
acid were added. The reaction mixture was d at 25°C for 24 h. The mixture was then d
with more dichloromethane and washed with saturated sodium bicarbonate solution and with
saturated sodium chloride solution. The e was then filtered through a hydrophobic filter and
concentrated. The residue was dried under reduced pressure. This gave 7 mg (31% of theory) of the
title compound.
UPLC-MS (Method A2): R1: 086 min
MS (ESIpos): m/z = 539 (M+H)+
1H NMR (400 MHz, DMSO-dé): 5 = 2.21 (s, 3 H), 2.29 (br, 5,, 2 H), 2.38 (br. 5., 2 H), 3.42 — 3.49
(m, 4 H), 3.54 (br. s., 2 H), 3.69 - 3-73 (m, l H), 5.50 (s, 2 H), 7.49 (s, 1 H), 7.72 (s, 1 H), 8.42 (s, 1
H), 8.64 (s, l H), 9.58 (s, l H).
Example 20
N-{6—Cyano[2-(4-methy1piperazinyl)oxoethy1]-2H-indazoly1}—6-
(ttifluoromethyl)pyridine—2—carboxamide
F I H o
/ _>—N/—\ N
N—CH
N / \ / 3
F O \N/
50 mg (0.10 mmol) of N—{6—bromo—2-[2—(4-methylpiperaziny1)oxoethy1]-2H-indazoln5-y1}~6-
(trifluoromethyl)pyridine—2—carboxamide (Example 15), 5 mg (0.005 mmol) of
tetrakis(triphenylphosphine)palladium(0) and 12 mg (0.10 mmol) of zinc cyanide were initially
charged in a microwave vessel and suspended in 1 m1 of MN—dimethylformamide. The reaction
mixture was stirred in the microwave at 150°C for 15 minutes. Since the reaction was still
incomplete, another 5 mg (0.005 mmol) of is(tripheny1phosphine)palladium(0) and 5.5 mg
(0.05 mmol) of zinc cyanide were added and the mixture was stirred in the microwave at 150°C for
a further 30 minutes. The on mixture was diluted with ethyl acetate and washed with water
2014/077877
and saturated sodium chloride solution. The solution was then filtered through a hydrophobic filter
and concentrated. The crude product was dissolved in 2.5 m1 of NW—dimethylfonnamide and
purified by preparative HPLC according to Method P1. The product fraction was lized. This
gave 25 mg (56% of theory) of the title compound.
LC-MS (Method A3): Rt = 1.07 min
MS (ESIpos): m/z = 472 (M+H)T
1H NMR (400 MHz, DMSO-d6): 6 = 2.22 (s, 3 H), 2.27 — 2.33 (m, 2 H), 2.36 — 2.42 (m, 2 H), 3.44
- 3.50 (m, 2 H), 3.52 - 3.58 (m, 2 H), 5.59 (s, 2 H), 8.21 - 8.26 (m, 2 H), 8.37 — 8.43 (m, 2 H), 8.43 -
8.47 (m, 1 H), 8.51 (d, 1 H), 10.66 (s, 1 H).
Example 2 1
6'-Methyl-N- {2-[2-{4—methylpiperazin—1 -yl)-2~oxoethyl]-2H—indazol-S-yl } —2.3 '-bipyn'dine
carboxamide
H O
H3C N
75 mg (0.16 mmol) of 6-bromo—N—{2-[2—(4—methylpiperazin—l—yl)—2—0xoethyl]—2H-indazol
yl}pyridine-2~carboxamide (Example 231) were ved in a degassed mixture of 1.73 ml of
dioxane and 0.25 ml of water, and 45 mg (0.33 mmol) of (6-methylpyridinyl)boronic acid, 13
mg (0.02 mmol) of 1,l'-bis(diphenylphosphino)ferrocenepalladium(ll) dichloride and 52 mg (0.49
mmol) of sodium carbonate were added. The reaction mixture was stirred in the microwave at
105°C for 90 minutes. The reaction mixture was then filtered and saturated ammonium de
solution and dichloromethane were added to the filtrate. The phases were separated and the organic
phase was washed with saturated sodium chloride solution, filtered through a hydrophobic filter
and concentrated. The crude product was ved in 2.5 m1 of N,N—dimethy1formamide and
purified by preparative HPLC according to Method P1. The product fraction was lyophilized. This
gave 40 mg (52% of ) of the title compound.
LC—MS (Method A3): R = 0.46 min
MS (ESIpos): mfz = 470 (M+H)l'
lH NMR (300 MHZ, DMSO-d6): 5 = 2.22 (s, 3 H), 2.31 (br. s., 2 H), 2.39 (br. s., 2 H), 2.57 (s, 3
H), 3.48 (br. s., 2 H), 3.55 (d, 2 H), 5.47 (s, 2 H) 7.44 (d, 1 H), 7.62 (s, 2 H), 8.08 — 8.20 (m, 2 H),
8.26 - 8.32 (m, 2 H), 8.34 (s, l H), 8.68 (dd, 1 H), 9.43 (d, 1 H), 10.54 (s, 1 H).
Example 22
hyl-N- (4—methy1piperazinyl)oxoethyl]-2H-indazol-5—yl} -2,3*-bipyridine
carboxamide
“@NfNL/NCH3
ously to Example 21,75 mg (0.16 mmol) of 6bromo-N- {2-[[2-(4-methy1piperazin—1—yl)2——
oxoethyl]~2H—indazolyl}pyfidine-Z-carboxamide were stirred with 45 mg (0.33 mmol) of (5-
methylpyridin—3—yl)b0ronic acid, 1 3 mg (0.02 mmol) of 1 ,1‘-
phenylphosphino)ferrocenepalladium(II) dichloride and 52 mg (0.49 mmol) of sodium
carbonate in a degassed mixture of 1.73 ml of dioxane and 0.25 ml of water in the microwave at
105°C for 90 minutes. Work—up and preparative HPLC ing to Method P1 gave 41 mg (53%
of theory) of the title compound.
LC-MS (Method A3): Rl = 0.51 min
IO MS (ESIpos): m/‘z = 470 (M+H)‘
lH NMR (300 MHz. DMSO-dfi): 5 = 2.23 (s. 3 H). 2.32 (br. s... 2 H). 2.41 (br. 5-. 2 H). 2.45 (s. 3
H), 3.48 (br. 5., 2 H), 3.56 (br. s., 2 H), 5.47 (s, 2 H), 7.62 (s, 2 H), 8.11 - 8.23 (m, 2 H), 8.27 - 8.37
(m, 3 H), 8.55 (s, 1 H), 8.60 (5, 1 H), 9.38 (d, 1 H), 10.55 (s, l H).
Examgle 23
4‘-Methyl-N—{2-[2-(4-methy1piperazin—l—yl)—2—ox0ethyl]-2H-indazolyl}-2,3‘-bipyridine
carboxamide
<1on
Analogously to Example 21, 75 mg (0.16 mmol) of 6-bromo—N {2-[[2—(4—methylpiperazin- I -y1-)2—
oxoethyl]-2H-indazol—5-yl}pyridine—2-carboxamide were stirred with 45 mg (0.33 mmol) of (4-
methylpyridin—3—yl)boronic acid, 13 mg (0.02 mmol) of 1, l '-
bis(diphenylphosphino)ferrocenepalladiumfll) dichloride and 52 mg (0.49 mmol) of sodium
carbonate in a degassed mixture of 1.73 ml of dioxane and 0.25 ml of water in the ave at
105°C for 90 minutes. Work—up and preparative HPLC according to Method P1 gave 16 mg (21%
of theory) of the title nd.
LC-MS (Method A3): R, = 0.45 min
MS (ESIpos): m/z = 470 (M+H)+
1H NMR (300 MHz, DMSO-d6): 5 = 2.21 (s, 3 H), 2.30 (br. s., 2 H), 2.38 (br. s., 2 H), 3.47 (br. 3.,
2 H), 3.54 (d, 2 H), 5.45 (s, 2 H), 7.42 (d, 1 H), 7.57 (d, 2 H), 7.91 (t, 1 H), 8.19 (d, 2 H), 8.28 (s, 1
H), 8.34 (s, 1 H), 8.54 (d, 1 H), 8.78 (s, 1 H), 10.41 (s, 1 H).
PCT/EP2014/O77877
Example 24
6'—Methoxy—N-{2-[2-(4—methylpiperazinyl)—2—oxoethy1]—2H—indazoly1}-2,3'-bipyridine-6—
carboxamide
H /—\
Analogously to Example 21, 50 mg (0.11 mmol) of 6—bromo—N—{2—[2—(4—methy1piperazin—1—yl)—2—
oxoethyl]—2H-indazol-5—y1}pyridine—Z—carboxamide were d with 33 mg (0.22 mmol) of (6—
methoxypyridinyl)boronic acid. 9 mg (0.01 mmol) of 1 . l '—
bis(dipheny1phosphino)fen‘ocenepalladium(II) dichloride and 35 mg (0.33 mmol) of sodium
carbonate in a degassed e of 1.15 ml of dioxanc and 0.17 ml of water in the microwave at
105°C for 90 minutes. Work-up and preparative HPLC according to Method P1 gave 28 mg (52%
of theory) of the title compound.
LC—MS (Method A3): R1 = 0.74 min
MS (ESIpos): m/z = 486 (M+H)+
1H NMR (400 MHz, DMSO-d6): 5 = 2.21 (s, 3 H), 2.30 (t, 2 H), 2.38 (t, 2 H), 3.45 — 3.52 (m, 2 H),
3.52 - 3.60 (m, 2 H), 3.96 (s, 3 H), 5.46 (s, 2 H), 6.96 - 7.01 (m, 1 H), 7.58 - 7.66 (m, 2 H), 8.07 -
8.11 (m, 1 H), 8.11 - 8.16 (m, 1 H), 8.24 (dd, 1 H), 8.30 (s, 1 H), 8.32 - 8.34 (m, 1 H), 8.74 (dd, 1
H), 9.22 (d, 1 H), 10.52 (s, 1 H).
Example 25
6'—Acetamid0-N— {2-[2-(4—methylpiperazin—1-yl)—2—oxoethy1]—2H—indazol—5 —y1}—2,3‘—bipyridine-6—
carboxamide
H O /—\
O N—CH3
/ )*N
JL N
H C N
Analogously to Example 21, 50 mg (0.11 mmol) of 6-bromo-N- (4-methy1piperazin—1~y1)—2—
oxoethyl]-2H-indazol—5—y1}pyfidine—2-carboxamide were stirred with 57 mg (0.22 mmol) of N—[S—
(4,4,5,5-tetramethy1—1,3,2—dioxaborolan-Z-yl)pyridin—2-y1]acetamide, 9 mg (0.01 mmol) of 1,1'—
phenylphosphino)ferrocenepalladiumfll) dichloride and 35 mg (0.33 mmol) of sodium
carbonate in a degassed mixture of 1.15 ml of dioxane and 0.17 ml of water in the microwave at
105°C for 90 minutes. Work-up and preparative HPLC according to Method P1 gave 21 mg (37%
of theory) of the title nd.
LC-MS (Method A3): R1 = 0.59 min
MS (ESIpos): m/z = 513 (M+H)+
1H NMR (400 MHz, DMSO—d6): 5 = 2.15 (s, 3 H), 2.21 (s, 3 H), 2.27 - 2.34 (m, 2 H), 2.35 — 2.41
(m, 2 H), 3.44 - 3.51 (m, 2 H), 3.52 — 3.58 (m, 2 H), 5.46 (s, 2 H), 7.58 - 7.68 (m, 2 H), 8.09 - 8.12
(m, 1 H), 8.12 — 8.17 (m, 1 H), 8.23 - 8.29 (m, 2 H), 8.30 (s, 1 H), 8.34 (s, 1 H), 8.79 (dd, 1 H), 9.32
(dd, 1 H), 10.53 (s, l H), 10.69 (s, 1 H).
Example 26
N-{2—[2-(4-Methy1piperazinyl)-2—oxoethyl]—2H-indazolyl}-6'-nitro-2,3‘-bipyridine
carboxamide
H O
N \_/
Analogously to Example 21, 75 mg (0.16 mmol) of 6—bromo—N—{2—[2—(4rmethylpiperazinyl)
oxoethyl]—2H—indazolyl}pyridinecarboxamide were stirred with 82 mg (0.33 mmol) of 2—
nitro-S-(4,4,5,5—tetramethyl—1,3,2-dioxaboro1anyl)pyridinc, 13 mg (0.02 mmol) of 1,1'—
bis(diphenylphosphino)ferrocenepalladiumfll) dichloride and 52 mg (0.49 mmol) of sodium
carbonate in a degassed e of 1.73 ml of e and 0.25 ml of water in the microwave at
105°C for 90 minutes. Work-up and preparative HPLC ing to Method P1 gave 26 mg (32%
of theory) of the title compound.
UPLC-MS (Method A1): R1; = 0.78 min
MS (ESIpos): m/z = 501 (M+H)+
1H NMR (300 MHz, DMSO—d6): 6 = 2.22 (s, 3 H), 2.31 (br. s., 2 H), 2.39 (br. s., 2 H), 3.48 (br. s.,
2 H), 3.56 (br. 5., 2 H), 5.47 (s, 2 H), 7.63 (s, 2 H), 8.22 - 8.38 (m, 4 H), 8.45 - 8.55 (m, 2 H), 9.22
(dd, 1 H), 9.72 (d, 1 H), 10.63 (s, 1 H).
Examgle 27
6’-Amino-N-{2-[2-(4—methy1piperazin—1~yl)oxoethyl]-2H-indazol—5 -yl} —2,3 '-bipyridine—6—
carboxamide
H O r—\
N U
HZN N
mg (0.04 mmol) of N-{2-[2-(4—methylpiperazinyl)oxoethyl]-2H-indazolyl}-6'—nitro-
ipyridinecarboxarnide were dissolved in 2.5 ml of methanol, 4 mg (0.004 mmol, 10%) of
palladium on carbon were added and the mixture was hydrogenated under a hydrogen atmOSphere
of 1 bar for 4 h. The reaction mixture was filtered off through , the filter cake was washed
repeatedly with methanol and the filtrate was concentrated and dried under reduced pressure. This
gave 8 mg (43% of theory) of the title compound.
UPLC-MS (Method A1): Rt = 0.81 min
MS (ESlpos): m/z = 471 (M+H)'
'H NMR (400 MHz, METHANOL-d4): 6 = 2.34 (s, 3 H), 2.43 - 2.49 (m, 2 H), 2.53 (br. 5., 2 H},
3.66 (br. 5.. 4 H), 5.46 (s, 2 H), 6.73 (d, l H), 7.51 - 7.58 (m. l H), 7.60 ~ 7.67 (m, 1 H). 7.94 - 8.04
(m, 2 H), 8.07 (d, I H), 8.21 (s, 1 H), 8.34 (br. 5., 2 H), 8.55 (s, l H), 8.77 (s, l H).
20 14/077877
General ure 2a
1.0 equivalent of the respective ediate, 1.0 equivalent of 1-hydroxy—1H—benzotriazole
hydrate and 2.0 equivalents of 1—(3 ~dimethylaminopropyl)—3 -ethylcarbodiimide hydrochloride were
stirred in 3 m1 of ydrofuran and 0.33 ml of dimethylformamide at 25°C for 30 min. 1.5
equivalents of the amine were then added and the mixture was stirred at 25°C for 30 min. The
mixture was poured into 50 ml of water, filtered off with suction, washed with water and dried.
General Procedure 2b
1.0 equivalent of the respective intermediate, 1.0 equivalent of l—hydroxy—lH-benzotriazole
hydrate, 2.0 equivalents of 1-(3dimethylaminopropyl)ethylcarbodiimide hydrochloride and 3.0
equivalents of triethylamine were stirred in 1.5 ml of methylf0rmamide at 25°C for 30 min.
1.2 equivalents of the amine were then added. The reaction mixture was diluted with a further 1.0
ml of.’\-’.."v’—dimethylformamide and purified by preparative HPLC according to Method PI.
General Procedure 2c
1.0 equivalent of the respective intermediate, 1.0 equivalent of oxy-lH—benzotriazole
hydrate, 2.0 lents of 1—(3-dimethylaminopropyl)ethy1carbodiimide hydrochloride, 3.0
lents of triethylamine and 1.2 equivalents of the amine were stirred in tetrahydrofuran at
25°C for 18 h. Water was added to the reaction mixture. The solid was filtered off with n,
washed with water and diethyl ether and dried.
l Procedure 2d
1.0 lent of the respective intermediate, 1.0 equivalent of 1—hydroxy—1H—benzotriazole
hydrate, 2.0 equivalents of 1—(3-dimethylaminopropy1)ethy1carbodiimide hydrochloride, 3.0
equivalents of triethylamine and 1.5 equivalents of the amine were stirred in tetrahydrofuran at
°C for 18 h. The reaction solution was diluted with water and extracted with ethyl acetate. The
ed organic phases were concentrated and the crude product was purified by preparative
HPLC according to Method P4.
General Procedure 2e
1.0 equivalent of the respective intermediate, 1.0 equivalent of l—hydroxy—lH—benzotriazole
hydrate, 2.0 equivalents of 1—(3-dimethylaminopropyl)—3—ethylcarb0diimide hydrochloride, 3.0
equivalents of triethylamine and 1.3 equivalents of the amine were stirred in tetrahydrofuran at
25°C for 18 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The
combined organic phases were concentrated, and 1 ml of dimethyl sulphoxide was added. The solid
was filtered off With suction, washed three times with in each case 0.5 ml of dimethyl sulphoxide
and three times with diethyl ether and dried. The filtrate was concentrated and purified by
ative HPLC according to Method P2. The resulting product fraction was combined with the
solid.
General Procedure 2f
1.0 equivalent of the respective intermediate, 1.0 equivalent of l-hydroxy-lH-benzotriazole
hydrate, 2.0 equivalents of l—(3~dimethylarninopropyl)—3—ethylcarbodiirnide hydrochloride, 4.0
equivalents of triethylamine and 1.2 equivalents of the amine were stirred in tetrahydrofuran at
25°C for 18 h. The precipitate formed was d off and washed with tetrahydrofuran. The solid
was triturated with methyl tert-butyl ether and ethyl acetate and then dissolved in romethane,
and water was added. The aqueous phase was extracted with dichloromethane and the combined
c phases were washed with saturated sodium chloride solution and dried over sodium
sulphate. After filtration, the solution was concentrated and the resulting product was dried.
General Procedure 2g
1.0 equivalent of the respective ediate, 1.0 lent of l—hydroxy—lH—benzotriazole
hydrate, 2.0 equivalents of 1-(3-dimethylaminopropyl)-3—ethylcarb0diimide hydrochloride, 3.0
equivalents of triethylamine and 1.3 equivalents of the amine were stirred in tetrahydrofuran at
50°C for 18 h. Water and ethyl acetate were added to the reaction mixture. The solid was d
off with suction, washed with water and diethyl ether and dried.
Table 2: Examples 28 — 71
The exemplary compounds were prepared by the general experimental procedures 2a-2g from the
apprOpriate intermediates and amines.
Ex. Prepared *
Structure/Name 1 H-NMR / LC—MS
No. from key
28 fl“ 9-1 and 2a (300 MHz, DMSO-d6): 5 =
F \ N
F °
F o ICE:~->r0 phenpriper (94% 3.38 — 3.75 5.51 (m, 8H),
0 b azin-l- ) (s, 2H), 7.40 - 7.56 (m,
y1)methanon 6H), 8.19 — 8.26 (m,
N {217(4be 1 _ , 1H),
- —. - nzoylp ptrazm--1 3'1) -
e 8.35 — 8.49 (m, 4H), 10.24
hyl]-6—fluoro—2H-indazol
(m, 1H) . ’ yl } ifluoromcthyl)pyridine—2-
UPLC-MS (Method Al):
carboxamide
1 RI = 1.15 min
MS (ESIpos): m/z = 555
(M+H)+
29 / 9-1 and
1 H (300 MHz, fi): 5 =
F \ N
F 0
F o :,N /—\ CYCIOPYOPYK 0.69 - 0.81 (m, 4H), 2.00 (s
) zm-l- br, 1H), 3.40 — 3.82 (m,
yl)methanon 8H), 5.52 (s, 2H), 7.53 (d,
N-(2- {2'14'
6 1H), 8.22 (m, 1H), 8.36
(cyc1opropylcarbonyl)piperazin—1 - -
8.49
yl]oxoethyl} flu0ro-2H— (m, 4H), 10.25 (m,
1H).
i11dazol-5—yl)
UPLC-MS (Method A1):
(tn'fluoromethyl)pyridine-2—
Rt = 1.09 min
carboxamide
MS (ESIpos): m/z = 519
(M+H)+
9-1 and 1- (300 MHz, DMSO-d6): 6 =
methylpipera 2.21 (s, 3H), 2.29 (m, 2H),
zine 2.38 (m, 2H), 3.47 (m, 2H),
N- {6-fluoro—2-[2-(4- 3.55 (m, 2H), 5.47 (s, 2H),
methylpiperazin-l -y1)0xoethyl]- 7.52 (d, 1H), 8.22 (m, 1H),
2H—indazol~5~y1} 8.34 — 8.48 (m, 4H), 10.24
(tn'fluoromethyl)pyridine (m, 1H).
carboxamide UPLC—MS (Method A1):
: 0.93 min
MS (ESIpos): m/z = 465
(M+H)+
(300 MHz, DMSO—dé): 5 =
0.68 - 0.82 (m, 4H), 2.01 (5
lbw-{214- piperazin-I - hr, 111), 2.63 (s, 3H), 3.40 4
y1)methanon ' 3.82
' (m, 8H), 5.52 (s, 2H),
(cwlopropylcarbonvlmiperazin- 1-
e 7.49 — 7.62 (m, 2H), 7.95 —
y1]oxoethyl}—6—fluoro-2H—
8.05 (m, 2H), 8.38 (s, 1H),
indazol-S-yl)methy1pyridine—2—
8.55 (d, 1H), 10.39 (d, 1H).
amide
S (Method A1):
Rt = 1.02 min
MS (ESIpos): m/z = 465
(IVHH)+
9—2 and 1— (300 MHZ, 6): 5 =
methylpipera 2.21 (s, 3H), 2.29 (m, 2H),
zine 2.38 (m, 2H), 2.63 (s, 3H),
N— {6—fluoro—2— [2—(4—
3.46 (m, 2H), 3.53 (m, 2H),
methylpipcrazin—I -y1)—2—oxoethy1]—
.45 (s, 2H), 7.47 — 7.62
2H-indazol-5 —y1}
(m, 2H), 7.93 (m, 2H), 8.36
methylpyridine-2—carboxamide
(s, 1H), 8.55 (d, 111), 10.55
(s, 1H).
UPLC—MS (Method A1):
Rt = 0.81 min
MS (ESIpos): m/z = 411
(M+H)+
33 (31%: 9-3 and 2a (300 MHz, DMSO-d6): 6 =
KINfpUx cyclopropy1( (82% 0.68 — 0.83 (m, 4H), 2.02 (s
piperazin-l- ) br, 1H),3.42 -3.85 (m, 8H),
N-(2-{2-[4-
meethanon [a] 3.93 (s, 3H), 5.53 (s, 2H),
( . '
CyC 01 p WIO lcarb011Y pp1) 1 erazm— 1 -
6 7.54 (d, 1H), 7.87 - 8.09
yI]—2-oxoethyl}fluoro-2H—
(m, 3H), 8.23 (5, 11—1), 8.38
indazol—S-yl)(1-methyl-1H-
(m, 2H), 8.54 (s, 1H), 10.52
pyrazol-4—yl)pyridine—2—
(s, 1H) .
carboxamide
UPLC-MS (Method A1):
Rt = 0.93 min
MS (ESIpos): m/z = 531
(M+H)+
34 “£26mfCbiA 9-3 and 23 (300 MHz, DMSO—d6): 5 =
. 7
(piper l(47% 3.40 — 3.79 (m, 8H), 3.94
‘ aiml- (s, 3H), 5.51 (s, 2H), 7.41 -
NZ{— -[2 W-(4 0)1p pci razin-1 -y )I
meethanon [b] 7.57 (m, 6H), 7.93 (t, 2H),
2—oxoethyl]flu0ro-2H-indazoI
e 8.04 (t, 1H), 8.22 (s, 1H),
y1}(1-methy1-1H-pyrazol
8.39 (m, 2H), 8.52 (s, 1H),
yl)pyridinecarboxamide
.51 (s, 1H).
S (Method Al):
Rt = 1.00 min
MS s): m/z = 567
(M+H)+
9-3 and 1- 2a (300 MHZ, DMSO—dé): 5 =
methylpipera (14% 2.21 (s, 3H), 2.30 (m, 2H),
zine ) 2.38 (m, 2H), 3.47 (m, 2H),
N'{6'flu°‘°'2‘[2‘(4' [b] 3.55 (m, 2H), 3.93 (s, 3H),
methylpiperazin—l -y1)oxoethyl] -
.47 (s, 2H), 7.52 (d, 1H),
azoly1}-6—(1-methy1-1H— 7.93 (t, 2H), 8.04 (t, 1H),
pyrazoly1)pyridine—2- 8.22 (s, 1H), 8.39 (m, 2H),
carboxamide
8.52 (s, 111), 10.50 (s, 1H).
UPLC-MS (Method A1):
Rt=0.74 min
MS (ESIpos): m/z = 477
(M+H)+
36 9-4 and 2a
0 (300 MHz, DMSO-d6): 5 =
N"%5 N
N m’ ‘3“Q " .51?"hen 1 1 er (64% 3.38 — 3.76 3.96
0 (m, 8H),
) (s, 3H), 5.51 (s, 2H), 7.41-
N—{2-[2-(4—benzoy1piperazjn—1-yl)- y1)methanon 7.56 (m, 6H), 7.93 — 8.05
2—oxoethy1]fluoro-2H-indazol-5~ e (m, 2H), 8.25 — 8.31 (m,
yl}—5—fluoro-6—(1-methy1—1H- 2H), 8.40 (s, 1H), 8.53 (m,
pyrazolyl)pyIidine 1H), 10.40 (s, 1H).
carboxamide
UPLC-MS (Method A1):
Rt = 1.07 min
MS (ESIpos): m/z = 585
(M+H)+
37 F
{\ 9—4 and 23
n o /_\ o g (300 MHz, DMSO-d6): 5 =
"(f :.~)_N\—/ Ecyclowopyfl (59% 0.69 - 0.83 (m, 4H), 2.0!
c, (s
":3 i piperazin—l- ) ibr, 1H), 3.4] — 3.85 (m,
N'{Z'{2'H' ; '
yl)mcthanon ‘ [a] 8H). 3.97 (s, 3H), 5.52 (s,
(cyclopropylcarbonyl)piperazin- l - e 2H), 7.52 (d, 1H), 7.93 -
oxoethyl}fluoro-2H- 8.06 (m, 2H), 8.28 (m, 2H),
indazol:5-y1)—5 -fluoro(1 1- 8.39 (s, 1H), 8.53 (s, 1H),
1H—pyrazoly1)pyridinc-2— 10.40 (s, 1H).
carboxamide
UPLC—MS (Method A1):
Rt = 1.00 min
MS (ESIpos): m/z = 549
(M+H)+
9—5 and 2a
D /_\ 0 (300 MHz, DMSO-dé): 8 =
CO{If}: N
o Fm"}NL/NJ© Phenylfiniper (78% 3.41 — 3.82 (m, 16H), 5.50
azin-l— ) (s, 2H), 7.15 (d, 1H), 7.47
N— {2-[2—(4—benzoy1piperazin-1 -y1)—
yl)methan0n (m, 7H), 7.81 (t, 1H), 8.37
2—oxoethy1]quoro-2H-indazol—S-
e (s, 1H), 8.48 (d, 1H), 10.27
(m0rph01in—4-y1)pyridine
(m, 1H).
amide
UPLC-MS (Method A1):
Rt= 1.06 min
MS (ESIpos): m/z = 572
(M+1—1)+
\ 9-5 and 2a (300 MHZ, DMSO-dé): 8 =
0 N N
~ “JCQJW/ cyclopropyl( (91% 0.67 - 0.83 (m, 4H), 2.01 (s
piperazin-l— ) br, 1H), 3.44 — 3.81 (m,
N-(2 - {2 -[4—
y1)methan0n [a] 16H), 5.50 (s, 2H), 7.15 (d,
(cyclopropylcarbonyl)piperazin-1 -
8 1H), 7.44 — 7.55 (m, 2H),
oxoethy1}-6—fluoro—2H—
7.81 (t, 1H), 8.37 (s, 1H),
indazol—S-y1)(morpholin—4-
8.48 (d, 1H), 10.27 (m,
yl)pyridinecarboxamide
1H).
UPLC—MS (Method A1):
Rt = 1.01 min
MS (ESIpos): m/z = 536
m+m+
409%km71 9-5 and I- la (300 MHZ, DMSO-d6): 5 =
methylpipera i (64% 2.21 (s, 3H), 2.30 (m. 2H),
2.38 (In, 2H), 3.47 (m. 2H), )
luoro-l[2.(4- ’
3.55 (m, 2H), 3.59 (m, 4H),
methylpiperazin-l -y1)oxoethy1]-
3.76 (m, 4H), 5.45 (s, 2H),
2H-indazoI—5—yl} -6—(m0rpholin
7.15 (d, 1H), 7.44 - 7.53
yl)py1idine—2—carboxamide
(m, 2H), 7.81 (tr, 1H), 8.36
(s, 1H), 8.47 (d, 1H), 10.27
(In, 1H).
UPLC—MS (Method A1):
Rt=0,79 min
MS (ESIpos): m/z = 482
(M+H)+
PCT/EP201 4/0778 77
41 / 9-6 and 1— 2b
I H 0 (400 MHz, DMSO-d6): 5 =
F \N N
/ N—cHl . o
FF \4 methylplpera (722; 2,21 3 2.26 - 2.33
0 m, (s, H),
j N
zine ) (m, 2 H), 2.34 - 2.43 (m, 2
: H), 3.43 - 3.50 (In, 2 H),
N-{6-(benzyloxy)[2-(4- 3.51 - 3.59 (m, 2 H), 5.31
methylpiperazin-l-yl)oxoethy1]— (s, 2 H), 5.39 (s, 2 H), 7.30
2H—indazol«5-y1} (s, 1 H), 7.34 — 7.45 (m, 3
(tn'fluoromethyl)pyridine H), 7.58 (dd, 2 H), 8.18
carboxamide (dd, 1 H), 8.25 (s, 1 H),
8.35 — 8.44 (m, 1 H), 8.44 -
8.50 (m, 1 H), 8.80 (s, l H),
.47 (s, 1 H).
LC‘MS (Method A3): Rt =
I 0.96 min
1 - MS (ESlpos): mfz = 553
(M+H)+
FfiYfi 9-7 ant) 1- (300 MHz, 6): 5 =
/ yNQflHS
F methylplpera 1.11 (s, 3 H), 1.13 (s, 3 H),
F 0 m“
H’cfij zine 2.17-2.23 (m, 1 H), 2.21 (s,
CH. 3 H), 2.25 - 2.33 (m, 2 H),
sobutoxy[2-(4- 2.37 (br. 5., 2 H), 3.46 (br.
methylpiperazin—l—yl)—2—oxoethyl]— s., 2 H), 3.54 (br. 5., 2 H),
2H-indazoIyl}—6— 3.96 (d, 2 H), 5.38 (s, 2 H),
(trifluoromethy1)pyridine-2— 7.07 (s, 1 H), 8.14 — 8.26
carboxamide (m, 2 H), 8.34 — 8.45 (m, 1
H), 8.45 — 8.53 (m, 1 H),
8.78 (s, 1 H), 10.58 (s, 1
LC—MS (Method A3): Rt =
1.06 min
MS (ESIpos): m/z 519
(MJFH)+
’1426
/ 9-7 and 2b
I (300 MHz, 6): 8 =
H 0
/ \
F \N N / _>‘N. ,0
F fiN morpholine (54% 3.47 (d, 2 H), 3.52 - 3.68
F o \ /
) (m, 6 H), 3.96 (d, 2
HC H),
ona 5.40 (s, 2 H), 7.07 (s, 1 H),
N— {6-isobutoxy—2-[2-(m0rpholin-4~ 8.19 — 8.25 (In, 2 H), 8.36 —
yl)oxoethyl]-2H—indazol-5 -y1} — 8.45 (m, 1 H), 8.46 — 8.52
6-(trifluoromethyl)pyridine (m, 1 H), 8.78 (s, 1 H),
carboxamide 10-58 (s, 1 H).
LC-MS (Method A3): Rt =
1.32 min
MS (ESIpos): m/z = 506
(M+H)+
/I, 9—7 and“2- 2b (300 MHZ, DMSO—dé): 6 =
l (49% )
:WW".o>_0—30“ idin—4— 1.056.611), 1.11 (s, 3 141),;
>11pmpan-2 - 1 ) 1.13 (s, 3 H). [.19 - 1.33!
Cu. 01
(m, 3 H), 1.36 - 1.52 (m, 1
N—(2- {2-[4—(2—hydroxypropan
H), 1.75 (t, 2 H), 2.11 -
yl)piperidin—l —yl]—2—oxoethy1} -6— 2.25 (m, 1 H), 2.90 - 3.09
isobutoxy-ZH-indazoI-S—y1)—6—
(m, 1 H), 3.96 (d, 2 H),
(trifluoromethy1)pyridine 4.02 (d, 1 H), 4.18 (s, 1 H),
carboxamide
4.42 (d, 1 H), 5.27 - 5.45
(m, 2 H), 7.07 (s, 1 H), 8.18
- 8.25 (m, 2 H), 8.35 - 8.45
(m, 1 H), 8.45 - 8.52 (m, 1
H), 8.77 (s, 1 H), 10.58 (s,
1 H).
LC-MS (Method A3): Rt =
1.34 min
MS (ESIpos): m/z = 562
(M+H)+
PCT/EP2014/O77877
45 / 9-7 and 1-
0 (400 MHz, DMSO-d6): a =
1 H CH3
F \ N
~ m M 0.18 - 0.25 (m, 1
. cyclopropyl- H), 0.33
1: o \N/
H30? N- (q, 1 H), 0.41 - 0.49 (m, 1
methylmetha H), 0.50 — 0.58 (m, 1 H),
namine 0.92 - 1.02 (m, 1 H), 1.11
N-(2-{2—
(s, 3 H), 1.13 (s, 3 H), 2.19
opropylmethyl)(methy1)amin
(dt, 1 H), 2.92 (s, 1 H) +
o]-2—oxoethyl}isobutoxy-2H-
3.13 (s, 2 H), 3.20 (d, 1 H),
indazol—S—y1)
3.34 (d, 1 H), 3.96 (d, 2 H),
(trifluoromethyl)pyridine—2—
.33 — 5.42 (m, 2 H), 7.07
carboxamidc
(s, 1 H), 8.16 — 8.28 (m, 2
H). 8.41 (t, 1 H), 8.49 (d, 1
8.78
, H). (s. 1 H). 10.57 (s.
i 1 m).
' LC-MS (Method A3): RI
I =
1.45 min
MS (ESIpos): m/z = 504
(M+H)+
46 9-8 and 1- 2b (400 MHz, DMSO-d6): 5 =
pipera (75% 0.39 — 0.51 (m, 2 H), 0.57 —
zine ) 0.70 (m, 2 H), 1.27 — 1.43
(m, 1 H), 2.21 (s, 3 H), 2.29
N- {6—(cyclopropy1methoxy)—2—[2-
(t, 2 H), 2.34 - 2.39 (m, 2
(4-methylpiperazin—l —yl)—2—
H), 3.43 - 3.49 (m, 2 H),
oxoethyl]—2H—indazo1—5—y1 } —6— 3.51 - 3.57 (m, 2 H), 4.03
(trifluoromethyl)pyridine—2—
(d, 2 H), 5.37 (s, 2 H), 7.05
carboxamide
(s, 1 H), 8.19 - 8.23 (m, 2
H), 8.41 (t, 1 H), 8.48 (d, 1
H), 8.76 (s, 1 H), 10.71 (s,
1 H).
LC-MS (Method A3): R1 =
1.01 min
MS (ESIpos): m/z = 517
(M+H)+ 1
PCT/EPZO 14/077877
9-8 and (400 MHz, DMSO—d6): 8 =
morpholine 0.40 - 0.48 (m, 2 H), 0.66
(dd, 2 H), 1.31 - 1.40 (m,1
H), 3.43 — 3.50 (m, 2 H),
N-{6-(cyclopropy1methoxy)—2-[2- 3.53 — 3.68 (m, 6 H), 4.03
(morpholin—4—y1)oxoethy1]-2H- (d, 2 H), 5.39 (s, 2 H), 7.05
l—S-y1} (s, 1 H), 8.19 - 8.23 (m, 2
(trifluoromethyl)pyfidine H), 8.38 — 8.44 (m, 1 H),
carboxamidc 8.45 — 8.50 (m, 1 H), 8.76
(s, 1 H), 10.71 (s, 1 H).
LC-MS (Method A3): Rt =
1.25 min
MS (ESIpos): m/z = 504
9-3 and 2- lbi (400 MHz, DMSO-d6): 6 =
(piperidin 0.41 - 0.48 (m, 2 H), 0.62 -
yl)pr0pan-2— 0.69 (m, 2 H), 1.05 (s, 6 H),
01 1.09 (d, 1 H), 1.13 - 1.29
N-[6-(Cyclopr0pylmethoxy)—2— {2—
(m, 2 H), 1.29 - 1.40 (m, 1.
[4-(2—hydr0xypropan—2-
H), 1.40 — 1.51 (m, I H),
yl)piperidin—1—y1]-2—oxoethy1}—2H-
1.75 (t, 2 H), 2.99 (t, 1 15-1),
l-S -yl]—6—
4.02 (d, 3 H), 4.16 (s, 1 H),
(trifluoromethy1)pyridine
4.42 (d, 1 H), 5.25 — 5.45
carboxamide
(In, 2 H), 7.04 (s, l H), 8.17
- 8.24 (m, 2 H), 8.41 (t, 1
H), 8.48 (d, 1 H), 8.75 (s, 1
H), 10.70 (s, 1 H).
LC-MS (Method A3): Rt =
1.27 min
MS (ESIpos): m/z = 560
(M+H)+
Yowjgj}% 9-8 and 1- (400 MHz, DMSO-d6): 6 =
cyclopropyl- 0.22 (q, 1 H), 0.33 (d, 1 H),
0.41 — 0.48 (m, 3 H), 0.50 —
methylmetha 0.57 (m, 1 H), 0.62 - 0.69
N—[6-(cyclopropy1methoxy){2- namlne (m, 2 H), 0.97 (br. s., 1 H),
[(cyclopropylmethyl)(methy1)amin 1.30 - 1.41 (m, 1 H), 2.92
0]0xoethyl}—2H-indazol-5—yl] (s, 1 H) + 3.13 (s, 2 H),
(trifluoromethyl)pyridine—2— 3.20 (d, 1 H), 3.34 (d, 1 H),
carboxamide 4.03 (d, 2 H), 5.29 - 5.43
(m, 2 H), 7.05 (s, 1 H), 8.19
- 8.25 (m, 2 H), 8.41 (t, 1
H), 8-48 (d. 1 H), 8.76 (s, l
H), 10.70 (s. 1 H). 1
LC-MS (Method A3): Rt =
1.38 min
MS s): m/z 502
(M+H)+
50 9-9 and 1— 2b (300 MHz, DMSO-d6): 5 =
methylpipera (75% 2.21 (s, 3 H), 2.24 - 2.33
zine (m, 2 H), 2.37 (br. 3., 2 H),
3.47 (br. s., 2 H), 3.55 (br.
N— {2-[2-(4—methy1piperazin-1 -y1)- 5., 2 H), 5.36 (s, 2 H), 5.40
2-0xoethyl]—6—(pyridin—2- (s, 2 H), 7.30 (s, 1 H), 7.36
ylmethoxy)-2H-indazol-5—y1}—6— - 7.47 (m, 1 H), 7.71 (d, 1
(trifluoromcthyl)pyridine—2— H), 7.79 - 7.90 (m, 1 H)
amide 8.19 (dd, 1 H), 8.26 (s, 1
H), 8.34 - 8.44 (m, 1 H),
8.45 - 8.52 (In, 1 H), 8.62
(d, 1 H), 8.81 (s, 1 H),
.50 (s, 1 H).
LC-MS (Method A3): Rt =
0.92 min
MS (ESIpos): m/z = 554
(M+H)+
2014/077877
51 / 9-9 and 2b (400 MHz, DMSO—dé): 5 =
l ° W
F \ 4
F morphohne (23% 3.40 _ 3.52 (m, 2 H), 3.59
F O meNL/O\/
N ) (d, 4 H), 3.62 - 3.68 (m, 2
I H), 5.36 (s, 2 H), 5.41 (s, 2
H), 7.30 (s, 1 H), 7.42 (dd,
N— {2-[2—(morpholiny1)
1 H), 7.70 (d, 1 H), 7.86
oxoethyl]—6-(pyridin—2—y1methoxy)—
(td, 1 H), 8.15 - 8.23 (m, 1
2H-indazoIy1}—6—
H), 8.27 (s, 1 H), 8.39 (1, 1
(trifluoromethyl)pyridine-2—
H), 8.48 (d, 1 H), 8.62 (d, 1
carboxamide
H), 8.81 (s, 1 H), 10.50 (s,
1 H).
LC-MS (Method A3): Rt =
H] min
MS (ESIpos): m/z = 541
(M+H)+
52 9-9 and 2- 2b (400 MHz, 6): 5 =
(piperidin (29% 1.05 (s, 6 H), 1.17 - 1.34
y1)propan ) (111,3 H), 1.37 - 1.52 (m, 1
01 H), 1.76 (1, 2 H), 2.91 -
N-[2- {2- [4-(2-hydr0xypr0pan-2— 3.08 (m, 1 H), 4.04 (d, 1
y1)piperidin—1~y1]oxoethyl} H), 4.17 (s, 1 H), 4.42 (d, 1
(pyridiny1meth0xy)-2H—indazo 1— H), 5.28 - 5.45 (m, 4 H),
—yl](trifluoromethy1)pyridine—2— 7.29 (s, 1 H), 7.36 - 7.47
carboxamide (m, 1 H), 7.70 (d, 1 H),
7.86 (td, 1 H), 8.19 (dd, 1
H), 8.26 (s, 1 H), 8.40 (t, 1
H), 8.48 (d, 1 H), 8.58 -
8.65 (m, 1 H), 8.81 (s, 1 H),
.50 (s, 1 H).
LC—MS (Method A3): Rt 2
1.15 min
MS (ESIpos): m/z = 597
(M+H)+
PCT/EP20l4/077877
S3 /
I O CH (400 MHz, DMSO-d6): 5 =
H 5
F \ N NI
N /‘11)!)— \_<] cyclopmpyl-
FF 0.19 - 0.26 (m, 1 H), 0.30 -
N- 0.37 (m, 1 H), 0.40 - 0.49
/~ methylmetha (m, 1 H), 0.51 - 0.60 (m, 1
namine H), 0.91 — 1.02 (m, 1
N-[2- {2_ H),
2.93 (s, 1 H)+ 3.14 (s, 2 H),
[(cyclopropylmethyl)(methy1)amin
3.21
o]oxoethy1} (pyridin (d, 1 H), 3.35 (d, 1 H),
.36
ylmethoxy)—2H-indazolyl]—6— (s, 2 H), 5.39 (s, 2 H),
7.30 1 H), 7.37 — 7.45
oromethyl)pyridine (s,
(m, 1 7.70
carboxamide H), (d, l H),
7.86 (td, 1 H), 8.19 (dd, 1
H), 8.27 (d, l H), 8.40 (t, l
H). 8.48 (d. 1 H), 8.62 (d, l
H), 8.81 (s, l H), 10.50 (s,
1 H).
LC-MS (Method A3): Rt =
1.24 min
MS (ESIpos): m/z — 539
(M+H)+
54 2c (300 MHZ, DMSO-d6): 5 = 9-11and
F :1 fl
s ‘5:me_°>—/_\No\Jb (piper (95% 3.40 - 3.82
F (m, 8H), 5.54
azin-l— (br. s., 2H), 7.41 - 7.52 (m,
N-{2-[2-(4-benzoy1piperazin—1-y1)- y1)methanon 5H), 7.91 (s, 1H), 8.23 (dd,
2-oxoethy1]chlor-2H-indazol c 1H), 8.37 - 8.49 (m, 3H),
yl} —6—(trifluoromethy1)pyridine 8.64 (s, 1H), 10.5 (s, 1H).
carboxamide
UPLC—MS (Method A1):
Rt = 1.22 min
MS (ESIpos): m/z = 571
(M+H)+
PCT/EPZO 14/077877
55 9-11 and 2d (400 MHz, DMSO-dé): 5 =
/ morpholine (44% 3.48 (d, 2H), 3.53 - 3.63
) (m, 4H), 3.66 (d, 2H), 5.52
N-{6-chloro—2-[2—(morpholinyl)— (s, 2H), 7.92 (s, 1H), 8.24
thy1]-2H-indazol-5 -y1} —6- (d, 1H), 8.38 — 8.44 (m,
(trifluoromethyl)pyridine—2- 2H), 8.45 - 8.49 (m, 1H),
carboxamide 8.66 (s, 1H), 105 (br. s.,
1H).
UPLC-MS (Method A1):
Rt = 1.16 min
MS (ESIpos): m/z = 468
(M+H)+
9-11 and 2d
] n (500 MHz, DMSO—dé): 8 =
l‘T/‘N\ oomNyN/fiu_<°_f ethylplpcml (41% 1.21 (z, 310337-353 (m,
l C \—/ C ne-l- ) 9H), 4.08 (q, 2H), 5.54 (s,
Ethyl 4'{[6£h1°r°‘5“[6' carboxylate 2H), 7.92 (s, 1H), 8.24 (dd,
oromethyl)pyridin-2—
1H), 8.39 _ 8.44 (m, 2H),
y1]carbony1}amino)-2H-indazol
8.45 _ 8.49 (m, 1H), 8.66 (s,
yl]acetyl}piperazine—l—carboxylate
1H), 10.5 (s, 1H).
UPLC-MS (Method A1):
Rt= 1.24 min
MS (ESIpos): m/z = 538
(M+H)+
57 9-1 1 and 4- 2d
| (400 MHz: DMSO-d6): 5 =
00.33:”).300 (pyrrolidin- (31% 1.25 - 1.37 (m, 1.39 —
. 1H),
1- ) 1.53 (m, 1H), 1.68 (br. 5.,
N-(6-ch10ro{2-oxo[4- yl)pipeddjne [C] 4H), 1.78 — 1.95 (m, 2H),
(pynolidin-l -y1)piperidin— 1 - 2.19 - 2.30 (m, 1H), 2.87 (t,
yl]ethyl}-2H—indazol-5 -yl)—6- 1H), 3.19 (t, 1H), 3.88 (d,
(trifluoromethyl)pyridine—2- 1H), 4.10 (d, 1H), 5.49 (d,
carboxamide 2H), 7.91 (s, 1H), 8.23 (d,
1H), 8.38 — 8.44 (m, 2H),
8.45 - 8.49 (m, 1H), 8.66 (s,
1H), 105 (br. s., 1H).
UPLC-MS (Method A1):
RI = 1.00 min
MS (ESIpos): m/z 535
(M+H)+
9-1 1 and 2- 2d (400 MHz, DMSO-d6,
(piperidin (32% selected signals): 5 = 1.05
pan-2— ) (s, 6H), 1.68 - 1.85 (m,
N-(6-Ch10ro—2— {2- [4-(2 - ol [d] 2H), 3.02 (t, 1H), 4.02 (d,
hydroxypropan—Z—yl)piperidin-1 - 1H), 4.17 (s, 1H), 4.42 (d,
yl]—2—oxoethy1}I—indazol-5 -yl)- 1H), 5.42 - 5.55 (m, 2H),
6—(trifluoromethyl)pyfidine—2~ 7.91 (s, 1H), 8.23 (d, 1H),
amide 8.38 - 8.51 (m, 3H), 8.65 (s,
1H), 10.5 (s, 1H).
UPLC-MS (Method A1):
Rt = 1.18 min
MS (ESIpos): m/z = 524
(M+H)+
WO 91426
59 / 9-11 and 3- 2d
I H (400 MHz, DMSO-dé): 5 =
F \ N
N /
F. .mwm . hydroxy-2,2- 1.18 (s, 6H), 3.39 — 3.72 (m,
an dimethyl—l - ) 10H), 4.61 (t, 1H), 5.54 (s,
(:11a 0
(piperazin—l - [e] 2H), 7.92 (s, 1H), 8.24 (d,
N—(6-ch10ro {2-[4—(3—hydroxy—
y1)propan-l - 1H), 8.38 - 8.44 (m, 2H),
2,2-dimethylpropanoyl)piperazin—1 —
one 8.45 - 8.50 (m, 1H), 8.66 (s,
yl]0xoethy1}-2H-indazol-5 -y1)-
1H), 10.5 (s, 1H).
6-(triflu0romethy1)pyridine
UPLC—MS (Method
carboxamide A1):
Rt = 1.13 min
MS (ESIpos): m/z = 567
(M+H)+
9—11 and 2e (400 MHZ, DMSO-dfi): 5 =
/ N,N- (31% 2.08 (s, 6H), 3.07 — 3.14 (m,
o r~ r.
a ’1 ”fig—”1
o c dimethylazeti 1 ) 1H), 3.70 (dd, 1H), 3.92
N~(6-chloro{2-[3- dine-3 -aminc ' 1 (dd, 1H), 4.02 (dd, 1H),
(dimethylamino)azetidin-1 -yl] 4.19 (t, 1H), 5.21 (s, 2H),
yl}—2H—indazol—5-y1) 7.92 (s, 1H), 8.23 (dd, 1H),
(trifluoromethy1)pyridine—2— 8.37 - 8.49 (m, 3H), 8.64 (s,
carboxamide 1H),10.5(s, 1H).
S d A2):
Rt = 1.13 min
MS (ESIpos): m/z = 481
(M+H)+
9—11 and 1— 26 (400 MHZ,
(azetidin—3— (53% CHLOROFORM-d): 5 =
) 1.69 (br. s., 4H), 2.36 (br.
[f] s., 4H), 3.19 (br. s., 1H),
N-(6-ch10ro {2—oxo-2—[3-
4.01 - 4.21 (m, 4H), 4.99 —
(piperidin—l -y1)azetidin—1 -yl] ethyl} -
.14 (m, 2H), 7.29 (s, 3H),
2H-inda201—5 -y1)
7.85 (s, 1H), 7.90 — 7.95 (m,
(trifluoromethyl)pyn'dine
1H), 8.11 - 8.21 (m, 2H),
carboxamide
8.53 (d, 1H), 8.94 (s, 1H),
.6.9 - 10.78 (m, 1H).
UPLC-MS (Method A2):
Rt = 1.28 min
MS (ESIpos): m/z = 521
(M+H)+
62 KOY 9-11 and 2- 2d (300 MHz, DMso-c16): 5 =
F :N
F °CTJ©QNVNC>1 methyl-l- (75% 0.88 1.36 (m, 10H,
Hie 0H (piperidin ) contains singlet at 1.11
y1)pr0pan [2;] ppm), 1.64 - 1.90 (m, 3H), N-(6-ch10ro {2-[4-(2-hydroxy
01 2.59 — 2.74 (m,
methylpropy1)piperidin-1 —yl]
superimposed by DMSO—
oxoethyl} -2H-indazol-5 -
(16 signal), 3.09 (t, 1H),
(trifluoromethyl)pyridine—2-
3.89
amide (d, 1H), 4.11 (s, 1H),
4.23 (d, 1H), 5.38 - 5.55
(m, 2H), 7.90 (s, 1H), 8.23
(dd, 1H), 8.37 - 8.49 (m,
3H), 8.63 (s. 1H). 10.5 (s,
1H).
UPLC-MS (Method A1):
Rt = 1.23 min
MS (ESIpos): m/z = 538
(M+H)+
63 / 9—1 1 and
] H (300 MHz, DMSO—d6): 5 =
F \ N
N /
. 1,4‘— 1.18 - 1.53
~ 1000 (In, 4H),1.64 —
bipipen'din- 1.83 (m, 4H), 2.18 (t, 2H),
N-{6-chloro[2-(4-hydroxy-1,4'-
4-01 2.53 ~ 2.80 (m, 41-1,
bipiperidin- 1 '—y1)—2—0xoethy1] -2H-
mposed by DMSO
indazol—S—yl}—6—
signal), 3.06 (t, 1H), 3.36 —
(trifluoromethyl)pyridine
3.46 (m, supen'mposed by
carboxamide
water signal), 3.97 (d, 1H),
4.32 (d, 1H), 4.51 (d, 1H),
.40 — 5.58 (m, 2H), 7.90 (s,
1H), 8.20 — 8.26 (m, 1H),
8.37 - 8.49 (m, 3H), 8.63 (s,
1H), 10.52 (s, 1H).
UPLC-MS (Method A1):
Rt = 0.93 min
MS (ESIpos): m/z = 564
(M+H)+
64 Fi/ENEWJ/N 9- 12 and 1- 2f (400 MHz, DMSO—dé)‘. 5 =
:mN)flfl\_/NHCH pipera (57% 2.21 (s, 3H), 2.30 (t, 2H),
zine ) 2.37 (d, 2H), 3.47 (d, 2H),
N—{6~methoxy[2-(4- 3.51 - 3.59 (m, 2H), 3.99 (s,
methylpiperazin—l -y1)0xoethyl] - 3H), 5.39 (s, 2H), 7.11 (s,
2H—indazolyl} 1H), 8.18 - 8.26 (m, 2H),
oromethyl)pyridine 8.37 - 8.43 (m, 1H), 8.44 —
carboxamide 8.49 (m, 1H), 8.71 (s, 1H),
.51 (s, 1H).
UPLC-MS (Method A1):
Rt = 0.91 min
MS (ESIpos): m/z = 477
(M+H}+
‘ 19-2 and l 2b (300 MHZ, DMSO-d6): 5 =
MmM\_/'
morpholinc
I 1 (85% 3.42 - 3.51 (m, 2 H). 3.53 ~
3.62 (m, 4 H), 3.62 - 3.68
(In, 2 H), 3.99 (s, 3 H), 5.40
N— {6—methoxy—2-[2-(morpholin
(s, 2 H), 7.12 (s, 1H), 8.19
y1)oxoethy1]-2H-indazoly1} -
- 8.25 (In, 2 H), 8.36 - 8.44
6-(triflu0r0methy1)pyridine—2—
(m, 1 H), 8.44 - 8.50 (m, 1
carboxamide
H), 8.71 (s, 1 H), 10.51 (S,
1 H).
LC-MS (Method A3): Rt =
1.14 min
MS (ESIpos): mfz = 464
(M+H)+
9-13 and 2g (400 MHz, DMSO-d6): 5 =
N,N- (63% 1.17 - 1.29 (m, 1H), 1.31 -
dimethylpipe ) 1.45 (m, 1H), 1.49 (t, 3H),
r1 me'd' —4- 1.69 — 1.83 (m, 2H), 2.17
N-(2-{2—[4—
amine (s, 6H), 2.28 - 2.38 (m,
(dimethylamino)piperidin-1 -yl]
1H), 2.66 (t, 1H), 3.08 (t,
oxoethyl}ethoxy-2H-indazol
1H), 3.96 (d, 1H), 4.15 —
yl)—6-(trifluoromethy1)pyridine
4.31 (m, 3H), 5.30 - 5.41
carboxamide
(m, 2H), 7.07 (s, 1H), 8.18
- 8.24 (m, 2H), 8.37 - 8.47
(m, 2H), 8.71 (s, 1H), 10.7
(s, 1H).
UPLC-MS (Method A1):
Rt = 0.93 min
MS (ESlpos): m/z = 519
(M+H)+
9-13 and 4-
0 2g (400 MHz, 6): 5 =
:>251er\N (pyrrolidin_ (43% 1.22 - 1.35 (m, 1H), 1.37 -
F O NJCEthNO—NO
O N
HcJ 1' ) 1.54 (m, 4H), 1.67 (br. 5.,
yl)piperidine {1] 4H), 1.84 (t, 2H), 2.19 -
N—(6—ethoxy {2 —ox0 [4-
2.26 (m, 1H), 2.43 — 2.58
lidin—l —y1)piperidin~1 —
(superimposed by DMSO—
yl]ethy1}—2H—indazol—5—yl)—6—
d6 signal), 2.84 (t, 1H),
(trifluoromethyl)pyn'dine—2—
3.16 (t, 1H), 3.87 (d, 1H),
carboxamide
4.09 (d, 1H), 4.20 (q, 2H),
.30 - 5.42 (m, 2H), 7.07 (s,
1H), 8.19 - 8.24 (m, 2H),
8.37 - 8.48 (m, 2H), 8.70 -
8.73 (m, 1H), 10.7 (s, 1H).
UPLC-MS (Method A1):
Rt = 0.96 min
MS (ESIpos): m/z = 545
(M+H)+
WO 201 5/09’1426
68 pf 9-13 and 1-
o n 2g (400 MHZ, DMSO-d6): 5 =
F \ N
F IfJ-U7* methyIpipera (51% 1.49 (t, 3H), 2.20 (s, 3H),
F o \I
0 N
HSC/l zine ) 2.26 - 2.41 (m, 4H), 3.42 —
[i] 3.58 (m, 4H), 4.20 (q, 2H),
N- {6-eth0xy{2-(4-
.37 (s, 2H), 7.07 (s, 1H),
methylpiperazin— 1 -y1)—2-oxoethy1]-
8.18 - 8.24 (m, 2H), 8.37 -
2H-indazol-5—yl}
8.47 (m, 2H), 8.71 (s, 1H),
(trifluoromethyl)pyridine-2—
.7 (s, 1H).
carboxamide
UPLC—MS (Method A1):
Rt = 0.92 min
MS s): m/z = 491
(M+H)+
69 9—13 and 2g (400 MHz, DMSO-dé): 5 = ;
. m1 C 1
g /_\ 3'
27f”; ICC/JV-\ phenyl(piper (71% i 1.49 (I, 3H), 3.33 — 3.79
Q R 117.111-]- )
J gum 8H),4.20 (q. 2H), 5.41 1
y1)mcthan0n (br. 5., 2H), 7.08 (s, 1H),
N- (4-benzoylpiperazin—1 —y1)—
C 7.41 - 7.50 (m, 5H), 8.19 —
2-oxoethyl]ethoxy-2H—indazol-
8.24 (m, 2H), 8.37 - 8.47
S—yl}-6—(trifluoromethy1)pyridine-
(m, 2H), 8.72 (s, 1H), 10.7
2—carboxamide
(s, 1H).
UPLC—MS (Method A1):
Rt= 1.23 min
MS (ESIpos): mjz = 581
(M+H)+
7o / 9—13 and 2- 2g (300 MHz, 6): 3 =
F \“l H
6?l m-' / }“C>_& ‘d‘ 4 790/ 0.97 - 1.29 (m, 8H, contains1 -
0H ( 0
F 0 mn
Haj y1)pr0pan ) s at 1.03), 1.37 - 1.56 (m,
01 4H), 1.74 (t, 2H), 2.42 —
N-(6-ethoxy{2-[4-(2-
2.63 (signal obscured by
hydroxypropan-Z-yl)piperidin— 1 -
DMSO-d6 signal) 2.93 (t,
yl] -2—oxoethy1} dazol-5 ~yl)-
1H), 4.02 (d, 1H), 4.14 -
6-(trifluoromethyl)pyridine—2-
4.25 (m, 3H), 4.40 (d, 1H),
carboxamide
.27 — 5.43 (m, 2H), 7.07 (s,
1H), 3.17 - 3.24 (m, 2H),
3.36 - 3.43 (m, 2H), 3.71 (s,
1H). 10.7 (s, 1H].
I UPLC-MS (Method .41):
l i ‘11:: 1.19 min
MS (ESlpos): [dz 534 ' =
i1M+H1+
(300 MHz, DMSO-dé): 3 =
”m“! 1.49 (t, 3H), 3.41 — 3.70
of \”/
(m, 3H), 4.20 (q, 2H), 5.33
(s, 2H), 7.07 (s, 1H), 3.13 -
N- {6-eth0xy—2~[2—(morpholin—4—
8.26 (m, 2H), 8.36 - 3.43
yl)Oxoethyl]-2H-1ndaZOl-5—yl}—
011,214), 871 (S, 111)) 1073
6~(trifluoromethyl)pyfidine
(S 1H)
carboxamide
UPLC-MS (Method A1):
Rt = 1.16 min
MS (ESIpos): m/z = 473
(M+H)+
* Prepared according to the stated procedure, the yield in % is indicated in brackets
: The piperazine was used as hydrochloride. In on to the piperazine, 1.6 equivalents of
triethylamine were added to the reaction mixture.
[b]: The product was purified by preparative HPLC according to Method P1.
: Gradient for the preparative HPLC: iso. ethanol / methanol / diethylamine 50:50:01; flow rate:
ml/min
[d]: Gradient for the preparative HPLC: iso. hexane / ethanol / lamine 70:30:01; flow rate:
40 ml/min
[e]: Gradient for the ative HPLC: iso. hexane / ethanol / diethylamine 70:30:01; flow rate:
31 mein
[f] N,N-Dimethylformamidc was used instead of dimethyl sulphoxide.
[g]: HPLC was carried out according to Method P1.
[h]: 1.5 equivalents of piperazine were used.
[i]: The product was triturated with N,N-dimethylformamide and dimethyl sulphoxide.
Example 72
N-{2-[2—(4-Benzoylpiperazin—1-y1)oxoethyl]—3—methyl-2H-indazolyl}
(trifluoromethyl)pyfidinecarboxamide
mid/ CH3
F \ N
N 7:14N m 0 F O \N —>_I N
Analogously to Intermediate 8-1, 103 mg (0.27 mmol) of 2-(5-amino—3«methyl—2H—indazol—2—yl)—l-
(4—benzoylpiperazin—1—y1)ethanone mediate 6—15, crude product) were reacted with 78 mg
(0.41 mmol) of 6—(trifluoromethyl)pyridinecarboxylic acid. After 24 h at 25°C, water was added.
The solid was filtered off, washed with water and diethyl ether and dried under d pressure.
This gave 43 mg (29% of theory) of the title nd.
UPLC-MS (Method A1): Rt = 1.12 min
MS (ESIpos): m/z = 551 (M+H)+.
IH-NMR (300 MHz, 6): 5 = 3.34 — 3.73 (m, 8H), 5.48 (br. 5., 2H), 7.42 - 7.58 (m, 7H),
8.14 — 8.23 (m, 2H), 8.32 — 8.43 (m, 2H), 10.35 (s, 1H).
Examnle 73
N- {2-[3-(4-Benzoy1piperazin—1 -yl)-3 —ox0propyl]—2H—indazol—5 —yl} —6-(trifluoromethy1)pyridine—2-
carboxamide
Analogously to Intermediate 8-1, 80 mg (0.21 mmol) of 3-[5-({[6-(trifluoromethy1)pyridin-Z-
yl]carbonyl}amino)—2H-indazolyl]propanoic acid (Intermediate 9—15) in 0.3 ml of MN-
hylformamide and 2.9 ml of tetrahydrofuran were stirred with 32 mg (0.21 mmol) of 1-
y-lH-benzotriazole e and 81 mg (0.42 mmol) 1—(3—dimethylaminopropy1)
ethylcarbodiimide hydrochloride for 30 minutes. 60 mg (0.32 mmol) of pheny1(piperazin-1—
yl)methanone were added. The reaction e was stirred at 25°C for 2.5 h and added dropwise
to 50 m1 of water. The aqueous phase was extracted three times with ethyl acetate. The combined
organic phases were washed with saturated sodium chloride solution, dried over sodium sulphate,
filtered and concentrated. The crude product was stirred in 2 m1 of dimethyl sulphoxide for 30 min,
filtered and washed with 30 m1 of water. The solid was d by preparative HPLC according to
Method P1. This gave 5 mg (4% of theory) of the title compound.
UPLC-MS (Method AI): R = 1.10 min
MS (ESIpos): m/z = 551 (M+H)'
1H NMR (400 MHz, DMSO—d6): 5 = 3.10 (hr. 5., 2 H), 3.50 (br. 5., 6 H), 4.65 (t, 2 H), 7.36 - 7.42
(m, 2 H), 7.42 - 7.47 (m, 3 H). 7.53 - 7.63 (m. 2 H), 8.17 (dd, 1 H). 8.28 (s. l H). 8.32 — 8.42 (m, 3
H), 10.35 (s, 1 H).
The exemplary compounds of Tables 3 - 17 were synthesized in an amide synthesis analogously to
Experimental Procedures la — 1g and 2a — 2g or by a method indicated in the table and analysed by
analytical LC-MS (Method A4).
Table 3: Examples 74 — 77
The exemplary compounds were prepared from 2-(5-amin0-2H-indazoly1)-l-[4-
(cy010pr0pylcarbonyl)piperazinyl]ethanone (Intermediate 6-10) and the starting material
indicated in the table.
Structure and name Starting material and notes
«YR:\ °
3 /—\ °
N,— 2—(pyridinyI)-1,3-thiazole
, 1A).;
\/ \_/
o m“ 43> carboxylic acid
N-(Z—{Z—[4—
(cyclopropylcarbonylmipemzin-l —
y1]oxocthyl}-2H—indazol—5—yl)- 1
2-(pyridinyl)-l,3—lhiazole—4-
amide
O 2-(pyridiny1)-1,3-thiazole—4—
MO / (WI/0 carboxylic acid
N-(2-{2—[4-
(cyclopropylcarbonyl)piperazin—1 -
yl]oxoethyl}-2H-indazolyl)-
idinyl)-1,3-thiazole
carboxamide
6-(tn'fluoromethyl)pyn'dine—2—
F F
o carboxylic acid
Fb7“ (\N
_..N o ”\J
/ 1W
N—(Z—{Z-[4-
(cyclopropylcarbonyl)piperazin
y1]oxoethy1}—2H—indazol—5-yl)-
6—(trifluoromethyl)pyridine—2—
carboxamide
WO 91426
“Ck fijfif“ o The 2-(5~amino-2H—indazolyl)[4-
/ <\_O>“N/—H\N ” U
o \ :N propylcarbonyl)piperazin
6-(azetidiny1amino)-N-(2- {2,[4_ anone starting material was
y1]—2—0xoethy1}-21~[—indazol—5— carboxylic acid. This gave N—(2-{2-[4—
yl)pyridinecarboxamide (cyclopropylcarbonyl)piperazin-1 -yl] -
2-oxoethyl}-2H—indazoIy1)
fiuoropyfidine—Z-carboxamide, which
was reacted with 2 equiv. of tert—butyl
3-aminoazetidinecarboxylate and
N—ethyl-N—isopropylpropane-Z-amine
in NMP at 100°C. The crude product
I obtained was then reacted with
i trifluoroacetic acid in
dichlommethane. Purification by ‘
preparative HPLC gave 14 mg of the
exemplary compound.
Table 4: Examples 78 — 83
The ary compounds were prepared from 2-(5-amino-2H—indazol—2—yl)—1 —(4—
methylpiperazin-l -y1)ethanone and the starting material indicated in the table.
Structure and name Starting material and notes
78 2-(pyridiny1)-1,3-thiazole
carboxylic acid
N— {2—[2—(4-methylpiperazin-1 -yl)—
2-0xoethy1]-2H—indazoI—5-y1}—2—
(pyridiny1)-1,3-thiazole
carboxamide
79 ‘\J\f“ 6-(1-methy1-1H-pyrazolyl)pyridine- 0.60
I Q / \
./ N, V
"x, l .
i /,Nf"\—/
N \ 2-carboxylic acid
HI.,c
N-{2-{2-(4-methy1piperazin-1~yl)-
2—oxoethy1]-2H—indazol-5—yl} (1 -
methyl-1H-pyrazolyl)pyridine-2—
carboxamide
\ 0.54
| 0 6-(1H—pyrazol—4—yl)py1idine—2—
H /‘_\
N/ N
/ / / f» N—CH,
N\ i \ /
N o carboxylic acid
\_ \N/
N— (4—methy1piperazin-1 -yl)-
2—oxoethyl]-2H-indazol-5 -yl}
(I H-pyrazolyl)pyridine
i carboxamide
81 6-(1,3-dimethyl—lH-pymzol—4—
y1)pyridinecarboxylic acid
-dimethy1-1H—pyrazol—4-y1)-
N- {2-[2-(4-methylpiperazin—1 -y1) -
2—oxoethyl]-2H-indazol
yl}pyridinecarboxamide
82 (\N/CH: 6-[3 -(trifluoromethy1)-lH-pyrazol 0.66
Wfiw—N - idine—2-carboxy1ic acid
N o
N: \
N- {2-[2-(4-methylpiperazin-1 -y1)-
2-0xoethyl]—2H—indazol—5-y1} [3 -
(trifluoromethyl)—1H—pyrazol
y1]pyridine—2-carboxamide
83 600m} 6—ethylpyfidine—Z—carboxylic acid 0.66
6-ethy1N {2-[2--(4-
methylpiperazin—l -y1)-2—oxoethy1]—
2H-indazol-5~yl}pyridine
carboxamide
PCT/EP2014/O77877
Table 5: es 84 — 85
The exemplary compounds were prepared from 2-(5-amino-2H—indazol—2—yl)—1—[4—(2,2,2—
trifluorethy1)piperazin-l-y1]ethanone (Intermediate 6-13) and the starting material indicated in the
table.
Example Structure and name Starting material and notes
6-(1-methy1—1H-pyrazol
l yl)pyridinecarboxylic acid
I H.C
i l
' ] 6-(1methyl-1H-pymzol—4—yl)—N—(2—{2-
oxo—Z-[4-(2,2,2—trifluoroethyl)piperazin-
I hy1} dazol—5 —yl)pyridine—2—
carboxamide
85 F
6-(trifluoromethyl)pyridine
p / n HF
N ” N)>N\_/N
F . carboxylic acid
N-(2- {2-oxo[4-(2,2,2—
trifluoroethyl)piperazin-l -y1] ethyl} —2H—
indazol-S —yl)—6-
(trifluoromethyl)pyridine—2-
carboxamide
Table 6: Example 86
The exemplary compounds were ed from 4-[(5-amino-2H-indazol—2—yl)acetyl]
ethylpiperazinone and the starting material indicated in the table.
Example Name and structure Starting material and notes MS
retenti
6-(1-methy1-1H-pyrazol
yl)pyridine—2-carboxylic acid
N-{2-[2-(4-ethy10x0piperazin—l -yl)-
2—oxoethyl]-2H-indazolyl}—6-(1—
methyl- 1 H—pyrazolafl—yl)pyridine
carboxamide
Table 7: Examples 87 — 121
The exemplary compounds were prepared from 2—(5—amino-2H—indazolyl)-1~(4—
benzoylpiperazin-l -y1)ethanone mediate 6-11) and the starting al indicated in the table.
Example Name and structure Starting material and notes
time
[min]
6—(trifluoromethy1)pyridine
| H o /—\
F N/ N
f\ )N N carboxylic acid
F N \_/
F o \N/
N— {2-[2-(4-benzoylpiperazin—l —yl)~2—
oxoethyl]—2H—indazoly1}-6~
(tn'fluoromethyl)pyridinecarhoxamide
6—methylpyridine-Z-carboxylic
| o
)N/—\ N acid
HC N/ /
N U
o \N/
N-{2-[2-(4-benzoylpipcraziny1)
oxoethyl]-2H-indazoly1}
methylpyridinecarboxamide —
6-(morpholin—4-y1)pyridine 0.94
IN: ZI
0' carboxylic acid
G @N}N©~
N-{2-[2—(4—benzoylpiperaziny1)
oxoethyl] -2H-indazolyl} (morph01in—
4-y1)pyfidinecarb0xamide
90 2—(pyridinyl)—1,3-thjazole— 0.79
NQfijw’ffufu“ \ H ° /—\ -
\ / N N 4-carbox 11c ac1d- y
| a
O \ \N/
! l-{4—benzoylpiperazin~l-y1)
i oxocthyI]-2}l-indazolyl}(pyridin '
yl)—l .3-Ihiazolecarboxamide
6-0hloropyfidine-Z-carboxylic
C) acid
_,N O
,.._/<N__
/:“rr
N-{2-[2-(4-benzoylpiperaziny1)-2—
oxoethyl]-2H—indazoI—5 -y1}
chloropyn'dine—Z-carboxamide
2-methyl-1,3—0xazol—5— 0.77
H341 ° ”“19
n carboxylic acid
o [@”‘>—N\—/N O
N- {2—[2-(4—benzoylpiperazin—l —y1)
oxoethyl]—2H—indazol-5 -y1} -2—methyl-l ,3 -
oxazole-S-carboxamide
6—aminopyridinecarboxylic
acid
6-amino—N- {2-[2-(4-benzoylpiperazin
oxocthyl]-2H—indazol-5 -y1} pyridine-
2-carboxamide
2014/077877
94 — opyrimidin 0.71
carboxylic acid
2-amino-N- {2-[2-(4-benzoylpiperazin—1 -
yl)-2—oxoethy1]-2H-indazol-5 —yl}pyrimidin—
4-carboxamide
95 0 / /N\ 2—methyl—1,3-oxazole—4— 0.77
carboxylic acid
N-{2~[2-(4-benmy1pipmzmy1)—2—
oxoethyI]-2H-indazol-S-y1}mcthyI-1,3-
; oxazole4-carb0xamide
6-methoxypyridine 0.96
carboxylic acid
N—{2-[2—(4-benzoy1piperazin-l -y1)
oxoethyl]—2H-indazol—5 —yl} —6—
methoxypyridine-2~carboxamide
2-cyclopropy1-1,3-oxazole 0.89
M\[‘1er @N)1 H ° Np
_ carboxylic acid
N\—/N
0 \ ’\N/
N— {2-[2-(4-benzoylpiperazin-1 -yl)-2—
oxoethyl]—2H—indazolyl} —2—cyclopropyl-
1,3—oxazole-4—carb0xamide
6-(4H-1,2,4—triazol—4— 0.74
y1)pyridine—2—carboxylic acid
N— (4-benzoylpiperazin-l -y1)
oxoethyl]-2H-indazol—5-yl} (4H—l ,2,4-
triazoly1)pyridine—2-carboxamide
Z-phenyI-ZH-l ,2,3-triazole
QN‘QYR_ /N\
)OLN/ ‘~-- carboxylic acid
Q 0
O \CEEN
N-{2-[2-(4-benzoy1piperazin—1-yl)—2-
oxoethyl] -2H-indazol—5 -y1} pheny1—2H—
1,2,3-triazolecarb0xamide
6~(1 —methy1-1 H-pyrazoI-S —
'dine—2—carboxylic acid
N~{2-[2-(4-benzoylpiperazin-l -y1)—2-
oxoethyl]-2H-indazolyl } ( l -mcthy1—
‘ lH-pymzol-S-yl)pyfidinc-Z-car’ooxamidc
101 ‘1 f _ 2—(trifluoromethyl)~l .3- 0.99
F—J _
“N (\ /
o thiazole—4—Carboxylic acid
N—{2—[2—(4—benzoylpiperazin-1 -y1)
oxoethyl]—2H-indazol-5 —y1}
(tfifluoromethy1)—l ,3—thiazole—4—
amide
102 <5 0 JR 6-(1H-pyrazoly1)pyr1dine 0.97
N. _‘>—N/—\N_ O
\N/N /N \
. .
; n L/
o E yhc 301d
N-{2-[2-(4-benzoy1piperaziny1)-2—
oxoethyl]-2H—indazoly1}(1H-pyrazol—
1 —y1)pyridine~2~carboxamide
103 ero“3 6-(1-methy1—1H—pyrazol—4— 0.91
NHNO/Eji/No y1)pyridine—2-carboxylic acid
N— (4—benzoylpiperazin—1 —y1)—2-
oxoethyl]-2H—indazoly1}(1—methyl-
1 H-pyrazol-4—y1)pyridinecarboxamide
l-ethyI-l zol
carboxylic acid
N- {2-[2-(4-benzoy1piperazin-l -y1)
oxoethyl]-2H-indazol-5 -yl} —] ~ethy1-1 H-
pyrdzole-B-carboxamide
6-(4-chloro-1H-pyrazol-1—
yl)pyridine—2—carboxy1ic acid
N— {2-[2—(4-benzoylpiperazin-l ~yl)
yl]-2H-indazol-S-yl}(4-chloro-
1H~pyrazol—I -y1)pyridinecarboxamide i
106 — 4-(trifluoromcthy1)-l ,3- 1.02
thiazol-Z-carboxylic acid
N~{2-[2-(4-benzoy1piperaziny1)
oxoethyl]-2H-indazoly1}
(trifluoromethyl)—1 ,3 -thiazole
carboxamide
107 PH“ 6-(1,3-dimcthyl-lH-pyrazol 0.95
y1)pyiidinecarboxylic acid
N-{2-[2-(4-benzoy1piperazin—1-y1)
oxoethyl]~2H-indazolyl}—6-(1,3-
dimethyl—l zoly1)pyridine-2—
carboxamide
108 2,4'-bipyIidinecarb0xy1ic
| o m
/ N/
acid
I /
N)fi \_/
N\ 0 \N/
N- {2-[2-(4-benzoylpiperazinyl)
2014/077877
oxoethyl]—2H-indazol-5 -yl} -2,4'-bipyridine—
6-carboxamide
6-(1H—pyrazol—4-yl)pyridine-2—
carboxylic acid
N- {2-[2-(4-benzoy1piperazin—1 ~y1)
oxoethyl]-2H—indazoIy1}(1H—pyrazol-
4—yl)pyridinecarboxamide
| 5-fluoro«6-(l -methyl—l H—
" /}
1 -' ! ly1)py1idine
: ‘\ 5
I Fwy“? .
x / carboxyllc acxd.
o H
. LEV-L a ‘L ~‘ +4 s
l 1 Q
N-{2-{2-(4-benzoylpiperazin-1—yl)—2—
oxoethyl]—2H-indazol-5 -y1}-5 -fluoro-6—(1-
methyl—1 I-l—pyrazo1y1)pyridine
carboxamide
6-(3-mcthy1—1H-pyrazol—4—
yl)pyfidine—2—carboxylic acid
'5“me
N—{2—[[2—(4—benzoylpiperazin— 1—yl)~2-
oxoethyl] —2H—indazol—5 —yl} -6—(3 —methy1 -
1H-pyrazoly1)pyridine-Z-carboxamide
6-(1H—1,2,4-triazol—1—
dinecarboxylic acid
N— {2-[2-(4-benzoylpiperazin—1 -yl)—2-
oxoethyl]—2H—indazol—5-y1}(1H-1,2,4-
triazol-l -yl)pyridinecarboxamide
113 6-[3-(trifluoromethyl)-lH- 0.97
l—4—y1]pyridine
carboxylic acid
N— {2-[2-(4-benzoylpiperazin-1 -yl)-2—
oxoethyl]-2H-indazol-5 —y1}—6-[3-
(tn'fluoromethyl)-1H-pyrazol—4-yl]pyridine-
2-carboxamide
1 14 6-ethoxypyfidinecarboxylic 1 .04
WONG 3 °\\ “C" acid
. n o
‘ ° vm’
; N-{2-[2-(4-benzoylpipcrazin-I -y1)—2- |
I oxoethyll-ZH-indazol-S-y] } 6- l
pyridine-2earboxamide
6— T
(cyclopropylmethoxy)pyfidine
~2-carboxylic acid
N— {2—[2—(4—benzoylpiperazin— 1 —yl)—2-
oxoethy1]-2H—indazol-5—y1} —6 -
(cyclopropylmethoxy)pyn'dine—Z—
carboxamide
1 16 6-ethy1pyridinecarboxylic 1 .03
me \Nl H / 4}“ \N acid
N \_/
N- {2-[2-(4-benzoy1piperazin— 1 -y1)
oxoethy1]-2H-indazol—5 —yl}
ethylpyridine-Z—carboxamide
1 l7 2-(4-methoxyphenyl)-l ,3- 1.12
\0¢. 21@meqN/—\
I O lecarboxylic acid
N-{2-[2-(4—benzoy1piperazin—1 -yl)—2-
oxoethyl]-2H-indazol~5—yl}(4-
methoxypheny1)-1 ,3-thiazole
carboxamide
kmycy 2-bromo-1,3-thiazole—4- carboxylic acid
N-{2-[[2-(4-benzoylpiperazin-1—y1)-2—
oxoethy1]-2H-inda201—5 —yl} —2—bromo-1 ,3 -
thiazolecarboxamjdc
2-(4-fluorophenyI)-1,3-
thiazole—4-carboxylic acid
N- (4—benzoylpiperazin-1 -yl)
oxoethyl]-2H-indazol-5 -yl} (4-
fluorophenyl)—1 ,3-thiazolecarboxamide I
6—fluoropyn'dine—2-carboxylic
1 .
'\ hf \ N\)LN/W amd
N-{2—[2—(4-benzoy1piperazinyl)
oxoethyl]—2H—indazol-5—yl}
fluoropyridine-Z-carboxamide
121 6-br0mopyridinecarboxy1ic
\ 111/ \ L\)LN/\ acid
N— {2—[2—(4—benzoy1piperazin-1 —
oxoethyl]—2H—indazol-5 -y]} -6~
bromopyridine—Z—carboxamide
2014/077877
Table 8: Examples 122 — 200
The exemplary compounds were prepared from [5-({[6-(trifluoromethyl)pyridin
yl]carbony1}amino)-2H-indazolyl]acetic acid (Intermediate 9-14) and the starting material
ted in the table.
retenti
Example Structure and name Starting material and notes
time
[min]
(4—fluorophenyl)(piperazin—1 - 1 .05
yl)methanone
N-(Z-{2-[4-{4-fluorobenzoyl)pipemzin—I- l
yl]oxoethyl}-2H-indazol—S -yl)—6—
(trifluoromethyl)pyridine—2-carboxamide
1-(pyridinyl)piperazine 0.75
o \z“ N/"'\N ;‘\
\_/ —
N—(2— {2-oxo—2—[4—(pyridin-Z-yl)piperazin-
l-yl]ethy1}-2H—indazol—S —yl)—6—
(trifluoromethyl)pyn'dine—Z-carboxamide
2—methoxy—l —(piperazin—l -
F N /—\ o y1)ethanone
N—(2- {2—[4—(methoxyacetyl)piperazin— 1 -yl] -
2—0xoethyl} —2H-indazol-5 -yl)
romethyl)pyridinecarboxamide
Ffiggkrnm/ _ 1 -cyclopentylpiperazinone
F N (—4
F o \ /
N >7N\ 1N0
N-{2-[2-(4-cyclopenty1oxopiperazin-l. -
2014/077877
yl)oxoethy1}-2H-indazoIy1}
(lrifluoromethy1)pyridinecarboxamide
126 / - l-phenylpiperazin-Q-one 1.01
F \ N O
N —o>/—NL/N_©
N-{2-[2-0xo(3-oxopheny1piperazin-1—
yl)ethyl]~2H—indazol—5 —yl} —6 —
(trifluoromethyl)pyr1'dine—Z-carboxamide
127 mH 2,2—dimethy1-1~(piperazin—l— 1.03
F\<\\ N
N /
. WWI-1m
o Eli-x m
” f—” N—‘x'
d/ \—/H1C—*::‘—CHE 1
N-(Z- {2-[4-(2,2- l
dimethylpropanoyl)piperazin-l -
oxoethyl} -2H-indazol-5 -y1)
(trifluoromethyl)pyridinecarboxamide
128 ng‘ififnmfil»/ 1- 0.70
(eyelopropylmethy1)piperalin€
/_\ J>
N N N
o \_/
N-(2- {2-[4-(cyclopropylmethy1)pipcrazin—
1-y1]0xoethyl}—2H—indazol—5—yl) -6—
(trifluoromethy1)pyridine—Z—carboxamide
129 {/jw pyridazine—4-arnin 0.86
F \ n
F o \N/ 3rHN
E\ f/N
N- {2-[2-0x0(pyridazin—4-
ylamino)ethyl]-2H—indazol—5-y1}—6—
(trifluoromethyl)pyridine—2—carboxamide
PCT/EPZO'I 4/077877
2-hydr0xy-2—methy1-l-
(piperazin-l-y1)pr0panone
N—(2-{2-[4-(2-hydroxy—2—
methylpropanoyl)piperaziny1]
oxoethyl}-2H—indazol—5-y1)
(trifluoromethyl)pyridine-2—carboxamide
1-(1—phenylethyl)piperazine 0.79
N—(Z—{Z—oxo-Z-[4—(1-pheny1ethyl)pipcrazin-
} 1-yI]ethy1}-2H-indazo1yl)~6-
I (trifluoromethyl)pyridinecarboxamjde
piperazin-l —yl(pyn'din-3— 0.86
yl)methan0ne
N-(2-{2-0xo[4—(pyridin—3—
ylcarbonyl)piperaziny1]ethy1}-2H—
l-S-y1)(trifluoromethy1)pyridine—2—
carboxamide
piperazin—l ridin—4— 0.83
y1)methan0ne
N— {2—[2—(4—isonicotinoylpiperazin—1 —y1)—2—
oxoethyl]—2H—indazol—5 —yl}-6—
(trifluoromethy1)pyridinecarboxamide
@33be morpholin-4—y1(piperazin-l - yl)methénone
N-(2- {2—[4-(morpholin
ylcarbonpriperazin- I —y1]—2—oxoethy1} —2H—
indazol-S-y!)(trifluoromethyl)py1idine-2—
amide
135 “WU? N-melhyl(piperazin—l - 0.69
p} yl)acetamide
l N—[2—(2—{4—[2—(methylamino)
l oxoethyl]piperazinyl}—2-—oxoethy1)2H-
l indazol-S-y1]-6—(t1ifluoromethyl)pyfidine
carboxamide
2-(piperazin-1—y1)pyrazine
N-(2- {2—0xo—2-[4-(pyrazin—2-y1)piperazin-
1-y1]ethyl} —2H—indazol y1)
oromethyl)pyridine—2-carb0xamide
137 (1R)—1 —(piperidiny1)ethanol
N-(2— {2—[4—(1 —hydroxyethyl)piperidin— 1 —
y1]-2—0xoethy1}-2H—indazoly1)-6~
(trifluoromethyl)pyridine-Z-carboxamide
138 y1—2,8-
diazaspiro[4.5]decane
N- {2-[2-(2-methyl-2, 8-diazaspiro[4.5 ] dec-
8-y1)0xoethy1] -2H-indazol-5 -yl }
(trifluoromethyl)pyridinecarboxamide
139 / 1-(2,6-diazaspiro[3.3]hept 0.84
l H
F \ N
N /
y1)ethanone
F o m“:
N _>/_N
N-{2-[2-(6-acetyl-2,6diazaspim[3.3]hept-
2-yl)0xoethy1]—2H—indazol—5-yl}
(trifluoromethyl)pyridine—2—carboxamide
140 m azaspiro[4.5]decan-3 -one 0.85
F\Y<R\N’N’NVfi/v
F ..
. :\ [re—a. /— /
F o MN\ 02»-N\_>CE:.
N- {2-[2-ox0(3—0xo—2,8-
diazaspiro[4.5]dec—8—yl)ethy1]—2H~indazol-
-yl}(trifluoromethyl)pyridine—2—
carboxamide
141 / 6—methy1-2,6- 0.67
diazaspiro[3.5]nonane
F F\N/\[ ©:\/N‘>‘
2—(6—methy1—2,6-diazaspiro[3.5]non-
2-y1)—2—0xoethyl]—2H-indazol—5 -
(trifluoromethyl)pyridine—2-carboxamide
142 *OYCCMO 7-oxa-2—azaspiro[3.5]nonane
N—{2—[2-(7-oxa-Z--azaspiro[3.]5] non-Z-y1)-2—
oxoethy1]-2H-1ndazol-5 -y1} -6—
(trifluoromethyl)pyridine—2-carboxamide
PCT/EP20l4/077877
I43 / 1,4'-bipiperidine 0.71
F \ n
F 1
y; 0 \©f\N\N/ ?FCL
N-{2-[2-(1,4'-bipiperidin-1‘-y1)—2-
oxoethyl]-2H-indazoly1}—6—
(trifluor0methyl)pyridine-2—carboxamide
144 (ZS)-piperidin—2-ylmethanol 0.94
1 N-{2-{2{2~(hydroxymethy1)piperidin~1-yl]-
2-oxoc1hyl } -2H-indazoI—5—yl)
(trifluoromethyl)pyridine-Z—carboxamide
145 (3S)—piperidin-3 -ylmethan01 0.91
F \ N
N-(2- {2-[3-(hydroxymethy1)pipen'din-1 —y1]-
2—oxoethy1}-2H-indazol-5 -yl)—6-
(tn'fluor0methy1)pyridine-Z-carboxamidc
146 KM dine-4—carboxamide 0.82
F \ N
N O
0 K»’
~ 3n—W
N-{2-[2-{4-carbam0y1pipefidin—1—y1)—2—
yl]—2H—indazol—5 -y1} —6—
(trifluoromethyl)pyfidinc-Z—carboxamide
147 / (3R)—N,N—dimethylpiperidine- 0.68
N / 3—amine
N-(2- {2-[3-(dimethylamin0)piperidin-1 -y1] -
WO 91426 2014/077877
2-oxoethy1}-2H-indazoly1)
(trifluoromethyl)pyridinecarb0xamide
4-[(3 eridin-3— 0.71
ylmethy1]morpholine
N-(Z— {2-[3 -(morpholin—4-
ylmcthyl)piperidin-1 -y1] 0xoethyl} -2H-
indazoI-S—y1)(tfifluoromethyl)pyridine
carboxamide
I 49 //\ N—(piperidin—4-
1% H
1 F\${:\\N/\I/N\5A//A“”_* 'r‘ 1:0 y’lky'clopropanecaxboxamide
I F o u-\ ,\ -’ - ’ ~__ i
1 V " 0W“ I
xxx-[24244- i
[(cyclopropylcarbony1)amino]piperidin- l -
yl} oxoethy1)-2H—indazol—5-y1]
(trifluoromethyl)pyridine—Z—carboxamide
150 4-(3—ethyl—1,2,4-0xadiazol-5— 1.08
yl)piperidine
N—(2-{2-[4—(3-ethy1—1,2,4-0xadiazol—5—
yl)piperidin—1 —yI]—2—oxoethy1}-2H-indazol—
-yl)—6—(tr1'fluoromethyl)pyridine—2-
carboxamide
151 4—[(5 —cyc10pr0pyl-1 ,2,4— 1.12
oxadiazol-3—
yl)methyl]piperidine
N—[2—(2— {4—[(5 —cyclopropy1—1 ,2,4-
oxadiazol—3—yl)methyl]piperidin-1—y1} —2-
oxoethyl)—2H—indazol~5-yl]
(trifluoromethy1)pyridine—2-carboxamide
152 /\| piperidin-4—y1(pyrrolidin—1 - 0.96
: H
FWLW'\ N
O y1)methanone
F o ’\/N
N yNO—(N
N-(2-{2-0x0—2-[4-(pyrrolidin-1—
ylcarbonyl)pipen'din—1-y1]ethy1}-2H—
indazol—S-y1)(trifluoromethyl)pyridine
carboxamide
153 / 1—methyl—4—(piperidin—4— 0.64
w"' F \ E
’ _
N /—\ yl)pipcrazmc
F o \N/ 1N3” N—CH,
U . 6/
N42-{2-[444-mc1hylpiperazin-l-
i I? yl)pipcfidin-l -oxocthyl}-2H-indazol-
-_v1}{trifluoromcthyl)pyfidine—2—
amide
4—[2—(piperidin—4— 0.71
yl)ethyl]morpholine
N-[2—(2-{4—[2—(morpholin
yl)ethyl]piperidin—1 —yl} 0xoethyl)-2H-
indazol—S—yl]—6—(tn'fluoromethy1)pyridine
amide
/ 4-[(5~methy1-1,2,4-oxadiazol— 1.03
l H
F \ N
" /
i F N cm 3-y1)methyl]piperidine
F o \ f
N—[Z-(2-{4-[(5—methy1-1,2,4-oxadiazol—3-
yl)methyl]piperidin~1 -y1} —2-oxoethyl)—2H—
indazol—S—yl]—6—(trifluoromethyl)pyridine-2—
carboxamide
(3 S)(pyrr01idin-1 -
ylmethyl)piperidine
Kowfirvfi
N—(-2 {22- [3-[(pyrr011din- 1-
ylmethyl)piperidin-1—y1]ethy1}-2H-indazol-
-y1)(trifluoromethy1)pyridine—2—
carboxamide
3—amino—N,N—
ylbenzenesuiphonamide
N-[Hl-{B-
(dimcthylsulphamoprhenyllamino}
axon-thy] ndazol_vl]—6—
(trifluoromethyl)pyridine-Z-carboxamide
158 / 1,2-0xazoIeamine 0.97
N-{2—[2—(1,2—oxazoly1amino)
oxoethyl] —2H—indazol—5 -yl} -6 -
(trifluoromcthy1)pyridine—2—carboxamide
159 / hy1sulphonyl)piperidine 0.89
N—(2— {2-[4—(methylsulphony1)piperidin—1 —
y1]—2—0xoethyl} -2H—indazol-5 -y1)
(trifluoromethy1)pyridinecarboxamide
160 / 2-(piperazin-1—y1)—1- 0.71
1 H
F F\” N
(pyrrolidin-l -y1)ethanone
F :W-CJOHQ
N-[2-(2-0X0{4-[2-0x0(pyrrolidin
y1)cthyl]piperaziny1}ethy1)—2H-indazol—
-y1](trifluoromethyl)pyridinc
carboxamide
4-(pheny1sulphonyl)pipen'dine
N—(Z- {2-oxo—2—[4—
(phenylsulph0nyl)pipen'din—I -y1]ethy1}-2H—
indazol-S {lfifluoromethpryridine—Z-
carboxamide
x,» \ Laminobcnzcncsulphonamidc
F\ Ax /' E ,
I'V/N.‘ .
.h_"_ .-
N-(Z- {2-oxo[(3-
moylphenyl)amino] ethyl} -2H-
indazol—S—y1)(triflu0romethyl)pyridine—2-
carboxamide
N—methyl—N—(piperidin-4—
yl)isonicotinamide
2- {4-
[isonicotinoyl(methy1)amino]pipen'din—1 —
yl} —2-oxoethyl)—2H—indazol—5 -y1]
(trifluoromethyl)pyfidine-Z—carboxamide
164 / 0.74
l‘ N-isopropyl(piperazin-1—
F “W N o “a; yl)acetamide
N—[2—(2— {4—[2«(isopr0pylamino)—2-
oxoethy1]piperazin—1—yl} —2—oxoethy1)-2H-
indazol-S-y1](trifluoromethy1)pyridine
carboxamide
PCT/EP2014/O77877
165 Flé'gf'vfl -
: :2“) /\\ dioxidotetrahydrothiophen-S-
N 6’
0 N\\/N\<:fi0 erazine
N—(2-{2-[4-(1,1-dioxidotetrahydrothiophen~
3-yl)p1'perazin-1 -y1] oxoethyl} -2H-
indazol-S-yl)—6-(trifluoromethyl)pyridine—2-
carboxamidc
166 / 2-methoxy-N-methyl-N-
l H
F \ N
N G '
F N ,CHa (plperl'd'1n—4—y)lacetamide
F 0 ‘N' 3—ND’N
O OhO-CHJ E
N-[2-(2-{4- E
{(methoxyacetyl)(mcthyl)amino]pipcfidin— E
1—yl}—2-oxoethyl)—2H-indazol_v1]
(trifluoromethyl)pyridine-2carboxamidc
167 ethyl piperazine—l —carboxy1ate
F \N
ethyl 4- {[5—( {[6-(trifluoromethyl)pyridin
y1]carbony1}amino)-2H-indazol—2—
yl]acety1}pipcrazine-1 —carboxy1ate
168 / cyclohexyl(piperazin
l H
F 1:»: N
/ y1)methan0ne
F 0 \N/ >— \\/NNd o
N-(2- (cyclohexylcarbonyl)piperazin-
1-y1]oxoethy1} -2H—indazol-5 —yI)—6—
(trifluoromethy1)pyridinecarboxamide
169 N-cyclopropy1-2~(piperazin
yl)aoetamide
ZO 14/077877
N-{Z-(Z- {4-[2-(cyclopropylamino)—2-
oxoethyl]piperazin—1 ~yl } oxoethyl)-2H-
indazol-S -y1](trifluoromethyIprridine-Z-
carboxam i de
170 2-(piperidin-2—yl)ethanol 0.98
N-(2— {2-[2—(2-hydroxyethyl)pipcfidin—1 —
yl]—2-oxoethy1 }-2H-indazolyI)
(Irifluoromethyl)pyfidine-Z-carboxamidc
171 4-(pyrrolidin- I -yl)piperidinc
N—(2— {2—oxo[4-(pyrr01idin4 —
efidin—1 —yl] ethyl } ~2H-indazol-5 -yl)-
6-(trifluoromethyl)pyridine—Z—carboxamide
172 4-(1H-pyrrol—I —y1)piperidine 1.13
N—(2— {2-0x0-2—[4-(1H—pyrr01—1 -
y1)piperidin— 1 -y1] ethyl } —2H—indazol-5 ~y1)-
6—(trifluoromethy1)pyridinccarboxamide
173 3-(piperazin—l -yl)pr0pan-1 ~01 0.65
N—(2— {2—[4—(3 —hydr0xypropyl)piperazin—1 —
yl]—2—0xoethyl}~2H-indazol-5 —yl)—6—
(trifluoromethyl)pyridinecarboxamide
piperazine-I -carboxamide
4- { [5-( riflu0r0methyl)pyridin
yl]carbonyl}amino)-2H-indazol—2—
yl]acetyl} piperazine—l -caxboxamide
1-(piperidin—4—yl)pyrrolidin—2—
N-(2- {2-0on—[4—(2-oxopyrrolidin-l -
yl)pipen'djn— l —yl]ethyl } -2H-indazo|~5 -yl)-
6-(trifluoromcthyl)pyn'dine—Z—carboxamide
N— {2-[2-(morpholiny1)—2—oxoethy1] -2H-
indazol-S-yl} (trifluoromethy1)pyridine-
2-carb0xamide
N-(IZ- (2—amino—2—0xoethy1)piperazin-
1-y1]-2—oxoethyl } —2H-indazol—5 -yl)
(trifluoromethyl)pyridine—2—carboxamide
thiomorpholine 1 I —dioxide
WO 91426
N— {2—[2—(1 ,1—di0xidothi0morpholin—4~y1)~2—
oxoethyl] -2H-indazol-S -yl} -6 -
oromethyl)pyridine-Z-carboxamide
179 / 1 —isopropylpiperazine
N—{2—[2-(4—isopropy1piperazin—1 —y1)—2—
oxoethyl] -2H-inda201yl}
(trifluoromethyl)pyridine-2—carboxamide
180 /\ piperazin-l-yl(2~ 1.01
1‘ a s
Ffi‘N/fifflwnfi thicnyl)methanone
‘ 0 /~\ t—wa a
I, LVN‘ET/‘L‘SRl O 51 \: l
N—(2— {2—oxo [4—(2—
thienylcarbonyl)piperazin—1 -yl]ethyl } —2H—
indazol-S-y1)(trifluoromcthy1)pyridine
carboxamide
181 / 1-cyclopropyl—2—(piperazin— 1 - 0.72
y1)ethanone
N—(Z— {2- cyclopr0pyl—2—
oxoethy1)piperazin-1—y1]-2—0x0ethy1}-2H—
indazol—S—y1)—6—(trifluoromethyl)pyridine—2—
carboxamide
182 {an1-[(1-methy1-1H-pyrazol1 math
”m: NO y) y ]p p1 i erazine
N-[2-(2- {4-[(1-methyl-1H-pyrazol-4—
y1)methy1]piperaziny1}oxoethy1)-2H-
indazol—S-yl]-6—(tn'fluoromethyl)pyridine-2—
carboxamide
file/H (1,5~dimethy1-1H-pyrazol 0.95
F r\" I N\©f\/N “CH“ y1)(piperazin-1—y1)methanonc
N Q70W701,
N—[2-(2-{4-[(1,5—dimethyl—1H-pyrazol
yl)carbonyl]piperazin—1 -yl} 0xoethy1)—
2H—indazol—5 —y1]—6—
(trifluoromethyl)pyfidine—2-Carboxamide
184 ‘//\", N,N-diethy1pipemzine—1— 1.04
H .
F\.l<F\\~/\H/N\r’/ :
./\N_ amide
1 "\ /—\\ C
F 0 MNI\I
N\ [N4
w n —-,_
< bx 1
N,N-diethyI{[5 -({[6—
(trifluoromethyl)pyridin
b0nyl}amin0)—21[—indazol—Z-
yl]acety1}piperazine—1—carboxamide
185 szKQTN thiomorphoiine 1.01
NQTNNVL/m
N— {2-[2-oxo-2—(thiomorpholin—4—y1)ethyl]—
2H—indazol-5—y1}—6—
(trifluoromethy1)pyridine—Z—carboxamide
186 «01“ 1-(2—fury1methy1)piperazine 0.74
Coo/ / fl
N-(2-{2-[4-(2-furylmethy1)piperazin—1-y1]-
thy1} -2H-indazol-5 —yl)—6—
(trifluoromethyl)pyridinecarb0xamide
1 -(3 -thienylmethyl)piperazine
N—(2— {2-ox0[4-(3-
thienyImethyl)piperaziny1]ethy1} -2H—
indazol-S-yl)(trifluoromethyl)pyridine
carboxamide
N-{l—[Z-(4'-methyl-i,4‘-bipipcridin—l'-yl)—
| 2-oxoethyl]-2H-indazolyl} l
(tn'fluoromethylmyridine-Z-carboxamidc I
189 / yl—2,6- 0.65
F \N / pir0[3.3]heptane
F 0 \N/N_>_
N- {2-[2-(6-methy1-2,6-diazaspir0 [3 .3 ] hept—
2—yl)—2—oxoethy1]~2H-indazol-5 -y1} —6—
(tn’fluoromethyl)pyridine—2-carboxamide
190 / 1 -cyclopentylpiperazine 0.72
F \“l
F N
F 0 ”C? \N/ yONUN
N— {2—[2-(4-cyclopenty1piperazin—1 -yl)
oxoethyl]—2H-indazol-5 -yl} —6 -
(trifluoromethy1)pyridine—Z—carboxamide
fl“/ 2—[2—(piperazin—l— 0.66
F \N N\©:\N I
I F OH yl)ethoxy]ethanol
F 0 \N/ 2% u"xN /_/
N-[2-(2-{4—[2-(2—
hydroxyethoxy)ethy1]piperazin-1 -y1}
oxoethyl)—2H-indazol-5 -
(trifluoromethyl)pyridinecarboxarnide
«OWL—p9 1-(pyridin—4—
y1)piperazine
N—(2- {2-0x0-2— [4—[(py1'idin—4—
ylmethy1)piperazin~1 -y1]ethyl}-2H—indazol—
—yl)—6-(trifluoromethy1)pyn'dine
carboxamide
YL?&:WM N,N-dimethylpiperazine~l —
sulphonamidc
\f‘NN
N—(2-{2-[4-(dimethylsulphamoyl)piperazin—
1-yl]oxoethy1}-2H-indazoly1)
(trifluoromethyl)pyridine—2-carboxamide
194 1—(pyridin—4—yl)piperazine 0.70
N—(2—{2-ox0[4-(pyridinyl)piperazin—
1-y1]ethy1} ~2H—indazol-5 -y1)
(tn'fluoromethyl)pyridinecarboxamide
195 / 1—(methylsulphony1)piperazine 0.92
[ H@
F \N
F N O
F o \ /
N >4 \N //
N-(2- {2—[4-(methylsulphonyl)piperazin-1 —
yl]—2-0xoethy1} -2H—indazol—5—yl)—6—
(trifluoromethyl)pyridinecarboxamide
196 1-[2—(1H—imidazol—1 —
F o \ MNJ—NVN yl)ethyl]p1perazme
PCT/EP2O 14/077877
formic acid 2—{4—[2—(1H—imidazol
y1)ethy1]piperazin-1 -y1} ethy1)-2H-
indazol-S-y1](trifluoromethyl)pyridine
carboxamide (1 :1)
N,N-diethy1piperazine-1 -
sulphonamide
N-(2- {2-[4-(diethylsulphamoyl)piperazin—1 —
oxoethyl} -2H-indazolyl)—6—
(trifluoromethyl)pyridine-2carboxamide
1-(pyridinyl)pipcrazine
N-(2— {2—0x0—2—[4—(pyn'din—3—yl)piperazin-
1-y1]ethy1}-2H—indazol-5 -yl)—6—
(trifluoromethyl)pyridinecarboxamide
1-(piperidin
ylsulphony1)piperazine
N—(Z- {2—oxo[4-(piperidin-l -
ylsulphony1)piperaziny1]ethy1}-2H-
....ndazol-S—y1)—6—(trifluoromethyl)pyridine—2-
carboxamide
1-[(1,5—dimethyI—IH-pyrazol-
4-y1)sulphonyl]piperazine
N—[2-(2-{4-[(1,5-dimethyl—lH—pyrazol
yl)sulphonyl]piperazin—1-yl} —2—0xoethyl)—
2H-indazol-S—y1]—6—
(trifluoromethyl)pyridinecarboxamide
Table 9: Examples 201 ~ 205
The exemplary compounds were prepared from 6-(1-methy1—lH-pyrazolyl)pyridin
yl]carbonyl}amino)-2H-indazolyl]acetic acid (Intermediate 9-10) and the starting material
ted in the table.
Example Name and structure Starting material and notes
“It:\ 1 -
N—N.
(cyclopropylmethyl)piperazine
\Z’LYN‘T/H A
\v‘f‘
\N—/-
0 v"
N-(2-{2-[4-(cycloprepylmethyl)piperazin-
1-yl]oxocthyl}—2H—indazol—5—yl)-6~(l -
methyl-1H-pyrazol—4—yl)pyridine—2—
carboxamide
2-(piperidinyl)propanol 0.85
I °
/ N N
/ CH3
0 mp1)—$69”;
N—(2—{2-[4—(2-hydroxypropan
yl)piperidin—1 —y1]—2*oxoethy1} dazoly1)-6—(1-rnethy1—1H-pyrazol
yl)pyridine-2—carb0xamide
4-(pyrrolidin—l-yl)piperidine
6-(1-methyl-1H-pyrazolyl)—N~(2-{2-ox0-
2-[4-(pyrrolidinyl)piperidin-1 —yl] ethyl} -
PCT/EP20l4/O77877
2H-indazoly1)py1idinecarboxamide
1 -ethy1piperazine
1 0
H (\NJ
/ N@ }N\/,
o \N
N-{Z-[Z—(4-ethylpiperazin—1—yl)—2—
oxoethyl}-2H-indazol—5 ~yl} (1-methyl—
1 zoiyl)pyridinecarboxamide
N,N-dimethylpiperidine—4-
amine
N-(Z-{2-[4-(dimethylamino)piperidin—1—y1]—
2-oxoethy1} -2H-indazol-5 -y1)-6—(1 —methyl—
azoly1)pyridine—2-carboxamide
Table 10: Examples 206 — 208
The exemplary compounds were prepared fmm the intermediates indicated in the table.
retenti
Name and structure Starting matenals and notes. .
time
[min]
The exemplary compound was 1.07
\N prepared from 2-(5-amino—6—methoxy—
0 CH3
”N N/
/ 2H—indazol—2-y1)-N—
omeLq \N (cyclopmpylmethyl)—N—
methylacetamide and 6-
N-(2 - {2-
methylpyridineearboxylie acid.
[(cyclopropylmethy1)(methyl)amino]
1H-NMR (300 MHz, DMSO-d6): 8 =
oxoethy1} methoxy-2H-indazol- 0.17 - 0.57 (m, 4H), 0.91 - 1.11 (m,
-y1)methy1pyridine 1H), 2.61 (s), 2.91 (s), 3.12 (s), 3.19
carboxamide (d), 3. (s, 3H), 5.33 — 5.40 (m, 2H),
7.09 (s, 1H), 7.55 (dd, 1H), 7.93 — 8.02
(m, 2H), 8.18 - 8.24 (m, 1H), 8.71 (s,
1H), 10.71 (s, 1H).
207 / The
I exemplary compound was 1.24
0 CH
l J
F /
\ H
N / prepared from 105 mg (0.26 mmol) of
.F O 03:39.}06
.39 [6-ethoxy({[6-
(tfifluoromethy1)pyfidin—2-
N-(2-{2-
yl]carbonyl}amino)v2H—indazol
opropylmethy1)(me1hy1)amino]
yl]acetic acid and 33 mg (1.5 eq.) of 1-
I Joxoethyl 1ethoxy-2H-indazol
1 cyclopropyI-N—methylmethanamine.
yl)—6—(trifluoromethyl)pyn'dine~2-
This gave 87 mg of the exemplary
l carboxamide
lH-NMR (300 MHz, DMSO-d6): 5 =
0.17 — 0.57 (m, 4H), 0.88 — 1.12 (m,
1H), 1.49 (t, 311), 2.91 (s, 1H), 3.09 —
3.24 (m, 3H), 3.34 (br. 8., 1H), 4.20 (q,
2H), 5.32 — 5.40 (m, 2H), 7.08 (s, 1H),
8.17 — 8.26 (m, 2H), 8.36 — 8.48 (m,
2H), 8.71 (s, 1H), 10.7 (s, 1H).
208 / The exemplary compound was 1.16
\N o prepared from 2—(5—amino—6-methoxy-
HN }N/CH3 2H-indazol—2—yl)—N-
oIf»: m \N propylmethyl)—N—
32H:
methylacetamide and 6-
N-(2—{2-
(trifluoromethy1)pyridine—Z-carboxylic
[(cyclopropylmethyl)(methyl)amino] acid.
-2—oxoethy1}-6 -methoxy-2H-indazol— 1H—NMR (300 MHz, DMSO-d6): 6 =
—y1)—6-(trifluor0methy1)pyridine
0.16 — 0.59 (m, 4H), 0.88 - 1.14 (m,
carboxamide
1H), 2.91 (s, 1H), 3.10 - 3.23 (m, 3H),
3.98 (s, 3H), 5.33 — 5.42 (m, 2H), 7.11
(s, 1H), 8.17 — 8.28 (m, 2H), 8.35 -
8.49 (m, 2H), 8.70 (s, 1H), 10.50 (s,
1H).
Table 11: Examples 209 — 210
The exemplary compounds (Ex) were prepared from 2-(5—amino—6—methoxy—2H—indazol—2-y1)
[4-(2-hydroxypropan—2-y1)piperidin-1 -y1]ethanone (Intermediate 6-5).
Ex. Name and ure Starting materials and notes
209 l .,/\
c ,__ 04 prepared from 100 mg of 2-(5—amino— 1.08
$HWHMfNJ—éffl 6-mcthoxy-2H-indazoly1)[4—(2—
1 hydroxypropan—Z—yl)pipendm—I —. .
anone and 6-
6-Cyclopropyl-N-(2- {2_{4_(2_
cyclopropylpyndme-Z-carboxy11e 301d.
hydroxypropan—Z—yl)piperidin—1-y1]
1H-NMR (400 MHZ, DMSO-d6): 5 =
oxoethyl}—6—methoxy—2H—indazol—5-
0.99 —1.14(m,11H), 1.14 -1.28(m,
y1)pyridinecarboxamide
1H), 1.38 — 1.49 (m, 1H), 1.74 (t, 2H),
2.21 - 2.30 (m, 1H), 2.98 (t, 1H), 3.97 —
4.08 (m, 4H), 4.15 (s, 1H), 4.41 (d,
1H), 5.26 — 5.43 (m, 2H), 7.08 (s, 1H),
7.58 - 7.64 (m, 1H), 7.87 — 7.96 (m,
2H), 8.17 — 8.23 (m, 1H), 8.65 (s, 1H),
.80 (s, 1H).
210 ed from 150 mg of 2—(5-amin0- 0.82
H6~methoxy-2H-indazoly1)-1~[4—(2—
hydroxypropan—2—yl)piperidin—1 -
6—(1-hydr0xyethy1)—N—(2-{2-[4—(2- y1]ethanone and 133 mg of potassium
hydroxypropanyl)pipen'din-1 -yl] —2— 6—(1-hydroxyethyl)pyridine-2—
oxoethyl} meth0xy-2H-indazol-5 - carboxylate (Intermediate 19-1).
yl)pyridinecarb0xamide lH-NMR (400 MHz, DMSO-d6): 5 =
0.99 - 1.13 (m, 7H), 1.15 — 1.29 (m,
1H), 1.34 - 1.48 (m, 1H), 1.51 (d, 3H),
1.74 (t, 2H), 2.99 (t, 1H), 3.95 - 4.07
(m, 4H), 4.16 (s, 1H), 4.41 (d, 1H),
2014/077877
4.81 - 4.90 (m, 1H), 5.28 - 5.43 (m,
2H), 5.58 (d, 1H), 7.08 (5, 11—1), 7.79
(dd, 1H), 8.01 — 8.10 (m, 2H), 8.20 (s,
1H), 8.67 (s, 1H), 10.78 (s, 1H).
Table 12: Examples 211 — 213
The exemplary compounds were prepared from 2-(5—amino-2H—indazol-2—yl)—1—(4—
benzoylpiperazin-l-yl)ethanone (Intermediate 6-11).
Name and structure
211 mg _°>_NflN ° 96 mg of 2—(5-amino—2H—indazol—2—
HN$\u ‘N \_/b
o @N y1)(4-benzoy1piperazin
yl)ethan0ne and 202 mg of 6-{[1-(tert-
6-(azetidiny1amino)—N—{2—[2-(4-
butoxycarbonyl)azet1d1n~3-
benzoylpiperazin-l-y1)-2—oxoethyl]—2H—
yuamim}pyridine'z'carboxync add
indazol-S-yl}pyridine-Z-carboxamide
(Intermediate 19-12) were reacted with
EDC, HOBt and triethylamine.
Aqueous work—up gave 252 mg of ten—
butyl 3-{ [6-( {2-[2-(4—
benzoylpiperazin—l -y1)oxoethy1] —
azolyl}carbamoyl)pyfidin—2—
y1]amino} azetidine-l -carboxylate as
crude product which was reacted with
trifluoroacetic acid in
dichloromethane. Purification by
HPLC according to Method P2 gave
19 mg of the title compound.
2 12 100 mg of 2-(5—amino—2H—indazol—2— 0.61
(<er /\| ° N?
H ' ‘
00 N N
/ yl)(4-benzoylp1perazm—1—
0' @912 °
anone and 265 mg of potassium
6-[(azetidinylmethyl)amino]-N- {212' 6-( { [1 -(tert-butoxycarbonyl)azetidin-2—
zoylpiperazin—l ~yl)oxoethyl] -
2H-indazoly1}pyridine y1]methyl}amino)pyridine
carboxamide carboxylate (Intermediate 19-13) were
reacted with EDC, HOBt and
ylamine. Aqueous work-up and
HPLC gave 93 mg of tert—butyl 2-({[6-
({2—[2-(4-benzoy1piperazin—1-y1)—2—
oxoethyl]-2H-indazol—5-
bamoyl)pyridin
yl]amino}methy1)azetidine-1 -
carboxylate which was reacted with
trifluoroacetic acid in
dichloromethane. HPLC purification
gave 50 mg of the title compound. lH—
NMR (400 MHz. DMSO—db, ed
I signals): 6 = 2.20 - 2.42 (m, 2H), 4.37
- 4.49 (m, 1H), 5.48 (br. 5., 2H), 6.77
(d, 1H), 7.24 (t, 1H), 7.32 (d, 1H), 7.39
— 7.53 (m, 6H), 7.53 — 7.65 (m, 2H),
8.28 (d, 2H), 10.17 (br. 3., 111).
213 ”0
b o 85 mg of N-{2-[2-(4- 0.81
CH_N 0 QN benzoylpiperazin-l-y1)oxoethy1]-
" / Gr“
\ /
‘N / ’hll o 2H-indazoly1}—6—ch10ropyridine—2-
carboxan’ude (Example 91) were
N- {2-[2—(4-benzoylpiperaziny1)
reacted with 3 equiv. of azetidin—3—01
oxoethy1]-2H-indazol 5 yl} 6 (3
hydrochlonde (1:1) and 115 pl of N-
yazetidin-l-y1)pyridine
ethyl—N—isopropylpropane—2—amine in
carboxamide
2 m1 NMP at 100°C. Purification by
HPLC gave 2 mg of the title
compound.
‘H-NMR (400 MHz, DMSO—d6,
selected signals): 5 = 3.82 (dd, 2H),
4.30 (t, 2H), 4.58 - 4.66 (m, 1H), 5.49
(br. s., 2H), 5.70 (d, 1H), 6.63 (d, 1H),
7.38 (d, 1H), 7.42 - 7.52 (In), 7.56 —
7.61 (m, 1H), 7.71 (t, 1H), 8.27 (s,
1H), 8.31 (s, 1H), 10.11 (s, 1H).
Table 13: Examples 214 — 216
Ex. Name and ure Preparation and notes
214 THE/(”>75 :©:\;14>_ \—>_O/ 75
° f ,6S)—2,6- 0.78
\l mg of
dimethylmorpholinyl]pyridine—2—
, carboxylic acid (Intermediate 19-14)
6-[(2R,6S)—2,6~dimethylmorpholin—4— were reacted with 118 mg of 2—(5-
yl]-N-(6-methyl {2—oxo[4- 6methyl-2H-indazolyl)—1—
(pyrrolidin—l -yl)piperidin- l -yl]ethyl}- [4-(pyrrolidinyI)piperidin-l-
2H-indazolyl)pyfidine yl]ethanone (Intermediate 6-2).
carboxamide ‘H-‘JMR (400 MHz, DMSO-dG): 5 = l I
1.18 (d, 6H), 1.21 ,
- 1431111211), 1.67 1
(br. 5., 4H), 1.84 (t, 2H), 2.20 - 2.28
(m, 1H), 2.28 — 2.39 (m, 1H), 2.114(1,
1H), 3.17 (t), 3.61 — 3.71 (m, 2H), 3.88
(d, 1H), 4.10 (d, 1H), 4.29 (d, 2H),
.34 - 5.46 (m, 2H), 7.14 (d, 1H), 7.41
- 7.50 (m, 2H), 7.77 (dd, 1H), 8.22 (s,
1H), 8.36 (s, 1H), 10.18 (s, 1H).
215 \ 0
0 400
F |
H mg [5-({[6- 0.71
F N/ N
I / f”
CH N/fi
F o
‘ K/N\c
\ \N/N (trifluoromethyl)pyridin-2 -
N—[2-(2-{4-methy1—4-[(4— yl]carbonyl}amin0)-2H—indazol
methylpipcrazin-l- y1]acetic acid were reacted with 296
yl)carbonyl]piperidin—1—y1}—2—oxoethyl) mg of ethyl 4-methylpiperidjne—4-
azolyl] —6- carboxylate hydrochloride (1:1) in the
(trifluoromethyl)pyridine presence of BBC, HOBt and
carboxamide triethylamine. This gave 544 mg of
ethyl 4-methyl—1—{[5-({[6-
(tn'fluoromethyl)pyridin—2-
yl] carbonyl} amino)—2H-indazol
tyl}piperidinecarboxylate as a
crude product. Ethanol and THF and
348 mg of lithium hydroxide
2014/077877
monohydrate in water were added, and
the e was stirred overnight and
acidified with citric acid solution.
Extraction with ethyl acetate and
purification by HPLC gave 89 mg of
4-methyl—1—{[5—({[6-
(trifluoromethyl)pyridin—2-
yl]carbonyl}amino)—2H—indazol
y1]acetyl}piperidine—4—carboxylic acid.
49 mg of this were reacted with 15 mg
of 1—methylpiperazine in the presence
of EDC, HOBI and triethylamine in
THF. ation by HPLC gave 29
mg of N-[2-(2-{4-methyI[(4-
methylpiperazin
bonyl]piperidin—I —yI} —2-
oxoethyl)—2H—indazol—5—yl]—6—
(trifluoromethyl)pyridine
carboxamide.
‘H-NMR (300 MHz, DMSO—d6,
selected signals): 5 = 1.25 (s, 3H), 1.36
— 1.57 (m, 2H), 1.98 — 2.22 (m, 5H),
2.27 (br. 5., 4H), 3.13 (t), 3.54 (s), 3.60
— 3.80 (m, 2H), 5.35 — 5.50 (m, 2H),
7.51 — 7.63 (m, 2H), 8.17 (dd, 1H),
8.26 - 8.42 (m, 4H), 10.37 (s, 1H).
216 / 100 mg of ([6-chloro—5-({[6—
I H
F \ N
N / (trifluoromethyl)pyridin
CI N—>—-N NH yl]carbony1}amino)-2H-indazol-2—
yl]acetic acid (Intermediate 9—1 1) were
N-(6-chlor0-2— {2-ox0[(3R)—piperidin—
reacted with 65 mg of tert—butyl (3R)-
3-ylamino]ethyl}—2H—indazol—5 —yl)—6-
3-aminopiperidine-1—carboxylate in the
(trifluoromethyl)pyridine—2-
presence of BBC, HOBt and
carboxamide
ylamine in THF. Addition of
water and extraction with ethyl acetate
gave, afier concentration, 148 mg of
tert-butyl (3R)( {[6-chloro( {[6-
(trifluoromethyl)pyridin
yl]carb0nyl}amino)-2H-indazol
yl]acety1}amino)piperidine—1 -
ylate as a crude product. Afier
addition of diehloromethane and
trifluoroacetic acid, the e was
stirred overnight, concentrated and
purified by HPLC. This gave 105 mg
of N-(6-chloro{2-oxo[(3R)-
din—3—y1amino]ethyl}—2H—
indazol-S-yl)—6-
oromethyl)pyridine
carboxamide.
"H-NMR (300 MHz, DMSO-dé,| ’ '
,- selected signals): 6 = 1.39 - 1.64 (m,
2H), 1.74 — 1.90 (m, 2H), 2.56 — 2.67
(m, 1H), 2.68 — 2.80 (m, 1H), 2.98 —
3.21 (in, superimposed), 3.10 - 3.21
(m, 2H), 5.07 - 5.22 (m, 2H), 7.92 (s,
1H), 8.18 - 8.27 (m, 1H), 8.36 - 8.53
(m, 4H), 8.64 (s, 1H), 10.53 (s, 1H).
Table 14: Examples 217 — 222
The exemplary compounds were prepared from [6-isopropoxy({[6-(trifluoromethy1)pyridin—2-
yl]carbony1}amino)—2H—indazol—2-yl]acetic acid (Intermediate 9—16) or (6—isoprop0xy{[(6-
methylpyridin—2—y1)carbony1]amino}—2H—indazol-2—yl)acetic acid (Intermediate 9—17) and starting
material indicated in the table according to General Procedure 2a.
Prepared
Ex. Structure/Name lH-NMR / LC-MS
from
217 / cyclopropyl 91
I (300 MHz, 6): 6 =
\ N
. .
H,c N 1/ /
N 0 (plperazm- 0.67 —- 0.82 (m, 4H), 1.45 (cl,
o \ / /__\
o N N N
H3 L/ 1-
o 6H), 1.92 — 2.09 (m, 1H),
yl)mcthano 2.62
N—(2- {2_[4_ (s, 3H), 3.38 — 3.86 (m,
(cyc10propylcarbony1)piperazin-1 - 8H), 4.76 — 4.90 (m, 1H),
.42 7.13
yl]oxoethy1} isopropoxy—2H- (s, 2H), (s, 1H),
7.53 -7.60 7.93 —
indazol-S-y1)methy1pyridine—2- (m, 1H),
8.02 (m, 2H), 8.21
carboxamide (s, 1H),
8.72 (s, 1H), 10.99 (s, 1H).
S (Method A1): Rt
= 1.14 min
MS (ESlpos): m/z = 505
(M+H}+
218 / cyclopropyl 75 (300 MHz, DMSO-dé): 5 =
1 R
F\ \
V .
" V/NxV/AV; ;
i F i: : Th ,H. ,o (P'Pemm' 0.67 — 0.82 (m. 4H), 1.41 (d,
F O o/anl )‘hfil «KN—«,4
/1\ o/ \‘\——J, 1" 6H), 1.92 — 2.08 (m, 1H),
+96 CH. ’
y1)methano 3.38 — 3.88 (m, 8H), 4.79 —
N-(2- {2_[4_
ne 4.93 (m, 1H), 5.43
(cyclopropylcarbonyl)piperazin (s, 2H),
7.16
yl]0xoethy1}—6-isopropoxy—2H— (s, 1H), 8.18 — 8.27 (m,
indazol-S-y1) 2H), 8.36 — 8.51 (m, 2H),
8.75 (s, 1H), 10.75 (s, 1H).
(trifluoromethyl)pyridinc
UPLC-MS (Method Al): Rt
carboxamide
= 1.20 min
MS (ESIpos): m/z 559
(M+H)+
phenyl(pipe 82 (300 MHz, DMSO-d6): 6 =
razin—l- 1.45 ((1, 61-1), 2.62 (s, 3H),
y1)methan0 3.37 — 3.86 (m, 8H), 4.76 —
ne 1H), 5.41
N— {2-[2—(4—benzoy1p1perazmy1)_ . 4.92 (m, (s, 2H),
7.13 (s, 1H), 7.39 ~ 7.51 (m,
yl]—6-isopropoxy-2H-indazol—
5H), 7.53 — 7.61 (m, 1H),
—y1}—6-methy1pyfidine—2-
7.92 — 8.04 (m, 2H), 8.20 (s,
carboxamide
1H), 8.72 (s, 1H), 10.98 (s,
1H).
UPLC—MS (Method A1): Rt
= 1.21 min
MS (ESIpos): m/z = 541
PCT/EP2O 14/077877
(M+H)+
phenyl(pipe 98 (300 MHz, DMSO-d6): 5 =
F \l n
FF” m o
razin-l- 1.41
0 m”\/ (d, 6H), 3.38 ~ 3.93 (m,
o N N N
x U 4%)
0 yl)methan0 8H), 4.79 — 4.93 (m, 1H),
113C CH,
118 5.42 (s, 211), 7.15
2-(4-benzoy1piperazin—1 - (s, 1H),
7.40 — 7.53 (m, 5H), 8.17 —
oxoethyl]-6—isopropoxy—2H—indazol—
8.26 (m, 2H), 8.35 — 8.51 (m,
S-yl}(trifluoromethyl)pyridinc
2H), 8.75 (s, 1H), 10.74
carboxamide (s,
1H).
UPLC—MS (Method AI): Rt
= 1.26 min
'MS {ESIpos}: m’z = 595
J } i (M+H)+
221 / 1- 36
I {(300 MHz, DMSO—dG): 5 =
F \ N
F 1.41 (d, 6H), 2.12 —2.70 (m,
F O : (N),
O ”HM—CH methyflplpe
“SC/kc“! O \_/ razme 4H), 3.37 — 3.78
, (m, 4H),
4.80 5 4.91 (m, 1H), 5.40 (s,
N— propoxy—2-[2—(4-
2H), 7.15 (s, 1H), 8.18 — 8.26
methylpiperazin-l —yI)—2-oxoethyl]—
(m, 2H), 8.36 — 8.49 (m, 2H),
2H-indazoIy1} —6-
8.74 (s, 1H), 10.75 (s, 1H).
(trifluoromethyl)pyridinc
UPLC—MS (Method A1): Rt
car oxamlb 'dC
= 101 H1111
MS (ESIpos): m/z = 505
(M+H)+
22:2 / 1- (300 MHz, DMSO-d6): 6 =
I H
F f“ "m” methylpipe 1.45 (d, 6H), 2.18 — 2.70 (m,
F o \ / /_\
i N NU“_C“ razine
0 4H),2.62(s,3H), 3.34—3.87
H30 CHJ
(m, 4H), 4.77 ~ 4.89 (m, 111),
N— {6—isopr0poxy—2— [2-(4-
.39 (s, 2H), 7.12 (s, 1H),
methylpiperazin—l -y1)—2~0xoethy1]—
7.53 — 7.58 (m, 1H), 7.93 —
2H—indazol—5—yl} —6-methylpyridinc-
8.02 (m, 2H), 8.20 (s, 1H),
2-carboxamide
8.72 (s, 111), 10.98 (s, 1H).
UPLC—MS (Method A1): Rt
= 0.95 min
WO 91426
MS (ESIpos): m/z = 451
(M+H)+
Table 15: es 223 — 226
The exemplary compounds were prepared from N-{2-[2-0xo—2-(piperazin-1—yl)ethyl]-2H—indazol—
-yl}—6-(trifluoromethyl)pyridincarboxamide (Intermediate 22-1) and the starting material
indicated in the table analogously to the examples above via an amide synthesis.
Example Name and structure Starting material and notes
«0%/ cyclobutanecarboxylic acid
‘ ‘~
F ”toN m O F o \N/ 1% EN
N-(Z- {2-[4-
(cyclobutylcarbony1)piperazin-l -yl]
oxoethy1}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
224 / cyclopentanecarboxylic acid 1.06
| H
F \ N
F O
F o \GQN_0>/"’\_/”/_\
N—(2—{2-[4—
(cyc10pentylcarbonyl)piperazin-l-yl]
yl}—2H—indazolyl)
(tfifluoromethyl)pyridineCarboxamide
225 3—(methylsulphonyl)benzoic 0.95
acid
(methylsulphonyl)benzoyl]piperazin
yl}oxoethyl)-2H-indazol-S -
(trifluoromethyl)pyridinecarboxamide
2-methoxy—5-
(methylsulphonyl)benzoic acid
N-[2—(2- {4-[2-methoxy
(methylsulphonyl)benzoyl]piperazin~1-
yl}—2-oxoethyl)-2H-indazolyl]
(trilluoromethyl)pyfidine—2-carboxamide
Table 16: Examples 227 — 244
The exemplary compounds were prepared from the intermediates and starting als indicated in
the table.
Name and structure Starting maten'al, preparation and 1H
6—bromopyridinecarb0xylic acid
‘H NMR (400 MHz, DMSO-d6,
selected signals): 5 = 1.21 - 1.36 (m,
1 H), 1.38 - 1.52 (m, 1 H), 1.69 (br.
6—brom0—N—(6—methyl - 5-, 4 H), 1-78 - 1-95 (m, 2 H), 221 '
2—[4—(pyrrolidin—1—yl)piperidin—1- 2.36 (m, 1 H), 2.39 (s, 3 H), 2.80 -
yl]ethyl}—2H—indazol—5- 2.91 (m, 1 H), 3.18 (t, l H), 3.82 —
yl)pyridine—2—carboxarnide 3.96 (In, 1 H), 4-04 - 4.18 (In, 1 H),
.45 (d, 1 H), 5.40 (d, 1 H), 7.48 (s, 1
H), 7.91 - 7.97 (m, 1 H), 8.02 (t, 1
H), 8.09 (s, 1 H), 8.17 (dd, 1 H), 8.23
- 8.27 (In, 1 H), 10.05 (s, 1 H).
2-(4—methoxypheny1)-1,3—thiazole 0.82
carboxylie acid
1H NMR (400 MHz, DMSO-d6,
selected signals): 6 = 1.21 ~ 1.36 (m,
1 H), 1.37 — 1.52 (m, 1 H), 1.68 (br.
H,C N
(t, 2 H), 2.18
2-(4-methoxyphenyl)-N -(6— s., 4 H), 1.85 — 2.28 (m,
1 H), 2.42 (s, 3 H), 2.80 — 2.92 (m, 1
methyl-Z- {2-0xo[4-(pyrrolidin-
H), 3.18 (t, 1 H), 3.85 (s, 3 H), 3.88 - 1-yl)piperidinyl]ethyl} ~2H—
3.94 (m, 1 H), 4.05 — 4.15 (m, 1 H),
indazol—S—y1)-1,3—thiazole—4-
.40
amide (d, 1 H), 5.45 (d, 1 H), 7.06 —
7.15 (m, 2 H), 7.49 (s, 1 H), 8.02 —
8.09 (m, 3 H), 8.25 (s, 1 H), 8.36 (s,
1 H), 9.86 (s, 1 H).
2-(4-fluorophenyl)-l ,3-thiazole—4-
carboxylic acid
5We ’H NMR (400 MHz,
mN}ONO0 HM CHLOROFORM-d): 8 = 1.26 (s, 1
HC N H), 1.36 (t, 1 H), 1.44 - 1.59 (m, 1
2—(4—flu0rophenyl)—N—(6—methy1— H), 1.82 (br. S" 2 H), 1.94 (d, 2 H),
2'{2'OX0'2'14'(P>’"°“di"'1' 2.33 (br. s, 1 H), 2.56 (s, 3 H), 2.63
YDPiPeridin'l"yllethYU'ZH‘ (br. s., 4 H), 2.81 - 2.92 (m, 1 H),
indazoI-S-yl)—1,3—thiazole—4— 301 (d, 1 H), 3.16 (t, 1 H), 3.98 (d, 1
carboxafnide
H), 4.44 (d, 1 H), 5.23 — 5.29 (m, 2
H), 7.16 — 7.24 (m, 2 H), 7.53 — 7.58
(m, 1 H), 7.96 - 8.04 (m, 3 H), 8.20
(s, 1 H), 8.55 (s, 1 H), 9.44 (s, 1 H).
230 6—2 6—(trifluoromethyl)pyridine—2—
carboxylic acid
1H NMR (300 MHz, DMSO-d6): 5 =
1.15 - 1.36 (m, 1 H), 1.42 — 1.45 (m,
1 H), 1.68 (br. s., 4 H), 1.86 (t, 2 H),
N-(6-methyl {2-oxo-2—[4—
2.19 — 2.32 (m, 1 H), 2.41 (s, 3 H),
lidin—l—y1)piperidin
2.85 (t, 1 H), 3.10 - 3.24 (In, I H),
y1}-2H-indazolyl)
3.89 (d, 1 H), 4.11 (d, 1 H), 5.43 (s, 2
(trifluoromethyl)pyridjne-2—
H), 7.49 (s, 1 H), 8.16 - 8.24 (m, 2
carboxamide
H), 8.26 (s, 1 H), 8.33 - 8.49 (m, 2
H), 10.15 (s, 1 H).
3/0))”:7:):fp\_/”'C” 61- 2 6—bron10pyridine—2—carboxy1ic acid 0.61
1H NMR (300 MHz, DMSO-d6): 5 =
0-N-{2-[2-(4_ 2.21 (s, 3 H), 2.24 - 2.34 (m, 2 H),
methylpiperazin—l ~y1) 2.34 - 2.42 (m, 2 H), 3.43 - 3.52 (m,
oxoethyl]—2H-indazol 2 H), 3'54 (d, 2 H), 5-45 (S3 2 H):
yl}pyridinecarboxamide 7-52 ' 7-63 (m, 2 H), 7-84 ' 7-95 (m,
1 H), 8.01 (t, 1 H), 8.15 (dd, 1 H),
8.26 - 8.36 (m, 2 H), 10.38 (s, 1 H).
6-bromopy11dine—2—carboxylic acid 0.82
KEN_O>—N/—\N—CH l
\_/ H NMR (300 MHz, 6): a =
.212. N
2.21 (s, 3 H), 2.25 — 2.33 (m, 2 H),
2.39 (br. s.. 2 H), 3.47 (br. 5., 2 H),
6-bromo-N- {21244-
1 3.54 (d. 2 H). 5.52 (s, 2 H), 7.74 (s, 1
methylpiperazin-l -yl)
1 1 - 8.10
oxoethyl]—6—(tn'fluoromethoxy)— 1 H), 7.94 — 8.01 (m, 1 H), 8.01
(m, 1 H), 8.19 (d, 1 H), 8.45 (s, 1 H),
ZH-indazol-S-yl1pyn'dine—2—
8.55 (s, 1 H), 10.28 (s, 1 H)
carboxamide
l H o 6-(4H—1,2,4-triazol—4—yl)py1‘idine—2— 0.56
N” N
/ MGM—CHJ
carboxyhc a01d_ .
o 0:13:94
F"1“ ]H NMR (400 MHz, DMSO-d6): 5 =
2.22 (s, 3 H), 2.27
N—{2-[2-(4-methy1piperazin- — 2.35
1. -yl)- (m, 2 11),
2.39 (br.
2-oxoethy1]—6-(trifluoromethoxy)— s., 2 H), 3.43 — 3.52 (m, 2
H), 3-52
azoly1}(4H—1,2,4-
‘ 3-60 (m, 2 H13 5-53 (S: 2
H), 7.72 (s, 1 H), 8.18 (dd, 2 H), 8.28
triazolyl)pyridine-2—
(s, 1 H), 8.34 (d, 1 H), 8.47 (s, 1 H),
carboxamide
9.62 (s, 2 H), 10.56 (s, 1 H).
>u~ 6-9 2-bromo—1,3-thiazole—4—carboxylic 0.72
SW1“H 0 ‘>— / \
N—CH acid
“v a
o \ /
BrI136N 1H NMR (300 MHz, DMSO-d6): 5 :
2—brom0—N— {6—bromo—2-[2—(4—
2.21 (s, 3 H), 2.25 — 2.34 (m, 2 H),
mathylpipe'azm‘l'yn'z' 2.38 (br. s., 2 H), 3.47 (br. 5., 2 H),
oxoethyl]‘2H'indaZOI'5'yl}‘1’3' 3.54 (br. s., 2 1-1), 5.49 (s, 2 H), 8.03
thiazolecarboxamide
(s, 1 H), 8.25 (s, 1 11), 8.35 - 8.420111,
1 1-1), 8.49 (s, 1 H), 9.96 (s, 1 H).
Analogously to Intennediate 8-7, 25 0.67
mg (0.05 mmol) of N—{6-
(benzyloxy)—2-[2-(4-
N- {6-hydroxy [2-(4- methylpiperazin—l -yl)oxoethyl]—
methylpiperazin- 1 ~y1)-2 - 2H-indazol-5 -yl} —6-
oxoethy1]-2I-I-indazol-S-yl} (trifluoromethyl)pyridine
(tn'fluoromethyl)pyridine amide (Example 41) were
carboxamide dissolved in 7 ml of ethanol, 4.8 mg
of palladium on carbon were added
and the mixture was hydrogenated
under standard en re for
6 h. Work—up gave 5 mg (34% of
theory) of the product.
lH NMR (400 MHz, DMSO—d6): 6 =
2.20 (s, 3 H), 2.28 (br. 5., 2 H), 2.35
{br. s.. 2 H), 3.46 (br. s., 2 H), 353
(br. s., 2 H), 5.31 (s, 2 H), 6.88 (s, l
H), 8.13 (s, 1 H), 8.20 (d, l H), 8.40
(t, I H), 8.47 (d, 1 H), 8.66 (s, 1 H),
.64 (br. s., 1 H).
236 , 9-18
I o
, 2-(pipen'din—4—yl)propan—2—ol 1.19
\N N
H,c / _>>N' F6014
N cu, 1H NMR (300 MHz, DMSO-d6): 5 =
0.96 - 1.17 (In, 1 H), 1.05 (s, 6 H),
1.18 _- 1.34 (m, 2 H), 1.36 - 1.54 (m,
N-[6-(benzyloxy) (2— l H), 1.76 (t, 2 H), 2.43 (s, 3 H), 3.00
hydroxypropany1)piperidin—1 -
(t, 1 H), 4.04 (d, 1 H), 4.19 (s, 1 H),
yl] oxoethy1 } -2H-indazol—5 -y1]— 4.42 (d, 1 H), 5.30 (s, 2 H), 5.38 (s, 1
6—methylpyridir1e—2—carboxamide
H), 5.37 (s, 1 H), 7.27 (s, 1 H), 7.37 —
7.54 (m, 4 H), 7.66 (d, 2 H), 7.87 —
8.02 (m, 2 H). 8.23 (s, 1 H) 8.78 (s, l
H) 10.87 (s, 1 H).
237 m“ 6-br0mopyridine-Z-carboxylic acid 0.77
1H NMR (300 MHz, DMSO-d6): 5 =
6-bromo-N-{6-br0mo[2-(4- 2.20 (s, 3 H), 2.23 - 2.33 (m, 2 H),
methylpiperazin—l -yl)—2— 2.37 (br. 5., 2 H), 3.46 (d, 2 H), 3.53
oxoethyII—ZH—indazol-S- (br. s., 2 H), 5.49 (s, 2 H), 7.94 — 7.99
yl} pyridinecarboxamide (m, 1 H), 8.01 - 8.08 (m, 2 H), 8.16 —
8.23 (m, 1 H), 8.39 (s, 1 H), 8.51 (s,
1 H), 10.38 (s, 1 H).
238 OW“/ 9—18 1~methy1piperazine 0.87
/ gym—m.
. u . H NMR (300 MHz, DMSO-dé): 5 =
O 1):).
3 N
2.21 (s, 3 H), 2.23
: - 2.33 (m, 2 H),
2.37 (br. s., 2 H), 2.42 (s, 3 H), 3.47
N‘{6‘(be“7‘y1°Xy)'2‘[2'(4'
(br. s., 2 H), 3.55 (br. s., 2 H), 5.30
methylpiperazin—l -y1)
(s, 2 1-1), 5.39 (s, 2 H), 7.27 (s, I H),
oxoethy1]—2H-indazol—5 -yI}
7.36 — 7.56 (m, 4 H), 7.62 — 7.69 (m,
methylpyridine-Zearboxamide
2 H), 7.90 - 8.02 (In, 2 H), 8.23 (s, 1
H), 8.78 (s, 1 H), 10.87 (s, 1 H).
239 6-11 According to General Procedure 10, 0.56
Unfinbfirfffo5 35 mg (0.09 mmol) of the
H2'(azetid;n'3-Vlal;lin0}-N-{2-[2- Intermediate 6‘1] were reacted With
(4-benzov1pipcmzin-l-vl)—2— 32 mg (0.1 mmol) of 2-{[1-(tel1-
oxoethy1]-2H-indazolyl}-1,3- carbonyl)azetidin-3 '
IhiazoleA-carboxamide 1 yllamino:-1,3vthiazoIecarboxylic 1
acid. This gave 10 mg (0.01 mmol)
of tefi—butyl 3—{[4-({2-[2-(4-
benzoylpiperazin—l-y1)—2—oxoethy1]—
azoly1}carbam0yl)—1,3—
thiazol—Z—yl] amino}azetidine—1 -
carboxylate.
1H NMR (400 MHz, DMSO-d6): a =
1.39 (s, .9 H), 3.55 (br. s., 4 H), 3.64
(br. s., 4 H), 3.78 (dd, 2 H), 4.25 (t, 2
H), 4.57 - 4.69 (m, 1 H), 5.48 (br. s.,
2 H), 7.39 - 7.52 (m, 7 H), 7.54 -
7.59 (m, 1 H), 8.22 (d, 1 H), 8.25 -
8.29 (m, 1 H), 8.43 (d, 1 H), 9.55 (s,
1 H).
50 mg (0.07 mmol) of tert-butyl 3-
{[4-({2—[2-(4-benzoylpiperaziny1)—
2-oxoethy1]-2H—indazol-5—
bamoy1)-1 ,3 —thiazol
yl]amino}azetidinecarboxy1ate
were dissolved in 200 pl of 4 M
hydrogen chloride in dioxane and the
e was stirred at room
temperature for 24 h. The reaction
mixture was concentrated and taken
up in romethane, washed with
saturated sodium bicarbonate
solution and saturated sodium
chloride solution, dried over sodium
sulphate, filtered and concentrated.
Drying gave 11 mg (0-02 mmol) of
2-(azetidin—3—ylamino)—N—{2-[2-(4-
benzoylpiperazin—I —yl)—2—0xoethyl]—
2H-indazolyl}-1,3-thiazole
carboxamide.
amidopyridinecarboxylic
acid
'H NMR (400 M11; DMSO—db): 6 = '
6—acctamido—N— {6—melhoxy[2-
2.21 (s, 3 H), 3.47 (d, 2 H), 3.51 -
(morpholin—4—y1)—2+)xoethyl]—2H— 3.62 (m, 4 H), 3.64 (d, 2 H), 4.03 (s,
indazol-S-yl}pyridine 3 H), 5.39 (s, 2 H), 7.10 (s, 1H), 7.87
carboxamide
(dd, 1 H), 8.04 (t, 1 H), 8.22 (s, 1 H),
8.28 (d, 1 H), 8.69 (s, 1 H), 10.34 (s,
1 H), 10.65 (s, 1 H).
241 “Mm19+;\ CH 6-5 ethy1amino)pyridinW
carboxylic acid IH NMR (400 MHz,
C113 DMSO-dé): 6 = 1.01 - 1.14 (m, 1 H),
6-(dimethy1amin0)-N—(2- {2-[4—(2—
1.05 (s, 6 H), 1.18 — 1.30 (m, 1 H),
hydroxypropan-Z-yl)piperidin-1 -
2.50—2.52 (m, 1 H) (signal under
yl]—2-oxoethyl}—6—methoxy-2H-
DMSO),1.44 (t, 1 H), 1.75 (t, 2 H),
l—S—yl)pyridine—2—
2.99 (t, 1 H), 3.16 (s, 6 H), 3.97 (s, 3
carboxamide
H), 4.03 (d, 1 H), 4.16 (s, 1 H), 4.42
(d, 1 H), 5.27 - 5.41 (m, 2 H), 6.94
(d, 1 H), 7.07 (s, 1 H), 7.36 (d, 1 H),
7.74 (dd, 1 H), 8.19 (s, 1 H), 8.67 (s,
1 H), 10.88 (s, 1 H).
6—(dimethylamin0)pyridine—2—
carboxylic acid 1H NMR (400 MHz,
DMSO-d6): 8 = 3.16 (s, 6 H), 3.47
6-(dimethy1amino)—N— {6- (d, 2 H), 3.53 - 3.61 (m, 4 H), 3.64
PCT/EPZO 14/077877
methoxy—Z—[2—(morpholinyl)—2- (d, 2 H), 3.98 (s, 3 H), 5.38 (s, 2 H),
oxoethyl]—2H-indazol-5— 6.94 (d, 1 H), 7.08 (s, 1 H), 7.36 (d, 1
yl}pyridinecarboxamide H), 7.74 (dd, 1 H), 8.17 - 8.21 (m, 1
H), 8.67 (s, 1 H), 10.88 (s, 1 H).
243 3:3 \ 6-5
CH3 6—acetamidopyridine-Z-carboxylic 0.83
1 0
° 2 "
., 3N)— acid 1H NMR (400 MHz, DMSO—
? N
“f“ (16): 6 = 0.98 — 1.12 (m, 1 H), 1.05 (s,
am1do-N—(2—{2—[4-(2-
6 H), 1.15 — 1.31 1 1.39 —
, __ (m, H),
hydroxypropan—Z-y1)p1pend1n-1 - .
1.50 (m, 1 H), 1.75 (t, 2 H), 2.21 (s, 3
0xoethyl}meth0xy—2H—
H) 2.52 - 2.57 , (m, I H) 2.99 (br. S
, .,
indazoI-S-yl)pyridine
1 - 4.08 (In, 1 H), 4.03 (s, 3
carboxannde_
H), 3.98
H), 4.16 (s. 1 H), 4.42 (d, 1 H). 5.36
I H). 7.87 (dd. 1 H), (d. 2 H). 7.09 (s.
‘ g
l i 8.04 (I, l H), 8.19 - 8.23 (m, l H),
1 8.23 (d, 1 H), 8.69 (s, I H), 10.34 (s,
1H), 1065(5, 1 H).
244 HAN/[Nag 6-17
/ }Nfl~—CH,\—/ 6-(dimet11y1aIHinl<))pyridine
CI”: 0 mu carboxyhc ac1d H NMR (400 MHz,
6-(dimet11ylamino)-N-{6- 6): 5 = 2.21 (s, 3 H), 2.27 -
2.31 (m, 2 H), 2.34 - 2.39 (m, 2 H),
methoxy—Z—[2—(4—methy1piperazin-
3.16 (s, 6 H), 3.43 - 3.51 (m, 2 11),
1-yl)oxoethyl]-2H-indazol
3.51 — 3.58 (m, 2 H), 3.97 (s, 3 H),
yl} pyridine—2—carboxamide
.36 (s, 2 H), 6.94 (d, 1 H), 7.08 (s, 1
H), 7.36 (d, 1 H), 7.74 (dd, 1 H), 8.19
(s, 1 H), 8.67 (s, 1 H), 10.88 (s, 1 H).
Table 17: Examples 245 — 247
Name and structure Preparation and notes
O/QT KEN} \—//| 80 mg of
0 6—[3-
\ n
H,C/|O~~ N/_\N—CH
(methylsu1phony1)phenyl]pyridine-2—
carboxylic acid (Intermediate 19-8) and
N—{2—[2-(4-methylpiperazinyl)
95 mg of 2-(5-amin0-2H-indazoly1)
oxoethyl]-2H-indazoIy1}[3-
(methylsulphonyl)phenyl]pyridine (4-1nethylpiperazin-l -yl)ethanone
carboxamide (Intermediate 6-12, crude product) were
d with EDC, HOBt and
triethylamine in THF at room temperature
overnight. The residue was diluted with
water and ethyl acetate. The solid was
filtered off with suction, washed with
water and diethyl ether and dried. This
gave 48 mg of the exemplary compound.
1H NMR (400 MHz, DMSO—dé): 5 = 2.20
(s, 3H), 2.24 — 2.42 (m, 4H), 3.36 (s, 3H),
3.42 ~ 3.51 (m. 2H), 3.51 - 3.61 (m. 2H).
.45 (s. 2H). 7.56 - 7.64 (m. 2H). 7.84 (1,
1H), 8.05 (d, 1H), 8.16 — 8.24 (m, 2H), 1
[ 8.30 (s. 1H). 8.34 - 8.40 (m. 2H), 8.75 - I
8.80 (m, 21-1), 10.56 (s, 1H).
246 100 mg of mino-2H-indazolyl)- 1.08
/ \ /
I 0
F \ fl‘ ~N’ ‘N l -(4-benzoylpiperazin-I -yl)propanone
F C ‘\ l
N CH1 (Intermediate 6-19) and 76 mg of 6-
N-{2-[1-(4-benzoylpiperazin—1 —yl)—l - oromethyl)pyridine-2—carboxylic
oxopropan-Z-yl]-2H-indazol—5 -yl} acid were reacted with BBC, HOBt and
(trifluoromethyl)pyridine triethylarnine in THF at room temperature
carboxamide overnight. After addition of water,
tion with ethyl acetate and
concentration, the product was purified by
preparative HPLC ing to Method
Pl. This gave 98 mg of the exemplary
compound.
1H NMR (400 MHz, DMSO-dé): 5 = 1.68
(d, 3H), 3.1 e 3.7 (broad signals,
superimposed), 5.91 (br. s., 1H), 7.34 —
7.45 (m, 5H), 7.52 — 7.61 (m, 2H), 8.14
(dd, 1H), 8.26 - 8.39 (m, 3H), 8.43 (s,
1H), 10.34 (s, 1H).
247 80 mg of [6-chloro({[6- 1.16
(trifluoromethyl)pyridin
yl]carbonyl}amino)—2H—indazol
N—[6-ch10r0(2-{[trans-4—(2— yl]acetie acid and 41 mg of 2-(trans
hydroxypropan-Z- aminocyclohexyl)propan01 were
yl)cyclohexyl]amino}—2~oxoethyl)- reacted with EDC, HOBt and
2H—indazoly1]-6— triethylamine in THF at room ature
(tn'fluoromethyl)pyridine overnight and at 50°C for 7 h. Water and
carboxamide ethyl acetate were added. The solid was
filtered off with n, washed with
water and diethyl ether and dried. This
gave 92 mg of the exemplary compound.
IH-NMR (300 MHz, DMSO—d6): 5 = 0.92
— 1.25 (11H, contains singlet at 1.01
ppm). 1.73 - 1.91 (m, 4H), 3.36 - 3.60
4.02
l (m). (s. 1H). 5.08 (s, 2H). 7.9l (s.
1H), 8.23 (d, 2H), 8.37 — 8.50 (m, 311), i
' 8.63 (s, 1H), 10.52 (s, 1H). 1
Table 18: Examples 248 - 260
The exemplary nds were prepared by the general experimental procedures 2a-2g from the
appropriate intermediates and amines.
Prepared
Structure/Name ‘H-NMR / LC—MS
from
\ Intermediat (400 MHz, DMSO-d6): 5 =
I H
HJC / N133
6 9-23 and 1.57 (s, 6 1—1), 3.42 — 3.52
CH3 0 , m
9 \N ‘>/_N 0
0 line
CH3 (m, 2 H), 3.52 - 3.62 (m, 4
H), 3.62 H),
6-(2-hydroxypr0pany1)-N—{6— - 3.68 (m, 2
3.99 (s, 3 H), 5.39 (s, 2 H),
methoxy-2—[2-(morpholin-4—y1)—2-
.47 (s, I H), 7.10 (s, 1 H),
oxoethyl]-2H-indazol—5-y1}pyridine-
7.93 (dd, 1 - 8.10
2-carboxamide H), 7.99
(m, 2 H), 8.19 — 8.23 (m, 1
H), 8.68 (s, 1 H), 10.93 (s,
I H).
UPLC-MS (Method AI):
Rt = 0.88 min
MS (ESIpos): m’z = 454'
E 5
(M+H)’
[2%:Cfm/ Intermedial (400 MHz, DMSO—db): 6 = '
1 I
\ R F
F 6 9-11 and 2.38 - 2.46 (In, 1 H), 2.54 - F
F o \ '
c1 ~ )wd
3,3— 2.61 (m, 1 H), 3.58 (t, 1 H),
N-{6-ch10r0[2-(3,3- difluoropyr 3_77 (t, 1 H), 337 (t, 1 H),
difluoropyrrolidin-l-y1)0xoethyl]- rolidine 4,11 (t, 1 H), 5,42 (s, 1 H),
2H-indazoly1}—6— 5.48 (s, 1 H), 7.93 (s, 1 H),
(trifluoromethyl)pyridine—2— 8.24 (dd, 1 H), 8.38 — 8.45
carboxamide (m, 2 H), 8.45 - 8.50 (m, 1
H), 8.64 - 8.67 (In, 1 H),
.53(s, 1H).
Fm“ Intermediat S (Method A2):
N e9-11and Rt=1.21 min
F o 1):}
‘3' N ?‘N@ pyrrolidine MS s): mfz = 452
N— {6-chloro—2-[2-oxo(pyrr01idin- (M+H)+
1—y1)ethy1]—2H—indazo1y1}~6—
(tn'fluoromethyl)pyridine
carboxamide
\ Intermodiat (300 MHz, DMSO-d6): 6 =
FYOYH/ N
13 9-1 1 and 1.75 (br. s., 2 [-I), 1.87 (br.
F 001 \N/ VNOC
O 2-oxa s., 2 H), 3.37 - 3.51 (m, 4
N— {6—chloro[2-(2—0xa—7—
azaspiro[3. H), 4.24 — 4.41 (m, 4 H),
azaspiro[3.5]nony1)oxoethy1]—
]n0nane 5.50 (s, 2 H), 7.91 (s, 1 H),
2H-indazol—5—y1}~6- (CAS24182 8.24 (d, 1 H), 8.36 — 8.51
(tfifluoromethyl)pyridine—2—
) (m, 3 H), 8.64 (s, 1 H),
carboxamide
.53 (s, 1 H).
S (Method A1):
R1 = 1.22 min
MS (ESIpos): m/z = 508
Intermediat
I 1 (300 MHz, 019150416,
6 9-1] and 1 selected signals): 5 = 1.11
0 "3,: ' 2-methyl-I- (s. 6 H}. 2.23 (s, 2 H), 2.59 i
N—(6-chloro{2-[4-(2-hydroxy
(pipemzim (ht S“ 2 H)’ 3.46 (1)15” 2
1nethy1propyl)piperazin-1 -yl] —2 -
1- H), 3.53 (br. 5., 2 H), 4.16
oxoethyI}-2H-indazol-5 -yl)—6-
pan- (s, 1 H), 5.49 (s, 2 H), 7.92
(trifluoromethyl)pyridine
2.01 (s, 1 H), 8.24 (dd, 1:7.4,
carboxamide
1.2 Hz, 1 H), 8.37 — 8.51
(m, 3 H), 8.64 (s, 1 H),
.53 (s, 1 H).
253 / Intermediat (400 MHZ, DMSO-dé): 5 =
F e9-12a11d 1.81 (s, 2 H), 1.91 — 1.98
F O DQNVNQ
pleohdIne (m, 2 H), 3.33 — 3.37 (m, 2
N- {6—methoxy[2-oxo H), 3.54 (t, 2 H), 3.99 (s, 3
H), 5.27 (s, 2 H), 7.12 (s, 1
(pyrrolidin—l hy1]-2H-indazol—5 -
H), 8.19 — 8.25 (In, 2 H),
yl}‘6-(trifluoromethyl)pyridine
8'42
carboxamide (d: 1 H), 8-44 - 8.49
(m, 1 H), 8.71 (s, 1 H),
.51 (s, 1 H).
UPLC-MS (Method A2):
Rt = 1.14 min
MS (ESIpos): m/z = 448
(M+H)'
PCT/EP20l4/077877
254 / Intermediat (400 MHz, DMSO-d6): 5 =
FYEEYH\ N
N / F
F F 6 9—12 and 2.37 - 2.44 (m, 1 H), 2.54 -
F o m”
9 N 3%
1 H), 3.58
CH, 0 3,3- 2.61 (m, (t, 1 H),
difluoropyr 3.76 (t, 1 H), 3.86 1
N— {2-[2-(3,3-difluoropyn‘olidin- 1 — (t, H),
rolidine 3.99 (s, 3 H), 4.10 (t, 1 H),
yl)oxoethy1]~6-Ineth0xy-2H—
.27 — 5.34 (m, 1
indazol-S-y1} -6 - H), 5.37
(s, 1 H), 7.12 (s, 1 H), 8.15
(tn'fluoromethyl)pyridine—2-
— 8.30 (m, 2 H), 3.37 - 8.45
amide
(m, 1 H), 8.45 — 8.51 (m, 1
H), 8.71 (s, 1 H), 10.51 (s,
1 H).
UPLC-MS (Method A2):
Rt = 1.17 min
MS (ESIpos): m/z = 484
{M+H)‘
/ Intennediat (400 MHz, 6): a =
FVIEYH\ N
N G 9-24 and 3.40 - 3.49 (m, 2 H), 3.53 -
F 0 m”) \ , ’ ‘
9 N N 0
0 " morpholine 3.62
CH3 (m, 4 H), 3.62 - 3.68
(m, 2 H), 4.00 (s, 3 H), 5.40
6-(dif1uoromethy1)—N— {6—methoxy—2-
(s, 2 H), 7.16 (t, 1 H), 7.11
[2—(m0rph01in—4—yl)-2—oxoethyl] ~2H-
(s, 1 H), 8.00 (d, 1 H), 8.23
indaZOI-S-yl}pyridine—2—carb0xamide
(s, 1 H), 8.27 — 8.38 (m, 2
H), 8.71 (s, 1 H), 10.56 (s,
1 H).
UPLC-MS (Method A1):
Rt = 0.99 min
MS (ESIpos): m/z = 446
(MJFH)+
256 Intermediat
0 (400 MHz, DMSO-d6): 5 =
H31:gr“
N 3N)— ti 6 9-19 and 2.35 - 2.48 (m, 1 H), 2.54 -
O \N’ F
0H, 3,3- 2.60 (m, 1 H), 2.63 (s, 3 H),
difluoropyr 3.58 1 H), 3.76 (s, 1 H),
N—{2-[2-(3,3-difluoropyrrolidin (t,
rolidine 3.86 (t, 1 H), 4.01
yl)—2—oxoethy1]—6—methoxy—2H- (s, 3 H),
4.04 — 4.16 (m, 1 H), 5.30
indazol-S-yl} -6 -methylpyridine
(s, 1 H), 5.36 (s, 1 H), 7.10
carboxamide
(s, 1 H), 7.56 (dd, 1 H),
7.94 — 8.02 (m, 2 H), 8.20 -
3.24 (m, 1 H), 8.72 (s, 1 H),
.71 (s, 1H).
UPLC-MS (Method Al):
Rt = 1.17 min
MS (ESIpos): m/z = 430
(M‘rHT
257 “ac/(NEW;H351)—NC°/ Intennediat
o (400 MHZ, DMSO-d6): 5 =
e 9—19 and 2.63 (s, 3 H), 3.47 (s, 2 H),
EH3 N
line 3.53 — 3.62 (m, 4 H), 3.64
(s, 2 H), 4.01 (s, 3 H), 5.39
ethoxy[2-(morpholi11—4—
(s, 2 H); 7.09 (s, 1 H), 7.56
yl)-2—oxoethyl]-2H-indazol-5 -y1}
(dd, 1:71, 1.5 Hz, 1 H),
methylpyridine—Z—carboxamide
7.93 - 8.03 (m, 2 H), 8.21
(s, 1 H), 8.72 (s, 1 H),
.71 (s, 1 H).
UPLC-MS (Method A1):
Rt = 1.00 min
MS (ESIpos): m/z = 410
(M+H)+
W1,:NNJLNOU Intermediat fl (400 MHz, DMSO-dé): 5 =
e 920 and 1.71 - 1.84 (In, 2 H), 1.92 -
CH, morpholine 2.02 (m, 2 H), 3.16 — 3.28
N- {6-methoxy[2-(morpholin (m, 1 H), 3.42 - 3.50 (m, 4
yl)0xoethy1] -2H-indazol-5—y1} -2— H), 3.53 - 3.62 (m, 4 H),
(tetrahydro-ZH-pyran-4—y1)-l ,3- 3.64 (d, 2 H), 3.88 - 3.95
oxazolecarboxamide (m, 2 H), 3.97 (s, 3 H), 5.38
(s, 2 H), 7.08 (s, 1 H), 8.20
(s, 1 H), 8.56 (s, 1 H), 8.74
(s, 1 H), 9.41 (s, 1 H).
UPLC—MS (Method A1):
Rt = 0.88 min
MS (ESIpos): m/Z = 470
(M+H)‘
259 $.ijIntermediat UPLCMS (Method A2):
6 9-12 and Rt = 1.12 min
1-thia MS (ESIpos): m/z = 524
N-{Z-[2-(1,1-dioxid0—1—thia—6- azaspiro[3. (M+H)"
azaspir0[3.3]hepty1)oxoethyl]— 3]heptane-
6-methoxy-2H-indazol-5 -y1} 1,1 —dioxide
(trifluoromethyl)pyridine (CASI3525
carboxamide 468)
260 Intermediat (300 MHz, DMSO—dé): 5 =
6 9-12 and 3.99 (s, 3 H), 4.10 (s, 2 H),
2—oxa 4.32 (s, 2 H), 4.67 (s, 4 H),
N- hoxy-2—[2-(2-0xa—6- ro[3. 5.06 (s, 2 H), 7.12 (s, 1 H),
ro[3 .3]hepty1)0xoethy1]— 3]heptane 8.22 (d, J=7.6 Hz, 1 H),
azol—5—y1}~6- (CAS 174— 8.25 (s, 1 H), 8.41 (s, 1 H),
(trifluoromethyl)pyridine-2— 78-7) 8.46 (s, 1 H), 8.70 (s, 1 H),
carboxamide 10.51 (s, 1 H).
UPLC—MS (Method A2):
Rt = 1.08 min
MS (ESIpos): m/z = 476
(M+H)+
WO 91426
Example 261
N-{6—(3-Hydroxy-2,2-dimethylpropoxy)[2-(morpholinyl)oxoethyl]-2H -indazol-5 -y1}
(trifluoromethyl)pyridine-Z-carboxamide
F H 0 /—\
1:):/‘>_N N/ N O
Step A:
N- {6-(3- {[ten-Butyl(dimethyl)silyljoxy} -2,2-dimethy1propoxy)[2—{morphol in-4~yI)
oxoelhyl]-2H-indazoIyl }-6—(Irif1uoromethyl)pyfidine—Z-carboxamide
Fl H O/—\
/N NO
F /)_LJN
F o \,
O N
\ ICHs
3CXSi‘CHs
“3‘3
CH3
100 mg (0.22 mmol) of N—{6-hydroxy—2-[2-(morpholiny1)ox0ethy1]~2H-indazolyl}—6-
(trifluoromethyl)pyridine—2—earboxamide (Example 287) were ved in 2.0 ml of MN-
ylformamide, and 46 mg (0.33 mmol) of potassium carbonate were added with stirring. The
suspension was stirred at 25°C for 10 minutes, and 94 mg (0.33 mmol) (3-brom0-2,2-
dimethylpropoxy)(tert—buty1)dimethylsilane were then added. The reaction mixture was stirred in
the microwave at 100°C for 1 h. The reaction mixture was then filtered and by preparative HPLC.
This gave 34 mg (24% of theory) of the title compound.
S (Method A1): R = 1.70 min
MS (ESIpos): m/z = 650 (M+H)+
]H NMR (400 MHz, DMSO—dé): 5 = —0.17 - —0.09 (m, 6 H), 0.75 (s, 9 H), 1.07 (s, 6 H), 3.42 — 3.51
(m, 2 H), 3.54 — 3.64 (m, 2 H), 3.54 — 3.64 (m, 4 H), 3.64 - 3.71 (m, 2 H), 3.88 (s, 2 H), 5.40 (s, 2
H), 7.05 (s, 1 H), 8.17 — 8.27 (m, 2 H), 8.42 (t, 1 H), 8.49 - 8.56 (m, 1 H), 8.79 (s, 1 H), 10.42 (s, l
Step B:
40 mg (0.06 mmol) of N—{6—(3—{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethylpr0poxy)[2-
(morpholin—4-yl)—2—oxoethyl]~2H-indazol-5—yl}(trifluoromethyl)pyridinecarboxamide were
dissolved in 2.5 ml of tetrahydrofuran, 185 111 (0.18 mmol) of a l M solution of
tetrabutylammonium fluorid and in ydrofuran were added and the mixture was stirred at 25°C
for 2 h. 5 ml of water were added, and the on mixture was trated. The resulting
precipitate was filtered off with suction, washed with water and diethyl ether and dried under
reduced pressure. This gave 26 mg (48% of ) of N— {6-(3-hydroxy-2,2-dimethylpropoxy)—2-
[2(morpholin—4-yl)oxoethyl]-2H-indazol—5-yl}—6-(trifluoromethyl)pyridine—2-carboxamide.
UPLC—MS (Method A1): K = 1.09 min
MS (ESIpos): m/z = 536 (M+H)‘
'H NMR (400 MHz, DMSO-dG): 6 = 1.06 (s, 6 H), 3.42 (d, Hz, 2 H), 3.45 - 3.51 (m. 2 H), 3.54 -
3.63 (m, 4 H), 3.63 - 3.68 (m, 2 H), 3.90 (s, 2 H), 4.63 - 4.69 (m, 1 H), 5.40 (s, 2 H), 7.05 (s, l H),
8.17 - 8.25 (m, 2 H), 8.41 (t. I H), 8.51 (d, 1 H), 8.81 (s, l H), 10.44 (s, 1 H).
Example 262
6-Ethy1-N— {6-methoxy—2—[2-(morpholinyl)oxoethyl] -2H—indazol—5—yl}pyridine—2—
carboxamide
KOWH\ 0 H
N O
N If” F’
CH3 0 \N'
3
50 mg (0.11 mmol) of 6-bromo—N—{6-methoxy—2—[2—(morpholinyl)oxoethyl]-2H-indazol
yl}pyridinecarboxamide (Intermediate 15—2) were suspended in 750 pl of dry dioxane, 86 ul
(0.09 mmol) of a 1.1 M solution of diethyl zinc in toluene and 4 mg (0.01 mmol) of 1,1'-
bis(diphenyiphospino)ferrocenepalladium(II) dichloride dichloromethane complex were added and
the mixture was stirred at 40°C for 24 h. Another 86 til (0.09 mmol) of a 1.1 M solution of diethyl
zinc in toluene and 4 mg (0.01 mmol) of 1,1‘-bis(diphenylphospino)ferrocenepalladium(II)
ride dichloromethane complex were added and the mixture was stirred at 60°C for a r
24 h. A further 86 pl (009 mmol) of a 1.1 M solution of diethyl zinc in toluene and 4 mg (0.01
mmol) of 1,1'—bis(diphenylphospino)ferrocenepalladium(II) dichloride dichloromethane x
were added and the mixture was stirred at 60°C for a further 24 h. The reaction mixture was filtered
and the filtrate was concentrated. The crude product was ved in 2.5 ml of dimethyl
sulphoxide and purified by preparative HPLC according to Method P1. The product fraction was
lyophilized. This gave 5.8 mg (11% of theory) of the title compound.
UPLC-MS (Method A1): R1: 1.11 min
MS (ESIpos): In/z = 424 (M+H)'
'H-NMR (300 MHz, é): 5 = 1.37 (t, 3 H), 2.92 (q, 2 H), 3.42 - 3.50 (m, 2 H), 3.58 (br. s.,
4 H), 3.62 — 3.69 (m, 2 H), 4.00 (s, 3 H), 5.39 (s, 2 H), 7.10 (s, 1 H), 7.57 (dd, 2 H), 7.97 - 8.02 (m,
2 H), 8.21 (s, 1 H), 8.71 (s, 1 H), 10.88 (s, 1 H).
Example 263
6-Isobutyl-N— {6-methoxy[2-(morpholinyl)—2-oxoethyl]-2H—indazol—5 -y1}py1idine-2—
carboxamjde
| o
H / \
NIf)?fit / 0
N U
o \ '
H30 CH3 9 N
50 mg (0.11 mmol) of 6-bromo-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H—indazol
yl;pyfidinecarboxaniide (Intermediate 15-2) were dissolved in 1.5 m1 of tetrahydrofiiran, 316 |J,l
(0.16 mmol) of a 0.5 M solution of 2—methylpropylzinc bromide in tetrahydrofuran and 3 mg (0.01
mmol) of bis(tIi-tert-butylphosphine)pa11adium(0) were added and the e was stirred at 25°C
for 48 h. The reaction mixture was filtered and the filtrate was concentrated. The crude product was
dissolved in 2.5 m1 of dimethyl sulphoxide and purified by preparative HPLC according to Method
P1. The t fraction was lyophilized. This gave 2.8 mg (6% of theory) of the title compound.
UPLC—MS (Method A1): Rt = 1.27 min
MS (ESIpos): m/z : 452 (M+H)+
1H-NMR (300 MHz, DMSO—d6): 5 = 0.99 (d, 6 H) 2.15 - 2.29 (In, 1 H) 2.77 (d, 2 H) 3.47 (d, 2 H)
3.53 - 3.69 (m, 6 H) 3.99 (s, 3 H) 5.39 (s, 2 H) 7.09 (s, 1 H) 7.53 (dd, 1 H) 7.94 — 8.03 (m, 2 H)
8.21 (s, 1 H) 8.71 (s, 1 H) 10.85 (s, 1 H).
Example 264
Methyl 2—[2—(morph01inyl)oxoethy1]—5—({ ifluoromethyl)pyridiny1]carbonyl}amino)—
2H—indazole—6—carboxyl ate
/ O
F o /—\
F HN o
/ )N
N \_/
100 mg (0.60 mmol) of methyl 5-({[6-(trifluoromethyl)pyridiny1]carbonyl}amino)-1H-indazole-
6-carboxy1ate (Intermediate 14-9) were ved in 1 m1 of tetrahydrofiiran, 228 mg (1.10 mmol)
of 2-bromo(morpholin-4—yl)ethanone and 235 pl (1.10 mmol) of N,N-dicycIohexylmethylamine
were added and the mixture was stirred at 75°C for 24 h. The reaction mixture was filtered using a
ne filter and the filtrate was diluted with 1 ml of dimethyl sulphoxide and purified by
preparative HPLC. The product fractions were lyophilized. This gave 15 mg (11% of theory) of the
title compound.
UPLC-MS d A2): Rl = 1.10 min
MS (ESIpos): m/z = 492 (M+H)+
lH NMR (400 MHz, CHLOROFORM—d): 6 = 3.45 - 3.50 (m, 2 H), 3.54 — 3.64 (m, 4 H), 3.64 —
3.70 (m, 2 H), 3.97 (s, 3 H), 5.59 (s, 2 H), 8.21 (dd, 1 H), 8.36 ~ 8.43 (m, 1 H), 8.44 - 8.49 (m, 3 H),
9.08 (s, 1 H), 12.52 (s, I H).
e 265
Methyl 5- { [(6—methylpyridin~2 —y1)carbonyl]amino} -2—[2-(morpholin—4-y1)-2—oxoethyl] —2H-
le-é-carboxylate
/ 0
H30 N
O /_\
HN / ’>—N o
N \___/
,0 \ ’
H30 N
50 mg (0.16 mmol) of (Intermediat 14-10) were dissolved in 2.5 m1 of tetrahydrofiiran, 134 mg
(0.64 mmol) of 2-bromo(morpholin-4—yl)ethanone and 138 ill (0.64 mmol) of MN-
dicyclohexylmethylamine were added and the mixture was stirred at 80°C for 16 h. The reaction
e was filtered and the filtrate was concentrated. The residue was dissolved in
dichloromethane and washed three times with 1 M hydrochloric acid solution and three times with
saturated sodium chloride solution, filtered through a hydrophobic filter and, during concentration,
adsorbed on Isolute® HM-N (Biotage). The Isolute was applied to a cartridge (40 g; Puriflash) pre-
equilibrated with hexane and chromatography was canied out using the Isolera® flash purification
system (Biotage) (mobile phase: hexane/ethyl acetate; flow rate: 25 mI/min; gradient: 90:10-
>25:75). The combined product fractions were concentrated and dried. This gave 20 mg (28% of
theory) of the title compound. UPLC—MS (Method A2): R1: 1.05 min
MS s): m/z = 438 (M+H)+
1H NMR (400 MHz, CHLOROFORM—d): 6 = 2.65 (s, 3 H), 3.48 (d, 2 H), 3.59 (dd, 4 H), 3.67 (d, 2
H), 3.99 (s, 3 H), 5.58 (s, 2 H), 7.55 (dd, 1 H), 7.81 - 8.04 (m, 2 H), 8.38 ~ 8.47 (m, 2 H), 9.09 (s, 1
H), 12.57 (s, l H).
Table 19: Examples 266 - 286
The ary compounds were prepared by the general experimental procedures 13. - 16 from the
appropriate intermediates and carboxylic acids.
Prepared 1
H-NMR / LC-MS
from
Intermediate (400 MHZ, DMSO—dé): 6 = 1.98 ~
6-16 and 6- 2.06 (m, 4 H), 3.44 - 3.49 (m, 2 H),
(pyrrolidin- 3.51 (br. 5., 4 H), 3-54 - 3.61 (m, 4
N-{6-methoxy—2—[2—(m0rpholin— 1- H). 3.61 - 3.68 (m, 2 H), 3.98 (s, 3
4-y1)oxoethyl]~2H-indazol I pryn'dine- H). 5.38 (s, 2 H). 6.73 (d. l H), 7.07
yl}{pynolidin—l~yl}p)Tidin6 ! 2-carboxylic (s, l H), 7.33 (d, l H), 7.72 (dd, 1 H).
carboxamide i add (CA5 8.19 (s, l H), 8.67 (s, l H), 10.93 (s,
l 450368-20— 1 H).
UPLC-MS (Method Al): R1 = 1.16
MS (ESIpos): m/z = 465 (M+H)+
Intermediate (400 MHz, DMSO—d6): 6 = 3.42 -
6-16 and 6- 3.50 (m, 2H), 3.53 - 3.68 (m, 10 H),
olin— 3.75 - 3.84 (In, 4 H), 3.97 (s, 3 H),
N-{6-methoxy[2-(m0rpholin— 4- 5.38 (s, 2 H), 7.09 (s, 1 H), 7.15 (d, 1
4—yl)—2—oxoethyl]~2H~indazol y1)pyridine- H), 7.46 (d, 1 H), 7.81 (dd, 1 H), 8.17
yl}-6—(morpholin—4—yl)pyridine 0xy1ic - 8.21 (m, 1 H), 8.66 (s, 1 H), 10.79
carboxamide flCid (CA5 (S, 1 H).
554405—17— UPLC-MS (Method A1): Rt = 0.96
3) min
MS (ESIpos): m/z = 481 (M+H)+
268 Ari/(Narq\ Intermediate (300 MHz, 6); 8 = 0.40
"\N' -
j H
6-16 and 6- 0.58 (m, 2 H), 0.74 - 0.89 (m, 2 H),
0H3 (cyclopropyl 2.60 - 2.79 (m, 1 H), 3.41 - 3.53 (m,
6-(cyc10pr0pylamino)-N- {6— pyridi 2 H), 3.53 — 3.69 (m, 6 H), 3.96 (s, 3
methoxy—2-[2—(morpholiny1)-2~ ne H), 5.38 (s, 2 H), 6.78 (d, 1 H), 7.06
oxoethyl]-2H-indazol carboxylic (s, 1 H), 7.26 (s, 1 H), 7.36 (d, 1 H),
yl}pyfidinecarb0xamide acd 7.64 (d, 1 H), 8.19 (s, 1 H), 8.72 (s, 1
(prepared H), 10.80 (s, 1 H).
according to LC-MS (Method A3): Rt = 0.95 min
Synthesis MS (ESIpos): 11112 = 451 (M+H)+
Scheme 8,
obtainable
from
1 Ukrorgsyntez 5 '
Ltd, Order
1 1
Number
BBV—
33897980)
Intermediate (300 MHz, DMSO-d6): 5 = 0.95 (t, 3
6—16 and 6— H), 1.44 (dq, 2 H), 1.63 (quin, 2 H),
(butylamino) 3.36 - 3.44011, 2 H), 3.44 - 3.51 (m,
6-(buty1amino)—N- {6-meth0xy
pyridine—2— 2 H), 3.58 (br. s., 4 H), 3.62 - 3.70
[2-(morpholinyl)—2—oxoethy1]-
carboxylic (m, 2 H), 3.98 (s, 3 H), 5.38 (s, 2 H),
2H-indazol-S-y1}pyridine acid (CAS 6.72 (d, 1 H), 7.02 (t, 1 H), 7.07 (s, 1
carboxamide
1250403 11), 7.26 (d, 1 H), 7.50 - 7.62 (m, 1
4) 11), 8.19 (s, 1 H), 8.69 (s, 1 H), 10.82
(s, 1 H).
LC-MS (Method A3): Rt = 1.07 min
MS (ESIpos): mfz = 467 (M+H)+
WO 91426
HQCwN/(NjYN\ Intermediate
] H 0 M (300 MHz, DMSO-d6): 6 = 1.00 (t, 3
N o
o m~JLu 6-16 and 6- H), 1.59 — 1.74 (m, 2 H), 3.34 — 3.42
a (propylamino (m, 2 H), 3.42 — 3.50 (m, 2 H), 3.58
N—{6-methoxy[2-(morpholin-
)pyridine-Z- (br. s., 4 H), 3.62 - 3.68 (m, 2 H),
4-yl)—2-oxoethy1]-2H-indazol
carboxylic 3.98 (s, 3 H), 5.38 (s, 2 H), 6.72 (d, 1
VI}‘6'(Propylamin0)1’yridine'2' aed H), 7.03 — 7.12 (m, 2 H), 7.26 (d, 1
carboxamide
(prepared H), 7.50 — 7.66 (m, 1 H), 8.19 (s, 1
according to H), 8.69 (s, 1 H), 10.83 (s, 1 H).
Synthesis UPLC-MS (Method A1): Rt = 1.05
Scheme 8, min
obtainable MS (ESIpos): m/z = 453 (M+H)*
from
Ukmrgsyntez
Ltd., Order
Number
BBV-
33897968)
271 \
1 H 0 Intermediate
/—\ (300 MHz, DMSO-d6): 5 = 1.00 (d, 6
mew) 0 KrfivN 6-16 and H) 1.84 - 2.02 (In, 1 H) 3.25 (t, 2 H)
CH CH
u a potassium 6- 3,47 (d, 2 H) 3.52 — 3.72 (m, 6 H)
6-(isobuty1amino)—N—{6—methoxy— (isobutylami 3.99 (s, 3 H) 5.38 (s, 2 H) 6.75 (d, 1
2-[2-(rnorpholir1—4—yl)-2— n0)pyridi.ne— H) 6.98 — 7.13 (m, 2 H) 7.26 (d, 1 H)
oxoethy1]—2H—indazol—5— 2- 7.57 (dd, 1 H) 8.19 (s, 1 H) 8.70 (s, 1
yl}pyridinecarb0xamide
carboxylate H) 10.75 (s, 1 H).
(Intermediate UPLC-MS (Method A1): Rt = 1.12
19-15) min
MS (ESIpos): m/z = 467 (M+H)+
Intermediate -
O (300 MHz, DMSO-dé): a = 3.42
F N ©3515be 6—16 and 3.52 (m,2H), 3.58 (br. 5.,4H), 3.62
01-! 0
CH3 potassium 6— - 3.67 (m, 2 H), 3.97 (s, 3 H), 5.29 -
N-{6-methoxy[2-(morpholin- (2,2,2— 5 .39 (m, 1 H), 5.40 (s, 2 H), 7.09 (s,
4—y1)—2—oxoethyl]—2H-indazol—5— trifluoro—l— 1 H)’ 7,31 (d, J=6.0 Hz, 1 H), 7.91 (t,
yl}(2,2,2-trifluoro hydroxyethyl J=4.5 Hz, 1 H), 8.16 - 8.25 (m, 3 H),
yethy1)pyridine )pyridine-Z— 8,67 (s, 1 H), 10.70 (s, 1 H).
carboxamide(Enantiomer1)* carboxylate UPLOMS (Method A2): Rt = 0.95
mediate min
19-10) MS (ESIpos): m/z = 494 (M+H)+
273 F / Intermediate 8 = 3.42 —
F I H O /—\ (300 MHz, DMSO—d6):
\ N O
F N —>“N\ , 6-16 and 3.52 (m, 2 H), 3.58 (br.
0H 0 3“\. 5., 4 H), 3.62
9 N
CH, potassium 6- — 3.67 (m, 2 H), 3.97 (s, 3 H), 5.29 -
N- {6-methoxy—2~[2-(morpholin- (2,2,2- 5.39 (m, 1 H), 5.40 (s, 2 H), 7.09 (s,
4-y1)—2—oxoethy1]—2H-indazol trifluoro 1 H), 7.31 (d, J=6.0 Hz, 1 H), 7.91 (t,
yl} (2,2,2-trifluoro-1 - hydroxyethyl 1:45 Hz, 1 H), 8.16 - 8.25 (m, 3 H),
hydroxyethyl)pyfidine-2— ine—Z— 8.67 (s, 1 H), 10.70 (s, 1 H).
carboxamide (Enantiomer 2)* carboxylate UPLC-MS (Method A2): Rt = 0.95
(Intermediate min
19-10) MS (ESIpos): m/z = 494 (M+H)+
o/ Intermediate
| H 0 /—\ (300 MHz, DMSO—dé): 5 = 1.52 (d, 3
OH O 6‘16 and
~N H), 3.41 - 3.51 (m. 2 H), 3.58 (br. 5.,
ca, potassium 6- 4 H), 3.63 - 3.69 (“L 2 H). 4.00 (s. 2
myc‘hylw'm' (1- H), 4.80 - 4.92 (m, 1 H). 5.39 (s, 2
methmy’z'lz*morphmim'yl1'3‘ hydmxyethyl H), 5.59 (d, 1 H), 7.10 (s, 1 H). 7.80
oxoethyI]-2H—indazoI—5— )pyn'dine—Z- (dd, 1 H), 8.00 - 8.13 (m, 2 H), 8.21
yl}pyridinecarboxamide carboxylate (s, 1 H), 8.69 (s, 1 H), 10.79 (s, 1 H).
(Intermediate UPLC—MS (Method A1): Rt = 0.85
191) min
MS (ESIpos): m/z = 440 (M+H)+
Intermediate 5 = 0.44
A P —
H 0
K‘ffiu/—\
(400 MHZ, DMSO—d6):
I N N N-CH.
1 N ~'
0‘? \N 6—17 and 6— 0.56 (m, 2 H), 0.77 — 0.87 (m, 3 H),
(cyclonrtvpyl 2.20 (s, 3 H), 2.25 — 2.31 (m, 2 H),
6-(cyclopropylamino)-N- {6-
amin0)pyn'di 2.36 (br. 8., 2 H), 2.63 - 2.74 (m, 1
methoxy-Z-[Z-(4-methy1piperazin— ne-Z- H), 3.46 (br. 8., 2 H), 3.54 (br. s., 2
1-y1)-2—oxoethyl]—2H-1ndazol
carboxylic H), 3.96 (s, 3 H), 5.36 (S, 2 H), 6.78
yl}pyr1d1necarboxam1de acid ((1, 1 H), 7.06 (S, 1 H), 7.24 (s, 1 H),
7.36 (d, I H), 7.65 (t, 1 H), 8.18 (s, 1
1-1), 8.71 (s, 1 H), 10.79 (s, 1 H).
UPLC—MS d A1): Rt z 0.89
MS (ESIpos): m/z = 464 (M+H)+
0 Intermediate (300 MHz, DMSO-d6, selected
HC\/\ mi:° N NCH—
N N 3
H /N_>‘ \—/
o? \N' 6-17 and 6- s): 6 = 1.00 (t, 3 H), 1.59 - 1.74
N—{6-methoxy[2-(4- (propylamino (m, 2 H), 2.28 (s, 3 H), 2.41 (br. s., 2
piperazin-l -y1)-2— )pyridine-Z- H) 3.21 — 3.43 (m, 2 H), 3.49 (br. s., 2
oxoethy1]-2H-indazol-5 —y1} -6— carboxylic H), 3.58 (br. s., 2 H), 3.98 (s, 3 H),
acid
(pr0py1am1n0)pyridine-2_ 5.38 (s, 2 H), 6.72 (d, 1 H), 7.00 -
carboxamide 7.09 (m, 2 H), 7.26 (d, 1 H), 7.57
(dd, 1 H), 8.18 (s, 1 H), 8.69 (s, 1H),
.82 (s, 1 H).
UPLC—MS (Method A1): Rt = 0.86
MS (ESIpos): m/z = 466 (M+H)‘
p ,.
Intermediate (400 MHZ. DMSO-d6): 5 = 1.00 (d, 6
a :
m n / }_ ,—\hogU
H’cfi) WE" 6-1 7 and
H) 1.94 (dt, 1 H) 2.20 (S, 3 H) 2.25 -
CH, CH. 6. .
mm 6-
2.33 (m, 2 H) 2.33 — 2.41 (m, 2 H)
(isobutylamino)-N—{6—methoxy
(isobutylami 3.25 (t, 2 H) 3.41 — 3.50 (m, 2 H)
[2-(4—methy1p1perazm«1 —
no)pyridine- 3.50 - 3.59 (m, 2 H) 3.99 (s, 3 H)
oxoethy1]-2H-indazol 2_ 5.36 (s, 2 H) 6.71 - 6.80 (m, 1 H)
y1}pyr1d1necarboxam1de
carboxylate 7.00 - 7.11 (111,2 H) 7.22 - 7.30 (m, 1
(Intermediate H) 7.57 (dd, 1 H) 8.18 (s, l H) 8.70
19-15) (s, 1 H) 10.75 (s, 1 H).
UPLC—MS (Method A1): Rt = 0.90
MS (ESIpos): m/z = 480 (M+H)+
278 fl? 0 m Intermediate (400 MHz, DMSO-d6): 6 = 1.52 (d, 3
H36 \N N
/ N-CH,
OH 0 Omeb 6-17 and H), 2.21 (s, 3 H), 2.26 - 2.32 (111, 2
potassium 6— H), 2.34 — 2.39 (111,2 H), 3.41 — 3.50
6-(1 -hydroxyethy1)—N— {6-
(1- (m, 2 H), 3.51 - 3.58 (m, 2 H), 4.00
methoxy[2-(4-methy1piperazin—
hydroxyethyl (s, 3 H), 4.87 (dd, 1 H), 5.37 (s, 2 H),
1-y1)oxoethy1]-2H-indazol—5-
)pyndlne—Z—, ,
.59 (d, 1 H), 7.09 (s, 1 H), 7.80 (dd,
y1}pyridinecarboxamide
carboxylate 1 H), 7.98 - 8.12 (m, 2 H), 8.21 (s, 1
(Intermediate H), 8.68 (s, 1 H), 10.79 (s. 1 H).
19-1) UPLC—MS (Method A1): Rt = 0.69
MS (ESIpos): m/z = 453 (M+H)+
279 on,
’ Intermediate (300 MHz, DMSO-d6): 5 = 2.21 (s, 3
| H 0 /—\
F N’ N1;)?
/ )0: 31-0143
. v 6-17 and 4- H), 2.25 — 2.33 (m, 2 H), 2.37 (br. s.,
F 00 N
CH3 methyl 2 H), 2.58 (s, 3 H), 3.46 (br. s., 2 H),
N— {6-meth0xy—2-[2-(4- oromet 3.54 (br. s., 2 H), 3.98 (s, 3 H), 5.38
piperazin-I -yl) hy1)pyridine- (s, 2 H), 7.11 (s, 1 H), 8.08 (s, 1 H),
oxoethy11—2H—1ndazo15-y1} oxylic 8.23 (s, 1 H), 8.30 (s, 1 H), 8.70 (s, 1
methyl-6— acid H), 10.52 (s, I H).
(trifluoromethyl)pyfidine—2- (obtainable UPLC-MS (Method A1): Rt = 0.99
carboxamide from min
Anichem Inc. MS (ESIpos): m/z = 491 (M+H)+
USA)
280 “K" o Intermediate
,—\ (300 MHz, DMSOd6): 5 = 3.43 —
F 00"KIAJHUJ‘8‘ 6.21 and 2- 3.53 (m. 2 H), 3.54
I - 3.63 (m, 4 H).
U .
[S-amino—é- 3.63 - 3.69 (m, 2 H), 5.31 (s, 2 H),
2H-lndazol-
(morphoiin-ll-yl)—2-oxoethy1]-2H- H)’ 7‘58 (d3 2 H)” 8‘1 8 (d, 1 H)’ 8'26
indazol-S-yl} (s, 1 H), 8.35 — 8.44 (m, 1 H), 8.44 —
(mOTPhOIiIl-
(tfifluoromethy1)pyridine_2_ 8.52 (m, 1 H), 8.81 (s, l H), 10.47 (s,
carboxamide 1 H)'
y1)ethan0ne UPLC-MS (Method A1): Rt = 126
(Intermediate min
6-20) MS (ESIpos): m/z = 540 (M+H)+
281 Intermediate
A (la :1)—Oi?” (400 MHz, DMSO-d6): 5 = 0.47 —
0 9:13 6-5 and 6- 0.55 (m, 2 H), 0.76 - 0.86 (m, 2 H),
(CYCIOPTOPyl 1.00 - 1.11 (m, 7 H), 1.16 — 1.31 (m,
6—(cyclopropylamino)—N—(2-{2-[4-
ammo)pyr1d1_ , ,
1 H), 1.37 — 1.50 (m, 1 H), 1.75 (t, 2
(2—hydroxypropan—2—yl)piperidin—
ne H), 2.64 - 2.77 (m, 1 H), 2.99 (t, 1
1—y1]—2—oxoethyl} —6—methoxy—2H—
carboxyhc_ H), 3.95 (s, 3 H), 4.03 (d, 1 H), 4.18
indazol-S-yl)pyn'dine
and, (s, 1 H), 4.42 (d, 1 H), 5.32 (d, 1 H),
carboxamide
.38 (d, 1 H), 6.78 (d, 1 H), 7.06 (s, I
H), 7.25 (d, 1 H), 7.36 (d, 1 H), 7.65
(dd, 1 H), 8.19 (s, 1 H), 8.71 (s, 1 H),
.79 (s, 1 H).
LC-MS (Method A3): Rt = 1.10 min
MS (ESIpos): m/z = 507 (M+H)+
2014/077877
I 0 CH, Intermediate
N (300 MHz, DMSO-d6): 5 = 0.95 (t, 3
HQCMN /
N / qu—écm
H \ ,N CH,
.\1 6-5 and 6-
c? H), 1.04 (s, 7 1-1), 1.18 - 1.31 (m, 1
3 6
(butylamino) H), 1.37 - 1.51 (m, 3 H), 1.55 -1.68
—(buty1amino)—N—(2-{2-[4-(2-
pyridine (m, 2 H), 1.68 - 1.81 (In, 2 H), 2.87 -
hydroxypropan—Z-yl)piperidin—1 -
carboxylic 3.05 (m, 1 H), 3.36 - 3.47 (m, 2 H),
yl]oxoethy1}methoxy-2H-
acid 3.97 (s, 3 H), 4.05 (br. s., 1 H), 4.18
inda201—5~yl)pyridine—2—
(s, 1 H), 4.41 (d, 1 H), 5.38 (d, 1 H),
carboxamide
.32 (d, 1 H), 6.72 (d, 1 H), 7.02 (t, 1
H), 7.07 (s, 1 H), 7.26 (d, 1 H), 7.50 -
7.63 (m, 1 H), 8.19 (s, 1 H), 8.69 (s,
1 H), 10.81 (s, 1 H).
LC—MS (Method A3): Rt = 1.12 min
MS (ESlpos): m/z = 523 (M+H)‘
,4 cu, Intermediate (300 MHZ, DMSO-d6. selected
Hc’own u, N
’ f%
u ~ 9-
c \ . ' 6-5 and 6—
? s): 5: 1.0415. 7 H), 1.17 - 1.31
N-(2-{2—[4-(2-hydroxypropan-2— [(2- (m, 1 H), 1.35 - 1.51 (m, 1 H), 1.75
yl)piperidiny1]oxoethyl} methoxyethy (t, 2 H), 2.99 (t, 1 H), 3.60 (s, 4 H),
methoxy—ZH—indazol-5~y1)[(2- 1)amino]pyri 3.94 — 4.09 (m, 1 H), 3.99 (s, 3 H),
methoxyethyl)amino]pyridine—2— dine—2— 4.18 (s, 1 H), 4.42 (d, l H), 5.38 (d,1
carboxamide carboxylic H), 5.32 (d, 1 H), 6.77 (d, 1 H), 7.07
acd (s, 1 H), 7.14 (br. s., 1 H), 7.28 (d, 1
(prepared H), 7.52 - 7.64 (m, 1 H), 8.19 (s, 1
according to H), 8.68 (s, 1 H), 10.82 (s, 1 H).
sis LC-MS (Method A3): Rt = 0.90 min
Scheme 8, MS (ESIpos): rn/z = 525 (M+H)+
obtainable
from
Ukrorgsyntez
Ltd., Order
Number
BBV—
33897975)
284 H Intermediate on,
+1,ch1%,]:1;
N/ N /N_>—NC>—€:n0 (300 MHz, DMSO-d6): 5 = 1.04 (s, 6
6-5 and 6- H), 1.00 (t, 3 H), 1.12 (br. s., l H),
CH, N_
lamino 1.15 - 1.30 (In, 1 H), 1.34 ~ 1.51 (m,
2- 2- 4- 2-h d
1 H), 1.58 - 1.83 (m, 2 H), 1.67 (sxt,
r1l ' -y]1oxoeth1y}
carboxylic 2 H), 2.91 — 3.07 (m, 1 H), 3.35 -
methoxy—ZH-indazoI-S-y1)
ac1d, 3.42 (m, 2 H), 3.98 (s, 4 H), 4.05 (hr.
(propylamino)pyn'dine
3., 1 H), 4.18 (s, 1 H), 4.42 (d, 1 H),
carboxamide
.35 (d, 2 H), 6.72 (d, l H), 7.02 -
7.10 (m, 2 H), 7.26 (d, 1 H), 7.57
(dd, 1 H), 8.19 (s, 1 H), 8.69 (s, 1 H),
.82 (s, 1 H).
UPLC-MS (Method A1): Rt = 1.09
MS (ESIpos): m/z = 509 ('M+H)_
285 Akfify,o.. ,c 6.. ediate (300 MHz, DMSO-dé): 6 = 0.99 (s, 3 ,
14.5) 0,? ‘u’ ’ 6-5 and 6- H), 1.01 (s, 3 H), 1.03 — 1.08 (In, 7
CH3 (2H,
(isobutylami H), 1.19 - 1.28 (m, 1 H), 1.38 — 1.50
N-(2-{2-[4-(2—hydroxypropan-2—
n0)py11'dine- (m, 1 H), 1.75 (t, 2 H), 1.94 (dt, 1 H),
yl)p1per1d1r1—1 -yl]0xoethy1} —6—. ‘ .
2-carboxylic 2.99 (br. s., 1 H), 3.25 (t, 2 H), 3.99
methoxy—ZH-lndazol—5—y1)—6-, .
acid
. . _ _ (s, 3 H), 4.03 (d, 1 H), 4.16 (s, 1 H),
([sobutylam1n0)pyr1dme
4.42 (d, 1 H), 5.38 (d, I H), 5.32 (d, 1
carboxamide
H), 6.75 (dd, 1 H), 7.07 (s, l H), 7.05
(t, 1 H), 7.23 - 7.29 (m, 1 H), 7.57
(dd, 1 H), 8.15 — 8.20 (m, 1 H), 8.70
(s, 1 H), 10.75 (s, 1 H).
UPLC—MS (Method A1): Rt = 1.16
111111
MS (ESIpos): m/z = 523 (M+H)‘
286 16; Intermediate (300 MHz, DMSO—d6): 6 = 1.04 (s, 6
6-5 and 5— H), 1.07 - 1.15 (m, 1 H), 1.17 — 1.35
6mN}~O$EH fluoro (m, 1 H), 1.36 - 1.52 (m, 1 H), 1.75
methylpyndl (t, 2 H), 2.59 (d, 3 H), 2.99 (1, 1 H),
—flu0ro-N-(2-{2-[4-(2-
ne 3.96 - 4.08 (m, 1 H), 4.00 (s, 3 H),
hydroxypropany1)piperidin-l -
carboxyhc . 4.19 (s, 1 H), 4.41 (d, 1 H), 5.33 (d,1
y1]—2-oxoethy1}methoxy-2H-
acid H), 5.39 (d, 1 H), 7.09 (s, 1 H), 7.90
indazol-S-yl)methylpyridine
carboxamide (t, 1 H), 8.09 (dd, 1 H), 8.21 1 H),
8.68 (s, 1 H), 10.52 (s, 1 H).
* The reaction of Intermediate 6-16 and potassium 6-(2,2,2-trifluoro-l-hydroxyethyl)pyridine
ylate gave N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}(2,2,2-
trifluoro-l-hydroxyethyl)pyridinecarboxamide as a racemic mixture. This mixture was separated
into the pure enantiomers by ative chiral HPLC using the following conditions:
System: Agilent: Prep 1200, 2xPrep Pump, DLA, MWD, Gilson: Liquid r 215
Column: Chiralpak IC 5pm 250x30 mm
Solvent: ethanol / methanol 50:50 (v/v)
Flow rate: 35 ml/min
Temperature: room temperature
Solution: 401 mg/ 8 m1 dichloromethanefMeOH
Injection: 10 x 0.8 m1
PCT/EP2014/O77877
Detection: UV 280 nm
Fraction Rt in min Purity in % Amount in Peak assignment
corresponds 8.0 — 8.7 98.8 70 peak 2 — 2.88 min
to Example
corresponds 10.1 — 11.1 99.1 59 peak 4 — 3.81 min
to Example
Workup: The fractions were trated by evaporation, admixed with tBuOH, frozen at —
65°C and then freeze—dried.
e 287
N-{6-Hydroxy[2-(rnorpholinyl)oxoethyl]-2H-indazoly1}(tri fluoromethyl)pyridine-2~
carboxamide
F | H 0 m
N/ N O
/ )—NM
F o 133 \,
HO N
2.43 g (4.50 mmol) of N-{6-(benzyloxy)[2-(morpholinyl)oxoethyl]-2H-indazol—5«yl}-6—
(trifluoromethyl)pyridine-2—carboxamide (Beispiel 280) were suspended in 470 m1 of
tetrahydrofilran, and the flask was evacuated and then flushed with nitrogen (this procedure was
repeated two more times). 958 mg (0.9 mmol, 10%) of palladium on carbon and 95 1111 (370.6
mmol) of a 25% strength ammonium formate solution was added and the mixture was stirred
vigorously at 25°C for 40 minutes. The on mixture was filtered through Celite and
concentrated. The precipitate formed was filtered off with suction, washed repeatedly with water
and dried in a drying cabinet at 50°C under reduced pressure. This gave 2.01 g (90% of theory) of
the title compound.
UPLC-MS d A2): Rt = 0.64 min
MS (ESIpos): m/z = 450 (M+H)+
1H NMR (400 MHz, 6): E5 = 3.40 — 3.50 (In, 2 H), 3.52 - 3.61 (m, 4 H), 3.61 - 3.67 (m, 2
H), 5.36 (s, 2 H), 6.91 (s, l H), 8.16 — 8.23 (111,2 H), 8.40 (t, 1 H), 8.47 (d, 1 H), 8.69 (s, l H), 10.55
(s, 1 H), 10.65 (s, 1 H).
General Procedure 3a
1.0 equivalent of N- { 6 -hydroxy[2-(morpholinyl)oxoethy1]-2H-indazol-5 -y1}
(trifluoromethyi)pyridinecarboxamide was d with 1.5 equivalents of the appropriate halide
and 3.0 equivalents of potassium carbonate in NJV—dimethylformamide at 100°C in the microwave
for l h. Water was added to the reaction mixture, and the resulting precipitate was filtered off,
washed with water and diethyl ether and dried.
General Procedure 3b
lent of N— { 6-hydroxy-Z—[Z—(rnorpholin—4—y1)—2-oxoethyl}-2H-indazol-5 -yl} —6-
(trifluoromethyl)pyridine—2—carboxamide was stirred with 1.5 equivalents of the riate halide
and 3.0 equivalents of potassium carbonate in NJV-dimethylformamide at 100°C in the microwave
for l h. The reaction mixture was filtered, dimethyl sulphoxide was added and the product was
purified by preparative HPLC according to Method Pl.
General Procedure 3c
1 .0 equivalent of N- {6-hydroxy-2 -[2-(morpholinyl)oxoethyl]-2H-indazoI-5 -yl }
(trifluorornethyl)pyridinecarb0xamide was stirred with 3.0 equivalents of the appr0priate halide,
.0 equivalents of potassium carbonate and 0.1 equivalent of potassium iodide in MN-
dimethylformamide at 150°C in the microwave for 1 h. The reaction mixture was filtered, dimethyl
xide was added and the product was purified by preparative HPLC according to Method P5
ent: 0 - 15 min 10 — 50% B).
Table 20: es 304 — 328
The exemplary nds were prepared from N—{6—hydroxy-2—[2—(morpholin—4—yl)oxoethyl]-
2H—indazoiy1}(trifluoromethyl)pyridinecarboxarnide and the halides listed in the table
according to General Procedures 33, 3b or 3c.
Ex. Prepared by *
Structure/Name 1H—NMR / LC-MS
N0. reaction with key
4- (400 MHz, DMSO-dé): 8 =
bromobutane (87% 2.21 (quin, 2 H), 2.77 (t, 2
nitrile ) H). 3.43 — 3.51 (m, 2 H),
3.53 — 3.62 (m, 4 H), 3.63 _
3.69 (m, 2 H), 4.25 (t, 2 H),
.40 (s, 2 H), 7.13 (s, 1 H),
N-{6-(3-cyanopropoxy)[2-
8.22 (dd, 1 H), 8.24 - 8.26
(morpholiny1)-2—oxoethyl]—2H~
(m, 1 H), 8.37 - 8.45 (m, 1
indazol—S-yl}
H), 8.45 — 8.50 (m, 1 H),
(trifluoromethyl)pyn'dine—2—
8.74 (s, 1 H), 10.55 (s, 1
carboxamide
UPLC-MS (Method Al):
Rt 2 1.05 min
MS (ESIpos): m/z = 517
(M+H)+
1,1,1- (300 MHz, DM8066): 5 =
ro-Z— 3.43 - 3.50 (m, 2 H), 3.53 -
hane 3.63 (m, 5 H), 3.63 - 3.69
(m, 2 H), 5.01 (d, 1 H),
4.95 (d, 1 H), 5.43 (s, 2 H),
N-{2-[2-(morpholinyl)
7.30 (s, 1 H), 8.21 (d, 1 H),
oxoethyl]—6—(2,2,2—trifluoroethoxy)-
8.30 (s, 1 H), 8.41 (t, 1 H),
2H—indazol—5—yl} —6—
8.45 — 8.51 (m, 1 H), 8.81
(tn'fluoromethyl)pyridine—2—
(s, 1 H), 10.53 (s, 1 H).
carboxamide
UPLC—MS (Method AI):
Rt = 1.16 min
MS (ESIpos): m/z = 532
(M+H)+
\ (bromomethy 3b (300 MHz, DMSO-dé): 5 =
F | H 0
F :©f\N—>— U/"\ ohexan (70% 1.07 - 1.37 (In, 6 H), 1.64 —
F o
o \NI
C ) 1.81 (m, 2 H), 1.86 - 2.02
(In, 3 H), 3.42 - 3.50 (m, 2
H), 3.53 ~ 3.69 (m, 6 H),
N-{6-(cyclohexy1methoxy)[2—
3.97 (d, 2 H), 5.39 (s, 2 H),
(morpholinyl)-2—oxoethy1]-2H-
7.08 (s, 1 H), 8.18 — 8.25
indazol—S-yl}—6-
(m, 2 H), 8.40 (t, 1 H), 8.48
(trifluoromethyl)pyridine—2—
(d, 1 H), 8.79 (s, 1 H),
carboxamide
.48 (s, 1 H).
LC—MS (Method A3): Rt =
1.40 min
MS (ESIpos): m/z = 546
(M+H)+
i 291 : .
Hedi-2,2- 3b (300 MHz, DMSO-dé): 5 =
F H O
/ N N
N dimethylprop (22% 1.03 - 1.21 (m, 9 H), 3.39 -
F O £6}J
O \N'
8116 3.53 (m, 2 H), 3.53 - 3.73
1113),)HC (m, 6 H), 3.84 (s, 2 H), 5.40
3 CH3
(s, 2 H), 7.07 (s, 1 H), 8.18
N- {6-(2,2-dimethylpr0p0xy)[2-
- 8.26 (m, 2 H), 8.41 (t, l
(morpholin-4—yl)oxoethyl]-2HH
), 8.51 (d, 1 H), 8.82 (s, 1
indazol-S -y1}
H), 10.47 (s, l H).
(trifluoromethyl)pyridinc
LC-MS d A3): Rt =
carboxamide
1.30 min
MS (ESIpos): m/z 520
(M+H)+
PCT/EPZO 14/077877
2- 3b (300 MHz, DMSO-d6): 5 =
—>_N\—/N (bromomethy (41 % 1.70 — 2.00 (m, 3 H), 2.05 —
1)tetrahydrof ) 2.20 (m, 1 H), 3.47 (d, 2
uran H), 3.53 — 3.68 (m, 7 H),
3.68 — 3.77 (m, 1 H), 3.77 —
N— {2-[2-(morpholin—4-yl)
3.89 (m, 1 H), 4.07 — 4.22
oxoethyl](tetrahydrofi1ran
(1:11, 2 H), 4.22 — 4.34 (m, 1
ylmethoxy)-2H-indazoly1} -6—
H), 5.40 (s, 2 H), 7.14 (s, 1
oromethyl)pyridine
H), 8.17 — 8.29 (m, 2 H),
carboxamide
8.41 (t, 1 H), 8.48 (d, 1 H),
8.75 (5, 1 H), 10.51 (s, 1
LC-MS (Method A3): R! =
LO? min
MS (ESlpos): m/z = 534
(M+H)+
293 \ iodocyclopen Z’JbfiJ (300 MHz, DMSO—d6): 8 =
F I 0
/ n
N meNUOf‘“\ tane (23% 1.67 (dd, 2 1-1), 1.80 (dd, 2
F o
o N ) H), 1.86 - 1.96 (m, 2 H),
1.97 - 2.10 (m, 2 H), 3.47
(d, 2 H), 3.54 — 3.62 (m, 4
N-{6—(cyclopentyloxy)—2-[2-
H), 3.65 (d, 2 H), 5.07 (t, 1
(morpholin—4—y1)—2—oxoethy1]—2H.—
H), 5.38 (s, 2 H), 7.07 (s, 1
indazol—S-yl} —6—
H), 8.18 - 8.24 (m, 2 H),
(trifluoromethyl)pyn'dine—2—
8.40 (t, 1 H), 8.47 (d, 1 H),
carboxamide
8.75 (s, 1 H), 10.62 (s, 1
UPLC-MS (Method A2):
Rt = 1.29 min
MS (ESlpos): m/z = 518
(M+H)+
294 FXENUY fithL/O|\ bromoaceton 311”]
0 (300 MHz, DMSO-dé): 8 =
F H /—\
/ N
itrile (10% 3.47 (d, 2 H), 3.55 - 3.62
F 0 \ '
O N ) (m, 4 H), 3.65 (d, 2 H),
N/ 5.39 (s, 2 H), 5.44 (s, 2 H),
cyan0methoxy)[2— 7.31 (s, 1 H), 8.23 (dd, 1
(morpholinyI)oxoethy1] —2H- H), 8.30 (s, 1 H), 8.42 (d, l
indazol-S-yl} H), 8.46 (s, 1 H), 8.73 (s, 1
(trifluoromethyl)pyridine H), 10.41 (s, 1 H).
carboxamide UPLC-MS (Method A2):
Rt = 1.01 min
MS (ESIpos): m/z = 489
(M+H}+
295 bromoacctic 3c {300 MHz. DMSO-dG): 8 =
F 1\ H 0 m! ,
/ N
N acid (9%) 3.47 (d, 2 H), 3.52 - 3.71
F 003331*”) \N’
(m, 6 H), 4.90 (s, 2 H), 5.41
90m) I
(s, 2 H), 7.12 (s, 1 H), 8.16
- 8.29 (m, 2 H), 8.40 (t, 1
({2-[2-(morpholinyl)-2 -
H), 8.48 (d, 1 H), 8.77 (s, 1
oxoethy1]-5—( { [6-
H), 10.58 (s, 1 H), 13.20
(trifluoromethyl)pyridin
(br. 5., 1 H).
y1]carbony1} amino)-2H-indazol
UPLC—MS d A2):
y1}0xy)acetic acid
Rt = 0.61 min
MS (ESIpos): m/z = 508
(M+H)+
296 \ (bromomethy 3a (300 MHz, DMSO—d6): 5 =
N” “g _O>_N© Dcyclobutane (59% 1 82 - 2 04 (m —
F ,N ' ’ ’ 4 H)’ 2 09'
N ) 2.24 (m, 2 H), 2.78
D) - 2.95
(m, 1 H), 3.47 (d, 2 H),
3.52 - 3.73
N- {6-(cyclobutylmeth0xy)—2-[2- (m, 6 H), 4.15
(d, 2 H), 5.40 (s, 2 H), 7.10
(morpholinyl)0xoethyl]-2H-
(s, 1
indazol-S-yl} —6- H), 8.16 - 8.28 (m, 2
H), 8.40 (t, 1 H), 8.48 (d, 1
(tn'fluoromethyl)pyridine
H), 8.76 (s, 1 H), 10.52
carboxamide (s,
1 H).
UPLC—MS (Method A1):
Rt = 1.32 min
’MS (ESIpos): m/z = 518
(M+H}+
1-{2— 32: (400 MHz, DMSO—dé): 6 =
F 1: 0 mi 5
N meN (54% 1.65 (dt,4H), 2.57 (br. 5.,4
F o \ ,
O N f” chloroethyl)pyrrolidine ) H), 2.97 (t, 2 H), 3.42 -
hlorid 3.50 (m, 2 H), 3.54 - 3.61
D e (m, 4 H), 3.61 — 3.68 (m, 2
N—{2—[2-(morpholiny1) H), 4.28 (t, 2 H), 5.39 (s, 2
7.13 (s, 1 H), 8.19
oxoethyl][2-(pyrrolidin H), —
8'25 (“1’2 H), 8-41
oxy]—2H—indazol—5—y1}-6— (t, 1 H),
8.48 (d, 1 H), 8.75
(trifluoromethyl)pyridine—2— (s, 1 H),
.58 (s, 1 H).
carboxamide
UPLC-MS (Method A1):
Rt=0.77 min
MS (ESlpos): m/z = 547
(M+1-1)+
298 mek\ 4(2 3a (400 MHz, DMSO-d6,
l H 0
F /—\
/ chloroethyl) (64% selected signals): 5 = 2.84 —
0 N morpholine ) 2.93 (m, 2 H), 3.43 - 3.51
H hydrochlorid (m, 2 H), 3.51 - 3.62 (m, 8
(:1 . H), 3.62 - 3.69 (m, 2 H),
4.31 (t, 2 H), 5.40 (s, 2 H),
N-{6-[2-(morpholinyl)ethoxy]-
7.16 (s, 1 H), 8.18 — 8.26
2-[2-(morpholin-4—yD-2 -oxoethy1]-
(m, 2 H), 8.41 (t, 1 H), 8.48
2H—indazol-5—yl}-6—
(d, 1 H), 8.74 (s, 1 H),
(tfifluoromethyl)pyridine—2—
.57 (s, 1 H).
carboxamide
UPLC-MS (Method A1):
Rt = 0.75 min
MS (ESIpos): m/z = 563
1 (M+H}+
299 '
Hz- 3a ;' (300 MHZ. DMSO-d6,
ethyl)p (72% selected signals): 6 = 1.29 -
ipcridinc ) 1.40 (m, 2 H), 1.40 — 1.53
hydrochlorid (m, 4 H), 2.73 (s, l H), 2.84
C (t, 2 H), 3.42 - 3.51 (m, 2
H), 3.58 (br. s., 4 H), 3.62 -
N— {2-[2-(morpholin—4—yl)—2—
3.68 (m, 2 H), 4.27 (t, 2 H),
oxocthy1][2 ridin-1~
.40 (s, 2 H), 7.14 (s, 1 H),
yl)ethoxy]—2H-indazol—5 —y1} -6—
8.19 - 8.25 (m, 2 H), 8.41
(tn'fluoromethyl)pyridine—2—
(t, 1 H), 8.48 (d, 1 H), 8.74
carboxamide
(s, 1 1-1), 10.58 (s, 1 H).
UPLC—MS (Method Al):
Rt = 0.83 min
MS (ESIpos): m/z = 561
(M+H)+
300 \
O (300 MHz, DMSO-d6): a =
F 1 /“"\
/ n
N 1.93 — 2.08 (m, 2 H), 3.43 -
F O :CiNjLNL/
«)0 N
3.52 (m, 2 H), 3.52 - 3.77
”0 butyl)dimeth (m, 8 H), 4.24 (t, 2 H), 4.59
N"{6"(3"hydr°XYPr°P°XY)'2'[2' ylsilane (t, 1 H), 5.40 (s, 2 H), 7.10
(morpholin—4-yl)—2-oxoethy1]-2H-
(s, 1 H), 8.17 — 8.25 (m, 2
indazol-S-yl}
H), 8.36 - 8.44 (m, 1 H),
(tfifluoromethyl)pyfidine-2— 8.45 - 8.50 (m, l H), 8.75
carboxamide
(s, 1 H), 10.64 (s, 1 H).
UPLC—MS (Method A1):
Rt = 0.97 min
MS (ESIpos): m/z = 508
(M+H)-‘
301 fiNfiszu°\ (300 MHz, DMSO—dé): 5:
F H 0 m I
bromopropan 1.32 (d. 3 H}, 3.42 ~ 3.51
F o
o \N'
_ (m, 2 H), 3.51 - 3.61 (m, 4
HOW) y1)oxy](tert- H), 3.61 - 3.69 (m, 2 H),
butyl)dimeth 3.86 — 3.95 (m, 1 H), 4.05 -
N— {6—(2—hydroxypropoxy)—2—[2—
ne 4.16 (m, 2 H), 4.96 (d, 1
(morpholin—4—yl)—2-oxoethyl]—2H—
H), 5.40 (s, 2 H), 7.09 (s, 1
indazol-S-y1}
H), 8.18 - 8.25 (m, 2 H),
(trifluoromethyl)pyridine
8.35 — 8.44 (m, 1 H), 8.44 —
carboxamidc
8.52 (m, 1 H), 8.76 (s, 1 H),
.54 (s, 1 H).
S (Method A2):
Rt = 0.98 min
MS (ESIpos): m/z = 508
(M+H)+
2014/077877
FXQW fir“)—\ ten-Butle-
1 H 0 fl Wis—686): 5 =
/ N N -
\ , 10doethoxy)d (52% 3.42 — 3.51 (m, 2 H), 3.58
F 0 ~ ’
N 1methy181lane. .
O ) (br. s.,4H), 3.62 -3.68 (m,
40¢ “1
2 H), 3.89 (q, 2 H), 4.20 (t,
N-{6-(2—hydroxyethoxy)—2-[2- (77% 2 H), 4.89 (t, 1 1-1), 5.40 (s,
(morpholiny1)oxoethyl]—2H- ) 2 H), 7.12 (s, 1 H), 8.21
indazol-S-yl} (dd, 1 H), 8.24 (s, 1 H),
(trifluoromethyl)pyn'dine
8.35 - 8.44 (m, 1 H), 8.44 _
carboxamide
8.49 (m, 1 H), 8.73 (s, 1 H),
.66 (s, 1 H).
LC—MS (Method A3): Rt =
0.84 min
MS (ESIpos): m/z = 494-
1M+H)+
o-Z- (300 MHz, DMSO-dé): 5 =
(27% 3.36 (s, 3 H), 3.42 — 3.51
) (m, 2 H), 3.54 - 3.62 (m, 4
H), 3.62 - 3.69 (m, 2 H),
N-{6-(2-methoxyethoxy)~2-[2- 3.82 (dd, 2 H), 4.30 (dd, 2
(morpholinyl)-2 -oxoethy1]-2H- H), 5.40 (s, 2 H), 7.13 (s, 1
indazoi—S —y1}—6~ H), 8.20 - 8.25 (m, 2 H),
(trifluoromethyl)pyridine-2— 8.37 — 8.44 (m, 1 H), 8.45 —
carboxamide 8.50 (m, 1 H), 8.77 (s, 1 H),
.58 (s, 1 H).
LC-MS (Method A3): Rt =
1.01 min
MS (ESIpos): m/z = 508
(M+H)+
304 mN_O>—p\_/ ethyl 313““ (300 MHz, DMSO-dé): 6 =
bromoacetate (59% 1.21 (t, 3 H), 3.42 - 3.50
) (m, 2 H), 3.52 - 3.62 (m, 4
H), 3.63 — 3.68 (m, 2 H),
4.20 (q, 2 H), 5.02 (s, 2 H),
ethyl ({2—[2-(morpholinyl)—2-
.41 (s, 2 H), 8.22 (dd, 1
oxoethy1]-5 -({[6-
H), 8.26 (s, 1 H), 8.36 -
(trifluoromethyl)pyridin-2—
8.45 (m, 1 H), 8.46 - 8.51
yl]carbonyl} amino)—2H—indazol—6—
(m, 1 H), 8.76 (s, 1 H),
yl} oxy)acetate
.56 (s, 1 H).
LC—MS (Method A3): Rt =
1.05 min
MS (ESlpos): m’z = 536
(1va+
305 mg)— (300 MHz, DMSO-dé): 5 = ’
\ ,° bromobutano 2.07 — 2.23 (m, 2 H), 2.62
(t, 2 H), 3.40 - 3.51 (m, 2
Hos H), 3.59 (s, 3 H), 3.53 -
3.63 (m, 4 H), 3.65 (br. s., 2
methyl 4-( {2-[2-(m0rph01in-4—y1)—
H), 4.19 (t, 2 H), 5.40 (s, 2
thy1]-5—( {[6-
H), 7.08 (s, 1 H), 8.21 (dd,
(trifluoromethyl)pyridin—2-
1 H), 8.23 (s, 1 H), 8.34 -
yl]carbony1}amino)-2H-indazol
8.52 (m, 1 H), 8.40 (t, 1 H),
y1}oxy)butan0ate
8.74 (s, 1 H), 10.58 (s, 1
LC—MS (Method A3): Rt =
1.05 min
MS (ESIpos): m/z = 550
(M+H)+
306 \ ethyl 2- 3bl‘“
O (300 MHz,DMSO-d6):6=
F l 11:CfofNL/O bromopropan/—\ ,
N (46% 1.13 (t,3H), 1.68 (d,3H),
F o \ ,
o N oate ) 3.43 — 3.52 (m, 2 H), 3.53 - HacVOWKLCHa 3.62 (m, 4 H), 3.62 — 3.69
(m 2 H, 4.13
ethyl 2—({2-[2-(morpholin—4-yl)—2- , ) (q 2
, H),
.28 (q,1H,S.4O s,2H,) ( )
oxoethy1]—5~({[6-
7.07 (s, 1 H), 8.22 (dd, 1
(trifluoromethyl)pyridin—2-
H), 8.26 (s, l H), 8.38 -
yl]carbonyl}amino)-2H-indazol
8.44 (m, 1 H), 8.46 - 8.51
yl}0xy)propanoate
(m, 1 H), 8.75 (s, 1 H),
.81 (s, l H).
LC—MS d A3): Rt =
1.12 min
MS (ESIpos): m/z = 550
(M+H)+
307 \ ethyl 2- 3b
0 (300 MHz, é): 5 =
F /—\
/ n I
N / NfNu br0m0pr0pan (51% 1.09 - 1.18
F (m, 9 H), 2.38
F o
o \N/
oate ) (d, 1 H), 3.43 - 3.49 (m, 2
HSCVOWCHG H), 3.53 — 3.62 (m, 4 H),
0 CH3
3.62 - 3.67 (In, 2 H), 4.16
ethyl 3-methy1( {2—[2—
(q, 2 H), 4.99 (d, 1 H), 5.40
(morpholiny1)—2—oxoethyl]—5—
(s, 2 H), 6.99 (s, 1 H), 8.22
({[6-(trifluoromethyl)pyridin—2—
(dd, 1 H), 8.26 (s, 1 H),
yl]carbony1}amino)-2H-indazol
8.42 (t, 1 H), 8.50 - 8.54
y1}oxy)butanoate
(m, 1 H), 8.82 (s, 1 H),
.53 — 10.56 (m, 1 H).
LC—MS (Method A3): Rt =
1.24 min
MS (ESIpos): m/z = 578
(M+H)+
* Prepared according to the stated procedure, the yield in % is indicated in brackets
[a]: Afier 60 minutens, another 1 equivalent of the halide was added and the mixture was stirred in
the microwave at 120°C for a further 60 minutes.
[b]: The crude product was purified by ative HPLC.
[c]: The crude product was purified by ative HPLC according to Method P5 (gradient: 0 - 15
min 30 — 70% B).
[d]: The reaction mixture was added to water, the precipitate was d off with suction and
washed with diethyl ether. The crude product was purified by preparative HPLC according to
Method P5 (gradient: 0 — 15 min 15 — 55% B).
[e]: The crude product was purified by preparative HPLC ing to Method P5 (gradient: 0 — 15
min 15 — 55% B).
[t] The following procedure was used for deprotecting the alkylated intermediate (the 2nd yield in
% indicated in the table refers to the ection). 1 equivalent of the silyl-protected ediate
was dissolved in tetrahydrofuran, 3 equivalents of a 1 M solution of tetrabutylammonium fluoride
in tetrahydrofuran were added and the mixture was stirred at 25°C for 24 h. Water was added to the
reaction mixture and the resulting precipitate was filtered off with suction, washed with water and
dried in a drying cabinet at 50°C under reduced pressure.
[g]: r 0.1 equivalent ofpotassium iodide was added to the reaction mixture.
[h]: The crude product was purified by preparative HPLC (column: XBridgc C18 5pm 100x30
mm).
Example 308
2-( {2-[2-(Morpholinyl)oxoethy1] —5 —( rifluoromethyl)pyridin-2—yl] carbonyl}aniino)—2H—
indazolyl} opanoic acid
\ .
F | H 0 /—\
N/ N1C0 O
/ )—N
. w
F O \ ’
O N
HOWKKCH3
ously to Intermediate 4-1, 50 mg (0.09 mmol) of ethyl 2-({2-[2—(morpholinyl)—2-
oxoethyl] —5—( {[6—(trifluoromethyl)pyridin-2—yl] carbonyl } amino)-2H-indazolyl} oxy)propanoate
(Example 306) were dissolved in 0.5 m1 of tetrahydrofuran, a solution of 11 mg (0.45 mmol) of
lithium hydroxide monohydrate in 164 pl of water was added and the mixture was stirred at 25°C
for 24 h. The reaction mixture was d, dimethyl sulphoxide was added and the product was
purified by preparative HPLC (column: XBridge C18 Sum 100x30 mm). This gave 7 mg (15% of
theory) of the title compound.
UPLC-MS (Method A2): Rt = 0.67 min
MS (ESIpos): m/z = 522 (M+H)+
lH NMR (400 MHz, DMSO—d6): 8 = 1.64 (d, 3 H), 3.46 (br. s., 2 H), 3.58 (br. 3., 4 H), 3.64 (d, 2
H), 4.99 (d, 1 H), 5.38 (s, 2 H), 6.97 (s, 1 H), 8.15 - 8.25 (m, 2 H), 8.35 - 8.45 (m, 1 H), 8.45 — 8.51
(m, 1 H), 8.73 (s, 1 H), 10.82 (s, 1 H).
WO 91426 PCT/EP2014/O77877
e 309
N- {6-(2-Hydroxypropanyl)[2-(morpholinyl)oxoethyl]-2H -indazol-5 -yl } -6 -
(tn'fluoromethyl)pyridine-Z-carboxamide
F \ O
F “5&9HN
H3C N
/ —>7N/—\
0 L/
536 mg (4 equiv.) of 2-bromo-I-(morpholinyl)ethanone were added to a mixture of 250 mg
(0.69 mmol) of N-[6-(2~hydroxypropanyl)-1H-indazol-S-yl](trif1uoromethyl)pyridine
carboxamide (Intermediate 14-11) and 0.59 ml of cyclohexylmelhylamine in 1.5 ml of THF.
and the mixture was stirred at 70°C overnight. Water was added. the mixture was extracted with
ethyl acetate and the extract was washed with ted aqueous sodium chloride solution, filtered
through a hydrOphobic filter and concentrated. The residue was purified by column
chromatography on silica gel oromethane / methanol). This gave 46 mg (14% of theory) of
the title compound.
lH-NMR (400MHz, DMSO-dé): 6 [ppm]= 1.62 (s, 6H), 3.46 (d, 3H), 3.42 — 3.69 (m), 5.45 (s, 2H),
.95 (s, 1H), 7.54 (s, 1H), 8.15 (dd, 1H), 8.25 (s, 1H), 8.36 (t, 1H), 8.45 (d, 1H), 8.73 (s, 1H), 12.35
(s, 1H).
UPLC-MS (Method A2): Rt = 0.99 min (UV-TIC), mass found 491.00.
Example 310
N-{6-Ch10ro[2-(4—methylpiperazinyl)oxoethyl]—2H—indazol—5-y1}
(difluoromethyl)pyridine-Z—carboxamide
/ O ,—
l H
F \N N N—CH
‘ p 3
F o N:CE\N
98 mg (0.32 mmol) of 2-(5—amino-6—chloro—2H—indazol—2—yl)—1—(4-methylpiperazin—l-y1)ethan0ne
(Intermediate 6—21) and 82 mg of 6-(difluoromethyl)pyridine-Z—oarboxylic acid 'were initially
charged in 3.0 ml of THF, 49 mg of 1-hydroxy-1H—benzotriazole hydrate, 121 mg of 1-(3-
dimethylaminopropyl)—3 -ethylcarbodiimide hloride and 0.13 ml of triethylamine were added
and the mixture was stirred at room temperature for 19.5 h. The mixture was diluted with water and
PCT/EP2014/O77877
the itated solid was filtered off, washed twice with water and three times with diethyl ether
and dried under reduced pressure. This gave 129 mg of the title compound.
lH-NMR (300MHz, DMSO—dé): 5 [ppm]: 2.21 (s, 3H), 2.25 — 2.42 (m, 4H), 3.42 - 3.59 (m, 4H),
.50 (s, 2H), 7.14 (t, 1H), 7.91 (s, 1H), 8.02 (dd, 1H), 8.29 - 8.44 (m, 3H), 8.64 (s, 1H), 10.60 (s,
1H).
UPLC-MS (Method A2): Rt = 1.06 min (UV-TIC), mass found 462.00.
Example 31 l
h10ro-2—[2-(morpholinyl)—2~0xoethyl]~2H—indazol~5 —y1}-6—(difluorornethyl)pyridine—2—
carboxamide
/ 0
l H
F \ 8 N. 0,
F o \ ’
Analogously to the preparation of Example 310, 137 mg of 2—(5-amino-6—chloro—2H—indazol—2—yl)—
1-(m01pholin—4—yl)ethanone (Intermediate 6-22) were reacted with 70 mg of 6—
(difluoromethyl)pyridinecarboxylic acid at room temperature for 68 h. Water was added and the
solid was filtered off with suction, washed with e, water and diethyl ether and dried under
reduced pressure. This gave 91 mg of the title compound.
UPLC-MS (Method A1): Rt = 1.06 min C), mass found 449.00.
lH-NMR (400MHz, DMSO-dé): 5 [ppm]= 3.42 - 3.68 (m, 8H), 5.50 (s, 2H), 7.90 (s, 1H), 8.01 (dd,
1H), 8.29 - 8.36 (m, 2H), 8.41 (d, 1H), 8.64 (s, 1H), 10.59 (s, 1H).
Assessment of physiological efficacy
The in-vitro ty of the compounds according to the invention can be shown in the following
assays:
Irak4 kinase assay
The Irak4-inhibitory activity of the substances ing to the ion of the present invention
was measured in the Irak4 TR-FRET assay (TR—FRET = Time Resolved scence Resonance
Energy Transfer) described in the paragraphs that follow.
Recombinant fusion protein from N-terminal GST (glutathione S-transferase) and human Irak4,
expressed in baculovirus-infected insect cells (Hi5, BTl~TN-SBl—4, cell line sed from
lmitrogcn, catalogue No. 3855-02) and purified via y tography, was used as enzyme.
The substrate used for the kinase reaction was the biotinylated peptide biotin-Alix-
KKARFSRFAGSSPSQASFAEPG (C-terminus in amide form) which can be sed, for
example, from Biosyntan GmbH n-Buch).
For the assay, 11 different concentrations in the range from 20 uM to 0.073 nM were prepared
from a 2 mM solution of the test substance in DMSO. For the assay, 50 111 of the respective solution
were pipetted into a black low—volume 384-well microtitre plate (Greiner e, Frickenhausen,
Germany), 2 pl of a on of lrak4 in assay buffer [50 mM HEPES pH 7.5, 5 mM MgClZ, 1.0
mM dithiothreitol, 30 uM activated sodium orthovanadate, 0.1 % (w/v) of bovine gamma—globulin
(BGG) 0.04% (v/v) nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min to
allow prebinding of the substances to the enzyme prior to the kinase reaction. The kinase reaction
was then started by addition of 3 ul of a solution of adenosine triphosphate (ATP, 1.67 mM = final
concentration in 5 pl of assay volume: 1 pM) and peptide substrate (0.83 MM = final concentration
in 5 ul assay volume: 0.5 uM) in assay buffer, and the resulting mixture was incubated at 22°C for
the reaction time of 45 min. The concentration of the Irak4 was adjusted to the respective activity
of the enzyme and set such that the assay was carried out in the linear range. Typical concentrations
were in the order of about 0.2 nM. The on was stopped by addition of 5 pl of a solution of
T detection reagents [0.1 uM streptavidin-XL665 (Cisbio Bioassays; France, catalogue
No. 6lOSAXLG) and 1.5 nM anti-phosphoserin antibody [Merck Millipore, "STK Antibody",
catalogue No. 35—002] and 0.6 nM LANCE EUaW1024-1abelled anti—mouse-IgG antibody (Perkin-
Elmer, product No. AD0077, alternatively it is possible to use a terbium cryptate—labelled anti-
mouse—IgG antibody from Cisbio Bioassays) in aqueous EDTA solution (100 mM EDTA, 0.4 %
[w/v] bovine serum albumin [BSA] in 25 mM HEPES pH 7.5).
The resulting mixture was incubated at 22°C for l h to allow formation of a complex of the
biotinylated orylated substrate and the detection ts. The amount of the phosphorylated
substrate was then evaluated by measuring the resonance energy transfer from europium e-
labelled anti-mouse-IgG antibody to streptavidin-XL665. To this end, the fluorescence ons at
620 nm and 665 run were measured after excitation at 350 nm in a TR-FRET measuring
instrument, for example a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux
(Perkin-Elmer). The ratio of the emissions at 665 nm and 622 nm was taken as a e of the
amount of phosphorylated substrate. The data were normalized (enzyme reaction without test
substance = 0% inhibition; all other assay components but no enzyme 2 100% inhibition).
Typically, the test substances were tested on the same microtitre plate at 11 different concentrations
in the range from 20 pM to 0.073 nM (20 pM, 5.7 uM, 1.6 uM, 0.47 uM, 0.13 pM, 38 nM, ll nM,
3.1 nM, 0.89 nM, 0.25 nM and 0.073 nM). The dilution series were prepared prior to the assay (2
mM to 7.3 nM in 100% DMSO) by serial dilutions. The [C50 values were calculated using a 4-
parameter fit.
Table 21: 1C50 values of the exemplary nds in the IRAK4 kinase assay
ICso
Example
1 l l l
WO 91426 PC17EP2014/077877
ICSO
Example Example
[nM]
90 45
91 312
93 498
95 638
101 638
102 242
104 830
105 475
106 979
107 190
108 101
109 16
110 93
111 27
112 92
113 20
114 537
115 817
116 270
117 47
118 528
‘ 125 442
WO 91426
Example
‘ 196
‘ 197
2014/077877
Example
TNF—a secretion in THP-1 cells
Using this test, it is le to test substances for their ability to inhibit secretion of TNF-a
r necrosis factor alpha) in THP-1 cells (human monocytic acute leukaemia cell line). TNF—a
is a cytokine involved in inflammatory processes. In this test, TNF-o secretion is triggered by
incubation with bacterial lysaccharide (LP S).
THP-1 cells are kept in continuous suspension cell culture [RPMI 1460 medium with L—Glutamax
(Gibco, Cat No. 61870—044) supplemented with foetal calf serum (FCS) 10% (Invitrogen, Cat No.
10082-147), 1% penicillin/streptomycin (Gibco BRL, Cat No. 15140-114)] and should not exceed
a cell concentration of 1x106 cells/ml.
The assay is carried out in cell culture medium (RPMI 1460 medium with L—Glutamax
supplemented with FCS 10%).
In each case 25 ul of the cell suspension (corresponds to 4000 cells) per well were dispensed
into a 384-well test plate (Greiner, Cat No. ) in which in each case 40-50 nl nce had
been dissolved in 100% DMSO. Here. in each case 10 different concentrations in the range from 20
1.1M to 0.073 nM were used for each substance. The cells were incubated at room temperature for
min. 2-2.5 341 of0.1 ug/ml LPS (Sigma, Escherichia colz' 055:85, Cat. No. L5418) dissolved in
cell culture medium (final concentration 0.05 ug/ml) were then dispensed into each well. As a
neutral control, cells were treated with 0.05 ug/ml LPS and 1% DMSO and, as inhibitor l,
only once with 1% DMSO.
The plates are centrifuged at 80 g for 30 s and incubated at 37°C, 5% C02 and 95% atmospheric
humidity for 17 h. The amount of TNF—a was determined using the TNF-alpha HTRF ion
Kit (Cisbio, Cat No. 62TNFPEB/C). To this end, in each case 2 ul of the detection solution
consisting of anti—TNF—u—XL665 conjugate and NF—a—cryptate conjugate, dissolved in
accordance with the instructions of the manufacturer in the reconstitution , were added for
the HTRF (Homogeneous Time-Resolved Fluorescence) test. After the on, the mixture was
incubated either at room temperature for 3 h or at 4°C overnight. The signals were then read at
620/665 nm using an HTRF-enabled measuring instrument such as the BMG PheraStar.
The ty of the substances is expressed as the ratio between neutral and inhibitor control in
percent. The lC50 values were calculated using a 4-parameter fit.
Table 22: 1C50 values of the exemplary compounds with respect to the secretion of TNF-a in THP—1
cells
WO 91426 '77
W0 091426
I IS
W0 2015/091426 2014/077877
ICso
Example
[HM]
221 0.26
222 0.22
223 15.34
225 2.36
226 4.96
227 19.82
228 2.45
229 1.18
230 13.82
231 16.34 not determined
232 1.22 2200*
233 2200*
234 14.66
235 3.36
236 271 0.86
237 272 0.55
238 1.16 273 3.99
239 2200* 274 0.68
240 2.87 275 3.50
241 0.64 276 0.53
242 0.57 277 0.41
6.89 278 0.91
244 0.88 279 2200*
WO 91426
*: highest ICSO value that can be
determined owing to assay
limitations
In Vitro LPS (lipopolysaccharide)-induced cytokine production in human PBMCs (peripheral
blood mononuclear cells)
The effect of the nds according to the invention on the induced ne production in
human PBMCs was examined. Here, cytokine production was induced by LPS, a TLR4 ligand,
which leads to activation of the IRAK4—mediated signal path.
The human PBMCs were ed from anti-coagulated human whole blood. To this end, 15 ml of
-Paque (Biochrom, Cat. No. L6115) were initially d in Leucosep tubes and 20 ml of
human blood were added. After centrifugation of the blood at 800 g for 15 min at room
temperature, the plasma including the platelets was removed and discarded. The PBMCS were
erred into centtifiigation tubes and made up with PBS (phosphate—buffered saline) (Gibco,
Cat. No. 14190). The cell suspension was centrifuged at room temperature at 250 g for 10 min and
the supernatant was discarded. The PBMCs were resu5pended in complete medium (RPM! 1640,
without L-glutamine (FAA. Cat. No. 1315-039). 10% FCS; 50 U/ml penicillin. 50 ug/ml
streptomycin (FAA, Cat. No. Pl 1-010) and 1% L-glutamine (Sigma, Cat. No. 07513)).
The assay was also carried out in complete medium. The PBMCs were sown in 96-well plates at a
cell density of 2.5x105 cells/well. The compounds according to the invention were subjected to
serial dilution in a constant volume of 100% DMSO and employed in the assay at 8 different
concentrations in the range from 10 uM to 3 nM such that the final DMSO concentration was 0.4%
DMSO. Prior to the actual stimulation, the cells were then pro—incubated therewith for 30 min. To
induce cytokine secretion, the cells were ated with 0.1 ug/ml LPS (Sigma, Cat. No. L4516)
for 24 hours. Cell viability was ined using the CellTiter-Glo luminescent assay (Promega,
Cat. No. G7571 (G755/G756A)) in accordance with the instructions of the manufacturer. The
amount of secreted TNF—u in the cell culture supernatant was determined using the Human
ammatory 9-Plex Tissue Culture Kit (MSD, Cat. No. B) in accordance with the
instructions of the manufacturer. By way of example, the Exemplary Compound 1 having an
activity between 1 and 10 uM and the Exemplary Compounds 47, 64 and 71 having an activity of S
1 uM are mentioned.
In vitro tumour-associated NF-kB reporter activity
The effect of the compounds according to the invention on the NF-kB signal pathway was
examined in human DLBCL (diffuse large B cell lymphoma) cell lines. TMD-B, HBL-l, U2932 ,
HT and CLZ cells were stably transduced with a lentivirus NF—kB reporter construct
(Cignal Lenti NFKB Reporter (luc) kit: CLS—013L, Qiagen), thus generating TMD—8—NF—kB—luc,
HBL-l-NF-kB-luc, U2932-NF-kB-luc, HT—NF-kB-luc and WSU-Dl.CL2-NF-kB-luc reporter cell
lines. 10,000 cells were transferred into 30 l in growth medium (RPMI (Biochrom, Cat. No.
PG 1215), 20% FCS (Biochrom, Cat. No. S 0615)) or into RPMI 1640 medium supplemented with
% FCS in a 384-Well plate (Perkin Elmer, white) and incubated at 37°C overnight. After 24 h,
the cells were treated with test substances and incubated at 37°C for 6 h and 24 h. The test
substances were added to the cells in 7-fold dilution — either alone or as combination of two test
substances of ent concentrations (ratios substance 1 and substance 2: 1:0, 5; 07:03;
05:05; 0.3107; 0.15:0.85; 0:1) using an HP D300 digital dispenser. As l, the cells were
treated with vehicle . After 6 h and 24 h, the cells were treated with 30 ill/well One—Glo
solution (Promega, Cat. No. E6110) and incubated at room temperature for 10 min, and the
luminescence was measured using a VICTOR V (Perkin Elmer) in order to ine the NF—KB
reporter activity at the end of the treatment. The effect on the NF—KB reporter activity in percent
and the ICSO values derived therefrom were determined for each test substance. The IC50 values
were calculated using a 4-parameter fit.
By way of example, the Exemplary Compound 289 having an activity between I and 10 nM with
the cell lines TMD-S-NF-kB-luc, HBL-l-NF—kB-luc, U2932-NF-kB-luc and WSU-DLCLZ-NF-
kB-luc is mentioned.
In vitro tumour-associated secretion of interleukin-6 and interleukin-10
The effect of the compounds according to the ion on the secretion interleukin-6 and
interleukin-10 was examined in human TMD-S DLBCL cells. 15000 cells/well were sown in 100
[.11 of fresh growth medium (RPMI (Biochrom, Cat. No. PG 1215), 20% FCS (Biochrorn, Cat. No.
S 10615)) in a l plate (Perkin . The test substances were added to the cells in 7—fold
dilution using an HP D300 l dispenser and incubated for 24 h. After the incubation time had
ended, the supernatants were collected and the interleukin concentration was determined using the
Human IL-6/IL—10 Elisa Kit, (Life Technologies, Cat. No. KHC0062, KHC0101) in accordance
with the instructions of the manufacturer. The effect on the interleukin ion in percent was
determined for each test substance.
By way of example, the Exemplary Compound 289 having an ty between 1 and 10 [AM on the
secretion of. interleukin—6 and interleukin-10 is mentioned.
The suitability of the compounds ing to the invention for the treatment of inflammatory
disorders, tumour disorders and ophthalmological disorders such as wet AMD (age-related macular
degeneration) can be shown in the following animal :
In vivo model of TLR—mediated inflammation
The compounds according to the invention were ed in a model of in viva diated
inflammation for their in vivo efficacy. This mechanistic model shows in particular the potential
effect of the compounds according to the invention on TLR4—mediated disorders since an LPS-
mediated inflammation model was used. Here, female Balb/c mice (about 8 weeks old; Charles
River Laboratories, Germany) were divided into groups of 5 animals each. The control group was
treated with the e in which the substance had been dissolved (substance vehicle) and also
with the vehicle in which the LPS had been dissolved. 0.2 mg of LPS/kg body weight (Sigma, Cat.
No. 1.4391) (lipopolysaccharides from E. coii 0] 1 l:B4) was administered intraperitoneally (i.p.) to
the groups treated with substance, and also to the positive control group. In addition, the positive
control group was treated with the substance vehicle described above. The substance was
administered orally 8 hours before induction of inflammation by administration of LPS. To
examine the effect of the compounds according to the invention on the ation, a final blood
sample was taken from the animals after 1.5 hours. The concentration of certain nes in the
plasma was determined using the Mouse ammatory 7-Plex Tissue Culture Kit (MSD, Cat.
No. K15012B) in accordance with the instructions of the manufacturer. Fig. 1 shows the amount of
TNF-a in the plasma, which is reduced in a dose-dependent manner by administration of
Exemplary Compound 64 in comparison with the duced concentration.
In vivo model of IL-lli—mediated inflammation
To evaluate the potential efficacy of the compounds according to the invention in IL-lB-mediated
disorders, IL—lB was administered i.p. to female Balb/c mice (about 8 weeks old, Charles River
Laboratories, Germany) and the effect of the compounds according to the invention on IL—lfi—
mediated cytokine secretion was examined. In each case, the group size was 5 animals. The l
group was treated with the vehicles used for dissolving the substance and the IL-1 [5. In each case 90
ug of IL—lB /kg body weight (R&D, Cat. No. 40l-ML/CF) were administered i.p to the groups
treated with substance and the ve control group. The substance or its vehicle in the ve
control group were stered 4 hours before the administration of IL-1 B. The determination. of
TNF-a in the plasma after the final removal of blood was carried out 2 heurs afier administration of
the IL-lB using the Mouse Prolnflammatory 7-Plex Tissue Culture Kit (MSD, Cat. No. B)
in accordance with the instructions of the manufacturer. Administration of IL-lB lead to an
elevated TNF-a plasma concentration which was inhibited by treatment with Exemplary
Compound 64. This is illustrated by Figure 2.
Oxygen-induced in viva retinopathy (OIR) model
It has been shown that oxygen-induced retinopathy is a useful animal model for the study of
pathological l angiogenesis. This model is based on the observation that hyperoxia during
early postnatal development in the retina causes arrest or delay of the growth of normal retinal
blood vessels. When, after a 7-day hyperoxia phase, the animals are returned to nonnoxic room air,
this is equivalent to relative hypoxia. The ischaemic situation caused in this manner results in an
abnormal neovascularization which has some similarities with pathophysiological
neovascularization in eye disorders such as wet AMD elated macular degeneration). In
addition, the cularization caused is highly reproducible, quantifiable and an important
parameter for examining the e mechanisms and possible treatments for various forms of
retinal disorders. This is why this model is suitable for examining the effect of the compounds
according to the invention on this pathological process.
To this end, young murine animals of an age of 7 days, for example young C57Bl/6 s, are
exposed to a hyperoxic nment (70% oxygen) for 5 days, From day 12 to day 17, the mice are
kept under normoxic conditions Norrnoxic means room air with 21% oxygen. During this period,
the animals are then ed to groups treated with substance and vehicle group and treated
according to the group. The animals are sacrificed on day 17, and the eyes are then removed and
fixated in 4% formalin. After washing in phosphate-buffered saline, the retina is excised, a flat
preparation thereof is produced and this is stained with isolectin B4 dy (Tual~Chalot,
Allinson, et al., J. Vis. Exp, 2013). Quantification of neovasculaiization is d out using a Zeiss
ApoTome.
In vivo model of laser-induced choroidal neovascularization
This study serves to igate the efficacy of a test substance on reduction of
extravasation/oedema formation and/or choroidal neovascularization in the rat model of laser-
induced choroidal neovascularization. In the animal model, laser-mediated photocoagulation leads
to destruction of Bruch's membrane with concomitant damage to the vessels and inflammation—
associated neovascularization. Both processes correspond to the pathomechanism of macular
degeneration (Grossniklaus, Kang, Berglin, Prog Retin Eye Res, 2010).
To ine the effect of the compounds ing to the invention, Brown Norway Rats (Charles
River Laboratories) are assigned to the appropriate groups (substance and vehicle) and
anaesthetized, and 0.5% tropicamide is instilled into the eyes to dilate the pupils. After the animals
have been anaesthetized (15 mg/kg xylazine and 80 mg/kg ketamine), choroidal neovascularization
is triggered by g six holes into the retina in each eye of each animal using a 532 nm argon
laser (lesion size: 50 um — 75 um; laser intensity: 150 mW; duration: 100 ms). The treatment of the
animals with the substance according to the invention or the corresponding vehicle is d out
either from day 1 or from day 7 up to and including day 23. Angiography is d out on day 21.
To this end, the animals are in each case anaesthetised, the pupils are dilated and 10% sodium
scein solution is injected subcutaneously. The angiogram is recorded at most 10 minutes
after the injection and assessed by three blinded observers using a score system (0: no ng =
no tissue injury, = slight staining = slight tissue , 2: moderate staining = moderate tissue
injury, 3: maximum staining = maximum tissue injury). The animals are sacrificed on day 23, after
which the eyes are removed and fixated in 4% strength paraformaldehyde solution for one hour at
room temperature. After one washing, the retina is carefully peeled off and the -choroidea
complex is stained using an FITC isolectin B4 antibody and then applied flat to a microscope slide.
The preparations obtained in this manner are evaluated using a fluorescence microscope (Apotom,
Zeiss) at an excitation wavelength of 488 nm. The volume or the area of choroidal
neovascularization is calculated by morphometric analysis using Axiovision 4.6 software.
PCT/EP2014/O77877
Working examples of pharmaceutical compositions
The compounds according to the invention can be converted to pharmaceutical ations as
follows:
Tablet:
Composition:
100 mg of the compound of Example 64, 50 mg of lactose (monohydrate), 50 mg of maize starch
(native), 10 mg of polyvinylpyrrolidone (PVP 25) (from BASF, Ludwigshafen, Germany) and 2
mg of magnesium te.
Tablet weight 212 mg. Diameter 8 mm, radius of curvature 12 mm.
Production:
The mixture of inventive compound, lactose and starch is ated with a 5% solution (w/w) of
the PVP in water. The granules are dried and then mixed with the magnesium steamte for 5
minutes. This mixture is compressed in a conventional tablet press (see above for format of the
tablet). The guide value used for the pressing is a pressing force of 15 kN.
Solution for oral administration:
Composition
500 mg of the compound of Example 64, 2.5 g of polysorbate and 97 g of polyethylene glycol 400.
g of oral solution correspond to a single dose of 100 mg of the compound according to the
invention.
tion
The compound ing to the invention is suspended in the mixture of polyethylene glycol and
polysorbate with stirring. The stirring operation is continued until dissolution of the compound
according to the invention is complete.
ition:
1 mg of the compound of Example 64, 15 g of polyethylene glycol 400 and 250 g of water for
injection es.
Production:
The compound according to the invention, together with polyethylene glycol 400, is dissolved in
the water by stirring. The on is sterilized by ion (pore diameter 0.22 pm) and dispensed
under aseptic conditions into heat-sterilized infusion bottles. The latter are closed with infusion
stoppers and crimped caps.
Patent claims
1. A compound of the l formula (I)
R2 R0
W N R13
N Y
R1 N ( )n
in which:
R0 represents hydrogen or C1-C4-alkyl, where the C1-C4-alkyl radical may ally
be mono- or polysubstituted by identical or different radicals from the group
consisting of hydroxy and halogen;
R1 represents hydrogen, halogen, cyano, C(=O)OH, C(=O)ORa, C(=O)NH2,
C(=O)N(H)Ra, C(=O)N(Ra)Rb, C(=O)Rd, hydroxy or C1-C6-alkyl, where the C1-C6-
alkyl l is optionally mono- or polysubstituted by identical or different
radicals from the group consisting of
hydroxy, halogen, cyano, C(=O)OH, C(=O)ORa, S(=O)2-C1-C6-alkyl, NH2,
NHRa, N(Ra)Rb, C1-C6-alkoxy which is ally mono- or
bstituted by identical or ent radicals from the group consisting
of halogen, C3-C8-cycloalkoxy which is optionally mono- or
polysubstituted by identical or different radicals from the group consisting
of halogen, heterocycloalkyl which is optionally mono- or polysubstituted
by identical or different radicals from the group consisting of Rc,
or represents C1-C6-alkoxy, where the C1-C6-alkoxy radical may optionally be
mono- or bstituted by identical or different radicals from the group
consisting of
hydroxy, halogen, cyano, C(=O)OH, Ra, S(=O)2-C1-C6-alkyl, NH2,
NHRa, N(Ra)Rb, C3-C8-cycloalkyl which is optionally mono- or
polysubstituted by identical or different radicals from the group consisting
of halogen, alkoxy which is optionally mono- or polysubstituted by
identical or different radicals from the group consisting of halogen, C3-C8-
cycloalkoxy which is optionally mono- or polysubstituted by identical or
different radicals from the group consisting of halogen, heterocycloalkyl
which is optionally mono- or polysubstituted by identical or different
radicals from the group consisting of Rc, aryl which is optionally mono- or
polysubstituted by identical or different ls from the group consisting
of Rc, or 5- or 6-membered heteroaryl which is optionally mono- or
polysubstituted by identical or different ls from the group consisting
of Rc,
or represents C3-C8-cycloalkoxy or heterocycloalkoxy which may optionally be
mono- or polysubstituted by identical or different radicals from the group
consisting of hydroxy, halogen, cyano and C1-C6-alkyl,
or represents aryloxy or 5- or 6-membered heteroaryloxy in which aryloxy and
- or 6-membered heteroaryloxy may optionally be mono- or polysubstituted by
identical or different radicals from the group consisting of hydroxy, halogen,
cyano, C(=O)OH, C(=O)ORa, C1-C6-alkyl and C1-C6-alkoxy,
or represents C3-C8-cycloalkyl or heterocycloalkyl which may optionally be monoor
polysubstituted by identical or different radicals from the group consisting of
hydroxy, n, cyano and C1-C6-alkyl,
or represents C2-C6-alkenyl or C2-C6-alkynyl,
or represents aryl, 5- to 10-membered heteroaryl, aryl-C1-C4-alkyl or 5- or 6-
membered aryl-C1-C4-alkyl, where aryl and heteroaryl may optionally be
mono- or polysubstituted by identical or different radicals from the group
consisting of n, hydroxy, cyano, C(=O)OH, C(=O)ORa, C1-C6-alkyl, C3-C8-
cycloalkyl and C1-C6-alkoxy;
Ra ents C1-C6-alkyl, C3-C10-cycloalkyl, heterocycloalkyl, aryl or aryl,
where alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl may optionally be
mono- or polysubstituted by identical or different radicals from the group
consisting of n, hydroxy, cyano, C1-C3-alkyl, C1-C3-alkoxy,
cycloalkyl, -C(=O)O-C1-C6-alkyl and S(=O)2-C1-C6-alkyl;
Rb represents C1-C6-alkyl or C3-C10-cycloalkyl;
or Ra and Rb er with the nitrogen atom form a 5- or 6-membered heterocycle which
may optionally be mono- or polysubstituted by identical or different radicals from the
group consisting of hydroxy, halogen, cyano, and C1-C6-alkyl;
Rc represents hydroxy, halogen, cyano, alkyl or C1-C3-alkoxy;
Rd represents hydrogen, C1-C6-alkyl or C3-C10-cycloalkyl;
R2 represents hydrogen, C1-C6-alkyl or C3-C6-cycloalkyl;
R13 represents hydrogen or C1-C6-alkyl;
W represents 5-membered heteroaryl which contains one to three heteroatoms
ed from the group consisting of N, O and S and may optionally be
monosubstituted by R3 and optionally be mono- or polysubstituted by identical or
different ls R4 or
W represents pyridyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl or 1,3,5-triazinyl which
may optionally be bstituted by R3 and optionally be mono- or
polysubstituted by identical or different ls R4;
R3 represents hydrogen, halogen, cyano, C(=O)Ra, NH2, NHRa, N(Ra)Rb,
N(H)C(=O)Ra or C1-C6-alkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of y, n, cyano,
C(=O)Ra, C(=O)OH, C(=O)ORa, S(=O)2-C1-C6-alkyl, NH2, NHRa,
N(Ra)Rb, C1-C6-alkoxy, C3-C8-cycloalkoxy,
where C1-C6-alkoxy and C3-C8-cycloalkoxy may optionally be
mono- or polysubstituted by identical or different halogen radicals;
or C1-C6-alkyl is optionally mono- or bstituted by identical or
radicals from the group consisting of C3-C6-cycloalkyl and
heterocycloalkyl,
where C3-C6-cycloalkyl and heterocycloalkyl may optionally be
mono-, di- or trisubstituted by identical or different radicals from
the group ting of n, cyano, C1-C3-alkyl and C1-C3-
alkoxy,
or C1-C6-alkyl is ally mono- or polysubstituted by identical or
different radicals from the group consisting of aryl and 5- or 6-membered
heteroaryl,
where aryl and 5- or 6-membered heteroaryl may optionally be
mono-, di- or trisubstituted by identical or different radicals from
the group consisting of halogen, cyano, C1-C3-alkyl and C1-C3-
alkoxy,
R3 represents C1-C6-alkoxy, where
alkoxy may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of hydroxy, halogen, cyano,
C(=O)ORa, S(=O)2-C1-C6-alkyl, N(Ra)Rb, C3-C8-cycloalkyl, C1-C4-alkoxy,
C3-C8-cycloalkoxy,
or represents C3-C6-cycloalkyl, heterocycloalkyl or C5-C11-spirocycloalkyl, where
lkyl, heterocycloalkyl and spirocycloalkyl may optionally be monoor
polysubstituted by identical or different radicals from the group
consisting of hydroxy, halogen, cyano, C(=O)Ra, C(=O)OH, C(=O)ORa,
C1-C6-alkyl and C1-C4-alkoxy;
or represents aryl or 5- to 10-membered heteroaryl, where
aryl and heteroaryl may optionally be mono- or polysubstituted by identical
or different radicals from the group consisting of n, hydroxy, cyano,
C(=O)ORa, S(=O)2-C1-C6-alkyl, NO2, NH2, NHRa, b, =O)Ra,
C3-C8-cycloalkyl, C1-C3-alkoxy and C1-C3-alkyl, where
C1-C3-alkyl may optionally be mono- or polysubstituted by identical or
ent halogen radicals;
R4 represents halogen, hydroxy, cyano or C1-C6-alkyl, where C1-C6-alkyl may
optionally be mono- or polysubstituted by identical or different radicals from the
group consisting of n, C1-C6-alkoxy, where C1-C6-alkoxy may optionally be
mono- or polysubstituted by identical or different radicals from the group
consisting of halogen, C2-C6-alkenyl, alkynyl, C3-C10-cycloalkyl, 3- to 10-
membered heterocycloalkyl and aryl, where aryl may optionally be mono- or
polysubstituted by identical or different radicals R,
R4 represents aryl or heteroaryl which may optionally be mono- or polysubstituted by
identical or different radicals R,
R4 represents a, C(=O)NH2, C(=O)N(H)Ra, C(=O)N(Ra)Rb, C(=O)ORa, NH2,
NHRa, N(Ra)Rb, N(H)C(=O)Ra, N(Ra)C(=O)Ra, N(H)C(=O)NH2,
=O)NHRa, N(H)C(=O)N(Ra)Rb, N(Ra)C(=O)NH2, N(Ra)C(=O)NHRa,
N(Ra)C(=O)N(Ra)Rb, N(H)C(=O)ORa, N(Ra)C(=O)ORa, NO2, N(H)S(=O)Ra,
N(Ra)S(=O)Ra, N(H)S(=O)2Ra, N(Ra)S(=O)2Ra, N=S(=O)(Ra)Rb, OC(=O)Ra,
OC(=O)NH2, OC(=O)NHRa, OC(=O)N(Ra)Rb, SH, SRa, S(=O)Ra, S(=O)2Ra,
S(=O)2NH2, S(=O)2NHRa, S(=O)2N(Ra)Rb or S(=O)(=N-Ra)Rb;
R represents halogen, cyano, C1-C6-alkyl, C2-C6-alkenyl,C2-C6-alkynyl, C3-C10-
cycloalkyl, 3- to 10-membered heterocycloalkyl, aryl, heteroaryl, a,
C(=O)NH2, C(=O)N(H)Ra, C(=O)N(Ra)Rb, C(=O)ORa, NH2, NHRa, N(Ra)Rb,
N(H)C(=O)Ra, N(Ra)C(=O)Ra, N(H)C(=O)NH2, N(H)C(=O)NHRa,
N(H)C(=O)N(Ra)Rb, N(Ra)C(=O)NH2, N(Ra)C(=O)NHRa, N(Ra)C(=O)N(Ra)Rb,
N(H)C(=O)ORa, (=O)ORa, NO2, N(H)S(=O)Ra, N(Ra)S(=O)Ra,
N(H)S(=O)2Ra, N(Ra)S(=O)2Ra, N=S(=O)(Ra)Rb, OH, alkoxy, OC(=O)Ra,
OC(=O)NH2, OC(=O)NHRa, OC(=O)N(Ra)Rb, SH, SRa, S(=O)Ra, S(=O)2Ra,
S(=O)2NH2, S(=O)2NHRa, S(=O)2N(Ra)Rb or S(=O)(=NRa)Rb;
n ents 0 or 1;
Y represents a group selected from:
R7a R7b
( )o( )p( )qR7d
R5 N Z
* N ( )r( )s R8d
R6 R8a
and R8b R8c (II)
where * ents the point of attachment of the group to the remainder of the molecule;
R5 represents hydrogen, C1-C6-alkyl or C3-C10-cycloalkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of hydroxy, halogen, cyano,
C(=O)OH, Ra, S(=O)2-C1-C6-alkyl, N(Ra)Rb, C1-C4-alkoxy and C3-
C8-cycloalkyl;
R6 represents hydrogen or C1-C6-alkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of hydroxy, halogen, cyano,
C3-C10-cycloalkyl, C(=O)Ra, C(=O)OH, C(=O)ORa, S(=O)2-C1-C6-alkyl,
N(Ra)Rb, C1-C4-alkoxy and C3-C8-cycloalkoxy,
or represents -cycloalkyl, where
-cycloalkyl may optionally be mono- or polysubstituted by identical
or ent radicals from the group consisting of hydroxy, halogen, cyano
and alkyl, where
C1-C6-alkyl may optionally be substituted by hydroxy,
or represents heterocycloalkyl, where
heterocycloalkyl may optionally be mono- or bstituted by identical
or different radicals from the group consisting of halogen, cyano, C1-C3-
alkyl and C1-C3-alkoxy,
or represents aryl or 5- or 6-membered heteroaryl, where
aryl and 5- or 6-membered heteroaryl may optionally be mono- or
polysubstituted by identical or ent radicals from the group consisting
of halogen, cyano, alkyl, C1-C3-alkoxy, S(=O)2NH2, S(=O)2NHRa
and S(=O)2N(Ra)Rb;
R7a represents hydrogen, halogen, N(Ra)Rb, alkyl or C3-C10-cycloalkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of hydroxy, halogen, cyano,
C(=O)OH, C(=O)ORa, S(=O)2-C1-C6-alkyl, N(Ra)Rb, C1-C4-alkoxy, C3-C8-
cycloalkyl and heterocycloalkyl;
R7b represents hydrogen, halogen or C1-C6-alkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of y, halogen, cyano,
C(=O)OH, C(=O)ORa, S(=O)2-C1-C6-alkyl, b, C1-C4-alkoxy, C3-C8-
cycloalkyl and heterocycloalkyl;
or R7a and R7b together with the carbon atom form C3-C6-cycloalkyl which may optionally
be mono- or polysubstituted by identical or different radicals from the group consisting of
y, n, cyano and C1-C6-alkyl,
or R7a and R7b together represent an oxo group;
R7c represents en, halogen, N(Ra)Rb, C1-C6-alkyl or C3-C10-cycloalkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of hydroxy, n, cyano,
C(=O)OH, C(=O)ORa, S(=O)2-C1-C6-alkyl, N(Ra)Rb, C1-C4-alkoxy, C3-C8-
cycloalkyl and heterocycloalkyl;
R7d represents hydrogen, halogen or C1-C6-alkyl, where
C1-C6-alkyl may optionally be mono- or bstituted by identical or
different radicals from the group consisting of hydroxy, halogen, cyano,
C(=O)OH, C(=O)ORa, -C1-C6-alkyl, b, C1-C4-alkoxy, C3-C8-
cycloalkyl and heterocycloalkyl;
or R7c and R7d together with the carbon atom form C3-C6-cycloalkyl which may optionally
be mono- or polysubstituted by identical or different radicals from the group consisting of
hydroxy, halogen, cyano and C1-C6-alkyl,
or R7c and R7d together ent an oxo group;
R8a represents hydrogen, halogen, N(Ra)Rb, C1-C6-alkyl or C3-C10-cycloalkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of hydroxy, halogen, cyano,
C(=O)OH, Ra, S(=O)2-C1-C6-alkyl, N(Ra)Rb, C1-C4-alkoxy, C3-C8-
cycloalkyl and heterocycloalkyl;
R8b represents hydrogen, halogen or C1-C6-alkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by cal or
different radicals from the group consisting of hydroxy, halogen, cyano,
C(=O)OH, C(=O)ORa, S(=O)2-C1-C6-alkyl, N(Ra)Rb, C1-C4-alkoxy, C3-C8-
cycloalkyl and cycloalkyl;
or R8a and R8b together with the carbon atom form C3-C6-cycloalkyl which may optionally
be mono- or polysubstituted by identical or different radicals from the group consisting of
hydroxy, halogen, cyano and C1-C6-alkyl,
R8c represents hydrogen, halogen, b, C1-C6-alkyl or C3-C10-cycloalkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of hydroxy, n, cyano,
C(=O)OH, C(=O)ORa, S(=O)2-C1-C6-alkyl, N(Ra)Rb, C1-C4-alkoxy, C3-C8-
cycloalkyl and cycloalkyl;
R8d represents hydrogen, halogen or C1-C6-alkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by cal or
different radicals from the group consisting of y, halogen, cyano,
C(=O)OH, C(=O)ORa, S(=O)2-C1-C6-alkyl, b, C1-C4-alkoxy, C3-C8-
cycloalkyl and heterocycloalkyl;
or R8c and R8d together with the carbon atom form C3-C6-cycloalkyl which may optionally
be mono- or polysubstituted by identical or different radicals from the group consisting of
hydroxy, halogen, cyano and C1-C6-alkyl,
or R8c and R8d together represent an oxo group;
o represents 0, 1 or 2,
p represents 0, 1 or 2,
q represents 0, 1 or 2,
r represents 0, 1 or 2,
s represents 0, 1 or 2,
where o, p, q, r and s do not simultaneously ent 0;
Z represents a group selected from C(=O), CR9R10, NR11, O, S, S(=O) and S(=O)2;
R9 represents hydrogen or C1-C6-alkyl,
R10 represents hydrogen, halogen, cyano, C(=O)Ra, C(=O)OH, C(=O)ORa, C(=O)NH2,
C(=O)N(H)Ra, C(=O)N(Ra)Rb, N(H)C(=O)Ra, N(Rb)C(=O)Ra, S(=O)2Ra, hydroxy,
N(Ra)Rb and alkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of hydroxy, halogen, cyano,
C(=O)Ra, C(=O)OH, C(=O)ORa, S(=O)2-C1-C6-alkyl, N(Ra)Rb, C1-C4-
alkoxy and C3-C8-cycloalkoxy,
or represents alkoxy, where
C1-C6-alkoxy may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of hydroxy, halogen, cyano,
C(=O)OH, C(=O)ORa, S(=O)2-C1-C6-alkyl, N(Ra)Rb, C3-C8-cycloalkyl, C1-
C4-alkoxy, C3-C8-cycloalkoxy, heterocycloalkyl, aryl and 5- or 6-
ed heteroaryl, where
aryl and 5- or 6-membered aryl may optionally be mono- or
polysubstituted by identical or different radicals from the group
consisting of halogen, cyano, C1-C3-alkyl and C1-C3-alkoxy,
or represents aryloxy or 5- or 6-membered heteroaryloxy in which
y and 5- or 6-membered heteroaryloxy may optionally be mono- or
polysubstituted by identical or different ls from the group consisting
of y, halogen, cyano, C(=O)OH, C(=O)ORa, C1-C3-alkyl and C1-C3-
alkoxy,
or represents C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C4-alkyl, heterocycloalkyl or
heterocycloalkyl-C1-C4-alkyl, which may optionally be mono- or polysubstituted
by identical or different radicals from the group ting of hydroxy, halogen,
cyano, C(=O)Ra, C(=O)OH, C(=O)ORa, C1-C6-alkyl and C1-C6-alkoxy, where
alkoxy may optionally be mono- or polysubstituted by identical or
different halogen radicals or an oxo group;
or represents C2-C6-alkenyl or alkynyl,
or represents aryl, 5- to 10-membered aryl, aryl-C1-C4-alkyl or 5- or 6-
membered aryl-C1-C4-alkyl, where
aryl and heteroaryl may optionally be mono- or polysubstituted by identical
or different radicals from the group consisting of halogen, hydroxy, cyano,
C(=O)OH, C(=O)ORa, NHRa, N(Ra)Rb, C1-C3-alkyl, C3-C8-cycloalkyl and
C1-C3-alkoxy;
or R9 and R10 together with the carbon atom form C3-C8-cycloalkyl or a 4- to 6-
ed heterocycle, where
the C3-C8-cycloalkyl radical or the 4- to 6-membered heterocycle may
optionally be mono- or polysubstituted by identical or different radicals
from the group consisting of hydroxy, halogen, cyano, C1-C6-alkyl,
C(=O)Ra and an oxo group;
R11 represents hydrogen, C(=O)Ra, C(=O)ORa, C(=O)NH2, C(=O)N(H)Ra,
C(=O)N(Ra)Rb, S(=O)2Ra, S(=O)2N(Ra)Rb or C1-C6-alkyl, where
C1-C6-alkyl may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of hydroxy, halogen, cyano,
C(=O)Ra, C(=O)ORa, C(=O)NH2, C(=O)N(H)Ra, C(=O)N(Ra)Rb, S(=O)2-
C1-C6-alkyl, N(Ra)Rb, C3-C8-cycloalkyl, alkoxy and C3-C8-
cycloalkoxy, where
C3-C8-cycloalkyl, C1-C4-alkoxy and C3-C8-cycloalkoxy may
optionally be mono- or polysubstituted by identical or different
radicals from the group consisting of hydroxy and halogen;
or represents C3-C8-cycloalkyl, heterocycloalkyl or heterocycloalkyl-C1-C4-alkyl
which may optionally be mono- or bstituted by cal or different ls
from the group consisting of hydroxy, halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy,
where alkyl and alkoxy may optionally be mono- or polysubstituted by identical or
different radicals from the group consisting of n and an oxo group,
or represents alkenyl or C2-C6-alkynyl,
or represents aryl, 5- to 10-membered heteroaryl, aryl-C1-C4-alkyl or 5- or 6-
membered heteroaryl-C1-C4-alkyl, where
aryl and heteroaryl may optionally be mono- or polysubstituted by identical
or different radicals from the group consisting of halogen, hydroxy, cyano,
C(=O)OH, C(=O)ORa, C1-C3-alkyl, C3-C8-cycloalkyl and C1-C3-alkoxy;
or a reomer, enantiomer, salt, e or solvate of a salt thereof.
2. A compound according to Claim 1 in which R1 represents hydrogen, halogen, hydroxy,
cyano, C1-C6-alkyl, C1-C5-alkyl substituted by hydroxy, C1-C6-alkoxy, C1-C6-alkoxy
substituted by C3-C8-cycloalkyl, alkoxy substituted by up to three fluorine atoms,
C1-C6-alkoxy substituted by aryl which is optionally mono- or polysubstituted by cal
or different radicals from the group ting of Rc or represents 5- or 6-membered
heteroaryl which is optionally mono- or polysubstituted by identical or different radicals
from the group consisting of Rc.
3. A compound according to Claim 1 or 2 in which W represents a group selected from
formulae (III) to (IX):
O S N N
* * * *
R12 N N
N R12 N O
R12 R12
III IV V VI
(R4 )m
* *
R12 N
R12 N N
VII VIII IX
in which
R12 represents hydrogen, n, C1-C6-alkyl which is optionally mono- or polysubstituted
by identical or different halogen radicals, C3-C6-cycloalkyl which is optionally mono- or
polysubstituted by identical or different halogen radicals, aryl which is optionally mono- or
polysubstituted by identical or different ls from the group ting of Rc or 5- or 6-
membered heteroaryl which is optionally mono- or polysubstituted by identical or ent
radicals from the group consisting of Rc or represents NHRa;
m represents 0, 1, 2 or 3 and
R3 and R4 have the meanings given above and
* represents the point of attachment of the group to the remainder of the molecule.
4. A compound ing to Claim 1 or 2 in which W represents a group of the general
formula (X)
R4 *
R3 (X)
and R3 and R4 have the meaning given in Claim 1.
. A compound according to any one of Claims 1 to 4 in which Y is a group of the general
formula (II) where R7a, R7b, R7c, R7d, R8a, R8b, R8c and R8d are as defined in Claim 1:
R7a R7b
( )o( )p( )qR7d
N Z
( )r( )s R8d
R8a R8b R8c (II).
6. A compound according to any one of Claims 1 to 4 in which Y is a radical NR5R6 where R5
and R6 are as defined in Claim 1.
7. A nd according to any one of Claims 1 to 3 in which W represents a group of the
general formula (IX)
(R4 )m
R3 (IX)
in which
m represents 0 and R2, R0 and R13 all represent hydrogen and R3 represents trifluoromethyl,
ethyl, methyl, cyclopropyl, 2,2,2-trifluorohydroxyethyl or 1-hydroxyethyl; Y represents
4-methylpiperazinyl, 4-ethylpiperazinyl or morpholinyl, n represents 0 and R1
represents cyclopropylmethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, chlorine, ethoxy,
methoxy, 2-hydroxypropanyl or 3-hydroxypentanyl.
8. A nd ing to Claim 7 in which R1 represents cyclopropylmethoxy, methoxy,
ethoxy or 2-hydroxypropanyl.
9. A compound ing to Claim 7 or 8 in which R3 is a trifluoromethyl or a cyclopropyl
radical.
. A nd according to Claim 1, selected from the group consisting of:
2-(4-benzoylpiperazinyl)oxoethyl]methyl-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
6-ethyl-N-(6-methyl{2-oxo[4-(pyrrolidinyl)piperidinyl]ethyl}-2H-indazol-
-yl)pyridinecarboxamide
-fluoro-N-(6-methyl{2-oxo[4-(pyrrolidinyl)piperidinyl]ethyl}-2H-indazol-
-yl)pyridinecarboxamide
N-(2-{2-[4-(3-hydroxy-2,2-dimethylpropanoyl)piperazinyl]oxoethyl}methyl-
2H-indazolyl)(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(methoxyacetyl)piperazinyl]oxoethyl}methyl-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}methoxy-2H-indazol-
-yl)(trifluoromethyl)pyridinecarboxamide
2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}methoxy-2H-indazol-
-yl)methylpyridinecarboxamide
N-(2-{2-[4-(cyclopropylmethyl)piperazinyl]oxoethyl}methoxy-2H-indazol
yl)(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(cyclopropylmethyl)piperazinyl]oxoethyl}methoxy-2H-indazol
yl)methylpyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]methoxy-2H-indazolyl}
cyclopropylpyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]methoxy-2H-indazolyl}(1-
hydroxyethyl)pyridinecarboxamide
N-{2-[2-(4-methylpiperazinyl)oxoethyl](trifluoromethoxy)-2H-indazolyl}-
6-(trifluoromethyl)pyridinecarboxamide
6-methyl-N-{2-[2-(4-methylpiperazinyl)oxoethyl](trifluoromethoxy)-2H-
indazolyl}pyridinecarboxamide
tert-butyl 3-{[4-({2-[2-(4-methylpiperazinyl)oxoethyl](trifluoromethoxy)-2H-
indazolyl}carbamoyl)-1,3-thiazolyl]amino}azetidinecarboxylate
N-{6-bromo[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
romo[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
methylpyridinecarboxamide
N-{6-bromo[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
cyclopropyl-1,3-oxazolecarboxamide
tert-butyl ({6-bromo[2-(4-methylpiperazinyl)oxoethyl]-2H-indazol
yl}carbamoyl)-1,3-thiazolyl]amino}azetidinecarboxylate
2-(azetidinylamino)-N-{2-[2-(4-methylpiperazinyl)oxoethyl]
(trifluoromethoxy)-2H-indazolyl}-1,3-thiazolecarboxamide
N-{6-cyano[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
6'-methyl-N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}-2,3'-
bipyridinecarboxamide
'-methyl-N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}-2,3'-
bipyridinecarboxamide
4'-methyl-N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}-2,3'-
bipyridinecarboxamide
6'-methoxy-N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}-2,3'-
bipyridinecarboxamide
6'-acetamido-N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}-2,3'-
bipyridinecarboxamide
N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}-6'-nitro-2,3'-
bipyridinecarboxamide
6'-amino-N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}-2,3'-
bipyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]fluoro-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(cyclopropylcarbonyl)piperazinyl]oxoethyl}fluoro-2H-indazol
yl)(trifluoromethyl)pyridinecarboxamide
N-{6-fluoro[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(cyclopropylcarbonyl)piperazinyl]oxoethyl}fluoro-2H-indazol
yl)methylpyridinecarboxamide
N-{6-fluoro[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
methylpyridinecarboxamide
N-(2-{2-[4-(cyclopropylcarbonyl)piperazinyl]oxoethyl}fluoro-2H-indazol
yl)(1-methyl-1H-pyrazolyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]fluoro-2H-indazolyl}(1-methyl-
1H-pyrazolyl)pyridinecarboxamide
N-{6-fluoro[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}(1-methyl-
1H-pyrazolyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]fluoro-2H-indazolyl}fluoro
hyl-1H-pyrazolyl)pyridinecarboxamide
N-(2-{2-[4-(cyclopropylcarbonyl)piperazinyl]oxoethyl}fluoro-2H-indazol
yl)fluoro(1-methyl-1H-pyrazolyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]fluoro-2H-indazolyl}
(morpholinyl)pyridinecarboxamide
2-[4-(cyclopropylcarbonyl)piperazinyl]oxoethyl}fluoro-2H-indazol
yl)(morpholinyl)pyridinecarboxamide
N-{6-fluoro[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
(morpholinyl)pyridinecarboxamide
N-{6-(benzyloxy)[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-isobutoxy[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
uoromethyl)pyridinecarboxamide
N-{6-isobutoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}isobutoxy-2H-
indazolyl)(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[(cyclopropylmethyl)(methyl)amino]oxoethyl}isobutoxy-2H-indazol
yl)(trifluoromethyl)pyridinecarboxamide
N-{6-(cyclopropylmethoxy)[2-(4-methylpiperazinyl)oxoethyl]-2H-indazol
yl}(trifluoromethyl)pyridinecarboxamide
N-{6-(cyclopropylmethoxy)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-[6-(cyclopropylmethoxy){2-[4-(2-hydroxypropanyl)piperidinyl]
oxoethyl}-2H-indazolyl](trifluoromethyl)pyridinecarboxamide
N-[6-(cyclopropylmethoxy){2-[(cyclopropylmethyl)(methyl)amino]oxoethyl}-
2H-indazolyl](trifluoromethyl)pyridinecarboxamide
N-{2-[2-(4-methylpiperazinyl)oxoethyl](pyridinylmethoxy)-2H-indazol
yl}(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(morpholinyl)oxoethyl](pyridinylmethoxy)-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-[2-{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}(pyridin
oxy)-2H-indazolyl](trifluoromethyl)pyridinecarboxamide
2-[(cyclopropylmethyl)(methyl)amino]oxoethyl}(pyridinylmethoxy)-
2H-indazolyl](trifluoromethyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]chloro-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-chloro[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
ethyl 4-{[6-chloro({[6-(trifluoromethyl)pyridinyl]carbonyl}amino)-2H-indazol
yl]acetyl}piperazinecarboxylate
N-(6-chloro{2-oxo[4-(pyrrolidinyl)piperidinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(6-chloro{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}-2H-indazol
yl)(trifluoromethyl)pyridinecarboxamide
N-(6-chloro{2-[4-(3-hydroxy-2,2-dimethylpropanoyl)piperazinyl]oxoethyl}-
2H-indazolyl)(trifluoromethyl)pyridinecarboxamide
N-(6-chloro{2-[3-(dimethylamino)azetidinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(6-chloro{2-oxo[3-(piperidinyl)azetidinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
hloro{2-[4-(2-hydroxymethylpropyl)piperidinyl]oxoethyl}-2H-
indazolyl)(trifluoromethyl)pyridinecarboxamide
N-{6-chloro[2-(4-hydroxy-1,4'-bipiperidin-1'-yl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-methoxy[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
2-[4-(dimethylamino)piperidinyl]oxoethyl}ethoxy-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(6-ethoxy{2-oxo[4-(pyrrolidinyl)piperidinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-{6-ethoxy[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]ethoxy-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(6-ethoxy{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}-2H-indazol
yl)(trifluoromethyl)pyridinecarboxamide
thoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]methyl-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[3-(4-benzoylpiperazinyl)oxopropyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(cyclopropylcarbonyl)piperazinyl]oxoethyl}-2H-indazolyl)
(pyridinyl)-1,3-thiazolecarboxamide
N-(2-{2-[4-(cyclopropylcarbonyl)piperazinyl]oxoethyl}-2H-indazolyl)
(pyridinyl)-1,3-thiazolecarboxamide
N-(2-{2-[4-(cyclopropylcarbonyl)piperazinyl]oxoethyl}-2H-indazolyl)
uoromethyl)pyridinecarboxamide
6-(azetidinylamino)-N-(2-{2-[4-(cyclopropylcarbonyl)piperazinyl]oxoethyl}-
2H-indazolyl)pyridinecarboxamide
N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}(pyridinyl)-1,3-
thiazolecarboxamide
N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}(1-methyl-1H-
pyrazolyl)pyridinecarboxamide
N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}(1H-pyrazol
yl)pyridinecarboxamide
6-(1,3-dimethyl-1H-pyrazolyl)-N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-
indazolyl}pyridinecarboxamide
N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}[3-(trifluoromethyl)-
1H-pyrazolyl]pyridinecarboxamide
6-ethyl-N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}pyridine
carboxamide
6-(1-methyl-1H-pyrazolyl)-N-(2-{2-oxo[4-(2,2,2-trifluoroethyl)piperazin
yl]ethyl}-2H-indazolyl)pyridinecarboxamide
N-(2-{2-oxo[4-(2,2,2-trifluoroethyl)piperazinyl]ethyl}-2H-indazolyl)
uoromethyl)pyridinecarboxamide
N-{2-[2-(4-ethyloxopiperazinyl)oxoethyl]-2H-indazolyl}(1-methyl-1H-
pyrazolyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}methylpyridine
carboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(morpholin
yl)pyridinecarboxamide
2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(pyridinyl)-1,3-
thiazolecarboxamide
2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}chloropyridine
carboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}methyl-1,3-
oxazolecarboxamide
6-amino-N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}pyridine
carboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}methyl-1,3-
oxazolecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}methoxypyridine
carboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}cyclopropyl-1,3-
oxazolecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(4H-1,2,4-triazol
yl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}phenyl-2H-1,2,3-
triazolecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(1-methyl-1H-
pyrazolyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(trifluoromethyl)-
1,3-thiazolecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(1H-pyrazol
yl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(1-methyl-1H-
pyrazolyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}ethyl-1H-pyrazole-
3-carboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(4-chloro-1H-
pyrazolyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(trifluoromethyl)-
1,3-thiazolecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(1,3-dimethyl-1H-
lyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}-2,4'-bipyridine
carboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(1H-pyrazol
yl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}fluoro(1-methyl-
1H-pyrazolyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(3-methyl-1H-
pyrazolyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(1H-1,2,4-triazol
yl)pyridinecarboxamide
2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}[3-
(trifluoromethyl)-1H-pyrazolyl]pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}ethoxypyridine
carboxamide
2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}
(cyclopropylmethoxy)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}ethylpyridine
carboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(4-
methoxyphenyl)-1,3-thiazolecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}bromo-1,3-
thiazolecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(4-fluorophenyl)-
1,3-thiazolecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}fluoropyridine
carboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}bromopyridine
carboxamide
N-(2-{2-[4-(4-fluorobenzoyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(pyridinyl)piperazinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(methoxyacetyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(4-cyclopentyloxopiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
2-oxo(3-oxophenylpiperazinyl)ethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(2,2-dimethylpropanoyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(cyclopropylmethyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-oxo(pyridazinylamino)ethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(2-hydroxymethylpropanoyl)piperazinyl]oxoethyl}-2H-indazol
yl)(trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(1-phenylethyl)piperazinyl]ethyl}-2H-indazolyl)
uoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(pyridinylcarbonyl)piperazinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
2-(4-isonicotinoylpiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(morpholinylcarbonyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[2-(methylamino)oxoethyl]piperazinyl}oxoethyl)-2H-indazol
yl](trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(pyrazinyl)piperazinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
2-[4-(1-hydroxyethyl)piperidinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(2-methyl-2,8-diazaspiro[4.5]decyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(6-acetyl-2,6-diazaspiro[3.3]heptyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-oxo(3-oxo-2,8-diazaspiro[4.5]decyl)ethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(6-methyl-2,6-diazaspiro[3.5]nonyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(7-oxaazaspiro[3.5]nonyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(1,4'-bipiperidin-1'-yl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[2-(hydroxymethyl)piperidinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[3-(hydroxymethyl)piperidinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(4-carbamoylpiperidinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[3-(dimethylamino)piperidinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[3-(morpholinylmethyl)piperidinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[(cyclopropylcarbonyl)amino]piperidinyl}oxoethyl)-2H-indazolyl]-
fluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(3-ethyl-1,2,4-oxadiazolyl)piperidinyl]oxoethyl}-2H-indazolyl)-
fluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[(5-cyclopropyl-1,2,4-oxadiazolyl)methyl]piperidinyl}oxoethyl)-
2H-indazolyl](trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(pyrrolidinylcarbonyl)piperidinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(4-methylpiperazinyl)piperidinyl]oxoethyl}-2H-indazolyl)
uoromethyl)pyridinecarboxamide
N-[2-(2-{4-[2-(morpholinyl)ethyl]piperidinyl}oxoethyl)-2H-indazolyl]
(trifluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[(5-methyl-1,2,4-oxadiazolyl)methyl]piperidinyl}oxoethyl)-2H-
indazolyl](trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[3-(pyrrolidinylmethyl)piperidinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-[2-(2-{[3-(dimethylsulphamoyl)phenyl]amino}oxoethyl)-2H-indazolyl]
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(1,2-oxazolylamino)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(methylsulphonyl)piperidinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-[2-(2-oxo{4-[2-oxo(pyrrolidinyl)ethyl]piperazinyl}ethyl)-2H-indazol
yl](trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(phenylsulphonyl)piperidinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[(3-sulphamoylphenyl)amino]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[isonicotinoyl(methyl)amino]piperidinyl}oxoethyl)-2H-indazolyl]-
6-(trifluoromethyl)pyridinecarboxamide
2-{4-[2-(isopropylamino)oxoethyl]piperazinyl}oxoethyl)-2H-indazol
yl](trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(1,1-dioxidotetrahydrothiophenyl)piperazinyl]oxoethyl}-2H-
lyl)(trifluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[(methoxyacetyl)(methyl)amino]piperidinyl}oxoethyl)-2H-indazol
yl](trifluoromethyl)pyridinecarboxamide
ethyl 4-{[5-({[6-(trifluoromethyl)pyridinyl]carbonyl}amino)-2H-indazol
yl]acetyl}piperazinecarboxylate
N-(2-{2-[4-(cyclohexylcarbonyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[2-(cyclopropylamino)oxoethyl]piperazinyl}oxoethyl)-2H-indazol-
-yl](trifluoromethyl)pyridinecarboxamide
N-(2-{2-[2-(2-hydroxyethyl)piperidinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(pyrrolidinyl)piperidinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
2-oxo[4-(1H-pyrrolyl)piperidinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(3-hydroxypropyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
4-{[5-({[6-(trifluoromethyl)pyridinyl]carbonyl}amino)-2H-indazol
yl]acetyl}piperazinecarboxamide
2-oxo[4-(2-oxopyrrolidinyl)piperidinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(morpholinyl)oxoethyl]-2H-indazolyl}(trifluoromethyl)pyridine
carboxamide
2-[4-(2-aminooxoethyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(1,1-dioxidothiomorpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(4-isopropylpiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(2-thienylcarbonyl)piperazinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(2-cyclopropyloxoethyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[(1-methyl-1H-pyrazolyl)methyl]piperazinyl}oxoethyl)-2H-
indazolyl](trifluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[(1,5-dimethyl-1H-pyrazolyl)carbonyl]piperazinyl}oxoethyl)-2H-
indazolyl](trifluoromethyl)pyridinecarboxamide
N,N-diethyl{[5-({[6-(trifluoromethyl)pyridinyl]carbonyl}amino)-2H-indazol
yl]acetyl}piperazinecarboxamide
N-{2-[2-oxo(thiomorpholinyl)ethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(2-furylmethyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(3-thienylmethyl)piperazinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
2-(4'-methyl-1,4'-bipiperidin-1'-yl)oxoethyl]-2H-indazolyl}
uoromethyl)pyridinecarboxamide
N-{2-[2-(6-methyl-2,6-diazaspiro[3.3]heptyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(4-cyclopentylpiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[2-(2-hydroxyethoxy)ethyl]piperazinyl}oxoethyl)-2H-indazolyl]
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(pyridinylmethyl)piperazinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
2-[4-(dimethylsulphamoyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(pyridinyl)piperazinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(methylsulphonyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
formic acid N-[2-(2-{4-[2-(1H-imidazolyl)ethyl]piperazinyl}oxoethyl)-2H-
indazolyl](trifluoromethyl)pyridinecarboxamide (1:1)
N-(2-{2-[4-(diethylsulphamoyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(pyridinyl)piperazinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-oxo[4-(piperidinylsulphonyl)piperazinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[(1,5-dimethyl-1H-pyrazolyl)sulphonyl]piperazinyl}oxoethyl)-2H-
indazolyl](trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(cyclopropylmethyl)piperazinyl]oxoethyl}-2H-indazolyl)(1-
methyl-1H-pyrazolyl)pyridinecarboxamide
N-(2-{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}-2H-indazolyl)(1-
methyl-1H-pyrazolyl)pyridinecarboxamide
6-(1-methyl-1H-pyrazolyl)-N-(2-{2-oxo[4-(pyrrolidinyl)piperidinyl]ethyl}-
2H-indazolyl)pyridinecarboxamide
N-{2-[2-(4-ethylpiperazinyl)oxoethyl]-2H-indazolyl}(1-methyl-1H-pyrazol-
4-yl)pyridinecarboxamide
N-(2-{2-[4-(dimethylamino)piperidinyl]oxoethyl}-2H-indazolyl)(1-methyl-
1H-pyrazolyl)pyridinecarboxamide
N-(2-{2-[(cyclopropylmethyl)(methyl)amino]oxoethyl}methoxy-2H-indazol
yl)methylpyridinecarboxamide
N-(2-{2-[(cyclopropylmethyl)(methyl)amino]oxoethyl}ethoxy-2H-indazolyl)-
6-(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[(cyclopropylmethyl)(methyl)amino]oxoethyl}methoxy-2H-indazol
yl)(trifluoromethyl)pyridinecarboxamide
6-cyclopropyl-N-(2-{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}
methoxy-2H-indazolyl)pyridinecarboxamide
6-(1-hydroxyethyl)-N-(2-{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}
methoxy-2H-indazolyl)pyridinecarboxamide
tidinylamino)-N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazol
yl}pyridinecarboxamide
6-[(azetidinylmethyl)amino]-N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-
indazolyl}pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazolyl}(3-hydroxyazetidin-
1-yl)pyridinecarboxamide
6-[(2R,6S)-2,6-dimethylmorpholinyl]-N-(6-methyl{2-oxo[4-(pyrrolidin
yl)piperidinyl]ethyl}-2H-indazolyl)pyridinecarboxamide
N-[2-(2-{4-methyl[(4-methylpiperazinyl)carbonyl]piperidinyl}oxoethyl)-
2H-indazolyl](trifluoromethyl)pyridinecarboxamide
hloro{2-oxo[(3R)-piperidinylamino]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(cyclopropylcarbonyl)piperazinyl]oxoethyl}isopropoxy-2H-
indazolyl)methylpyridinecarboxamide
N-(2-{2-[4-(cyclopropylcarbonyl)piperazinyl]oxoethyl}isopropoxy-2H-
indazolyl)(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]isopropoxy-2H-indazolyl}
methylpyridinecarboxamide
2-(4-benzoylpiperazinyl)oxoethyl]isopropoxy-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-isopropoxy[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-isopropoxy[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
methylpyridinecarboxamide
N-(2-{2-[4-(cyclobutylcarbonyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-(2-{2-[4-(cyclopentylcarbonyl)piperazinyl]oxoethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[3-(methylsulphonyl)benzoyl]piperazinyl}oxoethyl)-2H-indazol
yl](trifluoromethyl)pyridinecarboxamide
N-[2-(2-{4-[2-methoxy(methylsulphonyl)benzoyl]piperazinyl}oxoethyl)-2H-
indazolyl](trifluoromethyl)pyridinecarboxamide
6-bromo-N-(6-methyl{2-oxo[4-(pyrrolidinyl)piperidinyl]ethyl}-2H-indazol-
yridinecarboxamide
2-(4-methoxyphenyl)-N-(6-methyl{2-oxo[4-(pyrrolidinyl)piperidin
yl]ethyl}-2H-indazolyl)-1,3-thiazolecarboxamide
2-(4-fluorophenyl)-N-(6-methyl{2-oxo[4-(pyrrolidinyl)piperidinyl]ethyl}-
azolyl)-1,3-thiazolecarboxamide
N-(6-methyl{2-oxo[4-(pyrrolidinyl)piperidinyl]ethyl}-2H-indazolyl)
(trifluoromethyl)pyridinecarboxamide
o-N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}pyridine
carboxamide
6-bromo-N-{2-[2-(4-methylpiperazinyl)oxoethyl](trifluoromethoxy)-2H-
indazolyl}pyridinecarboxamide
N-{2-[2-(4-methylpiperazinyl)oxoethyl](trifluoromethoxy)-2H-indazolyl}-
6-(4H-1,2,4-triazolyl)pyridinecarboxamide
2-bromo-N-{6-bromo[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}-1,3-
thiazolecarboxamide
N-{6-hydroxy[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-[6-(benzyloxy){2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}-2H-
indazolyl]methylpyridinecarboxamide
6-bromo-N-{6-bromo[2-(4-methylpiperazinyl)oxoethyl]-2H-indazol
yl}pyridinecarboxamide
N-{6-(benzyloxy)[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
methylpyridinecarboxamide
2-(azetidinylamino)-N-{2-[2-(4-benzoylpiperazinyl)oxoethyl]-2H-indazol
yl}-1,3-thiazolecarboxamide
6-acetamido-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazol
yl}pyridinecarboxamide
6-(dimethylamino)-N-(2-{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}
methoxy-2H-indazolyl)pyridinecarboxamide
ethylamino)-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazol
yl}pyridinecarboxamide
6-acetamido-N-(2-{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}
methoxy-2H-indazolyl)pyridinecarboxamide
6-(dimethylamino)-N-{6-methoxy[2-(4-methylpiperazinyl)oxoethyl]-2H-
indazolyl}pyridinecarboxamide
N-{2-[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}[3-
lsulphonyl)phenyl]pyridinecarboxamide
N-{2-[1-(4-benzoylpiperazinyl)oxopropanyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-[6-chloro(2-{[trans(2-hydroxypropanyl)cyclohexyl]amino}oxoethyl)-2H-
indazolyl](trifluoromethyl)pyridinecarboxamide
6-(2-hydroxypropanyl)-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-
indazolyl}pyridinecarboxamide
N-{6-chloro[2-(3,3-difluoropyrrolidinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-chloro[2-oxo(pyrrolidinyl)ethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-chloro[2-(2-oxaazaspiro[3.5]nonyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-(6-chloro{2-[4-(2-hydroxymethylpropyl)piperazinyl]oxoethyl}-2H-
indazolyl)(trifluoromethyl)pyridinecarboxamide
N-{6-methoxy[2-oxo(pyrrolidinyl)ethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(3,3-difluoropyrrolidinyl)oxoethyl]methoxy-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
6-(difluoromethyl)-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazol
yl}pyridinecarboxamide
N-{2-[2-(3,3-difluoropyrrolidinyl)oxoethyl]methoxy-2H-indazolyl}
methylpyridinecarboxamide
N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}methylpyridine-
2-carboxamide
N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}(tetrahydro-2H-
pyranyl)-1,3-oxazolecarboxamide
N-{2-[2-(1,1-dioxidothiaazaspiro[3.3]heptyl)oxoethyl]methoxy-2H-
indazolyl}(trifluoromethyl)pyridinecarboxamide
N-{6-methoxy[2-(2-oxaazaspiro[3.3]heptyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
3-hydroxy-2,2-dimethylpropoxy)[2-(morpholinyl)oxoethyl]-2H-indazol-
-yl}(trifluoromethyl)pyridinecarboxamide
6-ethyl-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}pyridine
carboxamide
6-isobutyl-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}pyridine-
2-carboxamide
methyl 2-[2-(morpholinyl)oxoethyl]({[6-(trifluoromethyl)pyridin
yl]carbonyl}amino)-2H-indazolecarboxylate
methyl 5-{[(6-methylpyridinyl)carbonyl]amino}[2-(morpholinyl)oxoethyl]-
2H-indazolecarboxylate
N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}(pyrrolidin
yl)pyridinecarboxamide
N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}(morpholin
yl)pyridinecarboxamide
6-(cyclopropylamino)-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazol
yl}pyridinecarboxamide
6-(butylamino)-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazol
yl}pyridinecarboxamide
N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}
lamino)pyridinecarboxamide
6-(isobutylamino)-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazol
yl}pyridinecarboxamide
R-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}(2,2,2-
trifluorohydroxyethyl)pyridinecarboxamide
S-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}(2,2,2-
orohydroxyethyl)pyridinecarboxamide
6-(1-hydroxyethyl)-N-{6-methoxy[2-(morpholinyl)oxoethyl]-2H-indazol
yl}pyridinecarboxamide
6-(cyclopropylamino)-N-{6-methoxy[2-(4-methylpiperazinyl)oxoethyl]-2H-
indazolyl}pyridinecarboxamide
N-{6-methoxy[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
(propylamino)pyridinecarboxamide
6-(isobutylamino)-N-{6-methoxy[2-(4-methylpiperazinyl)oxoethyl]-2H-
indazolyl}pyridinecarboxamide
6-(1-hydroxyethyl)-N-{6-methoxy[2-(4-methylpiperazinyl)oxoethyl]-2H-
indazolyl}pyridinecarboxamide
N-{6-methoxy[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}methyl-
6-(trifluoromethyl)pyridinecarboxamide
N-{6-(benzyloxy)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
6-(cyclopropylamino)-N-(2-{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}-
oxy-2H-indazolyl)pyridinecarboxamide
6-(butylamino)-N-(2-{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}
methoxy-2H-indazolyl)pyridinecarboxamide
N-(2-{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}methoxy-2H-indazol-
-yl)[(2-methoxyethyl)amino]pyridinecarboxamide
2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}methoxy-2H-indazol-
-yl)(propylamino)pyridinecarboxamide
2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}methoxy-2H-indazol-
-yl)(isobutylamino)pyridinecarboxamide
-fluoro-N-(2-{2-[4-(2-hydroxypropanyl)piperidinyl]oxoethyl}methoxy-
2H-indazolyl)methylpyridinecarboxamide
N-{6-hydroxy[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-(3-cyanopropoxy)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(morpholinyl)oxoethyl](2,2,2-trifluoroethoxy)-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-(cyclohexylmethoxy)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-(2,2-dimethylpropoxy)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(morpholinyl)oxoethyl](tetrahydrofuranylmethoxy)-2H-indazol
yl}(trifluoromethyl)pyridinecarboxamide
N-{6-(cyclopentyloxy)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-(cyanomethoxy)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
-(morpholinyl)oxoethyl]({[6-(trifluoromethyl)pyridin
yl]carbonyl}amino)-2H-indazolyl}oxy)acetic acid
cyclobutylmethoxy)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(morpholinyl)oxoethyl][2-(pyrrolidinyl)ethoxy]-2H-indazolyl}-
6-(trifluoromethyl)pyridinecarboxamide
N-{6-[2-(morpholinyl)ethoxy][2-(morpholinyl)oxoethyl]-2H-indazolyl}-
6-(trifluoromethyl)pyridinecarboxamide
N-{2-[2-(morpholinyl)oxoethyl][2-(piperidinyl)ethoxy]-2H-indazolyl}-
6-(trifluoromethyl)pyridinecarboxamide
N-{6-(3-hydroxypropoxy)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
uoromethyl)pyridinecarboxamide
N-{6-(2-hydroxypropoxy)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-(2-hydroxyethoxy)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-(2-methoxyethoxy)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
ethyl ({2-[2-(morpholinyl)oxoethyl]({[6-(trifluoromethyl)pyridin
yl]carbonyl}amino)-2H-indazolyl}oxy)acetate
methyl 4-({2-[2-(morpholinyl)oxoethyl]({[6-(trifluoromethyl)pyridin
yl]carbonyl}amino)-2H-indazolyl}oxy)butanoate
ethyl 2-({2-[2-(morpholinyl)oxoethyl]({[6-(trifluoromethyl)pyridin
yl]carbonyl}amino)-2H-indazolyl}oxy)propanoate
ethyl 3-methyl({2-[2-(morpholinyl)oxoethyl]({[6-(trifluoromethyl)pyridin-
2-yl]carbonyl}amino)-2H-indazolyl}oxy)butanoate
2-({2-[2-(morpholinyl)oxoethyl]({[6-(trifluoromethyl)pyridin
yl]carbonyl}amino)-2H-indazolyl}oxy)propanoic acid
N-{6-(2-hydroxypropanyl)[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(trifluoromethyl)pyridinecarboxamide
N-{6-chloro[2-(4-methylpiperazinyl)oxoethyl]-2H-indazolyl}
(difluoromethyl)pyridinecarboxamide and
N-{6-chloro[2-(morpholinyl)oxoethyl]-2H-indazolyl}
(difluoromethyl)pyridinecarboxamide.
11. Compound of the formula (I) as defined in any one of Claims 1 to 10 for the treatment
and/or prophylaxis of a disease.
12. Compound of the formula (I) as defined in any one of Claims 1 to 10 for use in a method
for the treatment and/or prophylaxis of tumour disorders, dermatological ers,
gynaecological disorders, cardiovascular ers, pulmonary disorders, ophthalmological
disorders, neurological disorders, metabolic disorders, inflammatory disorders,
autoimmune disorders or pain.
13. Compound of the formula (I) as defined in any one of Claims 1 to 10 for use in a method
for the treatment and/or prophylaxis of lymphomas, macular degeneration, endometriosis,
sis, lupus erythematosus, multiple sclerosis, COPD or rheumatoid arthritis.
14. Use of a compound of the a (I) as defined in any one of Claims 1 to 10 for preparing
a medicament for the treatment and/or prophylaxis of tumour disorders, dermatological
disorders, gynaecological ers, cardiovascular disorders, pulmonary disorders,
ophthalmological disorders, neurological disorders, metabolic disorders, inflammatory
disorders, autoimmune disorders or pain.
. Compound of the formula (I) as defined in any one of Claims 1 to 10 for preparing a
medicament for the treatment and/or laxis of lymphomas, macular degeneration,
endometriosis, psoriasis, lupus erythematosus, multiple sis, COPD or rheumatoid
arthritis.
16. Medicament comprising a compound of the formula (I) as defined in any one of Claims 1
to 10 in combination with an inert, non-toxic, ceutically suitable excipient.
17. Process for ing a compound of the l formula (III) from a compound of the
general formula (II)
F F
F O F O
N N
F HN F HN
H C N R14 N
O N
H HO N
O R14
(II) (III)
by Grignard reaction with methyl- or agnesium bromide, wherein R14 is a methyl or
ethyl radical.
18. A compounds of the general formula (III)
F O
F HN
R14 N
HO N
(III)
in which R14 is a methyl or an ethyl radical.
15000
{pg/m 10000
tration 5000
80 40 10
Vehicle LPS
mglkg mglkg mglkg
Figure 1: Treatment of LPS—induced inflammation with Exemplary Compound 64 leads to a
reduced amount of secreted TNF—a
PCT/EPZO 14/077877
[pg/m
Concentration
80 40 1D
Vehicle [L-1p
mglkg mg/kg mgfkg
Figure 2: Treatment of an IL-lB-induced inflammation with Exemplary nd 64 leads to a
reduced amount of secreted TNF—a
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13198463.5 | 2013-12-19 | ||
EP13198463 | 2013-12-19 | ||
EP14189216.6 | 2014-10-16 | ||
EP14189216 | 2014-10-16 | ||
PCT/EP2014/077877 WO2015091426A1 (en) | 2013-12-19 | 2014-12-16 | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ720726A NZ720726A (en) | 2021-10-29 |
NZ720726B2 true NZ720726B2 (en) | 2022-02-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014364744B2 (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
CA2927510C (en) | Selectively substituted quinoline compounds | |
CA2874445C (en) | Tetrahydropyrazolopyrimidine compounds | |
CN107266455B (en) | Triazolopyrazine | |
JP6424224B2 (en) | New bisamide pyridine | |
CA2950238A1 (en) | Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors | |
EP1963315B1 (en) | Enzyme inhibitors | |
CA2905751A1 (en) | Novel compounds and compositions for inhibition of fasn | |
JP2016504990A (en) | BET protein inhibitory dihydropyridopyrazinone | |
TW201300374A (en) | Inhibitors of Bruton's Tyrosine Kinase | |
CA3108809C (en) | Heteroaromatic compounds, pharmaceutical compositions and uses thereof | |
BR112013000275B1 (en) | tetrahydro-pyrido-pyrimidine derivatives, their uses, pharmaceutical composition and composition | |
JP7391012B2 (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
CA2860723A1 (en) | Substituted imidazopyrazines as akt kinase inhibitors | |
CA3058260A1 (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers | |
EA027752B1 (en) | Therapeutically active pyrazolo-pyrimidine derivatives | |
CA3189873A1 (en) | 1h-benzo[d]imidazole derivatives as tlr9 inhibitors for the treatment of fibrosis | |
KR20150090044A (en) | Azaquinazoline carboxamide derivatives | |
AU2016349148B2 (en) | 1,4-dicarbonyl-piperidyl derivatives | |
JP2022532145A (en) | Substituted benzimidazolone compound | |
KR101739003B1 (en) | Novel triazolopyrimidinone or triazolopyridone derivatives, and use thereof | |
NZ720726B2 (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
CA3078583A1 (en) | Pyrimidine tbk/ikk.epsilon. inhibitor compounds and uses thereof | |
AU2014301669A1 (en) | Phthalazine derivatives | |
WO2024145505A1 (en) | Pyrimidine carboxamide compounds |